UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 20-F
☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2023
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report ________________
For the transition period from _______________________________ to _______________________________
Commission File No. 001-36345
GALMED PHARMACEUTICALS LTD.
(Exact name of Registrant as specified in its charter)
N/A
(Translation of the Registrant’s name into English)
State of Israel
(Jurisdiction of incorporation or organization)
16 Abba Hillel Road, Ramat Gan, Israel 5250608
(Address of principal executive offices)
Allen Baharaff
President and Chief Executive Officer
16 Abba Hillel Road
Ramat Gan, Israel 5250608
E-mail: ab@galmedpharma.com
Tel: +972.3.693.8448
Fax: +972.3.693.8447
(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)
Securities registered or to be registered pursuant to Section 12(b) of the Act.
Title of each class
Ordinary shares, par value NIS 0.15 per share
Trading Symbol(s)
GLMD
Name of each exchange on which registered
Nasdaq Capital Market
Securities registered or to be registered pursuant to Section 12(g) of the Act.
N/A
(Title of each class)
Securities registered or to be registered pursuant to Section 15(d) of the Act.
N/A
(Title of each class)
Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the
annual report (December 31, 2023): 5,045,324 ordinary shares are outstanding
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or
15(d) of the Securities Exchange Act of 1934. Yes ☐ No ☒
Note – Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 from their obligations under those Sections.
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required
to submit and post such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or an emerging growth
company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer ☒
Emerging growth company ☐
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards † provided pursuant to
Section 13(a) of the Securities Act. ☐
† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its
Accounting Standards Codification after April 5, 2012.
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its
internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting
firm that prepared or issued its audit report. ☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based
compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:
U.S. GAAP ☒
International Financial Reporting Standards
as issued by the International Accounting Standards Board
Other
If “Other” has been checked in response to the previous question indicate by check mark which financial statement item the Registrant has
elected to follow: Item 17 ☐ Item 18 ☐
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒
TABLE OF CONTENTS
PART I
ITEM 1. Identity of Directors, Senior Management and Advisers.
ITEM 2. Offer Statistics and Expected Timetable.
ITEM 3. Key Information.
ITEM 4. Information on the Company.
ITEM 4A. Unresolved Staff Comments.
ITEM 5. Operating and Financial Review and Prospects.
ITEM 6. Directors, Senior Management and Employees.
ITEM 7. Major Shareholders and Related Party Transactions.
ITEM 8. Financial Information.
ITEM 9. The Offer and Listing.
ITEM 10. Additional Information.
ITEM 11. Quantitative and Qualitative Disclosures About Market Risk.
ITEM 12. Description of Securities Other Than Equity Securities.
PART II
ITEM 13. Defaults, Dividend Arrearages and Delinquencies.
ITEM 14. Material Modifications to the Rights of Security Holders and Use of Proceeds.
ITEM 15. Controls and Procedures.
ITEM 16. [RESERVED]
ITEM 16A. Audit Committee Financial Expert.
ITEM 16B. Code of Ethics.
ITEM 16C. Principal Accountant Fees and Services.
ITEM 16D. Exemptions from the Listing Standards for Audit Committees.
ITEM 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers.
ITEM 16F. Change in Registrant’s Certifying Accountant.
ITEM 16G. Corporate Governance.
ITEM 16H. Mine Safety Disclosure.
ITEM 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
ITEM 16J. Insider Trading Policies.
ITEM 16K. Cybersecurity.
PART III
ITEM 17. Financial Statements.
ITEM 18. Financial Statements.
ITEM 19. Exhibits
2
5
5
5
5
55
92
92
99
120
121
122
122
135
136
136
136
136
136
137
137
137
138
139
139
139
139
141
141
141
141
141
141
141
142
ABOUT THIS ANNUAL REPORT
All references to “we,” “us,” “our,” “the Company” and “our Company”, in this Annual Report on Form 20-F, or our annual report, are to Galmed
Pharmaceuticals Ltd. and its subsidiaries, unless the context otherwise requires. All references to Aramchol mean Aramchol acid or Aramchol meglumine
(salt), unless the context otherwise requires. All references to “shares” or “ordinary shares” are to our ordinary shares, NIS 0.15 nominal par value per
share. All references to “Israel” are to the State of Israel. “U.S. GAAP” means the generally accepted accounting principles of the United States. Unless
otherwise stated, all of our financial information presented in this annual report has been prepared in accordance with U.S. GAAP. Any discrepancies in
any table between totals and sums of the amounts listed are due to rounding. Unless otherwise indicated, or the context otherwise requires, references in
this annual report to financial and operational data for a particular year refer to the fiscal year of our company ended December 31 of that year.
Our reporting currency and financial currency is the U.S. dollar. In this annual report, “NIS” means New Israeli Shekel, and “$,” “US$” and “U.S.
dollars” mean United States dollars.
All information in this Annual Report on Form 20-F relating to shares or price per share reflects the 1-for-15 reverse share split effected by us on
May 15, 2023.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This annual report contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product
development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives
have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking
words such as “believe,” “expect,” “intend,” “plan,” “may,” “should,” “anticipate,” “could,” “might,” “seek,” “target,” “will,” “project,” “forecast,”
“continue” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical
matters. These forward-looking statements may be included in, among other things, various filings made by us with the U.S. Securities and Exchange
Commission, or the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking
statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to
matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially
from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially
from the activities and results anticipated in forward-looking statements, including, but not limited to, the factors summarized below:
● our ability to pursue, evaluate and complete any strategic alternative that yields value for our shareholders;
● the timing and cost of our planned Primary Sclerosing Cholangitis, or PSC, clinical trial and our pivotal Phase 3 ARMOR trial, or the ARMOR
Study, if re-initiated, for our product candidates, Aramchol and Amilo-5MER, or for any other pre-clinical or clinical trials;
● completion and receiving favorable results of our planned PSC clinical trial and the ARMOR Study (if re-initiated) for Aramchol or any other pre-
clinical or clinical trial;
● regulatory action with respect to Aramchol or any other product candidate by the U.S. Food and Drug Administration, or FDA, the European
Medicines Authority, or EMA, or the Medicines and Healthcare Products Regulatory Agency, or the MHRA, including but not limited to
acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved
indication and labeling;
● the commercial launch and future sales of Aramchol and any future product candidates;
● our ability to comply with all applicable post-market regulatory requirements for Aramchol, Amilo-5MER or any other product candidate in the
countries in which we seek to market the product;
● our ability to achieve favorable pricing for Aramchol, Amilo-5MER or any other product candidate;
● our expectations regarding the commercial market for PSC, non-alcoholic steato-hepatitis, or NASH (also known as MASH), in patients or any
other targeted indication;
● third-party payor reimbursement for Aramchol, Amilo-5MER or any other product candidate;
● our estimates regarding anticipated capital requirements and our needs for additional financing;
● market adoption of Aramchol or any other product candidate by physicians and patients;
● the timing, cost or other aspects of the commercial launch of Aramchol or any other product candidate;
● our ability to obtain and maintain adequate protection of our intellectual property;
● the possibility that we may face third-party claims of intellectual property infringement;
● our ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost;
● our ability to establish adequate sales, marketing and distribution channels;
3
● intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory
and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do;
● the development and approval of the use of Aramchol or any other product candidate for additional indications or in combination therapy;
● our expectations regarding licensing, acquisitions and strategic operations;
● current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated
liquidity risk;
● our ability to maintain the listing of our ordinary shares on The Nasdaq Capital Market;
● security, political and economic instability in the Middle East that could harm our business, including due to the the recent attacks by Hamas and
other terrorist organizations from the Gaza Strip and elsewhere in the region and Israel’s war against them and military hostilities with Hezbollah
on the northern border of Israel
● those factors referred to in “Item 3.D. Risk Factors,” “Item 4. Information on the Company,” and “Item 5. Operating and Financial Review and
Prospects”, as well as in this annual report on Form 20-F generally.
We believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known and
unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be
materially different from those anticipated by the forward-looking statements. We discuss many of these risks in this annual report in greater detail under
the heading “Risk Factors” and elsewhere in this annual report. Given these uncertainties, you should not rely upon forward-looking statements as
predictions of future events.
All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified in
their entirety by the cautionary statements included in this annual report. We undertake no obligations to update or revise forward-looking statements to
reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements,
you should consider these risks and uncertainties.
EXPLANATORY NOTE
Market data and certain industry data and forecasts used throughout this annual report were obtained from internal company surveys, market
research, consultant surveys commissioned by the Company, publicly available information, reports of governmental agencies and industry publications
and surveys. Industry surveys, publications, consultant surveys commissioned by the Company and forecasts generally state that the information contained
therein has been obtained from sources believed to be reliable. However, this information may prove to be inaccurate because of the method by which some
of the data for the estimates is obtained or because this information cannot always be verified with complete certainty due to the limits on the availability
and reliability of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties. As a result, the market and industry
data and forecasts included or incorporated by reference in this annual report, and estimates and beliefs based on that data, may not be reliable. We have
relied on certain data from third-party sources, including internal surveys, industry forecasts and market research, which we believe to be reliable based on
our management’s knowledge of the industry. However, we have not ascertained the underlying economic assumptions relied upon therein. Forecasts are
particularly likely to be inaccurate, especially over long periods of time. In addition, we do not necessarily know what assumptions regarding general
economic growth were used in preparing the forecasts we cite. Statements as to our market position are based to the best of our knowledge on the most
currently available data. While we are not aware of any misstatements regarding the industry data presented in this annual report, our estimates involve
risks and uncertainties and are subject to change based on various factors, including those discussed under the heading “Risk Factors” in this annual report.
4
ITEM 1. Identity of Directors, Senior Management and Advisers.
Not applicable.
ITEM 2. Offer Statistics and Expected Timetable.
PART I
Not applicable.
ITEM 3. Key Information.
A. [Reserved.]
B. Capitalization and Indebtedness.
Not applicable.
C. Reasons for the Offer and Use of Proceeds.
Not applicable.
D. Risk Factors.
Summary of Risk Factors
An investment in our ordinary shares is subject to a number of risks. The following summarizes some, but not all, of these risks. Please carefully
consider all of the information discussed in “Item 3. Key Information—D. Risk Factors” in this annual report for a more thorough description of these and
other risks.
Risks Related to Our Financial Position and Capital Requirements
●
●
●
●
We are a biopharmaceutical company with a history of operating losses. We expect to incur significant additional losses in the future and may
never be profitable.
We have not yet commercialized any products and we may never be able to do so, and even if we do, the products may not gain market
acceptance.
We will need substantial, additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations.
We are unable to estimate our long-term capital requirements due to uncertainties associated with the development and commercialization of
Aramchol, Amilo-5MER or any other product candidate. If we fail to obtain necessary funds for our operations, we will be unable to develop and
commercialize Aramchol, Amilo-5MER or any other product candidate.
Risks Related to Our Business, Industry and Regulatory Requirements
●
●
●
●
Our activities to evaluate and pursue strategic alternatives may not be successful.
We are substantially dependent on our remaining employees to facilitate the consummation of a strategic transaction. We could lose such key
employees.
The clinical trial process is complex and expensive, and commencement and completion of clinical trials can be delayed or prevented for a number
of reasons.
We have historically developed Aramchol for the treatment of NASH, and there is significant uncertainty regarding the regulatory approval
process. In addition, during 2022, we discontinued our open label part of the ARMOR Study and we do not currently expect to initiate the second
part of the ARMOR Study. This makes it difficult to predict the timing and costs of the clinical development of Aramchol for the treatment of
NASH.
●
We depend largely on the success of our lead product candidate, Aramchol, and we may not obtain regulatory approval of Aramchol.
5
●
●
●
●
●
●
●
●
Commencement of our ARMOR Study in jurisdictions outside the United States is subject to acceptance of the foreign equivalent of our IND by
regulatory authorities.
We may be forced to abandon development of Aramchol or any other product candidate which would have a material adverse effect on our
business and may force us to cease operations.
The lack of a reliable non-invasive method for the diagnosis of NASH is likely to present a major challenge to Aramchol’s market penetration, if
ever commercialized.
Our Amilo-5MER program is being conducted under a license agreement with Yissum Research Development Company of the Hebrew University
of Jerusalem, or Yissum.
If we acquire or in-license additional technologies or product candidates, we may incur significant, incremental expenses, may have integration
difficulties and may experience other risks that could harm our business and results of operations.
Changes in regulatory requirements and guidance or unanticipated events during our clinical trials may occur, which may result in necessary
changes to clinical trial protocols, which could result in increased costs to us, delay our development timeline or reduce the likelihood of
successful completion of our clinical trials.
We manage our business through a small number of senior executive officers. We depend on them even more than similarly- situated companies.
Our business is subject to risks arising from epidemic diseases, such as the COVID-19 pandemic, which has impacted and could continue to
impact our business.
Risks Related to Our Reliance on Third Parties
●
●
●
We have no manufacturing capacity and anticipate reliance on third-party manufacturers for Aramchol, Amilo-5MER or any other
product candidate.
Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to
develop and commercialize our current and potential future product candidates.
We depend on third parties to conduct our clinical trials.
Risks Related to Our Intellectual Property
●
●
The failure to obtain or maintain patents, licensing agreements and other intellectual property rights that are sufficiently broad and
protective could impact our ability to compete effectively.
Our potential development of Aramchol meglumine may not result in improved bioavailability compared to the existing form of
Aramchol. Furthermore, although we have pending patent applications and granted patent covering Aramchol meglumine in
development, there is no assurance that we will receive any patents for them, and even if we receive one or more patents for our
Aramchol meglumine in development, they may be of little or no commercial value.
Risks Related to Ownership of Our Ordinary Shares
●
Our business, operating results and growth rates may be adversely affected by current or future unfavorable economic and market
conditions and adverse developments with respect to financial institutions and associated liquidity risk.
6
●
●
●
●
The market price of our ordinary shares is volatile and you may sustain a complete loss of your investment.
If we fail to comply with the continued listing requirements of the Nasdaq Capital Market, our ordinary shares may be delisted and the
price of our ordinary shares and our ability to access the capital markets could be negatively impacted.
Our President and Chief Executive Officer beneficially owns approximately 5.6% of our outstanding ordinary shares, as of March 27,
2024. Therefore, our principal shareholders will be able to exert significant control over matters submitted to our shareholders for
approval.
Our U.S. shareholders may suffer adverse tax consequences due to our classification as a passive foreign investment company.
Risks Related to Israeli Law and Our Operations in Israel
●
●
●
Our headquarters and other significant operations are located in Israel and, therefore, our results may be adversely affected by political,
economic and military instability in Israel, such as the recent attacks by Hamas and other terrorist organizations from the Gaza Strip and
elsewhere in the region and Israel’s war against them and military hostilities with Hezbollah on the northern border of Israel
Provisions of Israeli law and our articles of association, or Articles, may delay, prevent or otherwise impede a merger with, or an
acquisition of, our company, which could prevent a change of control, even when the terms of such a transaction are favorable to us and
our shareholders.
Your rights, liabilities and responsibilities as a shareholder will be governed by Israeli law and differ in some material respects from those
under U.S. law.
RISK FACTORS
An investment in our ordinary shares involves a high degree of risk. Prior to making a decision about investing in our ordinary shares, you should
carefully consider the risks, uncertainties and assumptions set forth below. Additional risks and uncertainties not presently known to us, or that we currently
see as immaterial, may also harm our business. If any of these risks occur, our business, financial condition and operating results could be harmed, the
trading price of our ordinary shares could decline and you could lose part or all of your investment.
Risks Related to Our Financial Position and Capital Requirements
We are a biopharmaceutical company with a history of operating losses. We expect to incur significant additional losses in the future and may never be
profitable.
We are a biopharmaceutical company with an operating history limited to pre-clinical and clinical drug development and no approved products.
During 2022, we discontinued the open-label part of the ARMOR Study having reached its objectives and initiated a strategic review process. Following
the discontinuation of our open label part of the ARMOR Study, we do not currently expect to initiate the second part of the ARMOR Study. In addition,
we have limited operating experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently
encountered by companies in new and rapidly evolving fields, particularly in the pharmaceutical industry. We have funded our research and development
programs and operations to date primarily through proceeds from private placements and public offerings. We currently have no products approved for
marketing in the United States or any other jurisdiction and have not generated any revenue from product sales to date, although we have generated revenue
from our licensing agreement with Samil Pharm. Co., Ltd., or Samil. We have incurred operating losses in each year since the inception of our predecessor
in 2000. Our loss attributable to holders of our ordinary shares for the years ended December 31, 2022, and 2023 was approximately $17.4 million and $7.2
million, respectively. As of December 31, 2023, we had an accumulated deficit of $193.0 million. Substantially all of our operating losses resulted from
costs incurred in connection with our development program and from general and administrative costs associated with our operations.
7
Our ability to become profitable depends upon our ability to generate revenue in excess of our expenses. To date, we have not generated any
revenue, excluding the licensing revenue we recorded in connection with that certain Samil Agreement (as defined below), as our lead product candidate,
Aramchol and has not been approved by the FDA, nor has any other product candidate. We do not know when, or if, we will generate any revenue from
sales of Aramchol, Amilo-5MER and/or any other product candidate. We do not expect to generate revenue other than subsequent royalties and/or
milestones that can be earned in connection with the Samil Agreement or other potential license agreements, unless and until we, or an ultimate third-party
licensor or acquirer, obtain regulatory and marketing approval of, and commercialize, Aramchol, Amilo-5MER or any other product candidate. Subject to
our strategic review, we will continue to incur significant research and development and general and administrative expenses related to our operations. We
expect to continue to incur losses before we can consummate any strategic alternatives, which may be significant.
Based on our current operating plan, which is subject to change pursuant to our strategic review, we expect to continue to incur significant
expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:
●
●
●
●
●
●
●
re-initiate the ARMOR Study and/or commence any additional clinical trials for Aramchol and Amilo-5MER, or any other product
candidate and initiate additional research and development programs;
seek regulatory approvals for Aramchol, Amilo-5MER or any other product candidate;
seek to in-license additional products or technologies to develop;
expand our operational, financial and management systems and personnel, including personnel to support our clinical development,
manufacturing and commercialization efforts and our operations as a public company;
hire additional management and other personnel;
move towards commercialization of Aramchol or any other product candidate;
explore and review a range of strategic alternatives for our company.
We may out-license Aramchol, Amilo-5MER or any other product candidate including through a territorial license, a worldwide license, or a
license for a particular indication, before it is approved by any applicable regulatory agency, commercialized and/or generates revenue, depending on a
number of factors, including, but not limited to, our ability to:
●
●
●
●
●
demonstrate a compelling and/or novel, pre-clinical, unique mechanism of action of Aramchol, Amilo-5MER or any other product
candidate;
obtain adequate clinical results from and progress from the clinical development of Aramchol or any other product candidate;
develop and obtain regulatory approvals in the countries and for the uses we intend to pursue for Aramchol, Amilo-5MER or any other
product candidate;
contract for the manufacture of commercial quantities of Aramchol, Amilo-5MER or any other product candidate by a current good
manufacturing practice, or cGMP, compliant manufacturing facility at acceptable cost levels if marketing approval is received; and
establish external, and potentially in the future, internal, sales and marketing capabilities to effectively market and sell Aramchol, Amilo-
5MER or any other product candidate in the United States and other countries.
8
Even if Aramchol, Amilo-5MER or any other product candidate is approved for commercial sale, it may not gain market acceptance or achieve
commercial success. In addition, we anticipate incurring significant costs associated with seeking regulatory approval and commercialization. We may not
achieve profitability soon after generating product revenue, if ever. If we are unable to generate product revenue, we will not become profitable and would
be unable to continue operations without additional funding.
We expect our research and development expenses to significantly increase if we re-initiate our ARMOR Study and initiate any other pre-clinical
or clinical trials. In addition, if we obtain marketing approval for Aramchol, Amilo-5MER or any other product candidate and opt to commercialize it
ourselves, we will likely initially incur significant expenses associated with outsourcing sales, marketing and manufacturing functions to third parties, as
well as continued research and development expenses. Furthermore, we expect to incur additional costs associated with operating as a public company. As
a result, and subject to our strategic review, we expect to continue to incur significant and increasing operating losses for the foreseeable future. Because of
the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses or when
we will become profitable, if at all.
Our limited operating history makes it difficult to evaluate our business and prospects.
Our operating history is limited to pre-clinical and clinical development of two products, and our operations to date have been limited primarily to
research and development, raising capital and recruiting scientific and management personnel and third-party partners. Therefore, it may be difficult to
evaluate our business and prospects. We have not yet demonstrated an ability to commercialize or obtain regulatory approval for any product candidate.
Consequently, any predictions about our future performance may not be accurate, and you may not be able to fully assess our ability to complete
development and/or commercialize our product candidates, obtain regulatory approvals or achieve market acceptance or favorable pricing for our product
candidates.
We have not yet commercialized any products and we may never be able to do so, and even if we do, the products may not gain market acceptance.
We have not yet commercialized any products and we may never be able to do so. During 2022, we discontinued the open-label part of the
ARMOR Study having reached its objectives and initiated a strategic review process. Following the discontinuation of our open label part of the ARMOR
Study, we do not currently expect to initiate the second part of the ARMOR Study and are currently developing Aramchol for PSC. We do not know when
or if we will complete development of Aramchol, Amilo-5MER or any other product candidate, obtain regulatory approval, or successfully commercialize
any approved products. Even if we are successful in developing products that are approved for marketing, we will not be successful unless these products
gain market acceptance for appropriate indications at favorable reimbursement rates. The degree of market acceptance for these products will depend on a
number of factors, including:
●
●
●
●
●
the timing and scope of regulatory approvals in the countries we intend to pursue with respect to the commercialization of Aramchol,
Amilo-5MER or any other product candidate, including the indications for which they are approved;
the competitive environment;
the ability for Aramchol, Amilo-5MER or any other product candidate to be manufactured, whether by us or third parties, in compliance
with applicable regulatory requirements, including cGMP;
our ability to effectively promote Aramchol or any other product candidate, whether directly or using third parties, consistent with the
approved indications and labeling in the countries in which we intend to pursue approval;
the acceptance by the medical community of the safety and clinical efficacy of Aramchol, Amilo-5MER or any other product candidate
and their potential advantages over other therapeutic products;
9
●
●
●
the development of a non-invasive method for diagnosing NASH as an alternative to the current gold standard of liver biopsy, which we
view as a rate-limiting factor to complete market uptake because of its expense and its risks and discomfort to patients;
the adequacy and success of distribution, sales and marketing efforts, including through strategic agreements with pharmaceutical and
biotechnology companies; and
the pricing and reimbursement policies of government and third-party payors, such as insurance companies, health maintenance
organizations and other plan administrators.
Physicians, patients, third-party payors or the medical community in general may be unwilling to accept, utilize or recommend, and in the case of
third-party payors, reimburse any of our planned future products. As a result, we are unable to predict the extent of future losses or the time required to
achieve profitability, if at all. Even if we successfully develop one or more products, we may not become profitable.
We will need substantial, additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations.
As of December 31, 2023, we had a net working capital of $10.5 million, cash and cash equivalents of $2.9 million, restricted cash of $0.1 million,
short term deposits of $2.3 million and marketable debt securities of $7.5 million. Based on our current operating plan, which is subject to change pursuant
to our strategic review, we currently estimate that our cash position will support our current operations as currently conducted for more than 12 months
from the date of issuance of this annual report. We will need to raise substantial, additional capital to fund our operations and to re-initiate the ARMOR
Study and develop Aramchol and Amilo-5MER for, and beyond their current development stage, and ultimately commercialize them, if we opt to do so
ourselves. In addition, we may expand our current research and development focus and clinical operations as well as the development of Aramchol or any
other product candidate for other indications or development of other molecules and/or combination of Aramchol with other molecules for NASH or other
liver and inflammatory diseases as well as non-invasive biomarkers, which we expect will also require additional capital. Our future capital requirements
will depend on many factors including:
●
●
●
●
●
●
●
●
●
●
the outcome of our review of our strategic alternatives:
the progress and costs of our pre-clinical studies, clinical trials and other research and development activities;
the regulatory pathway of Aramchol, Amilo-5MER or any other product candidate;
the scope, prioritization and number of our clinical trials and other collaboration, research and development programs;
the amount of revenues and contributions we receive under future licensing, development and commercialization arrangements with
respect to Aramchol, Amilo-5MER or any other product candidate;
the costs of the development and expansion of our operational infrastructure;
the costs and timing of obtaining regulatory approval for Aramchol, Amilo-5MER or any other product candidate;
the ability of us, or our collaborators, to achieve development milestones, marketing approval and other events or developments under
our potential future licensing agreements;
the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;
the costs and timing of securing manufacturing arrangements for clinical or commercial production;
10
●
●
●
●
●
●
●
the costs of contracting with third parties to provide sales and marketing capabilities for us;
the costs of acquiring or undertaking development and commercialization efforts for any future products, product candidates or
platforms;
the magnitude of our general and administrative expenses;
any cost that we may incur under future in- and out-licensing arrangements relating to Aramchol, Amilo-5MER or any other product
candidate;
market conditions;
our ability to maintain the listing of our orindary share on The Nasdaq Capital Market; and
the impact of any resurgence of the COVID-19 pandemic and the war between Israel and Hamas, which may exacerbate the magnitude of
the factors discussed above.
Under General Instruction I.B.5 to Form F-3, or the Baby Shelf Rule, the amount of funds we can raise through primary public offerings of
securities in any 12-month period using our registration statement on Form F-3 is limited to one-third of the aggregate market value of the ordinary shares
held by non-affiliates of the Company. As of March 27, 2024, our public float was approximately $1.8 million, based on 5,777,351 ordinary shares held by
non-affiliates and a price of $0.32 per share, which was the last reported sale price of our ordinary shares on the Nasdaq Capital Market on March 26, 2024.
We therefore are limited by the Baby Shelf Rule as of the filing of this annual report, until such time as our public float exceeds $75 million. If we are
required to file a new registration statement on another form, we may incur additional costs and be subject to delays due to review by the SEC Staff.
Changing circumstances may cause us to consume capital significantly faster than we currently anticipate, such as losing our Small and Medium
Enterprise status at the EMA, which entitles us to significant fee reductions. Because there are numerous risks and uncertainties associated with the
development and commercialization of Aramchol, Amilo-5MER or any other product candidate, we are unable to estimate the amount of increased capital
outlays and operating expenditures associated with our anticipated clinical trials. We have no committed external sources of funds. Additional financing
may not be available when we need it or may not be available on terms that are favorable to us and additional financing may cause significant dilution to
our existing shareholders. If adequate funds are not available to us on a timely basis, or at all, we may be required to terminate or delay planned or ongoing
clinical trials or other development activities for Aramchol, Amilo-5MER or any other product candidate.
Raising additional capital may be costly or difficult to obtain and will dilute current shareholders’ ownership interests, potentially substantially.
Any debt, equity or structured financing that we may need or desire may not be available on terms favorable to us, or at all. If we obtain funding
through a strategic collaboration or licensing arrangement, we may be required to relinquish our rights to certain of our technologies, products or marketing
territories. If we are unable to obtain required additional capital, we may have to curtail our growth plans or cut back on existing business, and we may not
be able to continue operating if we do not generate sufficient revenues from operations needed to stay in business.
We may incur substantial costs in pursuing future capital financing, including investment banking fees, legal fees, accounting fees, securities law
compliance fees, printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection with certain
securities we issue, such as convertible notes and warrants, which may adversely impact our capital structure, financial condition and results of operations.
In addition, our authorized share capital consists of 20,000,000 ordinary shares, par value NIS 0.15 per share. As of March 27, 2024, we had
6,009,654 ordinary shares issued and outstanding. As of the date of this Annual Report, we also had outstanding pre-funded warrants to purchase 1,280,000
ordinary shares and warrants to purchase 5,200,000 ordinary shares with an exercise price of $1.25 per share. To the extent that pre-funded warrants and
warrants are exercised, holders of our ordinary shares will experience dilution.
11
Any additional capital raised through the sale of equity or equity-linked securities, will dilute our current shareholders’ ownership in us,
potentially substantially, and could also result in a decrease in the market price of our ordinary shares. The terms and conditions of those securities issued
by us in future capital transactions may be more favorable to new investors and may include the issuance of warrants or other derivative securities, which
may have a further dilutive effect.
We are unable to estimate our long-term capital requirements due to uncertainties associated with our strategic review and the development and
commercialization of Aramchol, Amilo-5MER or any other product candidate. If we fail to obtain necessary funds for our operations, we will be unable
to develop and commercialize Aramchol, Amilo-5MER or any other product candidate.
Our long-term capital requirements are expected to depend on many potential factors, including, among others:
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
the outcome of our review of our strategic alternatives;
the number of product candidates in development;
the size, duration and scope of existing and future clinical trials and pre-clinical studies;
the regulatory pathway for the approval of Aramchol, Amilo-5MER or any other product candidate;
the results of our clinical trials, which are unpredictable in product candidate development;
our ability to successfully commercialize Aramchol, Amilo-5MER or any other product candidate, including securing commercialization
and out-licensing agreements with third parties and favorable pricing and market share;
the progress, success and cost of our clinical trials and research and development programs, including those associated with milestones
and royalties;
the costs, timing and outcome of regulatory review and obtaining regulatory approval of Aramchol, Amilo-5MER or any other product
candidate and addressing regulatory and other issues that may arise post-approval;
the breadth of the labeling, assuming that Aramchol, Amilo-5MER or any other product candidate are approved for commercialization by
a relevant regulatory authority, which may not occur;
our need, or decision, to acquire or in-license complementary technologies or new platform technologies or product candidates;
the costs of enforcing our issued patents and defending intellectual property-related claims;
the costs of investigating patents that might block us from developing potential product candidates;
the costs of recruiting and retaining qualified personnel;
the costs associated with contracting with third parties to manufacture the product and to perform other necessary services;
our revenue, if any; and
our consumption of available resources more rapidly than currently anticipated, resulting in the need for additional funding sooner than
anticipated.
12
If we are unable to obtain the funds necessary for our operations, we will be unable to develop and commercialize Aramchol, Amilo-5MER or any
other product candidate which would materially and adversely affect our business, liquidity and results of operations.
Our activities to evaluate and pursue strategic alternatives may not be successful.
Risks Related to Our Business, Industry and Regulatory Requirements
In May 2022, we announced that we will expand into new anti-fibrotic indications to maximize the potential of Aramchol while at the same time
discontinuing the open label part of the ARMOR Study having reached its objectives. Simultaneously, we initiated a cost reduction plan and at various
times have been evaluating our strategic options alternatives and our structuring to best optimize our resources to enhance shareholder value and achieve
our goals. In June 2023, we announced the closing of a strategic investment in OnKai, Inc., or OnKai, (see “Item 4. Information on the Company—
Strategic Collaborations, Research Arrangements and other Agreements—Onkai.”).
We also may acquire additional businesses, products or product candidates. Integrating any newly acquired business, product or product candidate
could be expensive and time-consuming. We may not be able to integrate any acquired business, product or product candidate successfully. If we do
acquire any additional business, products, or product candidates, our future financial performance will depend, in part, on our ability to manage any future
growth effectively and our ability to integrate any such acquired businesses, products or product candidates.
Any strategic transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures and may pose
significant integration challenges or disrupt our management or business, which could adversely affect our operations and financial results. For example,
these transactions may entail numerous operational and financial risks, including:
●
●
●
●
●
●
●
●
exposure to unknown liabilities;
incurrence of substantial debt or dilutive issuances of equity securities to pay for acquisitions;
higher than anticipated acquisition and/or integration costs;
write downs of assets or goodwill or impairment charges;
increased amortization expenses;
difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;
impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership;
and
the inability to retain our key employees or our other service providers or those of any acquired businesses.
Accordingly, there can be no assurance that we will undertake or successfully complete any strategic transactions of the nature described above
and any transactions that we do complete may be subject to the foregoing or other risks and could have a material adverse effect on our business, financial
condition and prospects.
We are substantially dependent on our remaining employees to facilitate the consummation of a strategic transaction. We could lose such key
employees.
Our cash conservation activities may yield unintended consequences, such as attrition and reduced employee morale, which may cause remaining
employees to seek alternative employment. Our ability to successfully complete a strategic transaction depends in large part on our ability to retain certain
personnel. Despite our efforts to retain these employees, one or more may terminate their employment on short notice. The loss of the services of any of
these employees could potentially harm our ability to evaluate and pursue strategic alternatives, as well as fulfill our reporting obligations as a public
company.
13
The clinical trial process is complex and expensive, and commencement and completion of clinical trials can be delayed or prevented for a number of
reasons.
We may not be able to complete or commence the clinical trials that would support our submission of an NDA to the FDA, a Marketing
Authorization Application or MAA, to the EMA or MHRA or any similar submission to regulatory authorities in other countries. Drug development is a
long, expensive and uncertain process, and delay or failure can occur at any stage of any of our clinical trials. The fact that the FDA, EMA, MHRA or other
regulatory authorities permit a company to conduct human clinical trials is no assurance or guarantee that the trials will be successful. On the contrary, most
candidate drugs that begin clinical trials do not prove to be successful and do not result in the filing of an NDA, MAA or similar filing. Drug candidates
that successfully complete one phase of clinical trials may prove unsuccessful at a subsequent phase. Human clinical trials are very expensive and difficult
to design and implement, in part because they are subject to rigorous regulatory requirements and in part because the results of clinical trials are inherently
uncertain and unpredictable. In addition, the design of a clinical trial can determine whether its results will support approval of a product, and flaws in the
design of a clinical trial may not become apparent until the clinical trial is well advanced. Regulatory authorities, such as the FDA, may decline to permit a
clinical trial to proceed or may suspend a clinical trial that it has previously permitted to proceed. Additionally, the clinical trial process is time-consuming,
and failure can occur at any stage of the trials. We may encounter problems that cause us to abandon, delay or repeat clinical trials. The commencement and
completion of clinical trials may be delayed by several factors, including:
●
●
●
●
●
●
●
●
●
●
difficulties obtaining regulatory authorization to commence a clinical trial or complying with regulatory requirements for clinical trials or
with the conditions imposed by a regulatory authority regarding the scope, duration or conduct of a clinical trial;
delays in reaching or failing to reach agreement on acceptable terms with prospective contract research organizations, or CROs, and trial
sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
insufficient or inadequate supply or quality of a product candidate or other materials necessary to conduct our clinical trials;
difficulties in obtaining institutional review board, or IRB, approval to conduct a clinical trial at a prospective site;
challenges in recruiting and enrolling patients to participate in clinical trials for a variety of reasons, including size and nature of patient
population, proximity of patients to clinical sites, eligibility and exclusion criteria for the trial, nature of trial protocol, the availability of
approved effective treatments for the relevant disease and competition from other clinical trial programs for similar indications;
challenges in identifying or recruiting sufficient study sites or investigators for clinical trials;
limitations on employee resources that would otherwise be focused on the conduct of our business including because of military reserve
duty call-ups in the future that impact our employees and the affect the current war between Israel and Hamas on the productivity of our
employees and external partners;
delays in necessary interactions with vendors, local regulators, and other important agencies and contractors due to limitations in
employee resources;
impacts from prolonged remote work arrangements, such as increased cybersecurity risks and strains on our business continuity plans;
and
lack of adequate funding to initiate or continue our clinical trials.
14
Even if we re-initiate the Phase 3 ARMOR Study, the ARMOR Study may still be terminated as a result of, but not limited to, safety signals, lack
of efficacy, uncertainties with regard to the regulatory pathway for the approval of NASH drugs, or commercial considerations based on the cost-benefit of
continuing to run the study. In addition, the ARMOR Study or other clinical trials may be suspended or terminated by us, the FDA or other regulatory
authorities, the principal investigator at a site, the IRBs at the sites where such boards are overseeing a trial or the data safety monitoring board, or the
DSMB, that is overseeing the clinical trial at issue, or other regulatory authorities due to a number of factors, including:
●
●
●
●
irregularities in conducting a clinical trial, including by way of example, failure to conduct the clinical trial in accordance with regulatory
requirements, in particular good clinical practice requirements, or GCP, or the FDA-authorized clinical protocols;
negative findings upon inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities;
safety issues or lack of clinical drug activity or effectiveness; and
lack of adequate funding to continue the clinical trials.
To date, we have already experienced material delays in both the ARMOR Study largely related to significantly slower than expected recruitment
and the ARREST Study largely related to significantly slower than expected recruitment and the length of time required to obtain regulatory authorizations
to proceed with clinical trials. We may experience further delays in any or all of our clinical trials and there can be no assurance that we will not experience
such risks in the future as we progress with our planned clinical trials.
Furthermore, positive results in previous clinical studies of our product candidates may not be predictive of similar results in future clinical trials.
Also, interim results, if at all, during a clinical trial do not necessarily predict final results. A number of companies in the pharmaceutical and biotechnology
industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in early- and mid-stage development.
Accordingly, the results from the completed pre-clinical studies and clinical trials for our product candidates may not be predictive of the results we may
obtain in later stage trials. Our clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct
additional clinical and/or pre-clinical trials, or to even terminate the development program entirely. Many companies that believed their product candidates
performed satisfactorily in pre-clinical and clinical studies have nonetheless failed to obtain FDA or EMA, or other regulatory agency, approval for their
products.
In addition, we or regulatory authorities may suspend our clinical trials at any time if it appears that we are exposing participants to unacceptable
health risks or if the regulatory authorities find deficiencies in our regulatory submissions or the conduct of such trials. Any suspension of clinical trials will
delay possible regulatory approval, if any, and adversely impact our ability to develop products and generate revenue.
We have historically developed Aramchol for the treatment of NASH and there is significant uncertainty regarding the regulatory approval process. In
addition, during 2022, we discontinued our open label part of the ARMOR Study and we do not currently expect to initiate the second part of the
ARMOR Study. This makes it difficult to predict the timing and costs of the clinical development of Aramchol for the treatment of NASH.
Pharmaceutical products generally are subject to rigorous nonclinical testing and clinical studies and other approval procedures mandated by the
FDA and foreign regulatory authorities. We have historically developed Aramchol for the treatment of NASH.
15
In September 2019, we initiated the ARMOR Study and during 2022 we discontinued the open-label part of the ARMOR Study having reached its
objectives. Following the discontinuation of our open label part of the ARMOR Study, we do not currently expect to initiate the second part of the ARMOR
Study.
Although there are guidelines issued by the FDA for the development of drugs for the treatment of NASH, it is our current assessment that despite
considerable efforts from the scientific community and regulatory agencies, there are significant uncertainties that remain unresolved with regards to the
conduct of NASH Phase 3 registrational studies. These risks include dependence on biopsies as the primary surrogate endpoint which are subjective in
nature and prone to sampling errors and inadequacy; high screen failure rates which pose a burden to patients, investigators, and study budget; lack of
validated biomarkers and the heterogenous population included under the NASH diagnosis. Moreover, pathology plays a role in NASH clinical trials with
histology being the current reference method to determine inclusion in trials and change in disease activity and fibrosis stage. Manual histological review is
complex, subjective, and prone to inter- and intra-reader variability and error. Existing pathology scoring systems and practices show only moderate to fair
reproducibility, limiting their utility for clinical research and practice.
In addition, the FDA has indicated that the results of the ARMOR Study must be unequivocal and highly persuasive for a single Phase 3 study to
support approval of an NDA. Therefore, even if the ARMOR Study meets all of its statistical goals and protocol endpoints, the FDA may not view the
results as sufficient to support an NDA.
We expect that the path for regulatory approval for NASH drugs to continue to evolve in the near term as we and other companies in late-stage
development of NASH drugs refine our regulatory approval strategies and interact with the FDA and other regulatory authorities. In particular, FDA
expectations about interpretation of liver biopsy data may evolve especially as more information is published about the inherent variability in interpretation
of liver biopsy data. Certain of our competitors have experienced regulatory setbacks for NASH therapies following communications from the FDA. See
also “Item 4. Information on the Company—Competition.” Even after we receive and incorporate guidance from the FDA or other regulatory authorities,
they could disagree that we have satisfied their requirements, which may require us to complete additional preclinical studies or clinical trials or impose
stricter approval conditions than we currently expect. Furthermore, as the path for regulatory approval for NASH drugs evolves, it may impact our
ARMOR Study in ways that could significantly increase the development costs and call into question the future viability of continuing to conduct the
ARMOR Study. Additionally, we are considering more robust changes to our development program for NASH. Changes may include focusing on higher
risk patients (F3), evaluating patients with compensated cirrhosis (F4) as well as changes to study design such as two smaller studies instead of one pivotal
study and the addition of a combination arm.
Any additional delays in the completion of the ARMOR Study or any additional preclinical studies or clinical trials would require us to expend
substantial additional resources and could significantly extend the timeline for clinical development prior to market approval. As a result of the foregoing,
the research and development, preclinical studies and clinical testing of Aramchol and any other product candidate is expensive and can take many years to
complete, and its outcome is inherently uncertain. Failure can occur at any time during the development process. If we experience delays in the completion
of, or if we terminate, any of our clinical trials, this would have a material adverse effect on our business, liquidity, operating results and financial condition
and may force us to cease operations.
We depend largely on the success of our lead product candidate, Aramchol, and we may not obtain regulatory approval of Aramchol.
We have invested almost all of our efforts and financial resources in the research and development (clinical and pre-clinical) of our lead product
candidate, Aramchol. As a result, subject to our strategic review, our business is largely dependent on our ability to complete the development of, obtain
regulatory approval for and successfully commercialize Aramchol in a timely manner. The process to develop, obtain regulatory approval for and
commercialize Aramchol is long, complex, costly and uncertain as to its outcome and we do not currently expect to initiate the second part of the ARMOR
Study.
The research, development, testing, clinical trials, manufacturing, labeling, approval, sale, marketing and distribution of drugs are subject to
extensive regulation by the FDA and other regulatory agencies in other countries. These regulations differ from jurisdiction to jurisdiction. We have not
received marketing approval for Aramchol in any jurisdiction. We are not permitted to market Aramchol, or any other product candidate, in the United
States until we receive approval of a New Drug Application, or NDA, from the FDA, or in any foreign countries until we receive the requisite approval
from the respective regulatory agencies in such countries. The results of clinical trials may be unsatisfactory, and even if we believe those clinical trials to
be successful, the FDA, or other regulatory authorities, may not grant marketing authorization should we be in a position to request it.
16
Even if we re-initiate the ARMOR Study, the requirements and length of time for approval vary in different jurisdictions and could involve
additional studies of Aramchol beyond those we currently anticipate, including potentially post-approval studies. The time required to obtain approval in
other countries might differ from that required to obtain FDA approval in the United States. The marketing approval process in other countries may include
all of the risks detailed above regarding FDA approval as well as other risks. In particular, in many countries outside the United States, it is required that a
product receive pricing and reimbursement approval before the product can be commercialized. This can result in substantial delays in such countries. In
other countries, product approval depends on showing superiority to an approved therapy. This can result in significant expense to conduct complex clinical
trials. Finally, we do not have any products approved for sale in any jurisdiction, including international markets, and we do not have experience in
obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain
required approvals or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full
market potential of Aramchol or any other product candidate will be harmed.
Marketing approval in one jurisdiction does not ensure marketing approval in another, but a failure or delay in obtaining marketing approval in
one jurisdiction may have a negative effect on the regulatory process in others. Failure to obtain marketing approval in other countries or any delay or
setback in obtaining such approval would impair our ability to develop foreign markets for Aramchol. This would reduce our target market and limit the
full commercial potential of Aramchol.
Commencement of our ARMOR Study in jurisdictions outside the United States is subject to acceptance of the foreign equivalent of our IND by
regulatory authorities.
In the event that the FDA or any other regulatory authority requires us to complete additional preclinical and/or clinical studies or we are required
to satisfy other FDA or other regulatory requests, the start of the ARMOR Study in the applicable jurisdiction or any of our other programs may be delayed
or not started at all. For example, certain regulatory agencies in Europe have required that we conduct additional clinical studies prior to initiating ARMOR
in those jurisdictions. Even after we receive and incorporate guidance from these regulatory authorities, the FDA or other regulatory authorities could
disagree that we have satisfied their requirements to commence our clinical trial or change their position on the acceptability of our planned trial design or
the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials or impose stricter approval conditions than
we currently expect. As a result of the foregoing, the research and development, preclinical studies and clinical testing of any product candidate is
expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the development process.
We may be forced to abandon development of Aramchol or any other product candidate which would have a material adverse effect on our business
and may force us to cease operations.
Upon the completion of any clinical or pre-clinical trial and/or tests, the results might not support the desired indications for use. Further, success
in earlier clinical trials does not ensure that later clinical trials will be successful, and the results of later clinical trials may not replicate the results of prior
clinical trials or pre-clinical testing. In addition, the design of a clinical trial can determine whether its results will support approval of a product, and flaws
in the design of a clinical trial or variability in interpretation of results may not become apparent until the clinical trial is well advanced. The clinical trial
process may fail to demonstrate that Aramchol or any other product candidate is sufficiently safe and/or effective for the indications we seek to receive
FDA or other regulatory approval. Any such failure may cause us to abandon Aramchol or any other product candidate and may delay development of
other potential product candidates. Any delay in, or termination or suspension of, our clinical trials may delay the requisite filings with the FDA or other
regulatory agencies and, ultimately, our ability to commercialize Aramchol or any other product candidate and generate product revenues. If the results of
the ARMOR Study or any other study, including in any interim readout, are not sufficiently compelling, then the completion of development of our product
candidates may be significantly delayed or abandoned which would have material adverse effect on our business, liquidity, operating results and financial
condition and may force us to cease operations.
17
We have in the past and may in the future develop Aramchol in combination with other therapies, which exposes us to additional risks.
We have in the past and, subject to our strategic review, may in the future develop Aramchol in combination with investigational therapies. We
will not be able to market and sell Aramchol or any product candidate we develop in combination with an unapproved therapy for a combination indication
if that unapproved therapy does not ultimately obtain marketing approval either alone or in combination with our product candidate. In addition,
unapproved therapies face the same risks described with respect to Aramchol or any other product candidate currently in development and clinical trials,
including the potential for serious adverse effects, delay in their clinical trials and lack of FDA, EMA or MHRA approval. If the FDA, EMA, MHRA or
comparable foreign regulatory authorities do not approve these other drugs or revoke their approval of, or if safety, efficacy, quality, manufacturing or
supply issues arise with the product candidates we choose to evaluate in combination with our product candidate we develop, we may be unable to obtain
approval of or market such combination therapy.
The lack of a reliable non-invasive method for the diagnosis of NASH and fibrosis is likely to present a major challenge to Aramchol’s market
penetration, if ever commercialized.
Liver biopsy is the standard approach for the diagnosis of inflammation and fibrosis associated with NASH. However, the procedure-related
morbidity and, in rare cases, mortality, sample errors, costs, patient discomfort and thus lack of patient interest in undergoing the procedure limit its use. As
such, only patients with a high risk of NASH, which includes patients with metabolic syndrome and an indication of Non-Alcoholic Fatty Liver Disease, or
NAFLD, are generally sent for liver biopsy. Because NASH tends to be asymptomatic until the disease progresses, many individuals with NASH remain
undiagnosed until the disease has reached its late stages, if at all. The lack of a reliable non-invasive method for the diagnosis of NASH and fibrosis is
likely to present a major challenge to Aramchol’s market penetration, as many practitioners and patients may not be aware that a patient suffers from
NASH and requires treatment. As such, use of Aramchol might not be as wide-spread as our actual target market and this may limit the commercial
potential of Aramchol.
A further challenge to Aramchol’s market penetration is that currently a liver biopsy is the standard approach for measuring improvement in
NASH patients. Because it would be impractical to subject all patients that take Aramchol, when and if it is approved, to regular and repeated liver
biopsies, it will be difficult to demonstrate Aramchol’s effectiveness to practitioners and patients unless and until a reliable non-invasive method for the
diagnosis and monitoring of NASH becomes available, as to which there can be no assurance.
While other companies in the industry are currently working on advancing non-invasive diagnostic approaches, none of these has been clinically
validated, and the timetable for commercial validation, if at all, is uncertain. Moreover, such diagnostics may also be subject to regulation by FDA or other
regulatory authorities as medical devices and may require premarket clearance or approval. See also “Item 3. Key Information—Risk Factors —Risk
Factors—Risks Related to Our Business, Industry and Regulatory Requirements —- We are developing Aramchol for the treatment of NASH, an indication
for which there are no approved products, and there is significant uncertainty regarding the regulatory approval process. This makes it difficult to predict
the timing and costs of the clinical development of Aramchol for the treatment of NASH.”
Our Amilo-5MER program is being conducted under a license agreement with Yissum Research Development Company of the Hebrew University of
Jerusalem, or Yissum.
Our Amilo-5MER program is being conducted under a license agreement from Yissum and is subject to various additional obligations, including
obligations with respect to funding, development and commercialization activities, and payment obligations upon entering into the license agreement and
achievement of certain milestones and royalties on product sales. Furthermore, if the license agreement is terminated or breached, we may:
●
●
lose our rights to research, develop or commercialize Amilo-5MER;
not be able to secure trade secret protection for Amilo-5MER;
18
●
●
experience significant delays in the development or commercialization of Amilo-5MER; or may have to cease development entirely;
incur liability for damages.
Additionally, even if not terminated or breached, our intellectual property licenses may be subject to disagreements over contract interpretation
which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations. If we
experience any of the foregoing, it could have a materially adverse effect on our business.
In January 2022, we announced the completion of our Phase 1 clinical trial of Amilo-5MER. The Phase 1 study was conducted in a single-center,
using a double-blind, randomized, placebo-controlled design. Results demonstrated that all doses of Amilo-5MER were well tolerated with no clinically
significant adverse events and none considered related to the investigational product. Due to its early stage of development, Amilo-5MER will require
significant additional research, development, manufacturing, preclinical and clinical testing, marketing authorization, and commitment of significant
additional resources prior to any commercialization. These activities will require significant cash for which we will need to raise additional capital. In
addition, Amilo-5MER is prone to the risks of failure inherent in pharmaceutical product development, including the possibility that Amilo-5MER will not
be shown to be sufficiently safe and effective for approval by regulatory authorities.
If we acquire or in-license additional technologies or product candidates, we may incur significant, incremental expenses, may have integration
difficulties and may experience other risks that could harm our business and results of operations.
We evaluate from time-to-time the acquisition or in-licensing of additional product candidates and technologies. Any product candidate or
technologies we in-license or acquire will likely require additional development efforts prior to commercial sale, including extensive pre-clinical or clinical
testing, or both, and approval by the FDA and applicable foreign regulatory authorities, if any. All product candidates are prone to risks of failure inherent
in pharmaceutical product development, including the possibility that the product candidate, or product developed based on in-licensed technology, will not
be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot assure that any product candidate that we
develop based on acquired or in-licensed technology that is granted regulatory approval will be manufactured or produced economically, successfully
commercialized or widely accepted or competitive in the marketplace. Moreover, integrating any newly acquired or in-licensed product candidates could be
expensive and time-consuming. If we cannot effectively manage these aspects of our business strategy, our business may not succeed.
Obtaining approval of an NDA, or other regulatory approval, even after clinical trials that are believed to be successful, is an uncertain process.
Even if we complete clinical trials and believe that the clinical data confirms that Aramchol, Amilo-5MER or any other product candidate is
sufficiently safe and effective for its intended use or uses, obtaining approval of an NDA, or other regulatory approval, is an extensive, lengthy, expensive
and uncertain process, and the FDA and other regulatory agencies may delay, limit or deny approval of such product candidate for many reasons, including,
without limitation, the fact that:
●
●
●
we may not be able to demonstrate to the satisfaction of the applicable regulatory agencies that the product candidate is safe and effective
for treatment of the targeted indication in patients;
the results of clinical trials may not meet the level of statistical significance or clinical significance required by the applicable regulatory
agencies for approval;
the applicable regulatory agencies may disagree with the number, design, size, conduct or implementation of our clinical trials;
19
●
●
●
●
●
●
●
●
●
●
the applicable regulatory agencies may not find the data from pre-clinical studies and clinical trials sufficient to demonstrate the clinical
and other benefits outweigh its safety risks;
the applicable regulatory agencies may disagree with our interpretation of data from pre-clinical studies or clinical trials;
the applicable regulatory agencies may not accept data generated at our clinical trial sites;
the data collected from pre-clinical studies and clinical trials may not be sufficient to support the submission of an NDA or similar
regulatory application;
the applicable regulatory agencies may not schedule an advisory committee meeting in a timely manner or the advisory committee may
recommend against approval of our application or may recommend that the applicable regulatory agencies require, as a condition of
approval, additional pre-clinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions;
the applicable regulatory agencies may require development of a risk evaluation and mitigation strategy, or REMS, as a condition of
approval;
the applicable regulatory agencies may require simultaneous approval for both adults and children, which would delay required
approvals, or we may have successful clinical trial results for adults, but not children, or vice versa;
the applicable regulatory agencies may change their approval policies or adopt new regulations that may impede consideration or
approval of our NDA, or similar regulatory application;
the applicable regulatory agencies may identify deficiencies in the manufacturing processes or facilities of third-party manufacturers, or
suppliers of active pharmaceutical ingredients, or APIs, with which we enter into agreements for clinical and commercial supplies; and
the applicable regulatory agencies may require post-marketing approval studies, such as Phase 4 clinical trials, in connection with
Aramchol or any other product candidate.
Before we can submit an NDA to the FDA or a similar approval application to other regulatory authorities, as applicable, we (or our
commercialization partner, as the case may be) must conduct one or more clinical trials that will be substantially broader than our prior completed trials.
We will also need to agree on a protocol with the FDA or any other regulatory authorities for any clinical trial(s) before commencing any such trial.
Clinical trials frequently produce unsatisfactory results even though prior clinical trials were successful. Therefore, the results of any prior trial or any
future clinical trials that we may conduct may or may not be successful. The applicable regulatory agencies may suspend all clinical trials or require that we
conduct additional clinical, pre-clinical, manufacturing, validation or drug product quality studies and submit data from these additional studies before
considering or reconsidering the NDA or similar regulatory application. Depending on the extent of these, or any other studies, approval of any applications
that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional
studies, if performed and completed, may not be considered sufficient by the applicable regulatory agencies to provide regulatory approval. If any of these
outcomes occur, we would not receive approval for Aramchol, Amilo-5MER or any other product candidate and may be forced to cease operations.
Even if we obtain regulatory approval for Aramchol, Amilo-5MER or any other product candidate, the approval might contain significant
limitations related to the indications for use for which the drug is approved, use restrictions including, without limitation, for certain labeled populations,
age groups, warnings, precautions or contraindications, or may be subject to significant post-marketing studies or risk mitigation requirements. If we are
unable to successfully commercialize Aramchol, Amilo-5MER or any other product candidate, we may be forced to cease operations.
20
Our product candidates may produce undesirable side effects or have other properties that could delay or prevent its regulatory approval or result in
significant negative consequences following marketing approval, if any, which could substantially increase commercialization costs or even force us to
cease operations.
Undesirable side effects caused by Aramchol or any other product candidate could cause us or regulatory authorities to interrupt, delay or halt
clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or applicable foreign regulatory
authorities. To date, we have completed seven clinical trials of Aramchol, and additionally one proof of concept study in patient with gallstones, and a
Phase 2a, investigator initiated clinical trial were completed. Although we have not seen any evidence of reactions causing a safety concern in our
completed clinical trials, it is possible that the FDA may ask for additional data regarding any adverse events seen in our trials. Results of our future trials
could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated
and the FDA or applicable foreign regulatory authorities could order us to cease further development of or deny approval for Aramchol, Amilo-5MER or
any other product candidate for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled
patients to complete future trials or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and
prospects significantly.
Even if Aramchol or any other product candidate receives marketing approval, we or others may later identify undesirable side effects caused by
the product. In such an event, regulatory authorities may:
●
●
●
●
●
suspend or withdraw their approval of the product;
require the addition of labeling statements, such as warnings, so-called “black box warnings,” contraindications or restrictions on the
product’s intended use;
require us to issue specific communications to healthcare professionals, such as “Dear Doctor” letters;
issue negative publicity regarding the affected product, including safety communications;
impose a risk evaluation and mitigation strategy (REMS), in the case of FDA, or similar risk management strategies in the case of foreign
regulators;
In addition to these potentially significant negative consequences, we could be required to change the way the product is administered, conduct
additional pre-clinical studies or clinical trials or restrict or cease the distribution or use of the product, and/or be sued and held liable for harm caused to
patients. The foregoing or other events could prevent us from achieving or maintaining market acceptance of the affected product candidate and could
substantially increase commercialization costs or even force us to cease operations.
If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient
population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, patient willingness to undergo a liver
biopsy in our NASH trials, competing clinical trials and clinicians’ and patients’ perceptions as to the potential advantages and disadvantages of the
product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are
investigating, and actual or threatened public health emergencies and outbreaks of disease (including, for example, any resurgence of the COVID-19
pandemic). Potential patients for Aramchol, Amilo-5MER or any other product candidate may not be adequately diagnosed or identified with the diseases
which we are targeting or may not meet the entry criteria for our studies.
We will be required to identify and enroll a sufficient number of patients in the U.S. with NASH for each of our clinical trials of Aramchol in this
indication. We also may encounter difficulties in identifying and enrolling U.S. NASH patients who meet the eligibility criteria for our planned clinical
trials. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible patients to participate in the clinical
trials required by the FDA or other foreign regulatory agencies. In addition, the process of finding and diagnosing patients may prove costly. To date, we
have already experienced significant delays in our clinical trials largely related to significantly slower than expected recruitment and the length of time
required to obtain regulatory authorizations to proceed with clinical trials. Our inability to enroll a sufficient number of patients for any of our clinical trials
could result in further significant delays, additional expenses, or may require us to abandon one or more clinical trials.
21
Changes in regulatory requirements and guidance or unanticipated events during our clinical trials may occur, which may result in necessary changes
to clinical trial protocols, which could result in increased costs to us, delay our development timeline or reduce the likelihood of successful completion
of our clinical trials.
Changes in regulatory requirements or guidance or unanticipated events during our clinical trials may result in the need for us to amend clinical
trial protocols. Amendments may require review and approval by regulators and/or IRBs, and re-consent subjects, which may adversely affect the cost,
timing or successful completion of a clinical trial. Even if we re-initiate the ARMOR Study, if we experience delays in the completion of, or if we
terminate, any of the ARMOR Study or any other clinical trials, this could have a material adverse effect on our business, liquidity, operating results and
financial condition and may force us to cease operations. See also “Item 3. Key Information—Risk Factors—Risk Factors—Risks Related to Our Business,
Industry and Regulatory Requirements - We are developing Aramchol for the treatment of NASH, an indication for which there are currently no approved
products, and there is significant uncertainty regarding the regulatory approval process. This makes it difficult to predict the timing and costs of the clinical
development of Aramchol for the treatment of NASH.”
Even if Aramchol, Amilo-5MER or any other product candidate that we develop, receives marketing approval, we will continue to face extensive
regulatory oversight and requirements, and any such product may still face future regulatory risks or new requirements.
Even if we receive regulatory approval to market a particular product candidate, any such product will remain subject to extensive regulatory
requirements, including requirements relating to manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion, distribution
and recordkeeping. Even if regulatory approval of a product is granted, the approval may be subject to limitations on the uses for which the product may be
marketed or the conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of
the product, which could negatively affect us by reducing revenues or increasing expenses, and cause the approved product candidate not to be
commercially viable. In addition, as clinical experience with a drug expands after approval, typically because it is used by a greater number and more
diverse group of patients after approval than during clinical trials, side effects and other problems may be observed over time after approval that were not
seen or anticipated during pre-approval studies. Any adverse effects observed after the approval and marketing of a product candidate could result in
limitations on the use of the approved product, withdrawal of FDA approval of the previously approved product, or voluntary withdrawal from the
marketplace of the approved product. Absence of long-term safety data may also limit the approved uses of Aramchol or any other product candidate, if
any. If we fail to comply with the regulatory requirements of the FDA, and other applicable U.S. and foreign regulatory authorities, or previously unknown
problems with any approved commercial products, manufacturers or manufacturing processes are discovered, we could be subject to administrative or
judicially imposed sanctions or other setbacks, including the following:
●
●
●
●
●
●
suspension or imposition of restrictions on operations, including costly new manufacturing requirements;
refusal to approve pending applications or supplements to applications;
suspension of any ongoing clinical trials;
suspension or withdrawal of marketing approval;
an injunction or imposition of civil or criminal penalties or monetary fines;
seizure or detainment of products;
22
●
●
●
●
banning or restriction of imports and exports;
issuance of warning letters or untitled letters;
suspension or imposition of restrictions on operations, including costly new manufacturing requirements; or
refusal to approve pending applications or supplements to applications.
In addition, various aspects of our operations are subject to federal, state or local laws, rules and regulations, any of which may change from time
to time. Costs arising out of any regulatory developments could be time-consuming and expensive and could divert management resources and attention
and, consequently, could adversely affect our business operations and financial performance.
Delays in regulatory approval, limitations in regulatory approval and withdrawals of regulatory approval may have a material adverse effect on us.
If we experience significant delays in testing or receiving approvals or sign-offs to conduct clinical trials, Aramchol or any other product candidate
development costs will increase and our ability to out-license our product candidates may be impeded.
If we obtain approval to commercialize any product candidate outside of the United States or out-license a product candidate to additional territories
outside the United States, a variety of risks associated with international operations could materially adversely affect our business.
If any product candidate is approved for commercialization outside the United States or we out-license a product candidate to additional territories
outside the United States, we will likely enter into agreements with third parties to commercialize a product candidate outside the United States. We expect
that we will be subject to additional risks related to entering into or maintaining international business relationships, including, without limitation:
●
●
●
●
●
●
●
●
●
●
●
different regulatory requirements for drug approvals in foreign countries;
differing U.S. and foreign drug import and export rules;
reduced protection for intellectual property rights in foreign countries;
unexpected changes in tariffs, trade barriers and regulatory requirements;
different reimbursement systems;
economic weakness, including inflation, or political instability in particular foreign economies and markets;
compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to
doing business in another country;
workforce uncertainty in countries where labor unrest is more common than in the United States;
production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;
potential liability resulting from development work conducted by these distributors;
23
●
●
business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters, emergence of a pandemic, or
other widespread health emergencies (or concerns over the possibility of such an emergency, including for example, the COVID-19
pandemic); and
risks associated with clinical co-development agreements in other jurisdictions prior to or post-regulatory approval.
A failure to timely and effectively address the additional risks related to entering into or maintaining international business relationships could
have a material adverse effect on our business, liquidity, operating results and financial condition.
If we receive marketing approval for a product candidate, sales will be limited unless the product achieves broad market acceptance.
The commercial success of a product candidate for which we obtain marketing approval from the FDA, or other regulatory authorities, will
depend on the breadth of its approved labeling and upon the acceptance of the product by the medical community, including physicians, patients and
healthcare payors. The degree of market acceptance of any approved product will depend on a number of factors, including, without limitation:
●
●
●
●
●
●
●
●
●
●
●
demonstration of clinical safety and efficacy compared to other products;
ability of physicians to accurately diagnose NASH in its early stages;
the relative convenience and ease of administration;
the prevalence and severity of any adverse side effects;
limitations, warnings or contraindications contained in the product’s approved labeling;
distribution and use restrictions imposed by the FDA, or other regulatory agencies, or agreed to by us as part of a mandatory or voluntary
REMS;
availability of alternative treatments, including, any competitive products already approved or expected to be commercially launched in
the near future;
pricing and cost effectiveness;
the effectiveness of our, or any future collaborators’, sales and marketing strategies;
our ability to obtain sufficient third-party coverage or reimbursement; and
the willingness of patients to pay for drugs out of pocket in the absence of third-party coverage.
If a product candidate is approved, but does not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not
generate sufficient revenue from the product, and we may not become profitable. In addition, our efforts to educate the medical community and third-party
payors on the benefits of the product may require significant resources and may never be successful.
24
The FDA and other regulatory agencies may actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found to
have improperly promoted off-label uses, we may become subject to significant liability.
The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products. In particular, a
product may not be promoted for uses that are inconsistent with the FDA-approved indications and other conditions or restrictions contained in the
approved labeling, including the prescribing information, for the product. In particular, any labeling approved by FDA or other foreign regulatory agencies
for a product candidate necessarily limits its use for certain conditions in certain patient populations. Also, regulatory agencies may impose further
requirements or restrictions on the distribution or use of Aramchol, Amilo-5MER or any other product candidate as part of a mandatory plan, such as
limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-
use criteria and requiring treated patients to enroll in a registry. If we receive marketing approval for a product candidate, physicians may nevertheless
prescribe the product candidate to their patients in a manner that is inconsistent with the approved labeling, which is commonly known as “off label” use. If
we are found to have promoted any product candidate for such “off label” uses, we may become subject to significant liability under a variety of statutory
theories typically alleged by U.S. regulatory authorities. In particular, the U.S. federal government has levied large civil and criminal fines against
companies for alleged improper promotion, has enjoined several companies from engaging in off-label promotion, and has requested that companies enter
into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.
Our business and operations may be materially adversely affected in the event of computer system failures or security or breaches due to cyber-attacks
or cyber intrusions, including ransomware, phishing attacks and other malicious intrusions.
In recent years, cybersecurity threats have become a greater risk and focus for companies. In particular, ransomware attacks, where a hacker locks
and threatens to delete or disclose the victim’s data unless a ransom is paid, has become a major risk. We and those of our CROs and other third parties on
which we rely are at risk of cyber-attacks or cyber intrusions via the Internet, computer viruses, break-ins, malware, ransomware, phishing attacks, hacking,
denial-of-service attacks or other attacks and similar disruptions from the unauthorized use of, or access to, computer systems (including from internal and
external sources). These types of incidents continue to be prevalent and pervasive across industries, including in our industry. In addition, we expect
information security risks to continue to increase due to the proliferation of new technologies and the increased sophistication and activities of organized
crime, hackers, terrorists and other external parties, including foreign state actors.
Despite the implementation of security measures, our internal computer systems, and those of our CROs and other third parties on which we rely,
are vulnerable to damage from computer viruses, unauthorized access, cyber-attacks, cyber intrusions, natural disasters, fire, terrorism, war, and
telecommunication and electrical failures. If such an event were to occur and interrupt our operations, it could result in a material disruption of our drug
development programs and inflict reputational harm upon us that may result in decreased market value and erode public trust. For example, the loss of
clinical trial data from ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to
recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, loss of trade
secrets or inappropriate disclosure of confidential or proprietary information, including protected health information or personal data of employees or
former employees, access to our clinical data, or disruption of the manufacturing process, we could incur liability and the further development of our drug
candidates could be delayed.
We may be subject to extensive environmental, health and safety, and other laws and regulations in multiple jurisdictions.
Our business involves the controlled use, through our service providers, of hazardous materials, various biological compounds and chemicals, and
as such, we, our agents and our service providers may be subject to various environmental, health and safety laws and regulations, including those
governing air emissions, water and wastewater discharges, noise emissions, the use, management and disposal of hazardous, radioactive and biological
materials and wastes and the cleanup of contaminated sites. The risk of accidental contamination or injury from these materials cannot be eliminated. If an
accident, spill or release of any regulated chemicals or substances occurs, we could be held liable for resulting damages, including for investigation,
remediation and monitoring of the contamination, including natural resource damages, the costs of which could be substantial. We may incur substantial
capital costs and operating expenses and may be required to obtain consents to comply with any environmental and health laws or regulations and the terms
and conditions of any permits required pursuant to such laws and regulations, including costs incurred by us to install new or updated pollution control
equipment for our service providers, modify our operations or perform other corrective actions at our facilities or the facilities of our service providers. In
addition, fines and penalties may be imposed on us, our agents and/or our service providers for noncompliance with environmental, health and safety and
other laws and regulations or for the failure to have, or comply with the terms and conditions of, required environmental or other permits or consents.
25
We expect the healthcare industry to face increased limitations on coverage of and reimbursement, rebates and other payments as a result of healthcare
reform, which could adversely affect third-party coverage of Aramchol, Amilo-5MER or any other product candidate and how much or under what
circumstances healthcare providers will prescribe or administer Aramchol, Amilo-5MER or any other product candidate.
In both the United States and other countries, sales of Aramchol Amilo-5MER or any other product candidate will depend in part upon coverage
of the product and the availability of reimbursement from third party payors, including governmental authorities, managed care organizations and other
private health insurers. Third-party payors are increasingly challenging the price and examining the coverage of products based on cost effectiveness of the
medical products and services.
Increasing expenditures for healthcare have been the subject of considerable public attention in the United States. Both private and government
entities are seeking ways to reduce or contain healthcare costs. Numerous proposals that would effect changes in the U.S. healthcare system have been
introduced or proposed in the U.S. Congress, or Congress, and in some state legislatures, including reducing reimbursement for prescription products and
reducing the levels at which consumers and healthcare providers are reimbursed for purchases of pharmaceutical products.
In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the Modernization Act, changed the way
Medicare covers and pays for most pharmaceutical products in a number of ways. Medicare is the single largest third-party payment program and is
administered by the Centers for Medicare & Medicaid Services, or the CMS. Medicare traditionally covered prescription drugs administered by physicians.
The Modernization Act introduced a new reimbursement methodology based on average sales prices for many of these drugs. The Modernization Act also
established a new competitive acquisition program for the purchase of Part B drugs. This program, when fully implemented, will likely reduce the prices of
these drugs. While the Medicare provisions of the Modernization Act apply only to drug benefits for Medicare beneficiaries, private payors often follow
Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from
federal legislation or regulation may result in a similar reduction in payments from private payors.
Most notably, the Modernization Act also expanded coverage through a new Part D to include ordinary self-administered outpatient drugs.
Medicare part D though operates through private insurers, and these insurers negotiate prices with pharmacies and with manufacturers. Intense negotiations
can result in reduced revenues to manufacturers.
Increasing expenditures for healthcare have been the subject of considerable public attention in the United States. Both private and government
entities are seeking ways to reduce or contain healthcare costs. Numerous proposals that would effect changes in the U.S. healthcare system have been
introduced or proposed in U.S. Congress, and in some state legislatures, including reducing reimbursement for prescription products and reducing the
levels at which consumers and healthcare providers are reimbursed for purchases of pharmaceutical products.
In March 2010, President Barack Obama signed into law the Patient Protection and Affordable Care Act and the Health Care and Education
Affordability Reconciliation Act of 2010, or the Affordable Care Act, a sweeping law intended to broaden access to health insurance, reduce or constrain
the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance
industries, impose new taxes and fees on pharmaceutical and medical device manufacturers and impose additional health policy reforms. The Affordable
Care Act expanded manufacturers’ Medicaid rebate liability to include covered drugs dispensed to individuals who are enrolled in Medicaid managed care
organizations, increased the minimum rebate due for innovator drugs from 15.1% of average manufacturer price, or the AMP, to 23.1% of AMP. The rebate
on innovator drugs is the greater of 23.1% of the AMP per unit or the difference between the AMP and the best price per unit and adjusted by the
Consumer Price Index-Urban (CPI-U) based on a launch date and current quarter AMP. The total rebate amount for innovator drugs is capped at 100.0% of
AMP. The Affordable Care Act and subsequent legislation also narrowed the definition of AMP. Furthermore, the Affordable Care Act imposes a
significant annual, nondeductible fee on companies that manufacture or import certain branded prescription drug products. The Affordable Care Act
appears likely to continue to put pressure on pharmaceutical pricing, especially under the Medicare and Medicaid programs, and may also increase our
regulatory burdens and operating costs.
26
There have been judicial and congressional challenges to the Affordable Care Act. If successful in the challenges, many if not all of the provisions
of the PPACA may no longer apply to prescription drugs. While we are unable to predict what changes may ultimately be enacted, to the extent that future
changes affect how any future products are paid for and reimbursed by government and private payers our business could be adversely impacted. On
December 14, 2018, a federal district court in Texas ruled that the PPACA is unconstitutional as a result of the Tax Cuts and Jobs Act, the federal income
tax reform legislation previously passed by Congress and signed by President Trump on December 22, 2017, that eliminated the individual mandate portion
of the PPACA. The case, Texas, et al, v. United States of America, et al., (N.D. Texas), is an outlier, and the ruling has been stayed by the ruling judge, but
in 2019, the Fifth Circuit Court of Appeals subsequently upheld the lower court decision which was then appealed to the United States Supreme Court. The
U.S. Supreme Court declined to hear the appeal on an expedited basis and so no decision is expected until sometime in 2021 before the end of the next
Supreme Court’s current term in early 2021. We are not able to state with any certainty what will be the impact of this court decision on our business
pending further court action and possible appeals. In November 2020, Joseph Biden was elected President and, in January 2021, the Democratic Party
obtained control of the Senate. As a result of these electoral developments, it is unlikely that continued legislative efforts will be pursued to repeal PPACA.
Instead, it is possible that executive and regulatory initiatives, as well as legislation will be pursued to enhance or reform PPACA. We are not able to state
with certainty what the impact of potential legislation will be on our business.
In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. In August 2011, President
Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend
to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of an amount greater than $1.2
trillion for the years 2013 through 2021, triggering the legislation’s automatic reduction to several government programs. This includes aggregate
reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, starting in 2013. These reductions will stay in effect through 2030
unless additional congressional action is taken. However, COVID-19 relief legislation suspended the 2% Medicare sequester from May 1, 2020 through
March 31, 2021. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced
Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments
to providers from three to five years. If we ever obtain regulatory approval and commercialization of Aramchol or any other product candidate, these laws
may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our customers and accordingly,
our financial operations. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional
activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance
or interpretations will be changed, or what the impact of such changes on the marketing approvals of Aramchol or any other product candidate may be.
Further, the Deficit Reduction Act of 2010, directed CMS to contract a vendor to determine “retail survey prices for covered outpatient drugs that represent
a nationwide average of consumer purchase prices for such drugs, net of all discounts and rebates (to the extent any information with respect to such
discounts and rebates is available).” This survey information can be used to determine the National Average Drug Acquisition Cost, NADAC. Some states
have indicated that they will reimburse based on the NADAC and this can result in further reductions in the prices paid for various outpatient drugs.
Various states, such as California and Florida, have also taken steps to consider and enact laws or regulations that are intended to increase the
visibility of the pricing of pharmaceutical products with the goal of reducing the prices at which pharmaceutical products are sold. On August 16, 2022,
President Biden signed into law the Inflation Reduction Act of 2022 that contains significant reforms affecting the pricing of drugs and biologics paid by
Medicare. The new requirements establish a timeline for certain drugs to negotiate with the federal government a “maximum fair price” for certain selected
drugs beginning in 2026. The numbers of drugs, as well as the selection criteria, is established for each year. Because these various actual and proposed
legislative changes are intended to operate on a state-by-state level and the new national law, we cannot predict what the full effect of state legislative
activities, and the IRA may be on our business in the future.
27
Although we cannot predict the full effect on our business of the implementation of existing legislation or the enactment of additional legislation
pursuant to healthcare and other legislative reform, we believe that legislation or regulations that would reduce reimbursement for, or restrict coverage of,
Aramchol or any other product candidate, could adversely affect how much or under what circumstances healthcare providers will prescribe or administer
our products. This could materially and adversely affect our business by reducing our ability to generate revenue, raise capital, obtain additional
collaborators and market Aramchol or any other product candidate. In addition, we believe the increasing emphasis on managed care in the United States
has and will continue to put pressure on the price and usage of pharmaceutical products, which may adversely impact any other product sales.
It will be difficult for us to profitably sell any product candidate if reimbursement for the product is limited by government authorities and third-party
payor policies.
In addition to any healthcare reform measures that may affect reimbursement, the market acceptance and sales of any product candidate will
depend on the reimbursement policies of government authorities and third-party payors. It will be difficult for us to profitably sell a product candidate if
reimbursement for the product is limited by government authorities or third-party payors. Government authorities and third-party payors, such as private
health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in
the U.S. healthcare industry and elsewhere is cost containment. Government authorities and these third-party payors have attempted to control costs by
limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage or reimbursement will be available for any
product candidate and, if coverage and reimbursement are available, of the extent of coverage and the level of reimbursement. Reimbursement may affect
the demand for, or the price of, any product for which we obtain marketing approval. In addition, third-party payors are likely to impose strict requirements
for reimbursement in order to limit off-label use of a higher priced drug. Reimbursement by a third-party payor may depend upon a number of factors
including the third-party payor’s determination that use of a product is:
●
●
●
●
●
a covered benefit under its health plan;
safe, effective and medically necessary;
appropriate for the specific patient;
cost-effective; and
neither experimental nor investigational.
Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly
process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of a product candidate to the payor. We may
not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. We cannot be sure that coverage or adequate
reimbursement will be available for any product candidates. Also, we cannot be sure that reimbursement amounts will not reduce the demand for, or the
price of, any product candidates. If reimbursement is not available, or is available only to limited levels, we may not be able to commercialize any product
candidates, profitably, or at all, even if approved. In addition, if physicians, government agencies and other third-party payors do not accept the use or
efficacy of any product candidates, we will not be able to generate significant revenue, if any.
Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any.
In some countries, particularly the countries of the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these
countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain
reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of Aramchol or
any other product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at
unsatisfactory levels, our business could be harmed, possibly materially.
28
If we or any of our independent contractors, consultants, collaborators, manufacturers, or service providers fail to comply with healthcare and data
privacy laws and regulations, we or they could be subject to enforcement actions, which could result in penalties and affect our ability to develop,
market and sell Aramchol or any other product candidate and may harm our reputation.
We are or may in the future be subject to federal, state, and foreign healthcare and data privacy laws and regulations pertaining to, among other
things, fraud and abuse of patients’ rights. These laws and regulations include:
●
●
●
●
The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully soliciting, offering, receiving, or paying any
remuneration, directly or indirectly, in cash or in kind, to induce or reward purchasing, ordering or arranging for or recommending the purchase or
order of any item or service for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and
Medicaid. Liability may be established without a person or entity having actual knowledge of the federal Anti-Kickback Statute or specific intent
to violate it. This statute has been interpreted to apply broadly to arrangements between pharmaceutical manufacturers on the one hand and
prescribers, patients, purchasers and formulary managers on the other. In addition, the Affordable Care Act amended the Social Security Act to
provide that the U.S. government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback
Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. A conviction for violation of the Anti-kickback
Statute requires mandatory exclusion from participation in federal health care programs. Although there are a number of statutory exemptions and
regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and those
activities may be subject to scrutiny or penalty if they do not qualify for an exemption or safe harbor.
The federal civil False Claims Act, or FCA, prohibits, among other things, knowingly presenting, or causing to be presented claims for payment of
government funds that are false or fraudulent, or knowingly making, using or causing to be made or used a false record or statement material to
such a false or fraudulent claim, or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay
money to the federal government. This statute also permits a private individual acting as a “whistleblower” to bring actions on behalf of the
federal government alleging violations of the FCA and to share in any monetary recovery. The FCA prohibits anyone from knowingly presenting,
conspiring to present, making a false statement in order to present, or causing to be presented, for payment to federal programs (including
Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent, claims for items or services not provided as
claimed, or claims for medically unnecessary items or services. This law also prohibits anyone from knowingly underpaying an obligation owed to
a federal program. Increasingly, U.S. federal agencies are requiring nonmonetary remedial measures, such as corporate integrity agreements in
FCA settlements. The U.S. Department of Justice announced in 2016 its intent to follow the “Yates Memo,” taking a far more aggressive approach
in pursuing individuals as FCA defendants in addition to the corporations. FCA liability is potentially significant in the healthcare industry
because the statute provides for treble damages and mandatory penalties assessed on a per false claim or statement basis. Government enforcement
agencies and private whistleblowers have investigated pharmaceutical companies for or asserted liability under the FCA for a variety of alleged
promotional and marketing activities, such as providing free product to customers with the expectation that the customers would bill federal
programs for the product; providing consulting fees and other benefits to physicians to induce them to prescribe products; engaging in promotion
for “off-label” uses; and submitting inflated best price information to the Medicaid Rebate Program.
The federal False Statements Statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making any
materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to
contain any materially false, fictitious or fraudulent statement or entry, in connection with the delivery of or payment for healthcare benefits,
items, or services.
The federal Civil Monetary Penalties Law authorizes the imposition of substantial civil monetary penalties against an entity, such as a
pharmaceutical manufacturer, that engages in activities including, among others (1) knowingly presenting, or causing to be presented, a claim for
services not provided as claimed or that is otherwise false or fraudulent in any way; (2) arranging for or contracting with an individual or entity
that is excluded from participation in federal healthcare programs to provide items or services reimbursable by a federal healthcare program; (3)
violations of the federal Anti-Kickback Statute; or (4) failing to report and return a known overpayment.
29
●
●
●
The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for knowingly and
willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying,
concealing or covering up a material fact or making any materially false statement in connection with the delivery of, or payment for, healthcare
benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or
specific intent to violate it in order to have committed a violation.
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH), which imposes requirements on
certain types of people and entities relating to the privacy, security, and transmission of individually identifiable health information, requires
notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information.
The federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which
payment is available under Medicare, Medicaid, or the Children’s Health Insurance Program, to report annually to the Centers for Medicare &
Medicaid Services (CMS) information related to payments and other transfers of value to physicians (defined to include doctors, dentists,
optometrists, podiatrists and chiropractors) and teaching hospitals, and ownership and investment interests held by physicians and other healthcare
providers and their immediate family members, which is published in a searchable form on an annual basis. Effective January 1, 2022, covered
manufacturers will also be required to report on payments and other transfers of value to physician assistants, nurse practitioners or clinical nurse
specialists, anesthesiologist assistants, certified registered nurse anesthetists, and certified nurse-midwives during the previous year.
●
●
●
●
●
●
State laws comparable to each of the above federal laws, such as, for example, anti-kickback and false claims laws that may be broader in
scope and also apply to commercial insurers and other non-federal.
Payors requirements for mandatory corporate regulatory compliance programs, and laws relating to patient data privacy and security.
Other state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the
relevant compliance guidance promulgated by the federal government; require drug manufacturers to report information related to
payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws
govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways
and often are not preempted by HIPAA, thus complicating compliance efforts.
In the European Union, the General Data Protection Regulation, or GDPR,—Regulation EU 2016/679—was adopted in May 2016 and
became applicable on May 25, 2018, or GDPR. The GDPR further harmonizes data protection requirements across the European Union
member states by establishing new and expanded operational requirements for entities that collect, process or use personal data generated
in the European Union, including consent requirements for disclosing the way personal information will be used, information retention
requirements, and notification requirements in the event of a data breach.
In the United Kingdom, following the UK’s exit from the European Union on 31 December 2020, the GDPR continues to form part of the
law in the UK with some amendments (UK GDPR). There is a risk of divergence in the future, which may increase our overall data
protection compliance costs.
The California Consumer Privacy Act of 2018, or CCPA, effective as of January 1, 2020, gives California residents expanded rights to
access and require deletion of their personal information, opt out of certain personal information sharing, and receive detailed information
about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for
data breaches, that is expected to increase data breach litigation.
In addition, failure to comply with the Israeli Privacy Protection Law of 1981, and its regulations, as well as the guidelines of the Israeli
Privacy Protection Authority, may expose us to administrative fines, civil claims (including class actions) and in certain cases criminal
liability. Current pending legislation may result in a change of the current enforcement measures and sanctions.
30
If our operations are found to be in violation of any such health care laws and regulations, we may be subject to penalties, including significant
administrative, civil and criminal penalties, monetary damages, disgorgement, imprisonment, the curtailment or restructuring of our operations, loss of
eligibility to obtain approvals from the FDA or foreign regulatory authorities, or exclusion from participation in government contracting, healthcare
reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely our financial results. Any action against us
for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management’s attention from the operation of
our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in
terms of money, time and resources.
Our employees, principal investigators, consultants, commercial partners or vendors may engage in misconduct or other improper activities, including
non-compliance with regulatory standards.
We are also exposed to the risk of employees, independent contractors, principal investigators, consultants, commercial partners or vendors
engaging in fraud or other misconduct. Misconduct by employees, independent contractors, principal investigators, consultants, commercial partners and
vendors could include intentional failures to comply with EU or UK regulations, to provide accurate information to the EMA, MHRA or EU Member
States authorities or to comply with manufacturing or quality standards we have or will have established. In particular, sales, marketing and business
arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and
other abusive practices such as promotion of products by medical practitioners. The EU Member States in which we operate have different statutory
provisions regulating the cooperation of pharmaceutical companies with healthcare professionals. In addition to these statutory provisions, codes of
conduct issued by business associations or other non-statutory standards may be applicable to our activities. Both statutory provisions and non-statutory
codes or standards restrict payments or other benefits provided to healthcare professionals, and in case of non-compliance, may result in severe sanctions
such as bans, administrative fines, criminal fines or even imprisonment. The advertising of medicinal products for human use in the EU is regulated by
Title VIII of European Directive 2001/83/EC, as amended. These provisions have been implemented into the law of the EU member States. Such laws inter
alia restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business
arrangements. Misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory
sanctions and serious and irreparable harm to our reputation.
This could also apply with respect to data privacy. In the EU (at that time including the United Kingdom), the EU Directive 95/46/EEC was
replaced by the GDPR on May 25, 2018. The GDPR as an EU regulation does not have to be implemented into Member States’ national law, but applies
directly in all Member States since May 25, 2018. It applies to companies with an establishment in the European Economic Area (EEA) and to certain other
companies not in the EEA that offer or provide goods or services to individuals located in the EEA or monitor individuals located in the EEA. The GDPR
implements more stringent operational requirements for controllers of personal data, including, for example, expanded disclosures about how personal
information is to be used, limitations on retention of information, increased requirements pertaining to health data and pseudonymized (i.e., key-coded)
data, increased cyber security requirements, mandatory data breach notification requirements and higher standards for controllers to demonstrate that they
have obtained a valid legal basis for certain data processing activities. The GDPR provides that EU Member States may continue to make their own further
laws and regulations in relation to the processing of genetic, biometric or health data, which could result in continued or new differences between Member
States, limit our ability to use and share personal data or could cause our costs to increase, and harm our business and financial condition. The GDPR
continues to form part of law in the United Kingdom with some amendments following the United Kingdom’s exit from the European Union on 31
December 2020 (UK GDPR) although there is a risk of divergence in the future which may increase our overall data protection compliance cost. We are
also subject to evolving and strict rules on the transfer of personal data out of the European Union and United Kingdom to the United States. Further
prospective revision of the Directive on privacy and electronic communications (Directive 2002/58/EC, as amended), or ePrivacy Directive, and equivalent
United Kingdom Legislation may affect our marketing communications.
31
We have implemented procedures to ensure compliance with the GDPR and UK GDPR and its requirements. Our actual or alleged failure to
comply with this regulation, or to protect personal data, could result in enforcement actions and significant penalties against us, which could result in
negative publicity, increase our operating costs, subject us to claims or other remedies and have a material adverse effect on our business, financial
condition, and results of operations. It is not always possible to identify and deter misconduct by employees or other parties. The precautions we take to
detect and prevent such activity may not protect us from legal or regulatory action resulting from a failure to comply with applicable laws or regulations.
Misconduct by our employees, principal investigators, consultants, commercial partners or vendors could result in significant financial penalties, criminal
sanctions, civil law claims and/or negative media coverage, and thus have a material adverse effect on our business, including through the imposition of
significant fines or other sanctions, and our reputation. In particular, failure to comply with EU laws, including failure under the GDPR, UK GDPR,
ePrivacy Directive and other laws relating to the security of personal data may result in fines up to €20,000,000 or up to 4% of the total worldwide annual
turnover of the preceding financial year, if greater, and other administrative penalties including criminal liability, which may be onerous and adversely
affect our business, financial condition, results of operations and prospects. Failure to comply with the GDPR, UK GDPR and related laws may also give
risk to increase risk of private actions, including a new form of class action that is available under the GDPR and UK GDPR.
If we or our manufacturers fail to comply with manufacturing regulations, our financial results and financial condition could be adversely affected.
Before an NDA is approved, and before we begin the commercial manufacture of any product candidate, contract manufacturers must register
with FDA or foreign regulators undergo regulatory inspection of their manufacturing facilities, processes and quality systems. In addition, pharmaceutical
manufacturing facilities are subject to periodic inspection by the FDA and foreign regulatory authorities after product approval. Due to the complexity of
the processes used to manufacture pharmaceutical products and product candidates, any potential third-party manufacturer may be unable to meet local,
federal, or international regulatory requirements either at the outset or on an ongoing basis, in a cost-effective manner, if at all.
We do not intend to engage in the manufacture of Aramchol or any other product candidate other than for pre-clinical and clinical studies, but we
or our materials suppliers may face manufacturing or quality control problems causing product production and shipment delays or a situation where we or
the supplier may not be able to maintain compliance with the FDA’s or foreign regulators’ requirements necessary to continue manufacturing Aramchol or
any other product candidate. Drug manufacturers are subject to ongoing periodic unannounced inspections by the FDA and corresponding foreign
regulators to ensure continuing compliance with applicable requirements. Any failure to comply with FDA or foreign regulatory requirements could
adversely affect our clinical research activities and our ability to develop and market Aramchol or any other product candidate.
If a third-party manufacturer with whom we contract is unable to comply with manufacturing requirements, we may be subject to fines,
unanticipated compliance expenses, recall or seizure of Aramchol or any other product candidate, total or partial suspension of production and/or
enforcement actions, including injunctions, and criminal or civil prosecution. These possible sanctions could adversely affect our financial results and
financial condition.
Our market is subject to intense competition. If we are unable to compete effectively, Aramchol, Amilo-5MER or any other product candidate that we
develop may be rendered suboptimal, noncompetitive or obsolete.
There are a number of products in development for our target indications, many of which are being developed by pharmaceutical companies that
are far larger than us, with significantly greater resources and more experience than us in all aspects of drug development and commercialization. Further,
our industry is highly competitive and subject to rapid and significant technological change. Our potential competitors include large, fully-integrated
pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and
research institutions. All of these competitors currently engage in, have engaged in or may engage in the future in the development, manufacturing,
marketing and commercialization of new pharmaceuticals, some of which may compete with Aramchol, Amilo-5MER or other product candidates. Smaller
or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies.
These companies may have products in development that are superior to any Aramchol or any other product candidate. Key competitive factors affecting
the commercial success of Aramchol or any other product candidate that we develop are likely to be efficacy, time of onset, safety and tolerability profile,
reliability, convenience of dosing, price and reimbursement.
32
Many of our potential competitors have substantially greater financial, technical and human resources than we do and significantly greater
experience in the discovery and development of drug candidates, obtaining FDA and other regulatory approvals of products and the commercialization of
those products. Accordingly, our competitors may be more successful than us in obtaining FDA and other marketing approvals for drugs and achieving
widespread market acceptance. Our competitors’ drugs may be more effective, or more effectively marketed and sold, than any drug we may
commercialize and may render the product candidates that we develop suboptimal, obsolete or non-competitive before we can recover the expenses of
developing and commercializing the product. We anticipate that we will face intense and increasing competition as new drugs enter the market and
advanced technologies become available. Finally, the development of new treatment methods for the diseases we are targeting could render Aramchol or
any other product candidate that we develop, non-competitive or obsolete. If we cannot successfully compete with new or existing products, our marketing
and sales will suffer and we may never be profitable.
Our competitors in the NASH field currently include companies with marketed products and/or advanced clinical programs. Our main competitors
of Aramchol include, but are not limited to Novo Nordisk, Akero Therapeutics, Inc., Inc., Madrigal Pharmaceuticals Inc., and Viking Therapeutics among
others. In March 2024, Madrigal Pharmaceuticals announced FDA approval of Rezdiffra (resmetirom) for the treatment of NASH with moderate to
advanced liver fibrosis. See also “Item 4. Information on the Company—Competition.” Moreover, several additional companies have reported the
commencement of research projects and proof-of-concept trials related to our target indications, including those mentioned in the preceding sentence.
We operate in a competitive sector. Several companies are working on technologies, therapeutic targets or drug or biomarker candidates that aim
to treat or diagnose the same diseases or identify the same patient population as our product candidates. While we believe that our drug candidates and
diagnostic solutions, combined with our expertise and know-how, provide us with competitive advantages, we face potential competition from various
sources, including pharmaceutical and biotechnology companies, as well as from academic institutions, governmental agencies and public and private
research institutions. We anticipate that we will face intense and increasing competition as new drugs and therapies enter the market and advanced
technologies become available. In some indications, off-label use of non-approved drugs can also be considered as competition.
We face potential product and other liability exposure, and, if claims are brought against us, we may incur substantial liability.
Our product candidates could cause adverse events. These adverse events may not be observed in clinical trials, but may nonetheless occur in the
future. If any of these adverse events occur, they may render Aramchol or any other product candidate ineffective or harmful in some patients, and our sales
would suffer, materially adversely affecting our business, financial conditions and results of operations.
In addition, potential adverse events caused by Aramchol or any other product candidate, could lead to product liability claims. Product liability
claims might be brought against us by consumers, healthcare providers or others coming into contact with Aramchol or any other product candidate. If we
cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities. In addition, regardless of merit or eventual
outcome, product liability claims may result in, among other things:
●
●
decreased demand for our product candidate for which we obtain marketing approval;
impairment of our business reputation and exposure to adverse publicity;
33
●
●
●
●
●
●
●
increased warnings on product labels or other regulatory actions;
withdrawal of clinical trial participants;
costs of related litigation;
distraction of management’s attention from our primary business;
substantial monetary awards to patients or other claimants;
loss of revenue; and
the inability to successfully commercialize any product candidates, for which we obtain marketing approval.
If we are unable to obtain adequate insurance with respect to our clinical trials against and from any losses or claims from third parties, our
financial condition could be adversely affected in the event of uninsured or inadequately insured loss or damage. We may not be able to obtain insurance
policies on terms affordable to us that would adequately cover loss or claims by third parties. To the extent our business suffers any losses or claims by
third parties, which are not covered, or adequately covered, by insurance, our financial condition may be materially adversely affected.
If product liability lawsuits are successfully brought against us, our insurance may be inadequate.
We have obtained insurance coverage for our clinical trials in accordance with market standards and in compliance with applicable Israeli law.
However, our insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is
becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to
protect us against losses due to liability. If and when we obtain marketing approval for any product candidate, we intend to expand our insurance coverage
to include the sale of commercial products; however, we may be unable to obtain this product liability insurance on commercially reasonable terms. On
occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. The cost of any product liability
litigation or other proceedings, even if resolved in our favor, could be substantial. A successful product liability claim, or series of claims, brought against
us could cause our share price to decline and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.
The product liability insurance we will need to obtain in connection with the commercial sales of any product candidate, if and when they receive
regulatory approval, may be unavailable in meaningful amounts or at a reasonable cost. If we are the subject of a successful product liability claim that
exceeds the limits of any insurance coverage we obtain, we would incur substantial charges that would adversely affect our earnings and require the
commitment of capital resources that might otherwise be available for the development and commercial launch of any product candidate’s programs.
We manage our business through a small number of senior executive officers. We depend on them even more than similarly- situated companies.
Because of the specialized scientific and managerial nature of our business, we rely heavily on our ability to recruit, attract, retain, manage and
motivate qualified senior executive officers with adequate operational, scientific and technical experience. The loss of the services of our senior executive
officers, including our President, Chief Executive Officer, or the inability to hire or retain experienced management personnel, could adversely affect our
ability to execute our business plan and harm our operating results. In particular, the loss of one or more of our senior executive officers could be
detrimental to us if we cannot recruit suitable replacements in a timely manner.
We do not currently carry “key person” insurance on the lives of members of senior management. The competition for qualified personnel in the
pharmaceutical field is intense. Due to this intense competition, we may be unable to attract and retain qualified personnel necessary for the development of
our business or to recruit suitable replacement personnel. Additionally, our ability to effectively recruit and retain qualified officers and directors could also
be adversely affected if we experience difficulty in obtaining adequate directors’ and officers’ liability insurance. We may be unable to maintain sufficient
insurance as a public company to cover liability claims made against our officers and directors. If we are unable to adequately insure our officers and
directors, we may not be able to retain or recruit qualified officers and directors to manage the Company.
34
Failure to build our finance infrastructure and improve our accounting systems and controls could impair our ability to comply with the financial
reporting and internal control requirements for publicly traded companies.
As a public company, we operate in an increasingly challenging regulatory environment which requires us to comply with the Sarbanes-Oxley Act
of 2002, or the Sarbanes-Oxley Act, and the related rules and regulations of the SEC and securities exchanges, expanded disclosures, accelerated reporting
requirements and more complex accounting rules. Company responsibilities required by the Sarbanes-Oxley Act include establishing corporate oversight
and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce
reliable financial reports and are important to help prevent financial fraud.
We are subject to the requirements of the Sarbanes-Oxley Act. Section 404 of the Sarbanes-Oxley Act requires companies subject to the reporting
requirements of the U.S. securities laws to do a comprehensive evaluation of its and its subsidiaries’ internal control over financial reporting. To comply
with this statute, we must document and test our internal control procedures and our management and issue a report concerning our internal control over
financial reporting. In addition, as long as we do not become an accelerated or large accelerated filer, we are exempt from the auditor attestation
requirements of Section 404(b) of the Sarbanes-Oxley Act. Under this exemption, our auditor will not be required to attest to and report on our
management’s assessment of our internal control over financial reporting until the date we are no longer a non-accelerated filer. We have an ongoing
program to perform the system and process evaluation and testing necessary to continue to comply with these requirements. During the course of our
review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a
material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be
materially misstated. We may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could
harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall.
To build our finance infrastructure, we may need to improve our accounting systems, disclosure policies, procedures and controls. If we are
unsuccessful in building an appropriate accounting infrastructure, we may not be able to prepare and disclose, in a timely manner, our financial statements
and other required disclosures, or comply with existing or new reporting requirements. Any failure to report our financial results on an accurate and timely
basis could result in sanctions, lawsuits, delisting of our shares from the Nasdaq Capital Market or other adverse consequences that would materially harm
our business. If we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed and investors could
lose confidence in our reported financial information.
We may need to significantly increase the size of our organization, and we may experience difficulties in managing growth.
Subject to our strategic review, we may experience rapid and substantial growth in order to achieve our operating plans, which will place a strain
on our human and capital resources. Successful implementation of our business plan will require management of growth, which will result in an increase in
the level of responsibility for management personnel. Any future growth will impose significant added responsibilities on members of management,
including the need to identify, recruit, maintain and integrate additional employees. To that end, we must be able to, among other things:
●
●
●
●
manage our clinical trials and the regulatory process effectively;
develop our administrative, accounting and management information systems and controls;
hire and train additional qualified personnel; and
integrate current and additional management, administrative, financial and sales and marketing personnel.
35
If we are unable to establish, scale-up and implement improvements to our control systems in an efficient or timely manner, or if we encounter
deficiencies in existing systems and controls, investors may choose not to invest in us, which could cause our share price to decline and negatively impact
our ability to successfully commercialize Aramchol or any other product candidate.
Failure to attract and retain sufficient numbers of talented employees will further strain our human resources and could impede our growth or
result in ineffective growth. If we are unable to manage our growth effectively, our losses could materially increase and it will have a material adverse
effect on our business, results of operations and financial condition.
Additional clinical trials may divert a significant amount of our resources and may ultimately be unsuccessful.
We are exploring the expansion of Aramchol for the treatment of other indications in order to expand our pipeline, commercial potential and
ultimately de-risk the Company for the success of any one given trial. If we initiate additional clinical trials, this may divert a significant amount of
Company resources and may be unsuccessful. The regulatory pathway may prove simpler than for NASH and as a result this may shift the priorities for
Aramchol in the future.
Environmental, social and corporate governance (ESG) issues, including those related to climate change and sustainability, may have an adverse effect
on our business, financial condition and results of operations and damage our reputation.
There is an increasing focus from certain investors, customers, consumers, employees and other stakeholders concerning ESG matters.
Additionally, public interest and legislative pressure related to public companies’ ESG practices continue to grow. If our ESG practices fail to meet
regulatory requirements or investor, customer, consumer, employee or other shareholders’ evolving expectations and standards for responsible corporate
citizenship in areas including environmental stewardship, support for local communities, Board of Director and employee diversity, human capital
management, employee health and safety practices, product quality, supply chain management, corporate governance and transparency, our reputation,
brand and employee retention may be negatively impacted, and our customers and suppliers may be unwilling to continue to do business with us.
Customers, consumers, investors and other shareholders are increasingly focusing on environmental issues, including climate change, energy and
water use, plastic waste and other sustainability concerns. Concern over climate change may result in new or increased legal and regulatory requirements to
reduce or mitigate impacts to the environment. Changing customer and consumer preferences or increased regulatory requirements may result in increased
demands or requirements regarding plastics and packaging materials, including single-use and non-recyclable plastic products and packaging, other
components of our products and their environmental impact on sustainability, or increased customer and consumer concerns or perceptions (whether
accurate or inaccurate) regarding the effects of substances present in certain of our products. Complying with these demands or requirements could cause
us to incur additional manufacturing, operating or product development costs.
If we do not adapt to or comply with new regulations, including the SEC’s newly adopted rules that require companies to provide expanded
climate-related disclosures in their periodic reporting, which may require us to incur significant additional costs to comply and impose increased oversight
obligations on our management and board of directors, or fail to meet evolving investor, industry or stakeholder expectations and concerns regarding ESG
issues, investors may reconsider their capital investment in our Company, we may become subject to penalties, and customers and consumers may choose
to stop purchasing our products, if approved for commercialization, which could have a material adverse effect on our reputation, business or financial
condition.
Our business is subject to risks arising from epidemic diseases, such as the COVID-19 pandemic, which has impacted and could continue to impact our
business.
Public health epidemics or outbreaks could adversely impact our business. In late 2019, a novel strain of COVID-19, also known as coronavirus,
was reported in Wuhan, China. Initially the outbreak was largely concentrated in China, but it rapidly spread to countries across the globe, including in
Israel and the United States. Many countries around the world, including in Israel and the United States, implemented significant governmental measures to
control the spread of the virus, including temporary closure of businesses, severe restrictions on travel and the movement of people, and other material
limitations on the conduct of business. In response, we implemented remote working and workplace protocols for our employees in accordance with Israeli
Ministry of Health requirements to ensure employees safety, experienced delays in recruitment to our ARMOR Study, and took several cost-reduction
measures.
36
If there is a resurgence of COVID-19 its spread may materially affect us economically. While the potential economic impact brought by, and the
duration of, any future resurgence of the COVID-19 pandemic may be difficult to assess or predict, it has already caused, and could result in further,
significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity and
financial position. In addition, the trading prices for other companies have been highly volatile as a result of the COVID-19 pandemic. As a result, we may
face difficulties raising capital through sales of our ordinary shares or other securities and such sales may be on unfavorable terms. To the extent that future
waves of COVID-19 disrupt normal business operations, we may face operational challenges with our services, and we likely will have to adopt remote
working and workplace protocols for employees in accordance with government requirements and other measures to minimize such impact, and we may,
subject to our strategic review, experience disruptions that could impact our business, clinical trials, and supply chains.
The extent to which COVID-19 impacts our operations will depend on future developments, which are highly uncertain and cannot be predicted
with confidence, including the duration and severity of the outbreak, and the actions that may be required to contain COVID-19 or treat its impact. In
particular, the extent to which any resurgence of the COVID-19 pandemic may impact our business and financial performance will depend on future
developments, which are highly uncertain and cannot be predicted with confidence. The impact of any resurgence of the COVID-19 pandemic may also
have the effect of heightening many of the other risks described in the “Risk Factors” section of this Annual Report on Form 20-F.
Risks Related to Our Reliance on Third Parties
We have no manufacturing capacity and anticipate reliance on third-party manufacturers for Aramchol, Amilo-5MER or any other product
candidates.
We do not currently operate manufacturing facilities for the production of Aramchol, Amilo-5MER or their API. We still have not, and may never,
develop facilities for the manufacture of product candidates or products for clinical trials or commercial purposes. We rely on third-party manufacturers to
produce bulk drug products required for our clinical trials. Our contract manufacturers have not completed commercial development and validation
processes of the Aramchol and Amilo-5Mer API and we have experienced delays in the development of the Aramchol meglumine formulation. Drug
product manufacturing processes may experience further difficulties and delays in production.
Additionally, if our contract manufacturers and their facilities, as applicable, are not approved by the FDA, or other applicable regulatory
authorities, our commercial supply of the drug substance will be significantly delayed and may result in significant additional costs. We purchase finished
Aramchol from a third-party under a clinical supply agreement. If we will be required to change the finished product manufacturer, we may encounter
significant delay and likely significant additional cost.
A failure by our contract manufacturer to achieve and maintain high manufacturing standards, in accordance with applicable good manufacturing
practices and other applicable regulatory requirements could result in patient injury or death, product shortages, product recalls or withdrawals, delays or
failures in product testing or delivery, cost overruns or other problems that could seriously harm our business. Contract manufacturers often encounter
difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel.
Our existing manufacturers and any future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing
business. In the event of a natural disaster, business failure, strike or other difficulty, we may be unable to replace a third-party manufacturer in a timely
manner and the production of our product candidates would be interrupted, resulting in delays and additional costs.
37
We intend to rely primarily on third parties to market and sell Aramchol, Amilo-5MER or any other product candidate.
We have no sales or distribution capabilities. To the extent we rely on third parties to commercialize Aramchol, Amilo-5MER or any other product
candidate, if marketing approval is obtained, we may receive less revenue than if we commercialize them ourselves. In addition, we would have less
control over the sales efforts of any third parties involved in our commercialization efforts. In the event we are unable to collaborate with a third-party
marketing and sales organization to commercialize Aramchol, Amilo-5MER or any other product candidate, particularly for broader patient populations,
our ability to generate revenue will be limited.
Although we may ultimately develop a marketing and sales force with technical expertise and supporting distribution capabilities in the longer
term, we do not currently intend to do so and, as such, we will be unable to market our product candidates directly in the near future. To promote any of our
potential products through third parties, we will have to locate acceptable third parties for these functions and enter into agreements with them on
acceptable terms, and we may not be able to do so. Any third-party arrangements we are able to enter into may result in lower revenues than we could
achieve by directly marketing and selling our potential products. In addition, to the extent that we depend on third parties for marketing and distribution,
any revenues we receive will depend upon the efforts of such third parties, as well as the terms of our agreements with such third parties, which cannot be
predicted in most cases at this time. As a result, we might not be able to market and sell our product candidates in the United States or overseas, which
would have a material adverse effect on us.
Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and
commercialize our current and potential other product candidates.
We intend to seek collaboration arrangements with pharmaceutical or biotechnology companies for the continued development and
commercialization of our current and potential other product candidates. We will face, to the extent that we decide to enter into collaboration agreements,
significant competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and time consuming to negotiate,
document and implement. We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements. The terms
of any collaborations or other arrangements that we may establish may not be favorable to us.
Any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the
efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to
these collaborations. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead
to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement.
These disagreements can be difficult to resolve if neither of the parties has final decision making authority. Moreover, collaborations with pharmaceutical
or biotechnology companies and other third parties are often terminated or allowed to expire by the other party. Any lack of effort or ability by our
collaborators or any such disagreement, termination or expiration could adversely affect us financially and could harm our business reputation.
We depend on third parties to conduct our clinical trials.
We rely on third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories to oversee
most of the operations of our clinical trials and to perform data collection and analysis. As a result, we may face additional delays outside of our control if
these parties do not perform their obligations in a timely fashion or in accordance with regulatory requirements. If these third parties do not successfully
carry out their contractual duties or obligations and meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data
they obtain is compromised due to the failure to adhere to our clinical protocols or for other reasons, our financial results and the commercial prospects for
Aramchol, Amilo-5MER or any other product candidate could be harmed, our costs could increase and our ability to obtain regulatory approval and
commence product sales could be delayed.
38
Risks Related to Our Intellectual Property
The failure to obtain or maintain patents, licensing agreements and other intellectual property rights that are sufficiently broad and protective could
impact our ability to compete effectively.
To compete effectively, we must develop and maintain a proprietary position with regard to our own technologies, intellectual property, licensing
agreements, product candidates and business. Legal standards relating to the validity and scope of claims in the biotechnology and biopharmaceutical fields
are still evolving. We cannot predict the scope and extent of patent protection for Aramchol, Amilo-5MER or any other product candidate because the
patent positions of pharmaceutical products are complex and uncertain. Therefore, the degree of future protection for our proprietary rights in our core
technologies and any product candidates or products that might be developed using these technologies is also uncertain. The risks and uncertainties that we
face with respect to our patents and other proprietary rights include, but are not limited to, the following:
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
while the patents we own have been issued, pending patent applications we have filed may not result in issued patents or may take longer
than we expect to result in issued patents;
we may be subject to interference, reexamination, inter pares review, or post-grant review proceedings in the U.S.;
we may be subject to opposition proceedings in certain foreign countries;
any patents that are issued may not provide meaningful protection for any significant period of time, if at all;
any issued patents may not be broad or strong enough to prevent competition from other products including identical or similar products;
we may not be able to develop additional proprietary technologies that are patentable;
there may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim;
there may be other patents or pending patent applications existing in the patent landscape that will affect our freedom to operate for our
product candidates;
other companies may challenge and invalidate patents licensed or issued to us or our customers;
a court could determine that a competitor’s technology or product does not infringe our patents;
other companies may independently develop similar or alternative technologies, or duplicate our technologies;
other companies may design around technologies we have licensed or developed;
if we are not awarded patents or if issued patents expire or are declared invalid or not infringed, there may be no protections against
competitors making generic equivalents;
enforcement of patents is complex, uncertain and expensive, and our patents may be found invalid or enforceable;
our patents could irretrievably lapse due to failure to pay fees or otherwise comply with regulations, or could be subject to compulsory
licensing; and
if we encounter delays in our development or clinical trials, the period of time during which we could market our product candidates
under patent protection would be reduced.
39
We cannot be certain that patents will be issued as a result of any of our pending applications, and we cannot be certain that any of our issued
patents, whether issued pursuant to our pending applications or licensed from third parties, will give us adequate protection from competing products. For
example, issued patents may be circumvented or challenged, declared invalid or unenforceable, or narrowed in scope. In addition, because publication of
discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain that we were the first to make our inventions or to
file patent applications covering those inventions. If any of our composition of matter patents, or pending applications, was subject to a successful
challenge or failed to issue, our business and competitive advantage could be significantly affected. Our current patents will expire or they may otherwise
cease to provide meaningful competitive advantage, and we may be unable to adequately develop new technologies and obtain future patent protection to
preserve our competitive advantage or avoid adverse effects on our business.
Subject to our strategic review, we plan to transition from Aramchol free acid to Aramchol meglumine (salt) in our double-blind, placebo-
controlled histology-based registrational part of the ARMOR Study and any other clinical trials of Aramchol. As part of our research and development
studies, we have confirmed that several Aramchol salts have improved solubility as compared to the existing form of Aramchol free acid. We have pending
patent applications and have been granted patents directed to composition of matter of Aramchol meglumine as well as a wide range of other salts.
There can be no assurance that the U.S. Patent and Trademark Office, or the USPTO, or any other foreign equivalent will issue any additional
patents based on the patent applications that we submitted to protect our Aramchol salts or Amilo-5MER, nor, should the USPTO or foreign equivalent
issue any patents to us with respect to the Aramchol salts or Amilo-5MER, that we will be provided with adequate protection against potentially
competitive products. Furthermore, if foreign equivalent issues us one or more patents for the Aramchol salts or Amilo-5MER or with respect to already
issued patents for the Aramchol salts or Amilo-5MER, there can be no assurance that the issued patents will be of any commercial value, or that private
parties or competitors will not successfully challenge these patents or circumvent these patents in the United States or their counterparts abroad. In the
absence of adequate patent protection, our business may be adversely affected by competitors who develop comparable technology or products and our
commercial prospects may be materially adversely affected.
Others may obtain issued patents that could prevent us from commercializing our product candidates or require us to obtain licenses requiring the
payment of significant fees or royalties in order to enable us to conduct our business. As to those patents that we have licensed, our rights depend on
maintaining our obligations to the licensor under the applicable license agreement, and we may be unable to do so.
In addition to patents and patent applications, we depend upon trade secrets and proprietary know-how to protect our proprietary technology. We
require our employees, consultants, advisors and collaborators to enter into confidentiality agreements that prohibit the disclosure of confidential
information to any other parties. We also require our employees and consultants to disclose and assign to us their ideas, developments, discoveries and
inventions. These agreements may not, however, provide adequate protection for our trade secrets, know-how or other proprietary information in the event
of any unauthorized use or disclosure.
Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years
from the PCT application. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our
product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or
biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such
candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us
with sufficient rights to exclude others from commercializing products similar or identical to ours.
40
We may not be able to enforce our intellectual property rights throughout the world. This risk is exacerbated for us because we expect Aramchol or
Aramchol meglumine and Amilo-5MER will be manufactured and used in a number of foreign countries.
The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies
have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. This risk is exacerbated for
us because we expect Aramchol or Amilo-5MER will be manufactured and used in a number of foreign countries.
The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property
protection, especially those relating to life sciences. This could make it difficult for us to stop the infringement of our other intellectual property rights. For
example, several foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, some
countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may
provide limited or no benefit.
Although most jurisdictions in which the Company has applied for, intends to apply for, or has been issued patents have patent protection laws
similar to those of the United States, some of them do not. For example, the Company expects to do business in South America, Eurasia, China and
Indochina in the future and the countries in these regions may not provide the same or similar protection as that provided in the United States.
Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other
aspects of our business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the
law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate protection for our technology and the
enforcement of intellectual property.
We may rely on third party patents.
We may not have rights under some patents or patent applications related to products we may commercialize in the future. Third parties may own
or control these patents and patent applications in the United States and abroad. Therefore, in some cases, to manufacture, sell or import some of our future
products, we or our collaborators may choose to seek, or be required to seek, licenses under third party patents issued in the United States and abroad or
under patents that might be issued from United States and foreign patent applications. In instances in which we must obtain a license for third party patents,
we may be required to pay license fees or royalties or both to the licensor. If licenses are not available to us on acceptable terms, we or our collaborators
may not be able to develop, manufacture, sell or import these products.
We may be unable to protect the intellectual property rights of third parties from whom we may license certain of our intellectual property or with
whom we have entered into other strategic relationships, which could have a material adverse effect on our business, results of operations and
financial condition.
Certain of our intellectual property rights may be licensed from third parties, including universities and strategic partners. Such third parties may
determine not to or fail to protect the intellectual property rights that we license from them and we may be unable to defend such intellectual property rights
on our own or we may have to undertake costly litigation to defend the intellectual property rights of such third parties. There can be no assurances that we
will continue to have proprietary rights to any of the intellectual property that we license from such third parties or otherwise have the right to use through
similar strategic relationships. Any loss or limitations on use with respect to such intellectual property licensed from third parties or otherwise obtained
from third parties with whom we have entered into strategic relationships could have a material adverse effect on our business, results of operations and
financial condition.
41
If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise
experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.
We may be party to license agreements with third parties and may need to obtain additional licenses from others to advance our research and
development activities or allow the commercialization product candidates we may identify and pursue. License agreements may impose various
development, diligence, commercialization, and other obligations on us. For example, we may be required to use commercially reasonable efforts to engage
in various development and commercialization activities with respect to licensed products, and satisfy specified milestone and royalty payment obligations.
In spite of our efforts, our licensors might conclude that we have materially breached our obligations under such license agreements and might therefore
terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license
agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would
have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and
commercialization of product candidates that we may identify. Any of the foregoing could have a material adverse effect on our competitive position,
business, financial conditions, results of operations, and prospects. Moreover, disputes may arise regarding intellectual property subject to a licensing
agreement, including:
●
●
●
●
●
●
the scope of rights granted under the license agreement and other interpretation-related issues;
the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to
the licensing agreement;
the sublicensing of patent and other rights under our collaborative development relationships;
our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our
licensors and us and our partners; and
the priority of invention of patented technology. In addition, the agreements under which we currently or in the future license intellectual
property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple
interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of
our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the
relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and
prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current
licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected
product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.
We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from
commercializing, or increase the costs of commercializing, Aramchol or Amilo-5MER or any other product candidate.
Our commercial success depends significantly on our ability to operate without infringing the patents and other intellectual property rights of third
parties. For example, there could be issued patents of which we are not aware that our product candidate infringes. There also could be patents that we
believe we do not infringe, but that we may ultimately be found to infringe. Moreover, patent applications are in some cases maintained in secrecy until
patents are issued. The publication of discoveries in the scientific or patent literature frequently occurs substantially later than the date on which the
underlying discoveries were made and patent applications were filed. Because patents can take many years to issue, there may be currently pending
applications of which we are unaware that may later result in issued patents that our product candidates infringe. For example, pending applications may
exist that provide support or can be amended to provide support for a claim that results in an issued patent that our product candidates infringes.
42
Third parties may assert that we are employing their proprietary technology without authorization. If a court held that any third-party patents are
valid, enforceable and cover any of our product candidates or their use, the holders of any of these patents may be able to block our ability to
commercialize any such product candidate unless we obtained a license under the applicable patents, or until the patents expire. In addition to litigation
proceedings which may be filed against us, we may not be able to enter into licensing arrangements or make other arrangements at a reasonable cost or on
reasonable terms. Any inability to secure licenses or alternative technology could result in delays in the introduction of our product candidates or lead to
prohibition of the manufacture or sale of products by us.
We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and
unsuccessful.
Competitors may infringe our patents or other intellectual property. Although we are not currently involved in any litigation, if we were to initiate
legal proceedings against a third party to enforce a patent covering our product candidates, the defendant could counterclaim that the patent covering our
product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or
unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including
lack of novelty, obviousness, written description or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone
connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The
outcome following legal assertions of invalidity and unenforceability is unpredictable.
Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the
priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to
attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially
reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or
interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In
addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical
trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our
product candidates to market.
Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of
our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of
hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a
material adverse effect on the price of our ordinary shares.
We may be unable to adequately prevent disclosure and unauthorized use of trade secrets and other proprietary information by third parties.
Our ability to obtain and maintain patent protection and trade secret protection for our intellectual property and proprietary technologies, our
product candidates and their uses is important to our commercial success. We rely on a combination of patent, copyright, trademark and trade secret laws,
non-disclosure and confidentiality agreements, licenses, assignment of inventions agreements and other restrictions on disclosure and use to protect our
intellectual property rights.
We also rely on trade secrets to protect our proprietary know-how and technological advances, especially where we do not believe patent
protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees,
consultants, outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information. These
agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized
disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. Costly and time-
consuming litigation could be necessary to enforce and determine the scope of our proprietary rights. Failure to obtain or maintain trade secret protection
could enable competitors to use our proprietary information to develop products that compete with our product candidates or cause additional material
adverse effects upon our competitive business position.
43
We cannot be certain that the steps that we have taken will prevent the misappropriation or other violation of our confidential information and
other intellectual property, particularly in foreign countries in which laws may not protect our proprietary rights as fully as in the United States and other
developed economies. Moreover, if we lose any key personnel, we may not be able to prevent the unauthorized disclosure or use of our technical
knowledge or other trade secrets by those former employees. If we are unable to maintain the security of our proprietary technology, this could materially
adversely affect our competitive advantage, business and results of operations.
Under applicable U.S. and Israeli law, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors
from benefiting from the expertise of some of our former employees. In addition, employees may be entitled to seek compensation for their inventions
irrespective of their agreements with us, which in turn could impact our future profitability.
We generally enter into non-competition agreements with our employees and certain key consultants, or our employment and consulting
agreements contain non-competition provisions. These agreements, to the extent they are in place and in effect, prohibit our employees and certain key
consultants, if they cease working for us, from competing directly with us or working for our competitors or clients for a limited period of time. We may be
unable to enforce these agreements under the laws of the jurisdictions in which our employees work and it may be difficult for us to restrict our competitors
from benefitting from the expertise our former employees or consultants developed while working for us. For example, Israeli courts have required
employers seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities of the former employee will
harm one of a limited number of material interests of the employer which have been recognized by the courts, such as the secrecy of a company’s
confidential commercial information or the protection of its intellectual property. If we cannot demonstrate that such interests will be harmed, we may be
unable to prevent our competitors from benefiting from the expertise of our former employees or consultants and our ability to remain competitive may be
diminished.
In addition, under the Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee in the course and as a result of or
arising from his or her employment with a company are regarded as “service inventions,” which belong to the employer, absent a specific agreement
between the employee and employer giving the employee service invention rights. The Patent Law also provides that if there is no such agreement between
an employer and an employee, the Israeli Compensation and Royalties Committee, or the Committee, a body constituted under the Patent Law, shall
determine whether the employee is entitled to remuneration for his or her inventions. Case law clarifies that the right to receive consideration for “service
inventions” can be waived by the employee and that in certain circumstances, such waiver does not necessarily have to be explicit. The Committee will
examine, on a case-by-case basis, the general contractual framework between the parties, using interpretation rules of the general Israeli contract laws.
Further, the Committee has not yet determined one specific formula for calculating this remuneration, but rather uses the criteria specified in the Patent
Law. Although we generally enter into assignment-of-invention agreements with our employees pursuant to which such individuals assign to us all rights to
any inventions created in the scope of their employment or engagement with us, we may face claims demanding remuneration in consideration for assigned
inventions. As a consequence of such claims, we could be required to pay additional remuneration or royalties to our current and/or former employees, or
be forced to litigate such claims, which could negatively affect our business.
Any lawsuits relating to infringement of intellectual property rights necessary to defend ourselves or enforce our rights will be costly and time
consuming.
We may be required to initiate litigation to enforce our rights or defend our activities in response to alleged infringement of a third-party. In
addition, we may be sued by others who hold intellectual property rights and who claim that their rights are infringed by our product candidates. These
lawsuits can be very time consuming and costly. There is a substantial amount of litigation involving patent and other intellectual property rights in the
biotechnology and pharmaceutical industries generally.
A third-party may claim that we are using inventions claimed by their patents and may go to court to stop us from engaging in our normal
operations and activities, such as research, development, and the sale of any future products. Such lawsuits are expensive and would consume time and
other resources. There is a risk that such court will decide that we are infringing the third-party’s patents and will order us to stop the activities claimed by
the patents, redesign our products or processes to avoid infringement or obtain licenses, which may not be available on commercially reasonable terms. In
addition, there is a risk that a court will order us to pay the other party damages for infringement.
44
Moreover, there is no guarantee that any prevailing patent owner would offer us a license so that we could continue to engage in activities claimed
by the patent, or that such a license, if made available to us, could be acquired on commercially acceptable terms. In addition, third parties may, in the
future, assert other intellectual property infringement claims against us with respect to other product candidates, technologies or other matters.
In addition, our patents and patent applications could face challenges. Any of these challenges, if successful, could result in the invalidation of, or
in a narrowing of the scope of, any of our patents and patent applications subject to challenge. Any of these challenges, regardless of their success, would
likely be time consuming and expensive to defend and resolve and would divert our management’s time and attention.
Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect Aramchol, Amilo-5MER or any other
product candidate.
As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and
enforcing patents in the biopharmaceutical industry involve both technological and legal complexity. Therefore, obtaining and enforcing pharmaceutical
patents is costly, time-consuming, and inherently uncertain. In particular, the United States has recently enacted, and is currently implementing, wide-
ranging patent reform legislation. The United States Supreme Court has ruled on several patent cases in recent years, and could do so again in the future,
either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition
to increasing uncertainty regarding our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of
patents, once obtained. Depending on decisions by applicable courts and legislatures in the countries in which we may pursue patent protection, including
those of the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents and the interpretations of such laws could change
in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.
Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and
other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent
application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market
earlier than would otherwise have been the case.
Risks Related to Ownership of Our Ordinary Shares
Our business, operating results and growth rates may be adversely affected by current or future unfavorable economic and market conditions and
adverse developments with respect to financial institutions and associated liquidity risk.
Our business depends on the economic health of the global economies. If the conditions in the global economies remain uncertain or continue to
be volatile, or if they deteriorate, including as a result of the impact of military conflict, such as the war between Russia and Ukraine, terrorism or other
geopolitical events, our business, operating results and financial condition may be materially adversely affected.
In addition, increases in inflation raise our costs for commodities, labor, materials and services and other costs required to grow and operate our
business, and failure to secure these on reasonable terms may adversely impact our financial condition. Additionally, increases in inflation, along with the
uncertainties surrounding any resurgence of the COVID-19, geopolitical developments and global supply chain disruptions, have caused, and may in the
future cause, global economic uncertainty and uncertainty about the interest rate environment, which may make it more difficult, costly or dilutive for us to
secure additional financing. A failure to adequately respond to these risks could have a material adverse impact on our financial condition, results of
operations or cash flows.
45
There can be no assurance that future credit and financial market instability and a deterioration in confidence in economic conditions will not
occur. Our general business strategy may be adversely affected by any such economic downturn, liquidity shortages, volatile business environment or
continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or if adverse developments are experienced by
financial institutions, it may cause short-term liquidity risk and also make any necessary debt or equity financing more difficult, more costly, more onerous
with respect to financial and operating covenants and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms
could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to alter our operating plans. In
addition, there is a risk that one or more of our service providers, financial institutions, manufacturers, suppliers and other partners may be adversely
affected by the foregoing risks, which could directly affect our ability to attain our operating goals on schedule and on budget.
The market price of our ordinary shares is volatile and you may sustain a complete loss of your investment.
Since our initial public offering, the trading price of our ordinary shares has been volatile and is likely to continue to be volatile. In addition, the
trading volume is and has been volatile and oftentimes relatively illiquid. The following factors, some of which are beyond our control, in addition to other
risk factors described in this section, may have a significant impact on the market price and trading volume of our ordinary shares:
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
the outcome of our review of strategic alternatives;
delays in existing clinical trials;
inability to obtain the approvals necessary to commence further clinical trials;
unsatisfactory or inconclusive results of clinical trials;
termination of clinical trials;
adverse events in our ongoing clinical trials;
announcements of regulatory approval or the failure to obtain it, or specific label indications or patient populations for its use, or changes
or delays in the regulatory review process;
announcements of therapeutic innovations or new products by us or our competitors;
adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing
activities;
changes or developments in laws or regulations applicable to our product candidates;
any adverse changes to our relationship with manufacturers or suppliers;
any product liability actions or intellectual property infringement actions in which we may become involved;
announcements concerning our competitors or the pharmaceutical industry in general;
achievement of expected product sales and profitability or our failure to meet expectations;
our commencement of, or involvement in, litigation;
46
●
●
●
●
●
●
●
●
●
●
●
any major changes in our board of directors, management or other key personnel;
legislation in the United States, Europe and other foreign countries relating to the sale or pricing of pharmaceuticals;
announcements by us of significant strategic partnerships, out-licensing, in-licensing, joint ventures, acquisitions or capital commitments;
expiration or terminations of licenses, research contracts or other collaboration agreements;
public concern as to the safety of drugs we, our licensees or others develop;
success of research and development projects;
variations in our and our competitors’ results of operations;
changes in earnings estimates, cash flow guidance, or recommendations by securities analysts;
developments by our licensees, if any;
future issuances of ordinary shares or other securities; and
natural disasters and political and economic instability, including wars, terrorism, political unrest, results of certain elections and votes,
emergence of a pandemic, or other widespread health emergencies (or concerns over the possibility of such an emergency), boycotts,
adoption or expansion of government trade restrictions, and other business restrictions.
These factors and any corresponding price fluctuations may materially and adversely affect the market price and trading volume of our ordinary
shares and result in substantial losses by our investors.
In addition, the stock market in general, and the Nasdaq Capital Market and the market for biotechnology companies in particular, have
experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of our Company and
that of small companies. Broad market and industry factors may negatively affect the market price of our ordinary shares, regardless of our actual operating
performance. Further, a systemic decline in the financial markets and related factors beyond our control may cause our share price to decline rapidly and
unexpectedly. Price volatility of our ordinary shares might be worse if the trading volume of our ordinary shares is low. Following periods of market
volatility or a material decrease in the value of our ordinary shares, shareholders may institute securities class action litigation. If we were involved in
securities litigation, it could have a substantial cost and divert resources and attention of management from our business, even if we are successful. Future
sales of our ordinary shares could also reduce the market price of such stock. Any adverse determination in litigation could also subject us to significant
liabilities.
Moreover, the liquidity of our ordinary shares has been limited, not only in terms of the number of shares that can be bought and sold at a given
price, but by delays in the timing of transactions and reduction in security analysts’ and the media’s coverage of us, if any. These factors may result in
lower prices for our ordinary shares than might otherwise be obtained and could also result in a larger spread between the bid and ask prices for our
ordinary shares. In addition, without a large float, our ordinary shares are less liquid than the stock of companies with broader public ownership and, as a
result, the trading prices of our ordinary shares are more volatile. In the absence of an active public trading market, an investor may be unable to liquidate
its investment in our ordinary shares. Trading of a relatively small volume of our ordinary shares may have a greater impact on the trading price of our
stock than would be the case if our public float were larger. We cannot predict the prices at which our ordinary shares will trade in the future.
47
If we fail to comply with the continued listing requirements of the Nasdaq Capital Market, our ordinary shares may be delisted and the price of our
ordinary shares and our ability to access the capital markets could be negatively impacted
Our ordinary shares are listed on the Nasdaq Capital Market. As such, we are required to meet the continued listing requirements of the Nasdaq
Capital Market and other Nasdaq rules, including those regarding director independence and independent committee requirements, minimum shareholders’
equity, minimum share price and certain other corporate governance requirements. In particular, we are required to maintain a minimum bid price for our
listed ordinary shares of $1.00 per share.
On September 19, 2023, we were notified by the Nasdaq Stock Market, LLC, or Nasdaq, that we were not in compliance with the minimum bid
price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires
listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum
bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The notification provided that we had 180 calendar
days, or until March 18, 2024, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of our ordinary shares must
have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. Since we did not regain compliance by March 18, 2024,
we requested and received from The Nasdaq Capital Market an additional 180 calendar days or until September 16, 2024 to comply with the minimum bid
price. If we fail to regain compliance during the second compliance period, then Nasdaq will notify us of its determination to delist our ordinary shares, at
which point we will have an opportunity to appeal the delisting determination to a Hearings Panel. No assurance can be given that we will be able to regain
compliance with the Rule. If we do not meet these or other continued listing requirements, our ordinary shares could be delisted. A delisting of our ordinary
shares from Nasdaq could materially reduce the liquidity of our ordinary shares and result in a corresponding material reduction in the price of our ordinary
shares. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result
in the potential loss of confidence by investors, employees and fewer business development opportunities and strategic alternatives. No assurance can be
given that we will be able to regain compliance with the Rule. If we do not meet these or other continued listing requirements, our ordinary shares could be
delisted. Delisting of our ordinary shares from the Nasdaq Capital Market would cause us to pursue eligibility for trading on other markets or exchanges, or
on the pink sheets. In such case, our shareholders’ ability to trade, or obtain quotations of the market value of, our ordinary shares would be severely
limited because of lower trading volumes and transaction delays. These factors could contribute to lower prices and larger spreads in the bid and ask prices
for our securities. There can be no assurance that our ordinary shares, if delisted from the Nasdaq Capital Market in the future, would be listed on a national
securities exchange, a national quotation service, the Over-The-Counter Markets or the pink sheets. Delisting from the Nasdaq Capital Market, or even the
issuance of a notice of potential delisting, would also result in negative publicity, make it more difficult for us to raise additional capital, adversely affect
the market liquidity of our ordinary shares, reduce security analysts’ coverage of us and diminish investor, supplier and employee confidence. Additionally,
the threat of delisting or a delisting of our ordinary shares from the Nasdaq Capital Market, could reduce the number of investors willing to hold or acquire
our ordinary shares, thereby further restricting our ability to obtain equity financing, and it could reduce our ability to retain, attract and motivate our
directors, officers and employees. In addition, as a consequence of any such delisting, our share price could be negatively affected and our shareholders
would likely find it more difficult to sell, or to obtain accurate quotations as to the prices of, our ordinary shares.
Our President and Chief Executive Officer beneficially owns approximately 5.6% of our outstanding ordinary shares, as of March 27, 2024. Therefore,
our principal shareholders will be able to exert significant control over matters submitted to our shareholders for approval.
Our President and Chief Executive Officer currently beneficially owns approximately 5.6% of our outstanding ordinary shares as of March 27,
2024. Therefore, our President and Chief Executive Officer will be able to exert significant control over matters submitted to our shareholders for approval.
As our President and Chief Executive Officer could significantly influence or even unilaterally approve matters requiring approval by our shareholders,
including the election of directors and the approval of mergers or other business combination transactions. The interests of our President and Chief
Executive Officer may not always coincide with our interests or the interests of other shareholders. This significant concentration of share ownership may
adversely affect the trading price for our ordinary shares because investors often perceive disadvantages in owning stock in companies with controlling
shareholders.
48
Sales of a substantial number of our ordinary shares in the public market could cause our share price to fall.
Sales of a substantial number of our ordinary shares in the public market, or the perception that these sales might occur, could depress the market
price of our ordinary shares and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect
that sales may have on the prevailing market price of our ordinary shares. Sales of shares by our existing shareholders would likely result in the supply of
our ordinary shares far exceeding the demand for our ordinary shares and could have a material adverse effect on the trading price of our ordinary shares.
Raising additional capital would cause dilution to our existing shareholders, and may restrict our operations or require us to relinquish rights.
Subject to our strategic review, we will need to raise additional capital and may seek additional capital through a combination of private and public
equity offerings, “at-the-market” issuances, equity-linked and structured transactions, debt (straight, convertible, or otherwise) financings, collaborations
and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest
will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a shareholder. Debt financing, if available,
would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific
actions such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through collaboration, strategic alliance and
licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates, or
grant licenses on terms that are not favorable to us. Depending upon market liquidity at the time, additional sales of shares registered at any given time
could cause the trading price of our ordinary shares to decline.
Our U.S. shareholders may suffer adverse tax consequences due to our expected classification as a passive foreign investment company.
Generally, if for any taxable year 75% or more of our gross income is passive income, or at least 50% of the average value of our assets is
attributable to assets that are held for the production of, or produce, passive income, we would be characterized as a passive foreign investment company,
or PFIC, for U.S. federal income tax purposes. Based upon our review of our financial data, we believe that we were a PFIC for our 2023 taxable year and
expect to be a PFIC for the 2024 taxable year. Because PFIC status is determined annually and is based on our income, assets and activities for the entire
taxable year, it is not possible to determine with certainty whether we will be characterized as a PFIC for the 2024 taxable year until after the close of the
year, and there can be no assurance that we will not be classified as a PFIC in any future year. If we were to be characterized as a PFIC for U.S. federal
income tax purposes in any taxable year during which a U.S. Holder (as defined below) owns ordinary shares, such U.S. Holder could face adverse U.S.
federal income tax consequences. For example, such U.S. Holder could be subject to additional taxes and interest charges upon certain distributions by us
and any gain recognized on a sale, exchange or other disposition of our shares, whether or not we continue to be characterized as a PFIC. Certain adverse
consequences of PFIC status can be mitigated if a U.S. Holder makes a “mark -to -market” election or an election to treat us as a qualified electing fund, or
QEF. Upon request, we expect to provide the information necessary for U.S. Holders to make “qualified electing fund elections” if we are classified as a
PFIC. There is no assurance, however, that we will have timely knowledge of our status as a PFIC, or that the information that we provide will be adequate
to allow U.S. Holders to make a QEF election Each investor is urged to consult its tax advisor with respect to the application of the PFIC rules. See also
“Item 10. Additional Information—E. Taxation— Certain Material U.S. Federal Income Tax Considerations.”
If a United States person is treated as owning at least 10% of our shares, such holder may be subject to adverse U.S. federal income tax
consequences.
49
If a United States person is treated as owning (directly, indirectly or constructively) at least 10% of the value or voting power of our shares, such
person may be treated as a “United States shareholder” with respect to each “controlled foreign corporation” in our group (if any). A United States
shareholder of a controlled foreign corporation may be required to annually report and include in its U.S. taxable income its pro rata share of “Subpart F
income,” “global intangible low-taxed income” and investments in U.S. property by controlled foreign corporations, whether or not we make any
distributions, and may be subject to tax reporting obligations. An individual that is a United States shareholder with respect to a controlled foreign
corporation generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder that is a U.S.
corporation. A failure to comply with these reporting obligations may subject you to significant monetary penalties and may prevent the statute of
limitations with respect to your U.S. federal income tax return for the year for which reporting was due from starting. We cannot provide any assurances
that we will assist any shareholder in determining whether such shareholder is treated as a United States shareholder with respect to any “controlled foreign
corporation” in our group (if any) or furnish to any United States shareholders information that may be necessary to comply with the aforementioned
reporting and tax paying obligations. A United States investor should consult its tax advisors regarding the potential application of these rules to its
investment in the shares.
If the securities analysts that currently cover our stock, or will do so in the future, or industry analysts do not publish or cease publishing research or
reports about us, our business or our market, or if they adversely change their recommendations or publish negative reports regarding our business or
our shares, our share price and trading volume could be negatively impacted.
The trading market for our ordinary shares is influenced by the research and reports that industry or securities analysts may publish about us, our
business, our market or our competitors. We do not have any control over these analysts and we cannot provide any assurance that analysts will cover us or
provide favorable coverage. If any of the analysts who do cover, or may cover us in the future, adversely change their recommendation regarding our
shares, or provide more favorable relative recommendations about our competitors, our share price would likely decline. If any analyst who cover us cease
coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could negatively impact
our share price or trading volume.
Because we do not intend to declare cash dividends on our ordinary shares in the foreseeable future, shareholders must rely on appreciation of the
value of our ordinary shares for any return on their investment.
We have never declared or paid cash dividends on our ordinary shares. We currently anticipate that we will retain future earnings for the
development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. Moreover, the
Israeli Companies Law, 5759-1999, or the Companies Law, imposes certain restrictions on our ability to declare and pay dividends. See “Item 8. Financial
Information—Consolidated Financial Statements and Other Financial Information—Dividend Policy” for additional information.
The requirements associated with being a public company require significant company resources and management attention.
We are subject to the reporting requirements of the Securities Exchange Act of 1934, or the Exchange Act, the Sarbanes-Oxley Act, the listing
requirements of the Nasdaq Capital Market, on which our ordinary shares are traded, and other applicable securities rules and regulations. The Exchange
Act requires that we file periodic reports with respect to our business and financial condition and maintain effective disclosure controls and procedures and
internal control over financial reporting. In addition, subsequent rules implemented by the SEC and the Nasdaq Capital Market may also impose various
additional requirements on public companies. As a result, we incurred and will continue to incur additional legal, accounting and other expenses that we did
not incur as a privately-held company, particularly since, as of December 31, 2020, we are no longer considered an “emerging growth company” as defined
in the JOBS Act. Further, the need to establish the corporate infrastructure demanded of a public company may divert management’s attention from
implementing our development plans. We have made and will continue to make changes to our corporate governance standards, compensation policy,
disclosure controls and financial reporting and accounting systems to meet our reporting obligations and applicable law. The measures we take, however,
may not be sufficient to satisfy our obligations as a public company, which could subject us to delisting of our ordinary shares, fines, sanctions and other
regulatory action and potentially civil litigation.
50
As a “foreign private issuer,” we are permitted to and currently do follow certain home country corporate governance practices instead of otherwise
applicable SEC and Nasdaq Capital Market requirements, which may result in less protection than is accorded to investors under rules applicable to
domestic U.S. issuers.
As a “foreign private issuer,” we are permitted to, and currently do, follow certain home country corporate governance practices instead of those
otherwise required under the Listing Rules of the Nasdaq Capital Market, or the Nasdaq Listing Rules, for domestic U.S. issuers. For instance, we currently
follow home country practice in Israel with regard to, among other things, director nomination procedure and approval of compensation of officers. In
addition, we may follow our home country law instead of the Nasdaq Listing Rules that require that we obtain shareholder approval for certain dilutive
events, such as the establishment or amendment of certain equity based compensation plans, an issuance that will result in a change of control of the
company, certain transactions other than a public offering involving issuances of a 20% or greater interest in the company, and certain acquisitions of the
stock or assets of another company. Following our home country governance practices as opposed to the requirements that would otherwise apply to a U.S.
company listed on the Nasdaq Capital Market may provide less protection to you than what is accorded to investors under the Nasdaq Listing Rules
applicable to domestic U.S. issuers. See “Item 16G. Corporate Governance.”
In addition, as a “foreign private issuer,” we are exempt from the rules and regulations under the Exchange Act related to the furnishing and
content of proxy statements and certain individual executive compensation information, and our officers, directors and principal shareholders are exempt
from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. Furthermore, foreign private issuers are not
required to file their annual report on Form 20-F until 120 days after the end of each fiscal year, while U.S. domestic issuers that are accelerated filers are
required to file their annual report on Form 10-K within 75 days after the end of each fiscal year and U.S. domestic issuers that are large accelerated filers
are required to file their annual report on Form 10-K within 60 days after the end of each fiscal year. Additionally, as a “foreign private issuer,” we are also
not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. These exemptions and leniencies reduce the
frequency and scope of information and protections to which you are entitled as an investor.
If our ordinary shares become a “penny stock,” it may be more difficult for investors to sell their ordinary shares, and the market price of our ordinary
shares may be adversely affected.
Our ordinary shares could become a “penny stock” if, among other things, the share price is below $5.00 per share, we are not listed on a national
securities exchange or we have not met certain net tangible asset or average revenue requirements. Broker-dealers who sell penny stocks must provide
purchasers of these stocks with a standardized risk-disclosure document prepared by the SEC. This document provides information about penny stocks and
the nature and level of risks involved in investing in the penny-stock market. A broker must also give a purchaser, orally or in writing, bid and offer
quotations and information regarding broker and salesperson compensation, make a written determination that the penny stock is a suitable investment for
the purchaser, and obtain the purchaser’s written agreement to the purchase. Broker-dealers must also provide customers that hold penny stock in their
accounts with such broker-dealer a monthly statement containing price and market information relating to the penny stock. If a penny stock is sold to an
investor in violation of the penny stock rules, the investor may be able to cancel its purchase and get its money back.
If applicable, the penny stock rules may make it difficult for investors to sell their ordinary shares. Because of the rules and restrictions applicable
to a penny stock, there is less trading in penny stocks and the market price of our ordinary shares may be adversely affected. Also, many brokers choose not
to participate in penny stock transactions. Accordingly, investors may not always be able to resell their ordinary shares publicly at times and prices that they
feel are appropriate and the market price of our ordinary shares may be adversely affected.
Inflation could adversely affect our business and results of operations.
While inflation in the United States and global markets had been relatively low in recent years, during 2021, 2022 and 2023, the economy in the
United States and global markets encountered a material increase in the level of inflation. The impact of COVID-19, geopolitical developments such as the
Russia-Ukraine conflict and global supply chain disruptions continue to increase uncertainty in the outlook of near-term and long-term economic activity,
including whether inflation will continue and how long, and at what rate. Increases in inflation raise our costs for commodities, labor, materials and
services and other costs required to grow and operate our business, and failure to secure these on reasonable terms may adversely impact our financial
condition. Additionally, increases in inflation, along with the uncertainties surrounding any resurgence of the COVID-19, geopolitical developments and
global supply chain disruptions, have caused, and may in the future cause, global economic uncertainty and uncertainty about the interest rate environment,
which may make it more difficult, costly or dilutive for us to secure additional financing. A failure to adequately respond to these risks could have a
material adverse impact on our financial condition, results of operations or cash flows.
51
Risks Related to Israeli Law and Our Operations in Israel
Our headquarters and other significant operations are located in Israel and, therefore, our results may be adversely affected by political, economic and
military instability in Israel.
Our executive office is located in Ramat Gan, Israel. In addition, certain of our key employees, officers and directors are residents of Israel.
Accordingly, political, economic and military conditions in the Middle East may affect our business directly. Since the establishment of the State of Israel
in 1948, a number of armed conflicts have occurred between Israel and its neighboring countries and terrorist organizations active in the region, including
Hamas (an Islamist militia and political group in the Gaza Strip) and Hezbollah (an Islamist militia and political group in Lebanon).
In October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military
targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in
other areas within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers. Following the attack,
Israel’s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued
rocket and terror attacks. In addition, since the commencement of these events, there have been continued hostilities along Israel’s northern border with
Lebanon (with the Hezbollah terror organization) and southern border (with the Houthi movement in Yemen, as described below). It is possible that
hostilities with Hezbollah in Lebanon will escalate, and that other terrorist organizations, including Palestinian military organizations in the West Bank as
well as other hostile countries, such as Iran, will join the hostilities. Such clashes may escalate in the future into a greater regional conflict.
In connection with the Israeli security cabinet’s declaration of war against Hamas and possible hostilities with other organizations, several hundred
thousand Israeli military reservists were drafted to perform immediate military service. Although many of such military reservists have since been released,
they may be called up for additional reserve duty, depending on developments in the war in Gaza and along Israel’s other borders. While none of our
employees in Israel have been called to active military duty, we rely on service providers located in Israel and have entered into certain agreements with
Israeli counterparties. Employees of such service providers or contractual counterparties may be called for service in the current or future wars or other
armed conflicts with Hamas as well as the other pending or future armed conflicts in which Israel is or may become engaged, and such persons may be
absent for an extended period of time. As a result, our operations may be disrupted by such absences, which disruption may materially and adversely affect
our business and results of operations.
While our executive offices are located in Ramat Gan, Israel, which is not near Israel’s borders where the main hostilities are currently taking
place and none of our employees have been called into military reserve duty, to help mitigate the effects of Israel’s war with Hamas, we have taken several
measures, including work-from-home measures and have a business continuity plan. Nevertheless, we experienced disruptions to our work and over the
past few weeks have been returning to full activity together with our local vendors and consultants. As a result, in November 2023, we determined that the
commencement of our Phase 2 PSC study was to be delayed by seven to nine months. We expect to commence our Phase 2 PSC study following the end of
such period.
Further disruptions that could severely impact our business, clinical trials, and supply chains, include:
● limitations on employee resources that would otherwise be focused on the conduct of our business including because of military reserve duty call-
ups in the future that impact our employees and the affect the current war between Israel and Hamas on the productivity of our employees and
external partners;
● delays in necessary interactions with vendors, local regulators, and other important agencies and contractors due to limitations in employee
resources; and
● impacts from prolonged remote work arrangements, such as increased cybersecurity risks and strains on our business continuity plans.
52
The intensity and duration of Israel’s current war against Hamas is difficult to predict, as are such war’s economic implications on the Company’s
business and operations, on Israel’s economy in general, on the trading price of shares of our ordinary shares and could impact our ability to raise additional
capital on a timely basis or at all. These events may be intertwined with wider macroeconomic indications of a deterioration of Israel’s economic standing
that may involve a downgrade in Israel’s credit rating by rating agencies (such as the recent downgrade by Moody’s of its credit rating of Israel from A1 to
A2, as well as the downgrade of its outlook rating from “stable” to “negative”), which may have a material adverse effect on the Company and its ability to
effectively conduct its operations. The impact of the current war between Israel and Hamas may also have the effect of heightening many of the other risks
described in this section and in the “Risk Factors” section of our 2022 Annual Report.
In addition, some countries around the world restrict doing business with Israel and Israeli companies, and additional countries may impose
restrictions on doing business with Israel and Israeli companies if hostilities in Israel or political instability in the region continue or increase. In addition,
there have been increased efforts by countries, activists and organizations to cause companies and consumers to boycott Israeli goods and services. In
addition, in January 2024 the International Court of Justice, or ICJ, issued an interim ruling in a case filed by South Africa against Israel in December 2023,
making allegations of genocide amid and in connection with the war in Gaza, and ordered Israel, among other things, to take measures to prevent genocidal
acts, prevent and punish incitement to genocide, and take steps to provide basic services and humanitarian aid to civilians in Gaza. There are concerns that
companies and businesses will terminate, and may have already terminated, certain commercial relationships with Israeli companies following the ICJ
decision. The foregoing efforts by countries, activists and organizations, particularly if they become more widespread, as well as the ICJ rulings and future
rulings and orders of other tribunals against Israel (if handed), may materially and adversely impact our business, clinical trials, and supply chains.
Furthermore, following Hamas’ attack on Israel and Israel’s security cabinet declaration of war against Hamas, the Houthi movement, which
controls parts of Yemen has launched attacks on Israeli-controlled or owned ships in the Red Sea, resulting in shipping companies rerouting their cargo
ships or ceasing shipments to Israel in the case of the latter. The hostilities with Hamas, Hezbollah, the Houthi movement and other terrorist organizations,
include and may include terror, missile and drone attacks. In the event that our facilities are damaged as a result of hostile actions, or hostilities otherwise
disrupt our ongoing operations, our ability to deliver or provide products and services in a timely manner to meet our contractual obligations towards
customers and vendors could be materially and adversely affected. Any hostilities involving Israel or the interruption or curtailment of trade between Israel
and its present trading partners could have a material adverse effect on our business and could make it more difficult for us to raise capital. Our insurance
policies do not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers the
reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be
maintained or that it will sufficiently cover our potential damages. Any losses or damages incurred by us could have a material adverse effect on our
business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could harm our results of
operations.
Finally, political conditions within Israel may affect our operations. Israel has held five general elections between 2019 and 2022, and prior to
October 2023, the Israeli government pursued extensive changes to Israel’s judicial system, which sparked extensive political debate and unrest. In
response to such initiative, many individuals, organizations and institutions, both within and outside of Israel, voiced concerns that the proposed changes
may negatively impact the business environment in Israel including due to reluctance of foreign investors to invest or transact business in Israel, as well as
to increased currency fluctuations, downgrades in credit rating, increased interest rates, increased volatility in security markets and other changes in
macroeconomic conditions. To date, these initiatives have been substantially put on hold. If such changes to Israel’s judicial system are again pursued by
the government and approved by the parliament, this may have an adverse effect on our business, our results of operations and our ability to raise additional
funds, if deemed necessary by our management and board of directors.
53
Exchange rate fluctuations between the U.S. dollar and the New Israeli Shekel currencies may negatively affect our earnings.
Our functional currency is the U.S. dollar. We incur expenses in U.S. dollars and New Israeli Shekels, or NIS. As a result, we are exposed to the
risks that the NIS may appreciate relative to the U.S. dollar, or, if either the NIS devalues relative to the U.S. dollar, that the inflation rate in Israel may
exceed such rate of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the U.S. dollar cost
of our operations in Israel would increase and our U.S. dollar-denominated results of operations would be adversely affected. The average exchange rate for
the year ended December 31, 2023 was $1.00 = NIS 3.62. We cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation, if
any, of the NIS against the U.S. dollar. As of the date hereof, the inflation rate in Israel has exceeded the rate of devaluation of the NIS, respectively, during
the calendar years 2021, 2022 or 2023.
Provisions of Israeli law and our articles of association, or Articles, may delay, prevent or otherwise impede a merger with, or an acquisition of, our
company, which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.
The Companies Law regulates, among others, mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special
approvals for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to such types of
transactions. See “Item 10. Additional Information—B. —Mergers and Acquisitions under Israeli Law” for additional information.
Furthermore, Israeli tax considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does
not have a tax treaty with Israel exempting such shareholders from Israeli tax. See “Item 10. Additional Information—E. Taxation—Certain Israeli Tax
Considerations” for additional information.
Moreover, the classification of our Board into three classes with terms of approximately three years each, per our Articles, the requirement of
affirmative vote of at least 75% of the voting rights of the Company represented personally or by proxy and voting thereon at a general meeting in order to
amend or replace our Articles, together with the other provisions of the Articles and Israeli law, could deter or delay potential future merger, acquisition,
tender or takeover offers, proxy contests or changes in control or management of the Company.
It may be difficult to enforce a judgment of a United States court against us, our officers, directors and the Israeli experts named in this annual report
in Israel or the United States, to assert United States securities laws claims in Israel or to serve process on our officers, directors and these experts.
We were and continue to be organized in Israel. Most of our executive officers and directors reside outside of the United States, and all of our
assets and most of the assets of these persons are located outside of the United States. Therefore, a judgment obtained against us, or any of these persons,
including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United States and may not
necessarily be enforced by an Israeli court. It also may be difficult to effect service of process on these persons in the United States or to assert U.S.
securities law claims in original actions instituted in Israel. Additionally, it may be difficult for an investor, or any other person or entity, to initiate an
action with respect to United States securities laws in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of United States
securities laws reasoning that Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a
claim, it may determine that Israeli law and not United States law is applicable to the claim. If United States law is found to be applicable, the content of
applicable United States law must be proven as a fact by expert witnesses, which can be a time consuming and costly process. Certain matters of procedure
will also be governed by Israeli law. There is little binding case law in Israel that addresses the matters described above. As a result of the difficulty
associated with enforcing a judgment against us in Israel, our shareholders may not be able to collect any damages awarded by either a United States or
foreign court.
54
Your rights, liabilities and responsibilities as a shareholder will be governed by Israeli law and differ in some material respects from those under U.S.
law.
Because we are an Israeli company, the rights and responsibilities of our shareholders are governed by our Articles and Israeli law. These rights,
liabilities and responsibilities differ in some material respects from the rights, liabilities and responsibilities of shareholders in a U.S. corporation. In
particular, a shareholder of an Israeli company has a duty to act in good faith towards the company and other shareholders and to refrain from abusing his,
her or its power in the company, including, among other things, when voting at the general meeting of shareholders on certain matters. Israeli law provides
that these duties are applicable to shareholder votes on, among other things, amendments to a company’s articles of association, increases in a company’s
authorized share capital, mergers and interested party transactions requiring shareholder approval. In addition, a controlling shareholder, a shareholder who
knows that it possesses the power to determine the outcome of a shareholders’ vote or a shareholder who has the power to appoint or prevent the
appointment of a director or executive officer in the company, has a duty of fairness towards the company. However, Israeli law does not define the
substance of this duty of fairness. There is little case law available to assist in understanding the implications of these provisions that govern shareholder
behavior. These provisions may be interpreted to impose additional obligations and liabilities on holders of our ordinary shares that are not typically
imposed on shareholders of U.S. corporations. See “Item 10. Additional Information—B Memorandum and Articles of Association—Shareholder Duties”
for additional information.
Any of the risk factors referred to above could significantly and negatively affect our business, results of operations or financial condition, which may
reduce our ability to pay dividends and lower the trading price of our ordinary shares. The risks referred to above are not the only ones that may exist.
Additional risks not currently known by us or that we deem immaterial may also impair our business operations.
ITEM 4. Information on the Company.
A. Historical Background and Corporate Structure
Galmed Pharmaceuticals Ltd., was incorporated in Israel on July 31, 2013 as a privately held company and is governed by the Companies Law.
However, our business has been operating since 2000 under a different group of companies established in the same year, or the Group. Originally, we
operated under the parent company, GHI. GHI held all of the equity rights in and to Galmed 2000 Inc., a holdings company incorporated in the British
Virgin Islands, or GTTI. GTTI held all of the equity rights in and to Galmed International Limited, a company incorporated in Malta, or GIL (other than
0.1% of the share capital held by GHI). GIL held all of the equity rights in and to Galmed Medical Research Ltd., an Israeli company, or GMR. Our
intellectual property was held by GIL. The research and development was conducted by GMR as a service to GIL on a cost plus basis. GIL was responsible
for all product development.
On February 2, 2014, we underwent the Reorganization, pursuant to which all of our intangible assets (including our intellectual property) were
transferred from GIL to Galmed Research and Development Ltd., or GRD. The Reorganization was effectuated by share transfers and asset transfers,
resulting in the Company as the parent company and 100% equity-owner of the following companies: (1) GRD, which holds all the Group’s intellectual
property, including the Company’s patent portfolio; (2) GIL, which is an inactive company; and (3) GTTI, which was liquidated in 2017. GIL held GMR,
which became an inactive company in 2015 and was liquidated in February 2019. The Reorganization was conducted in order to simplify our capital
structure, reduce our operating cost and to improve our ability to raise funds. Immediately prior to the Reorganization, all our shareholders collectively held
9,739 ordinary shares of GHI. In connection with the Reorganization, and in accordance with the Tax Pre-Ruling, we issued to all such shareholders
ordinary shares, such that upon the Reorganization all our shareholders collectively held 7,099,731 of our ordinary shares, in the same proportion among all
shareholders, which reflected a ratio of 729 of our ordinary shares for each ordinary share of GHI. In July 2023, GRD established a new wholly-owned
subsidiary incorporated under the laws of England and Wales called Galmed Therapeutics UK Limited, or Galmed UK.
The following is a diagram of our corporate structure (following GTTI’s liquidation and the incorporation of Galmed UK):
55
On March 18, 2014, we completed our initial public offering and since then have been listed on the Nasdaq Capital Market under the symbol
“GLMD”.
Our principal executive offices and registered office in Israel is located at 16 Abba Hillel Road, Ramat Gan, Israel 5250608 and our telephone
number is +972-3-693-8448. Our lease at our prior principal executive offices expired on March 21, 2024. We did not extend the lease and are currently
headquartered in Ramat Gan, Israel while we are in the process of searching for a new permanent location for our principal executive offices. Our website
address is http://www.galmedpharma.com. The information contained on, or that can be accessed through, our website is neither a part of nor incorporated
into this annual report. We have included our website address in this annual report solely as an inactive textual reference. Puglisi & Associates, or Puglisi,
serves as our authorized representative in the United States for certain limited matters. Puglisi’s address is 850 Library Avenue, Newark, Delaware 19711.
The SEC maintains an internet site that contains reports, proxy and information statements and other information regarding issuers that file
electronically with the SEC at http://sec.gov. We use our website (http://www.galmedpharma.com) as a channel of distribution of Company information.
The information we post through this channel may be deemed material. Accordingly, investors should monitor our website, in addition to following our
press releases, SEC filings and public conference calls and webcasts. The contents of our website are not, however, a part of this annual report.
Other than as described in “Item 5. Operating and Financial Review and Prospects—Contractual Obligations”, we have not had any material
commitments for capital expenditures, including any anticipated material acquisition of plant and equipment or interests in other companies, since January
1, 2014. Additionally, we have not had any material capital divestitures since January 1, 2014.
B. Business Overview
We are a biopharmaceutical company focused on the development of Aramchol. We have focused almost exclusively on developing Aramchol for
the treatment of liver disease and are currently developing Aramchol for PSC and exploring the feasibility of developing Aramchol for other fibro-
inflammatory indications outside of liver disease. We are also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino
acid synthetic peptide.
56
We believe that our lead product candidate, Aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including
NASH, which is a chronic disease that constitutes a large unmet medical need.
Aramchol is a synthetic conjugate of 3-amino cholic acid, or a type of modified bile acid, and arachidic acid, or a type of saturated fatty acid,
which in its non-synthetic forms, is naturally occurring. The conjugated molecule acts upon important metabolic pathways, reducing fat accumulation in
the liver, improving fatty acid oxidation and regulating the transport of cholesterol. The ability of Aramchol to decrease liver fat content may also reduce
the inflammation and fibrosis in the liver and the risk of cardiovascular complications associated with NASH. Pre-clinical studies suggest Aramchol’s
effect on fibrosis is also direct via collagen production from human hepatic stellate cells. We believe that Aramchol’s ability to reduce liver fat and liver
fibrosis and the safety profile observed to date will enable it to be a treatment for all stages of NASH in patients who are overweight or obese and have pre
diabetes or type II diabetes mellitus and prevent the hepatic complications associated therewith.
In September 2019, we initiated our Phase 3 ARMOR Study to evaluate the efficacy and safety of Aramchol in subjects with NASH and fibrosis.
The ARMOR Study was originally comprised of two parts, a randomized, double-blind, placebo-controlled histology-based registrational part and a
clinically based part where subjects will continue with the same treatment for approximately five years. In December 2020, we announced the addition of a
150-patient open label part to the ARMOR Study and suspended randomization of new patients into the double-blind, placebo-controlled histology-based
registrational part of ARMOR as all enrolled patients were transitioned to the open label part.
In May 2022, we announced our plan to expand into new anti-fibrotic indications to maximize the potential of Aramchol while at the same time
discontinuing the open label part of its ARMOR Study having reached its objectives. Simultaneously, we initiated a cost reduction plan and initiated a
process to evaluate our strategic alternatives. Following the discontinuation of our open label part of the ARMOR Study, we do not currently expect to
initiate the second part of the ARMOR Study in the near term.
In May 2023, we announced the initiation of a new clinical program to evaluate Aramchol meglumine for the treatment of PSC, a rare disease for
which there is no approved treatment. We initially planned to initiate a Phase 2a study in the last quarter of 2023 however as a result of Hamas-Israel war,
we currently estimate a delay of ~7-9 months in the initiation of the study.
The randomized, double-blind, proof-of-concept clinical study (NCT06095986) will evaluate the effects of 48 weeks of treatment with Aramchol
meglumine vs. placebo in approximately 24 patients with PSC. The study’s endpoints will include the conventional relevant laboratory parameters (alkaline
phosphatase and bilirubin), sophisticated imaging including liver stiffness using MR Elastography (MRE), imaging of the biliary tract using MR
cholangiopancreatography, or MRCP, and hepatocyte-specific contrast agents, histological fibrosis and molecular assessment as well as a range of
biomarkers of disease activity and fibrosis. These endpoints are expected to provide a robust assessment of the underlying disease and the effects of
Aramchol.
While PSC is more common in men, especially in Northern European heritage, and is often diagnosed between ages 30-40, we currently estimate
that the number of patients to be around 60,000, or 1 per 10,000, consisting of around 33,5000 patients in the United States and 32,500 patients collectively
in France, Germany, Italy, Spain and the United Kingdom. In the preclinical stage, PSC likely involves ulcerative colitis (UC) leading to biliary
inflammation. As biliary fibrosis progresses to cirrhosis, it is coupled with complications and competing risks, while about 50% of patients with PSC report
clinical symptoms. While there are currently no approved drugs for the treatment of PSC, there is a potential to gain orphan drug status.
We initially planned to initiate a Phase 2 study in the last quarter of 2023 to evaluate Aramchol meglumine for the treatment of PSC. This study
will be followed by a Phase 2b or a phase 2/3 confirmatory adaptive design trial. As a result of the outbreak of the Hamas-Israel war, in November 2023,
we determined that there would be a delay of seven to nine months in the initiation of the Phase 2 PSC study. We expect to commence our Phase 2 PSC
study following the end of such period. As PSC is a fibro-obliterative cholangiopathy where the disease progression is predominantly determined by biliary
fibrosis, Aramchol meglumine has been shown to downregulate Stearoyl-CoA desaturase 1 (SCD1), a key liver enzyme involved in lipid metabolism,
attenuate fibrogenesis by hepatic stellate cells (HSCs). Aramchol meglumine may have direct effects on cholangiocytes to reduce the production of
fibrogenic and inflammatory signals that activate HSCs suggesting that Aramchol meglumine may be beneficial in treating PSC.
57
In addition, in May 2023, we entered into a definitive agreement, or the OnKai Agreement, for a $1.5 million equity investment in OnKai, a US-
based technology company developing an AI-based platform to advance healthcare for underserved populations across the United States by facilitating
alignment between healthcare stakeholders. The signing of the definitive agreement followed an announcement that we made in January 2023 that we had
entered into a non-binding termsheet for an equity investment in OnKai. The OnKai Agreement provided that we will invest $1.5 million in exchange for
series seed preferred shares of OnKai (which is in addition to a $1.5 million investment that was made by us in OnKai through a Simple Agreement for
Future Equity, or SAFE, and which converted at a 15% discount into series seed preferred shares upon consummation of the Investment Round (as defined
below)). Our investment in OnKai was part of an approximately $6 million investment round, or the Investment Round, with other investors that was led by
us of which SAFE notes of approximately $3.8 million were converted into preferred shares. On June 19, 2023, the Investment Round closed. Following
the Investment Round, we hold approximately 23.9% of the outstanding share capital of OnKai on an as-converted and fully diluted basis and our Chief
Executive Officer and director, Allen Baharaff serves as a board member of OnKai. In connection with the OnKai Agreement, our wholly-owned
subsidiary, Galmed Research and Development Ltd., or GRD, entered into a services agreement, or the OnKai Services Agreement, with OnKai. The
OnKai Services Agreement provides that GRD shall on a non-exclusive basis (i) provide support services to OnKai relating to finance, business
development, strategic planning, execution and others; and (ii) lend its experience to OnKai in building a strategy and for the development of treatments for
the underserved and that OnKai shall on a non-exclusive basis (i) take part in plan preparation to serve GDR’s vision of developing drugs for the
underserved population and (ii) when relevant, design a process on the clinical trial dashboard that could potentially serve GDR’s future trial. See “Item 4.
Information on the Company— Strategic Collaborations, Research Arrangements and other Agreements—Onkai.” In July 2023, we announced that OnKai
will apply its artificial intelligence models for enrollment and execution of clinical trials in underserved communities, starting with our PSC clinical
program.
While we previously announced that we were no longer evaluating our strategic alternatives following the initiation of our PSC clinical program
and our investment and collaboration with Onkai, we have recently reinitiated the process of evaluating our strategic options alternatives and our
structuring to best optimize our resources to enhance shareholder value and achieve our goals. See “Item 3. Key Information—Risk Factors—Risks Related
to Our Business, Industry and Regulatory Requirements—Our activities to evaluate and pursue strategic alternatives may not be successful” for additional
information.
Non-Alcoholic Fatty Liver Disease (NAFLD) / Non-Alcoholic Steato-Hepatitis (NASH)
It is estimated that the global prevalence of NAFLD, the precondition to NASH, is approximately 25% in the general population and much higher
in certain high risk groups. This disease is also now recognized as one of the most common liver disorders, and a significant growing public health
problem. In the US alone, 80 - 100 million people are said to be affected by NAFLD, and its prevalence is rapidly growing in parallel with metabolic
syndromes, particularly obesity and diabetes.
NAFLD is characterized by the accumulation of fat of 5% or greater in the liver of people who drink alcohol only in moderation, or not at all.
There may be numerous causes of NAFLD, however, the disease is mostly associated with a high fat, fructose-rich diet. Although NAFLD is generally
asymptomatic, it is a major risk factor for liver inflammation (NASH) and scarring (fibrosis and cirrhosis). In addition, NAFLD is also associated with
metabolic syndrome and cardiovascular disease. Currently, NAFLD can only be managed through lifestyle improvements, such as weight reduction and
physical activity.
NASH is an emerging world crisis impacting an estimated 3% to 5% of the U.S. population and an estimated 2% to 4% globally, and is associated
with increased risk of liver cirrhosis, liver failure, hepatocellular cancer, as well as metabolic and cardiovascular diseases. The major characteristics of
NASH are elevated liver fat, inflammation, ballooning and fibrosis.
However, despite the growing need, there are currently no approved therapeutic treatments for NASH. Modification of risk factors, such as obesity
and hyperlipidemia, and proper diabetic control is generally recommended for the treatment of NASH, and the standard of care includes lifestyle changes to
promote weight loss, including low-calorie, low-fat diets and physical activity. Although weight loss can be potentially significant in delaying the
progression of NASH, studies have shown that, for most individuals, it is generally very difficult to maintain over the long-term, even following bariatric
surgery.
58
There are currently no drugs approved by regulatory authorities for the treatment of NASH. Even though certain drugs, such as insulin sensitizers
and antihyperlipidemic agents, are prescribed for some NASH patients, they are not approved for the treatment of NASH and their efficacy has not been
proven in adequate and well-controlled clinical studies.
Currently, it is impossible to predict which of the NAFLD patients will deteriorate to NASH as it is unclear what causes NASH to develop.
Researchers are now focusing on several factors that may contribute to the development of NASH. Therefore, lifestyle changes are recommended for all
patients with NAFLD.
There is an exceptionally wide range of estimates regarding the potential commercial market for NASH. This uncertainty stems from (i) the
overall size of the patient population, (ii) the percentage of the addressable market that will be diagnosed and, subsequently, seek treatment, (iii) the
ultimate cost of the therapies, (iv) the number of approved drugs for NASH and their profile, and (v) uncertainty regarding the regulatory approval process.
Some of these factors cannot be known until NASH drugs begin to hit the market or biomarkers replacing the biopsy diagnosis are validated. Independent
estimates generally estimate a commercial multi billion market in developed countries, though we do not endorse any estimates, which are based on a
number of different underlying assumptions.
Aramchol for NASH
Overview
Our product candidate, Aramchol, is a first-in-class synthetic fatty acid-bile acid conjugate molecule, or FABAC, molecule that we are developing
for oral treatment for NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.
Early in its development, Aramchol’s ability to modulate hepatic lipid metabolism was observed and validated in numerous pre-clinical trials with
different animal species. Mice fed a high fat diet and treated with Aramchol did not develop fatty liver as compared to non-treated mice. In these early
studies, we also observed that the mechanism of this effect was not a result of malabsorption of fat in the intestines because the FABAC-treated mice
gained weight throughout the test periods to a similar degree to the control mice. This led us to conclude that FABAC therapy triggers a beneficial
modulation of intra-hepatic lipid metabolism and reduces liver fat content.
In in-vitro and in vivo studies, Aramchol down regulates the SCD1 enzyme, an enzyme recognized as playing an important role in the metabolism
of fatty acids. The SCD1 enzyme is essentially the gateway that regulates the use and storage of fat in the body by converting saturated fatty acids to
monounsaturated fatty acids. Experimental animal studies showed that complete inhibition of the SCD1 enzyme protects against diet-induced obesity,
hepatic steatosis, or fatty liver, and insulin resistance by instructing the body to use, rather than store, all fatty acids. However, various animal studies have
indicated that such complete SCD1 enzyme inhibition has mechanism based serious side effects, such as atherosclerosis, and eye and skin disorders. As
observed by us in our pre-clinical and clinical studies performed to date, and subsequently published in the European Journal of Gastroenterology and
Hepatology and Archives of Medical Research in 2008 and 2010 respectively, one of Aramchol’s unique characteristics is that it down regulates the SCD1
enzyme but does not inhibit it completely – a partial effect. To date, side effects that have been observed in animals with knock out of SCD1 have not been
observed in our toxicology and clinical studies.
To better understand the role of Aramchol in NASH, we analyzed the effect of Aramchol in MCD diet model. The aim of this study was to
investigate Aramchol’s mechanism of action and its effect on fibrosis using the methionine- and choline-deficient (MCD) diet model of NASH. We
collected liver and serum from mice fed a MCD diet containing 0.1% methionine (0.1MCD) for four weeks, which developed steatohepatitis and fibrosis,
as well as mice receiving a control diet; the metabolomes and proteomes were determined. 0.1MCD fed mice were given Aramchol (5mg/kg/day for the
last 2 weeks); liver samples were analyzed histologically. Aramchol administration was found to reduce features of steatohepatitis and fibrosis in 0.1MCD
fed mice. Aramchol downregulated the SCD1 enzyme, a key enzyme involved in triglyceride biosynthesis whose loss enhances fatty acid β-oxidation. In
addition, Aramchol increased the flux through the transsulfuration pathway, leading to a rise in glutathione (GSH) and GSH/GSSG ratio, the main cellular
antioxidant that maintains intracellular redox status. Comparison of the serum metabolomic pattern between 0.1MCD-fed mice and patients with NAFLD
showed a substantial overlap. These findings were published in Hepatology Communications, Vol. 1, No. 9, 2017.
59
As the effect of Aramchol on fibrosis was first reported we further analyzed the direct effect of Aramchol on collagen production and reported
down regulation of collagen production from the hepatic stellate cells (HSCs) by Aramchol. With that we could conclude that Aramchol has potential direct
effect on collagen production and therefore reduces fibrosis indirectly by down regulation of steatosis by reducing the sequence of events but also directly
affecting collagen producing cells. These findings were published in Hepatology Communications, Vol. 1, No. 9, 2017.
These findings led us to further analyze the effect of Aramchol using the Thiocatemide (TAA) rat model. TAA is the most commonly used toxic
agents to induce liver fibrosis. Repeated IP injections of TAA leads to sever fibrosis / cirrhosis. Among all models for fibrosis, the TAA model share
multiple characteristics with human liver fibrosis and is considered to best predict efficacy in humans. Results demonstrated that treatment with Aramchol
5mg/kg, significantly prevented TAA induced fibrosis in a dose dependent manner. These findings were presented at EASL, Amsterdam in April 2017 (The
anti Fibrotic effect of Aramchol on liver Fibrosis in TAA animal model).
Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers (NCT00776841)
Aramchol was evaluated in two Phase 1 clinical trials (under a single protocol) to study its safety, tolerability and PK profile in healthy volunteers,
in both single and multiple dose administrations. The first Phase 1 clinical trial was an escalating single-dose trial conducted in 17 healthy subjects testing
Aramchol doses ranging from 30 mg to 900 mg, performed in one center in Israel. The subsequent Phase 1 clinical trial was a repeated-dose trial conducted
over four days in 25 healthy subjects testing repeated daily doses of Aramchol of 30 mg and 300 mg, performed in one center in Israel. The profiles for the
groups were similar and the maximal plasma concentration of Aramchol increased with the higher doses. The PK profile demonstrated that Aramchol is
suitable at each dose for once-daily administration and there were neither significant adverse events observed in either Phase 1 trial nor any notable
changes in biochemical, hematologic, cardiovascular or other safety parameters.
Phase 2a Trial: Aramchol Treatment in NAFLD or NASH Patients (NCT01094158)
In January 2012, we completed a 60 patient multi-center, randomized, double-blind, placebo-controlled Phase 2a clinical trial of Aramchol in
patients with NAFLD or NASH between the ages of 18 and 75 in 12 centers in Israel. The Phase 2a study results were published in July 2014 in the peer-
reviewed Clinical Gastroenterology and Hepatology Journal. The trial was performed in patients with either NAFLD or NASH, which design was deemed
acceptable by the FDA in 2007 at a pre-IND scientific advisory meeting. The trial’s primary efficacy endpoint was a reduction in liver fat content, and did
not consider inflammation or fibrosis, which can be diagnosed only by liver biopsy. We believe that the short study duration of three months of treatment
followed by a one-month follow-up period did not warrant repeated biopsies. The trial evaluated the effects on liver fat content of 100 mg and 300 mg
once-daily doses of Aramchol compared to a placebo. At the end of the three month treatment period, statistically significant reductions in liver fat
concentration as measured by MRS were observed in the 300 mg patient group. Specifically, a 12.57% mean liver fat content reduction was observed in the
300 mg group, as compared to a mean reduction of 2.89% in the 100 mg group and a mean increase of 6.39% in the placebo-treated patients. These results
indicate that the effects of Aramchol are dose-dependent, as demonstrated in the graph below, which presents the results with respect to the 57 patients who
successfully completed the entire treatment period (three patients were excluded from data analysis because of one protocol violation and two withdrawal
consents).
Relative Change in MRS from Baseline after Three Months of Treatment
60
The table above shows that the primary endpoint of the study was attained. The study demonstrated a statistically significant, dose dependent
reduction in fat content in the livers of patients treated with Aramchol, with a 19% difference between the 300 mg dose group and the placebo group, while
the difference between the 100 mg dose group and the placebo group was not statistically significant. Notably, the minimal effective dose of Aramchol for
fat reduction has been defined.
There were no statistically significant differences among the three treatment groups for any of the secondary end points. There was a non-
statistically significant trend of mild weight reduction (P=.1) in the high dose Aramchol group. Serum adiponectin levels increased (0.2 ± 1.7 μg/mL) in the
high-dose Aramchol group but decreased in the low-dose (-0.3 ± 1.5 μg/mL) and placebo groups (-0.7 ±_1.3 μgg/mL) (P= 0.88 for trend of dose-response
relationship by linear regression). FMD increased non-statistically significantly by 1.28% ± 2.92% in the high-dose group, by 0.34% ±3.54% in the low-
dose group, and by 0.46% ± 2.28% in the placebo group.
The frequency of adverse events was similar in all treatment groups, and none of them were considered to be related to the treatment. All adverse
events in the active treatment arms were mild or moderate and none were serious. None of the patients withdrew as a result of adverse events. The
following table shows the most frequent adverse events (occurring in ≥ 2 patients in any group) in the study.
MedDRA
preferred term
Abdominal pain
Abdominal pain
upper
Constipation
Asthenia
Back pain
Musculoskeletal
pain
Upper
respiratory tract
infection
Placebo
(N=20)
No.
Events Subjects %
No.
Aramchol 100mg/d
(N=20)
No.
Events Subjects %
No.
Aramchol 300mg/d
(N=20)
No.
Events Subjects %
No.
2
1
2
2
3
2
2
1
2
2
3
2
10%
5%
10%
10%
15%
2
2
—
—
—
1
2
—
—
—
5%
10%
—
—
—
1
—
—
—
—
1
—
—
—
—
5%
—
—
—
—
10%
—
—
—
—
—
—
—
—
—
—
—
—
2
2
10%
61
The results of our Phase 2a clinical trial of Aramchol in the peer-reviewed Clinical Gastroenterology and Hepatology Journal were published in
December 2014. The trial manuscript, entitled “The Fatty Acid-Bile Acid Conjugate Aramchol Reduced Liver Fat Content in Patients with Nonalcoholic
Fatty Liver Disease,” provides the full report of the Phase 2a trial, which was completed in January 2012 and presented at the 47th Annual Meeting of the
European Association for the Study of the Liver in 2012. Based on this Phase 2a proof-of-concept results, we established a development plan that we
believe may confirm: (i) the good safety profile of Aramchol, (ii) the optimal dose of Aramchol, and (iii) efficacy on steatosis as well as fibrosis in patients
with NASH.
Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol and Food Effect in Healthy Volunteers (NCT02374437)
On April 28, 2014, we commenced PK and food effect studies of Aramchol. In written correspondence from December 2013 regarding a requested
pre-IND meeting, the FDA recommended that we conduct such studies prior to commencing our Phase 2b ARREST Study.
We conducted the food effect and PK study at the Sourasky Medical Center in Tel Aviv, Israel involving 66 healthy volunteers to evaluate the PK
of Aramchol following single and multiple escalating doses (200 mg, 400 mg and 600 mg), as well as to evaluate the effect of a high-fat, high-calorie meal
on the PK of Aramchol following a single dose in healthy volunteers.
The results showed dose-related, but less than dose-proportional, increases in the mean Aramchol plasma concentrations, or Cmax, area under the
curve, or AUC, (0-t), and AUC (inf) of 200 mg, 400 mg and 600 mg doses administered under fasting conditions or following a light meal, both at single
and repeated dose administration. Cmax and AUC are metrics used to indicate the significance of a drug’s exposure. Steady-state was achieved by 144
hours (day seven). Administration of Aramchol after a high-fat, high-calorie meal afforded a 2.6 fold increase in exposure, as measured by Cmax, AUC(0-
t), and AUC(inf) compared to the fasting group.
No serious adverse events or deaths occurred during the study. Adverse events were equally distributed between placebo and Aramchol doses,
were mild (with only one moderate adverse event) and the majority defined unrelated to Aramchol. The PK study provides additional safety data to further
support existing safety data from our pre-clinical studies and our Phase 1 and Phase 2a clinical trials of Aramchol.
Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol Administered under Fed Conditions in Healthy Chinese Volunteers (NCT
02803996)
In 2016, we performed the Chinese PK Study involving Chinese patients who are domiciled in the United States. We enrolled 66 patients in this
study, consisting of two parts. In part A, 32 subjects received a single escalating dose; Part B enrolled 34 subjects which received a multiple escalating
dose. Dr. Evelyn Darius served as the Study Investigator. No safety signal was identified in this study and we deemed no changes were required in the
enrollment of Chinese patients into the ARREST Study.
Phase 2b ARREST Study for Aramchol (NCT 02279524)
In September 2014, the FDA granted Fast Track designation status to Aramchol for the treatment of NASH. Fast Track designation may accelerate
the development process and may expedite the review of drugs that show promise in treating serious, life-threatening medical conditions for which no other
drug either exists or is as effective.
On February 1, 2015, we began our ARREST Study. The ARREST Study was a Phase 2b, multicenter, global, randomized, double-blind, placebo
controlled study to evaluate the efficacy and safety and of two doses of Aramchol for the treatment of NASH in patients who are overweight or obese and
have pre diabetes or type II diabetes mellitus. In order to be eligible to participate in the ARREST Study, patients had to be affected by NASH, as
diagnosed by a biopsy centrally read (steatosis ≥1 + inflammation ≥1 + ballooning ≥1, total activity NAS score of 4 or more), have a fibrosis stage of 1-3,
be overweight or obese as measured by a Body Mass Index between 25 and 40 or waist circumference between 88cm to 200cm for women, and between
102cm to 200cm for men, and who are pre diabetic or type II diabetic. We targeted this specific population as it is at the greatest risk of developing NASH
and its complications. We have generated data from animal models that lead us to believe that Aramchol targets all three main pathologies of the disease:
steatosis, inflammation and fibrosis.
62
A total of 247 patients (approximately one third in the US, one third in Latin America and one third in Europe and Israel) with liver biopsy-proven
NASH who were overweight or obese and had pre-diabetes or type II diabetes mellitus were randomized. Patients were randomized in a ratio of 2:2:1
(600mg, 400mg and placebo) taking once-daily oral Aramchol (in the Aramchol treatment arms) or a placebo (in the placebo arm). The treatment part of
the trial was 12 months in duration and patients completing this phase were observed for a three month follow-up period. In February 2017, we completed
randomization of the ARREST Study. Baseline histology of patients enrolled into the ARREST study demonstrated a population with advanced disease,
with 60% having stage 2 and 3 fibrosis and 70% have NAS>5 at baseline.
The primary endpoint of the study was the change from baseline to end of study in liver triglycerides ratio as measured by magnetic resonance
spectroscopy, or MRS (Aramchol 600mg vs. placebo). Secondary endpoints, demonstrated through biopsy, included fibrosis improvement by at least one
stage or more without worsening of NASH (defined by an increase of inflammation and or ballooning) and NASH resolution (defined by ballooning score
0 and inflammation score 0-1 at termination) without worsening of fibrosis. Other secondary endpoints included improvement (2 points or more) in NASH
activity index, as measured by NAS or SAF, without worsening fibrosis and change in baseline to week 52/termination in ALT (U/L).
On June 12, 2018, we announced top-line results of the ARREST Study and on November 13, 2018 an oral abstract presentation of one-year
results of the ARREST Study was presented during a Late Breaking Abstract Oral Session at The Liver Meeting® 2018 during the American Association
for the Study of Liver Diseases 2018 Annual Meeting.
Of the 247 patients, 48 patients were in the placebo arm, 101 patients in the Aramchol 400mg arm and 98 in the Aramchol 600mg treatment arm.
The majority of subjects completed 52 weeks of treatment and 13 weeks of follow up (89.1%, 89.8%, 85.4% in the 400 mg, 600 mg and placebo arms,
respectively). The leading cause of discontinuation was consent withdrawal and early termination due to adverse events; the incidence of early termination
due to AEs was very low and similar across study arms.
Patients in the ARREST study were planned to undergo MRS, and a liver biopsy at baseline and week 52, which were centrally read, blinded to
treatment allocation. The statistical analysis plan included pre-defined analysis sets: (i) a full analysis set for MRI (FAS -— MRI): all intent to treat, or ITT,
patients with baseline and at least one second MRS. 214 patients were included in this analysis set (41 in placebo; 90 in Aramchol 400mg; and 83 in
Aramchol 600mg); and (ii) a full analysis set for liver biopsy (FAS -— biopsy): all ITT patients with baseline and a second biopsy. 198 patients were
included in this analysis set (40 in placebo; 80 in Aramchol 400mg; and 78 in Aramchol 600mg).
Results from the study showed a statistically significant reduction in liver fat by MRS with Aramchol 400mg vs. placebo (p=0.0450) and not with
600mg (p=0.0655) and thus did not reach the primary endpoint of the study. In a post-hoc analysis, a cutoff of 5% absolute reduction in liver fat was used
as a surrogate for potentially clinically meaningful MRI reduction. In this responder’s analysis, a dose-response could be observed; the responder rate was
47.0%, 36.7% and 24.2%, in the Aramchol 600mg, 400mg and placebo arms, respectively. The proportion of the Aramchol 600mg arm compared to
placebo was statistically-significant (p=0.0279).
Results for the two biopsy endpoints, which may currently constitute a primary endpoint for a Phase 3 trial to support an FDA marketing
application, demonstrated the following: (i) significantly more patients treated with Aramchol 600mg vs. placebo achieved NASH resolution without
worsening of fibrosis (16.7% vs. 5.0%; p=0.0514); and (ii) a higher proportion of patients showed at least one-point improvement in fibrosis score without
worsening of NASH in Aramchol 600mg vs. placebo (29.5% vs. 17.5%; p=0.2110).
Statistically significant reductions in live enzymes alanine transaminase (ALT) and aspartate transaminase (AST) were demonstrated in both
Aramchol arms vs. placebo (p≤0.0002) and (p<0.0001), respectively.
Secondary endpoints based on NAS and SAF activity score, ≥2 points improvement, showed a higher proportion of patients with improvement in
the Aramchol arms (600mg>400mg>placebo; P>0.05).
Exploratory endpoints of glycemic parameters showed statistically significant reductions in HbA1c with both Aramchol arms vs. placebo
(p<0.007) implying a potential effect on glycemic control.
At 52 weeks of treatment, Aramchol continued to show a favorable safety and tolerability profile. Serious adverse events were reported in 12.5%,
8.9% and 9.2% of patients in placebo, Aramchol 400mg and 600mg arms, respectively. No clustering of event type or atypical events for the studied
population was reported in either Aramchol arms. Severe adverse events were reported in 10.4%, 6.9%, and 6.1% of patients in placebo, Aramchol 400mg,
and 600mg arms, respectively. Early terminations due to adverse events occurred in 4.2%, 3.0% and 4.1% in placebo, Aramchol 400mg and 600mg arms,
respectively.
The following table summarizes the most frequent adverse events.
63
The following table summarizes the ARREST results:
MRS- –Absolute change from baseline in mean liver fat (1)
MRS responders- Reduction of ≥5% in absolute change from baseline (1)
NASH resolution without worsening of fibrosis (2)
NASH resolution (2)
Fibrosis improvement (≥1 stage) without worsening of NASH (2)
Progression to Cirrhosis (Post-Hoc Analysis) worsening of NASH (2)
ALT (U/L) Change from baseline (3)
AST (U/L) Change from baseline (3)
HbA1C Change from baseline (4)
Placebo
Aramchol
400 mg
Aramchol
600 mg
(0.09)%
24.4%
5%
7.5%
17.5%
7.5%
+11.82
+6.67
+0.32
(3.41)%
P=0.0450
36.7%
P=0.0878
7.5%
P=0.4955
12.5%
P=0.2237
21.3%
P=0.8425
7.5%
P=0.5693
-12.0
P=0.0002
(7.20)
p=0.0011
(0.04)
p=0.0061
(3.18)%
P=0.0655
47.0%
P=0.0279
16.7%
P=0.0514
19.2%
P=0.0462
29.5%
P=0.2110
1.3%
P=0.1008
(17.3)
P<0.0001
(10.83)
p<.0001
(0.13)
p=0.0008
(1) Placebo N=41; 400mg N=90, 600mg N=83; Mixed Effect Model Repeat Measurement (MMRM) adjusted mean changes from baseline; p-values
for comparison of active treatment arm vs. placebo.
(2) Placebo N=40, 400mg N=80, 600mg N=78; Baseline adjusted logistic regression; p-values for comparison of active treatment arm vs. placebo.
(3) Placebo N=47, 400mg N=100, 600mg N=98; MMRM adjusted mean changes from baseline; p-values for comparison of active treatment arm vs.
placebo.
(4) Placebo N=47, 400mg N=98, 600mg N=96; MMRM adjusted mean changes from baseline; p-values for comparison of active treatment arm vs.
placebo.
64
Dose Splitting Pharmcokinetic Study (NCT03774173)
As a result of the dose response pattern observed in the ARREST Study, we recently conducted a Phase 1, open-label, crossover PK study to
assess whether dose splitting of Aramchol 600mg to twice daily 300mg will significantly increase plasma levels. 16 healthy subjects took part in two study
periods. Eight subjects received each regimen in the first period and the alternate regimen in the second period. A PK profile was obtained over the dosing
interval at steady state on day ten of each period.
Results of the study showed that the administration of Aramchol 300 mg twice daily resulted in 24-hour plasma concentrations significantly
greater than those observed with the administration of Aramchol 600 mg once daily. (P<0.0001). The average plasma levels (exposure) were 53% higher
and exposure was greater in all 16 subjects with the twice daily dosing. The treatment in both dosing regimens were similar in terms of safety and were
well tolerated.
First in Human Aramchol Meglumine Pharmcokinetic Study
In December 2020, we announced new data from a Phase 1, first in human study that compared Aramchol meglumine to Aramchol acid.
Armachol acid and Aramchol megluine was administered twice daily to 12 subjects. Below is a summary of the results:
65
These initial results demonstrated that the new salt form of Aramchol meglumine has a plasma PK profile that is very similar to Aramchol acid. It
also showed that the administration of both forms resulted in the same form of Aramchol in the blood, regardless of which drug product is administered and
that less Aramchol meglumine is needed for the same exposure of Aramchol acid in the blood.
Phase 3 ARMOR Study for Aramchol
In September 2019, we initiated the ARMOR Study, a Phase 3 pivotal study of Aramchol for the treatment of NASH, following a successful End-
of-Phase 2 meeting with the FDA in April 2019 in which we reached general agreement on key aspects of the Phase 3 development and registration plan
for Aramchol. The ARMOR Study was originally comprised of two parts, a randomized, double-blind, placebo-controlled histology -based registrational
part where 1200 subjects will be treated with Aramchol or matching placebo for 52 weeks and a clinically based part where subjects will continue with the
same treatment for approximately five years, taking into consideration draft guidance issued by the FDA in December 2018 entitled “Noncirrhotic
Nonalcoholic Steatohepatitis with Liver Fibrosis: Developing Drugs for Treatment”, or the “December Guidance”. The histology-based data is intended to
serve as the basis for the submission of a marketing authorization application under regulatory provisions of Sub-part H accelerated/conditional approval.
In light of the rapid development of the Aramchol meglumine program and due to the delays resulting from the COVID-19 pandemic, in
December 2020, we announced the addition of an open label part to the ARMOR Study and temporarily suspended randomization of new patients into the
double-blind, placebo-controlled histology-based registrational phase of ARMOR as currently enrolled patients are transitioned to the open label part.
In August 2021, we announced that the FDA agreed with our plan to use Aramchol meglumine (in lieu of Aramchol free acid) in our ARMOR
Study without the need to conduct additional nonclinical and clinical studies other than planned limited pharmacology studies relating to Aramchol
meglumine. In addition, the Medicines and Healthcare products Regulatory Agency, or MHRA, the pharmaceuticals regulator in the UK, also agreed with
our plan to proceed with our proposed clinical studies with Aramchol meglumine in lieu of Aramchol free acid without the need to repeat nonclinical and
clinical studies other than planned limited pharmacology studies relating to Aramchol meglumine.
In November 2021, we announced positive interim data on the open label part of the ARMOR Study showing clinically significant effect on
fibrosis improvement based on histology in the first 16 patients. Subsequently in November 2021, we announced that new analyses of biomarkers
corroborate this effect showing statistically significant reductions in biomarkers associated with liver fibrosis including ALT, AST, Fib-4 and ProC-3.
Reductions of a similar magnitude were seen in a cohort of the first 20 patients for which paired biopsy have been analyzed and a cohort of 50 patients for
which biomarker data was analyzed based on all available data at that time. In addition, we reported that Aramchol continues to show excellent safety and
tolerability profile. Data support that a higher dose of Aramchol could provide statistically and clinically meaningful effect on fibrosis in the double-blind
placebo controlled part for submission of the ARMOR Study to support an NDA under Sub-part H.
66
In April 2022, we announced further positive interim data on the open label part of the ARMOR Study showing robust fibrosis improvement
across multimodality histological assessment. Results of post baseline biopsies performed either at 24 weeks or at 48 weeks from 46 subjects with NASH
and F1-3 that received Aramchol support the anti-fibrotic effect of Aramchol and reinforce the favorable safety profile of Aramchol.
In May 2022, we announced the discontinuation of the open label part of our ARMOR Study having reached its objectives and in January 2023,
we announced full results from the open label part of the ARMOR Study. Following the discontinuation of our open label part of the ARMOR Study, we do
not currently expect to initiate the second part of the ARMOR Study.
The Phase 3 study is a two-part study, an open-label part and a randomized, double-controlled, placebo part, designed to evaluate the safety and
efficacy of Aramchol and to be conducted in approximately 200 sites in the U.S., Europe and Latin America.
Part One: Open Label Study
The first part, an open-label study, was originally designed to evaluate treatment response kinetics, pharmacokinetics and safety of twice daily
administration of Aramchol 300mg in approximately 150 subjects with NASH and liver fibrosis stage 1-3 (F1 capped at 30 subjects), subjects with NASH
who may or may not be overweight, and subjects with NASH who may or may not have type 2 diabetes or be pre-diabetic. Patients were randomized
(1:1:1) into three groups with post-baseline liver biopsy being performed at 24 weeks, 48 weeks, or 72 weeks, respectively. A second post-baseline liver
biopsy was conducted after one year for subjects whose post-baseline liver biopsy at week 24, 48 or 72 does not show at least one stage improvement in
fibrosis. The open label part was being conducted at approximately 50 selected sites in the U.S., and around the world which have been less affected by the
COVID-19 pandemic.
The open label study enrolled 157 subjects. Fifty-one (51) subjects underwent post-baseline biopsies prior to study discontinuation (28 subjects at
<48 weeks and 23 subjects at ≥48 weeks). The study was designed to assess the safety, pharmacokinetics (PK) and efficacy kinetics as a function of
treatment duration. Three independent pathologists and three different histopathology reading methodologies were used to assess the antifibrotic effect of
Aramchol: fibrosis stage based on NASH CRN; ranked assessment (improvement/worsening/stable) of paired (pre- and post-baseline) biopsies, blinded to
sequence; and an automated and continuous score of Fibrosis Composite Severity (FCS), using FibroNest™, a quantitative AI digital pathology image
analysis method. Noninvasive tests (NITs) included imaging (fibroscan) and biomarkers (liver enzymes, FIB-4, Pro-C3 and ELF).
Aramchol treatment resulted in a high proportion of subjects showing fibrosis improvement based on all three biopsy reading methodologies, with
a larger treatment effect with longer duration of therapy. Following a treatment duration of 48 weeks or more, improvement in fibrosis was demonstrated in
39% of subjects according to NASH CRN and 61% of subjects according to ranked assessment. At Week 48 AI demonstrated fibrosis improvement in
100% of subjects when responders were defined by an absolute reduction of the FCS score >0.3, 65% when responders were defined by a relative reduction
of >25%, and a statistically significant reduction from baseline in mean FCS score (p<0.0001). NASH resolution without worsening of fibrosis was
demonstrated in 26.5% of subjects.
Fibroscan, ALT, AST, and FIB4 were analyzed using MMRM, based on all subjects (N=154). Fibroscan results were consistent, with an
improvement in fibrosis showing a mean absolute reduction from baseline to week 72 of 2.5 kPa (p<0.0001). At Week 72, ALT was reduced by 22 U/L
(p<0.0001), AST was reduced by 18 U/L (p<0.0001), and FIB-4 was reduced by 0.30 (p<0.0001).
Pro-C3 and ELF were analyzed for 43 subjects at week 24 showing reduction in both Pro-C3 levels (p<0.0001) and ELF (p=0.0038).
The Open Label part demonstrated the good safety profile of Aramchol 300mg BID including long-term follow up. The incidence of serious
adverse events (SAEs) was consistent with the population (10.4%) and early discontinuation rates due to adverse events (AEs) were low (4.5%).
67
Part Two: Histology-Based and Clinically-Based Study
The second part of the ARMOR Study is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Aramchol
300 mg BID to support regulatory approval, with both a histology-based phase and a clinically-based phase. As currently designed, a total of 2000 subjects
with NASH and liver fibrosis stage 2 and 3 who are overweight and are either pre-diabetic or have type 2 diabetes would be randomized 2:1 to receive
Aramchol 300mg BID or matching placebo. In the histology-based phase, we intend to treat 1000 subjects with Aramchol or matching placebo for 72
weeks until the second biopsy. The histology-based data is intended to serve as the basis for the submission of a Sub-part H marketing authorization
application under regulatory provisions of accelerated/conditional approval. The primary histology-based endpoint is NASH resolution without worsening
of fibrosis or fibrosis improvement without NASH worsening. In the clinically-based phase, all subjects will continue with the same treatment assignment
for up to seven years until study completion to confirm clinical efficacy. We may announce end-of-study at the time when a total of 380 subjects have
experienced at least one pre-specified clinical event or at five years from last subject randomization, whichever comes first. The primary clinically-based
endpoint is expected to be based on clinical events including all-cause mortality, histological progression to cirrhosis, MELD score >15, and hepatic
decompensation events (e.g., hepatic encephalopathy, variceal bleeding, ascites). If the clinical trial results in the histology-based phase are positive, we
plan to submit an NDA for Sub-part H accelerated/conditional approval to the FDA. As discussed elsewhere, we suspended the initiation of the double-
blind placebo-controlled histology-based registrational part of ARMOR and are seeking to initiate the double-blind placebo-controlled histology-based
registrational part of ARMOR in the second half of 2023, subject to, among other things, the results of our open label part, sufficient funding and
clarification of the regulatory approval process for NASH drugs.
The following is a depiction of part two of the ARMOR Study:
Amilo-5MER
In August 2020, we announced significant progress in the development of Amilo-5MER, a 5 amino acid synthetic peptide MTADV (Methionine,
Threonine, Alanine, Aspartic acid, Valine). The 5 amino acids sequence of Amilo-5MER is homologue to a specific MTADV sequence in the human CD44
variant found in synovial fluid cells from joints of rheumatoid arthritis, or RA patients.
Amilo-5MER is being developed through a research collaboration between us and the Hebrew University of Jerusalem. The molecule originated
in the laboratory of Prof. David Naor, from the Lautenberg Center for Immunology and Cancer Research, Faculty of Medicine, The Hebrew University.
Prof. Naor and his team were the first to publish this specific sequence in the prestigious scientific communication Journal of Clinical Investigation 1.
68
Amilo-5MER binds to three pro-inflammatory amyloid proteins, Serum Amyloid A, or SAA, Transthyretin and Apolipoprotein B with high
affinity. The first two are known to be active only in their aggregated forms. By binding to SAA, Amilo-5MER interferes with SAA aggregation and
therefor inhibits the destructive autocrine, self-amplifying cytokine loop that causes additional inflammatory reaction.
SAA constitutes acute phase reactants, whose concentration in serum rise rapidly in response to acute stimuli such as infection and trauma. An
elevated concentration of SAA was identified in sera of patients with multiple autoimmune diseases and more recently, an outstanding increase of SAA was
also detected in COVID-19 infected patients2-3. SAA in its aggregated form, is a potent and rapid inducer of cytokine secretion (particularly Interleukin 6
(IL-6). IL-6 plays an important role in chronic inflammation and is implicated in the pathogenesis of many autoimmune diseases, such as Multiple
Sclerosis, or MS, RA, Inflammatory Bowel Disease, or IBD and acute COVID 19. Interference with SAA polymerization and aggregation is a valid target
to prevent chronic inflammatory conditions.
Amilo-5MER has been shown to significantly reduce chronic inflammation in animal models of RA, IBD and MS (research work supported by a
grant to Prof. Naor from the National Multiple Sclerosis Society (NMSS) of the USA). Amilo-5MER provides a unique mechanism of action to interfere
with this vicious cycle, enabling a specific treatment for chronic inflammatory diseases. Data generated from multiple in-vitro, in-vivo and human ex-vivo
models have shown that Amilo-5MER significantly improves clinical symptoms. Histological improvements and reduction of pro-inflammatory cytokine
secretion were also observed.
Amilo-5MER is considered a New Chemical Entity. As such, it is eligible for NCE patent protection until July 2034. Patents have been granted
and maintained in the US (US 1061181937), Europe (EP 3169343) and Australia (AU 2015291151) and have been allowed in Japan (JP 6671363).
In March 2021, we dosed the first subject in our first in human Phase 1 trial of Amilo-5MER for the treatment of chronic inflammatory diseases.
The trial was a three-part, single center, double-blind, randomized, placebo-controlled first in human study of single ascending doses (Part 1) and multiple
doses (Part 2) of Amilo-5MER in young healthy adult male subjects and a single dose cohort in healthy elderly male and female subjects (Part 3). Overall,
55 healthy male and female subjects were enrolled in the study. Cohorts of 8 subjects were randomized to receive Amilo-5MER or placebo by
subcutaneous injection in a ratio of 6:2. In Part 1, cohorts of young male adults received single ascending doses of 10, 30, 90, 180 and 360 mg; in Part 2, a
single cohort received doses of 180 mg BID for 5 consecutive days and in Part 3 a single cohort of healthy elderly male and female subjects received a
single dose of 180 mg. The primary objectives of the trial were to evaluate the safety, tolerability, and pharmacokinetics of Amilo-5MER. In January 2022,
we announced results in which all doses of Amilo-5MER were well tolerated with no clinically significant adverse events and none considered related to
the investigational product. All subjects completed the study as per protocol. Overall exposure to Amilo-5MER increased with an increase in dose, with
statistically significant dose proportionality over the 10 mg to 360 mg dose range. We are currently evaluating which indication to pursue further
development of Amilo-5MER.
Additional Pre-clinical and Clinical Studies Required for Regulatory Submissions
Toxicology Studies
Since the completion of the Phase 2a study, pre-clinical toxicology studies have been conducted to support our ongoing clinical programs and
regulatory submissions. These studies were performed in compliance with the EMA’s ICH M3 (R2) guidelines. The toxicity program for Aramchol
included repeat dose studies of up to six months in rats and up to nine months in dogs by oral administration, the intended route of administration in the
clinical trials and beyond. The dose level of 1000 mg/kg/day in rats and 1500 mg/kg/day in dogs, which is the maximal feasible dose in both species
showed no side effect and therefore the highest dose of the study was selected as the no-observed-adverse-effect-level, or NOAEL. There were no
observations noted in the rat study. The findings in the dog study were limited to changes in plasma lipids, including decreases in total blood cholesterol
levels, LDL, HDL and phospholipids, and a slight increase in the size of the adrenal glands, which were considered to be an extension of the primary
pharmacology of Aramchol and non-toxic effects, and skin scales from week 13 onwards in all Aramchol-treated groups, with a dose-related incidence.
After six months this was not accompanied by any microscopic alteration of the skin and therefore considered not toxicologically relevant. Results from the
study show that after nine months the presence of scales in all Aramchol-treated groups was accompanied by minor test item-related microscopic findings
in the skin: Hyperkeratosis of the epidermis, correlating to the scales, and keratin plugs in the hair follicles (in males at 750/500 and 1500 mg/kg). After a
12-week treatment-free recovery period, fewer scales were noted and microscopically there was partial recovery. As these findings were minor and no
clinical symptoms like scratching were noted, these findings were considered not adverse.
69
Aramchol was non-mutagenic in vitro in the Ames test and chromosomal aberrations test, each of which is a test to determine whether the subject
chemical can cause mutations in the DNA of an organism. In addition, in bone marrow micronucleus test in male rats at a 2000 mg/kg oral dose (the
maximum recommended dose in accordance with ICH S2 (R1)), Aramchol was not clastogenic, meaning it did not give rise to or induce disruption or
breakages of chromosomes, nor was it aneugenic, meaning it did not cause the number of chromosomes in the nucleus of a cell to not be an exact multiple
of the monoploid number of a particular species.
Embryo-fetal development toxicity was assessed in rats and rabbits. No maternal or fetal development toxicity was observed in either species. The
NOAEL for maternal and development toxicity was at least 1000 mg/kg in rats and 750 mg/kg in rabbits (the maximum feasible dose in both species).
No maximum tolerated doses were reached in the studies. Over 50-fold safety margin exposure was achieved in dogs but not in rats. However, for
rats, at least three of the four ICH M3(R2) safety margin criteria were met, and for dogs all four criteria were met. Blood tests revealed a decrease in total
blood cholesterol levels, including LDL, HDL and phospholipids, and there was a slight increase in the size of the adrenal glands of the dogs, which WIL
Research assessed as a physiologic compensatory response to the decrease in blood cholesterol levels. WIL Research did not consider the decrease in blood
cholesterol levels or the physiologic response of the adrenal glands as a toxic effect, but rather as a pharmacodynamic effect, which is a biochemical and
physiological effect of the drug on the body. Based on the above, it was concluded that the overall safety data for Aramchol is sufficient to support the
proposed Phase 2b clinical trial.
To support any potential future NDA, we have commenced or are planning to commence several safety studies. Additionally, we plan in the future
to conduct a study of Aramchol in the pediatric population.
In addition, we have conducted carcinogenicity studies to identify whether Aramchol has any tumorigenic potential upon long-term administration
in support of any future NDAs or MAAs. Under FDA guidance, we are required to perform two studies, one in rats and the other in mice. The
carcinogenicity study in rats is a two-year study which was initiated in February 2020 and finalized during 2022. There were no significant adverse
findings reported over the course of the study.
Aramchol for the Treatment of Other Indications
On February 14, 2018, we announced topline results from the investigator initiated ARRIVE Study for HIV associated lipodystrophy and NAFLD
patients. HIV patients have advanced liver disease which is a major cause for morbidity and mortality. ARRIVE, a Phase 2a, investigator initiated clinical
trial conducted at the University of California
San Diego by Professor Rohit Loomba was a randomized, double-blinded, placebo-controlled, 12 weeks, proof-of-concept study that evaluated the
safety and efficacy of Aramchol at 600mg/day versus placebo in 50 patients with HIV-associated lipodystrophy and NAFLD. The primary end point of
successful therapy was improvement in hepatic steatosis at 12 weeks, as measured by MRI-PDFF. Secondary endpoints were improvement in total body
fat, metabolic profile, and liver biochemistry. Liver biopsies were not included as part of the evaluation in this pilot trial. The trial showed no difference
between HIV patients receiving Aramchol for 12 weeks when compared with HIV patients in the placebo arm. Aramchol showed a favorable safety and
tolerability profile. Although the pathology (fatty liver) is similar to “garden variety” NASH, the pathogenesis involved in the HIV lipodystrophy and
NAFLD is different and multi factorial including the effect of the virus itself and the anti-HIV medications.
70
On November 13, 2014, we announced the first administration of Aramchol in a proof-of-concept Phase 2a clinical trial for the treatment of newly
formed cholesterol gallstones following bariatric surgery. The primary end-point was to prove that Aramchol dissolves newly formed gallbladder gallstones
following bariatric surgery. Patients were to be assigned to one of three treatment arms; 400mg tablets, 600mg tablets and placebo. Only 9 patients were
enrolled, and 7 patients completed the study. Due to poor patient recruitment and change in Company focus, we decided to terminate the study on October
1, 2015. We currently believe that it is unlikely that we will revive another study in cholesterol gallstones.
In July 2022, we announced results showing significant effects of Aramchol in pre-clinical model of both lung and gastrointestinal (GI) fibrosis.
Fibrosis is a common complication of chronic inflammation and can affect all organs and tissues. To date, only limited anti-fibrotic drugs are approved or
are in development, most of which have restricting side effects. Aramchol is a partial inhibitor of SCD1 with distinctive, direct, anti-fibrotic activity
demonstrated in several pre-clinical models. Treatment with Aramchol resulted in statistically significant fibrosis improvement in a validated bleomycin
model of lung fibrosis (IPF), comparable to Pirfenidone which is the gold standard treatment. Findings were seen across all important indicators for the
severity of fibrosis including hydroxyproline (a marker for collagen deposition in the fibrotic tissue) P< 0.05, Ashcroft score P < 0.005, % CPA (Percentage
Collagen Proportionate Area of the lung) P < 0.001, and immunohistochemistry (type I collagen and a SMA) P < 0.005 for both staining. Statistically
significant improvements were also demonstrated in a validated DSS model of inflammatory bowel disease (IBD). Dextran sulfate sodium (DSS) induced
colitis model is widely used because of its similarities with human ulcerative colitis. Clinical improvements were statistically significant at least by p value
< 0.05 while in histological score (based on inflammation and colon structural changes) significance was as low as p<0.01. Aramchol was found to be the
most effective compound tested. Control groups included 5-ASA and local steroids which are the gold standards for current treatment.
In May 2023, we announced the initiation of a new clinical program to evaluate Aramchol meglumine for the treatment of PSC, a rare disease for
which there is no approved treatment. We initially planned to initiate a Phase 2a study in the last quarter of 2023 however as a result of Hamas-Israel war,
we currently estimate a delay of ~7-9 months in the initiation of the study. While PSC is more common in men, especially in Northern European heritage,
and is often diagnosed between ages 30-40, we currently estimate that the number of patients to be around 60,000, or 1 per 10,000, consisting of around
33,5000 patients in the United States and 32,500 patients collectively in France, Germany, Italy, Spain and the United Kingdom. In the preclinical stage,
PSC likely involves ulcerative colitis (UC) leading to biliary inflammation. As biliary fibrosis progresses to cirrhosis, it is coupled with complications and
competing risks, while about 50% of patients with PSC report clinical symptoms. While there are currently no approved drugs for the treatment of PSC,
there is a potential to gain orphan drug status.
Strategic Collaborations, Research Arrangements and other Agreements
Samil Pharma. Co., Ltd.
On July 28, 2016, we entered into a license agreement, referred to herein as the Samil Agreement, with Samil for the commercialization of
Aramchol (with the option to manufacture) in the Republic of Korea, or the Territory.
Under the terms of the Samil Agreement, the Company has granted Samil an exclusive licence, or the Samil License, for fatty liver indications
including NASH, or the Field of Use, in the Republic of Korea, or the Territory to such information concerning Aramchol as may be required to support
Samil’s applications for regulatory approvals, or the Licensed Information, and the patents for the import, marketing, use, sale, offer for sale,
commercialisation and distribution (and, if the option is exercised, manufacture) of Aramchol in tablet form, or any other physical form as may be
produced or manufactured by or on behalf of Galmed or by a third party for Galmed and, if the option set out below is exercised, any products within the
Field of Use, the development, manufacture or sale of which is based, in whole or in part, on, or involves the use of, the Licensed Information or covered
under any patent, or the Product.
The Samil License shall remain in force with respect to each Product (if the Samil Agreement is not early terminated) until the later of: (i) the date
of expiry in the Territory of the last of any patent covering such Product or any formulation, dosing or administration form thereof; and (ii) the date of
expiry of a period of 20 years commencing on the date of first commercial sale by Samil or a sublicensee of such Product in the Territory.
Upon the signing of the Samil Agreement, Samil paid the Company a gross upfront fee of approximately $2.1 million and in September 2018, we
received a milestone payment of $1.5 million. Samil has also agreed to pay additional clinical and regulatory-based milestone payments, which may
aggregate to an additional $4.5 million, as well as tiered, double-digit royalties payable on sales (lower if sales of a generic equivalent commence in the
Territory).
Pursuant to the terms of the Samil Agreement, following the first achievement of US$25 million of net sales in any calendar year following the
first commercial sale of the Product in the Territory, Samil shall have the option to request that the Licensed Information include methods for the
formulation of Aramchol from its API, to allow for the manufacture of Aramchol by Samil; provided, however, that we shall have the option, to widen the
definition of the Licensed Information as aforesaid at any time.
71
We shall be entitled, at our option: (i) to modify the Samil License with respect to any Product so that it is non-exclusive only; or (ii) to terminate
the Samil License hereunder, with respect to any Product if: (a) a first purchasing order from Samil for at least one Product shall not have been placed by 6
months following the grant of the Korean Ministry of Food and Drug Safety new drug approval; or (b) commercial sale of such Product having commenced
and either (i) there shall be a period of 1 year during which no sales of any Product shall take place, or (ii) within 1 year of such commencement, aggregate
sales of Products shall not have reached a reasonable level, as determined by the joint development committee, in each case, except as a result of force
majeure or other factors beyond the control of Samil. Further, we shall be entitled to terminate the Samil Agreement if Samil challenges the validity of any
of the patents. If any such challenge is unsuccessful, Samil shall (in addition to our right to terminate) pay us liquidated damages in the amounts of US
$8,000,000. Either party may terminate the Samil Agreement (i) upon the other party’s material breach if such party fails to cure such breach within 30
days, or, in the case of failure by Samil to pay any amount due from Samil to us pursuant to or in connection with the Samil Agreement 14 days after
receiving written notice thereof, or (ii) upon customary events such as the granting of a winding-up order if such order or act is not cancelled within 60
days.
In the event that we do not achieve the primary endpoint as defined in the study protocol, or Successful Completion, of the ARREST Study, we
shall as soon as practicable notify Samil of the non-achievement of such Successful Completion, and within 60 days thereof, notify Samil in writing either:
(i) that we have decided not to develop the Licensed Information further for the Field of Use, or the Cessation Notice, or (ii) that we intend to continue with
such development notwithstanding the non-achievement of such Successful Completion, or the Licensor Continuation Notice. Also, in the event that we do
not achieve the Successful Completion of the potential Phase 3 Study, we shall, as soon as practicable, notify Samil accordingly, or the Notice of Non-
Success. Samil shall thereafter have the option, by notice in writing served to us within 45 days of Samil’s receipt of either a Cessation Notice, a Licensor
Continuation Notice or a Notice of Non-Success, as applicable, to indicate its intention either: (i) to terminate the Samil License, or (ii) to continue research
and development of the Licensed Information in the Field of Use in the Territory, or the Licensee Continuation Notice. In the event Samil shall serve a
Licensee Continuation Notice following the service of a Cessation Notice or a Notice of Non-Success, any such continuation by Samil shall be subject to
the entry by Samil into a written agreement with us as to the terms and conditions which would govern such continued research and development, which
would be carried out according to Samil’s own development plan and at its sole expense. In the event Samil serves a Licensee Continuation Notice
following the service of a Licensor Continuation Notice, or Agreed Continuation, the Samil Agreement shall continue in accordance with its terms. In
August 2018, Samil sent a Licensee Continuation Notice to us.
Additionally, following the Successful Completion of the ARREST Study or Agreed Continuation following non-achievement of Successful
Completion of the ARREST Study, Samil shall, for a period of 90 days following the date of written notification to it by us of such Successful Completion
or following the date of Agreed Continuation following non-achievement of Successful Completion, have the option to require that the Territory be
extended to include Vietnam, or the Extension Option. In the event that Samil exercises its Extension Option, the parties shall conduct negotiations in good
faith for up to 30 days thereafter in order to agree on milestone payments which would replace those set out in the Samil Agreement. In the event that
agreement is not reached in such regard within such period, the Extension Option shall terminate. Discussions for the extension of the Samil License to
Vietnam are ongoing.
Amilo 5-MER
We have entered into a research and option agreement with Yissum, the tech transfer company of the Hebrew University with respect to our
Amilo-5MER, a 5 amino acid synthetic peptide MTADV (Methionine, Threonine, Alanine, Aspartic acid, Valine). Under this agreement, we are able to
research and initially develop Amilo-5MER, are required to fund the initial research and have been granted an exclusive option to negotiate and enter into a
definitive license agreement with Yissum for Amilo-5MER upon certain pre-agreed upon terms and such other terms to be agreed upon.
72
As a result of the success in the Phase 1 study, we exercised our option and on June 28, 2021, we entered into a license agreement with Yissum
pursuant to which Yissum granted us a worldwide, exclusive and irrevocable license to develop and commercialize Amilo-5MER. In November, 2021, the
grant of the license took effect when it was approved by the Israel Innovation Authority. Under the license agreement, we are responsible for carrying out
the development and commercialization of Amilo-5MER and the prosecution and maintenance of the licensed patents under the license agreement. In
consideration for the grant of the license, we have agreed to pay to Yissum an upfront license fee of $100,000, payments of up to $950,000 upon meeting
certain regulatory milestones, single digit royalties on any future net sales and a share of any sublicense fees. Unless earlier terminated, the license will
continue in effect on a product-by-product and country-by-country basis until the later of (i) the expiration of the last to expire patent covering the licensed
technology in such country, (ii) the expiration of any exclusivity on Amilo-5MER granted by a regulatory body in such country, and (iii) 15 years from the
first commercial sale in such country. The license agreement may be terminated early for material breach or bankruptcy. In addition, we may terminate the
license agreement without cause upon 90 days prior written notice to Yissum and Yissum may terminate the license agreement upon written notice to us
under certain limited circumstances.
Onkai
In May 2023, we entered into the OnKai Agreement for a $1.5 million equity investment in OnKai, a US-based technology company developing
an AI-based platform to advance healthcare for underserved populations across the United States by facilitating alignment between healthcare stakeholders.
The signing of the definitive agreement followed an announcement that we made in January 2023 that we had entered into a non-binding termsheet for an
equity investment in OnKai. The OnKai Agreement provided that we will invest $1.5 million in exchange for series seed preferred shares of OnKai (which
is in addition to a $1.5 million investment that was made by us in OnKai through a SAFE and which converted at a 15% discount into series seed preferred
shares upon consummation of the Investment Round). Our investment in OnKai was part of an approximately $6.0 million Investment Round with other
investors that was led by us of which SAFE notes of approximately $3.8 million were converted into preferred shares. On June 19, 2023, the Investment
Round closed. Following the Investment Round, we hold approximately 23.9% of the outstanding share capital of OnKai on an as-converted and fully and
our Chief Executive Officer and director, Allen Baharaff serves as a board member of OnKai. In connection with the OnKai Agreement, our wholly-owned
subsidiary, GRD entered into the OnKai Services Agreement with OnKai. The OnKai Services Agreement provides that GRD shall on a non-exclusive
basis (i) provide support services to OnKai relating to finance, business development, strategic planning, execution and others; and (ii) lend its experience
to OnKai in building a strategy and for the development of treatments for the underserved and that OnKai shall on a non-exclusive basis (i) take part in plan
preparation to serve GDR’s vision of developing drugs for the underserved population and (ii) when relevant, design a process on the clinical trial
dashboard that could potentially serve GDR’s future trial. In July 2023, we announced that OnKai will apply its artificial intelligence models for enrollment
and execution of clinical trials in underserved communities, starting with our PSC clinical program.
OnKai is developing a proprietary technology, a “smart grid”, that maps local clinics serving millions of underserved Americans and streams to
these clinics resources, including funding, specialists, training, and access to clinical studies. This is intended to facilitate faster clinical trial enrollment and
provide clinical trials as a healthcare option in these communities by bringing novel medications, such as access to orphan drugs, to communities in need.
We believe that it will potentially benefit in the future from enhanced access to a pool of clinical trial participants for the advancement of our product
candidates.
Competition
The pharmaceutical industry is characterized by rapidly evolving technology, intense competition and a highly risky, costly and lengthy research
and development process. Adequate protection of intellectual property, successful product development, adequate funding and retention of skilled,
experienced and professional personnel are among the many factors critical to success in the pharmaceutical industry.
We operate in a competitive sector. Several companies are working on technologies, therapeutic targets or drug or biomarker candidates that aim
to treat or diagnose the same diseases or identify the same patient population as our product candidates. While we believe that our drug candidates and
diagnostic solutions, combined with our expertise and know-how, provide us with competitive advantages, we face potential competition from various
sources, including pharmaceutical and biotechnology companies, as well as from academic institutions, governmental agencies and public and private
research institutions. We anticipate that we will face intense and increasing competition as new drugs and therapies enter the market and advanced
technologies become available. In some indications, off-label use of non-approved drugs can also be considered as competition.
73
Companies, including Inventiva Pharma, Cirius Therapeutics and Novo Nordisk A/S, have molecules currently in Phase 3 clinical development.
Additionally, there are a host of other potential competitors in earlier stages of clinical development relative to us for the treatment of NASH. Eli Lilly and
Company, Pfizer, Novartis, Bristol-Myers Squibb, Novo Nordisk A/S, Merck, Viking Therapeutics, Inc., Metacrine, Inc., Poxel SA, Can-Fite BioPharma,
89bio, Inc., Sagimet Biosciences Inc. Terns, Inc., AstraZeneca and Hepanova Inc. and others.
In December 2022, Madrigal announced positive topline results from its pivotal Phase 3 MAESTRO-NASH biopsy clinical trial of resmetirom, a
liver-directed selective thyroid hormone receptor agonist. MAESTRO-NASH, in which Madrigal reported that it achieved both liver histological
improvement endpoints that FDA proposed as reasonably likely to predict clinical benefit to support accelerated approval for the treatment NASH with
liver fibrosis.
In March 2024, Madrigal announced FDA approval of Rezdiffra (resmetirom) for the treatment of NASH with moderate to advanced liver
fibrosis.
Notwithstanding the foregoing, see “Item 3. Key Information—Risk Factors—Risks Related to Our Business, Industry and Regulatory
Requirements—Our market is subject to intense competition. If we are unable to compete effectively, Aramchol or any other product candidate that we
develop may be rendered noncompetitive or obsolete” and “Item 3. Key Information—Risk Factors—Risks Related to Our Business, Industry and
Regulatory Requirements—We are developing Aramchol for the treatment of NASH, an indication for which there are no approved products, and there is
significant uncertainty regarding the regulatory approval process. This makes it difficult to predict the timing and costs of the clinical development of
Aramchol for the treatment of NASH.”
Intellectual Property and Patent Strategy
The proprietary nature of, and protection for, Aramchol or Amilo-5MER or any other product candidate and our discovery programs for new
indications, processes and know-how are important to our business. We own patent rights to Aramchol and Amilo-5MER in various jurisdictions
worldwide, including within and outside of Israel. We have sought patent protection in the United States and internationally for Aramchol and Amilo-
5MER, our discovery programs, and any other inventions to which we have rights, where available and when appropriate.
We have granted patents and pending patent applications in various jurisdictions relating to (1) the composition of matter of Aramchol meglumine
as well as a wide range of other salts, or the CoM Patent; (2) a method for treating/inhibiting hepatic fibrosis and non-hepatic fibrosis associated or non-
associated with NASH or NAFLD, or the Hepatic Fibrosis Patent; and (3) a method of treating dysbiosis, or the Dysbiosis Patent. In addition, we have
pending patent applications for Aramchol meglumine and other salts, including a granted U.S. patent for low dose composition of Aramchol (US
10,849,911 B2) and other salts. We have been allowed or granted patents for Aramchol and other salts which includes claims for the treatment of fatty liver
in Europe and certain other countries. The CoM Patent application was granted in the United States, Brazil and India. The CoM Patent that was granted in
the United States and the expected term is December2034,. The Hepatic Fibrosis Patent has been granted in United States (US 11,197,870 B2), Europe,
Japan, Canada and in Israel and has an expected term in each jurisdiction of 2037. The Dysbiosis Patent was granted in U.S., Israel and Mexico and has an
expected term in US of 2038 and of 2037 in Israel and Mexico; and was allowed in Brazil. In addition, patent applications were granted in Israel relating to
Aramchol use in hepatic fibrosis treatment, optionally associated with NAFLD and NASH ; and in Mexico relating to Aramchol use to treat pulmonary
fibrosis. Also, a patent was granted in Mexico and Europe relating to Aramchol use for inhibition of fibrosis in NAFLD patients (having fibrosis score of
zero (0)). We also have granted patentsfor combination therapy for the treatment of liver disease in Canada, Europe, and Mexico.
74
We have an exclusive license to a US granted patent directed to Amilo-5MER and anti-inflammatory compositions thereof On 2023 our
collaborator, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD was granted a new patent
(US 11,560, 417 B2, a division of US 10,611,819 B2) for using the 5MER for the treatment of inflammatory diseases which has an expected term until
2035.
Our policy is to pursue, maintain and defend patent rights, whether developed internally or licensed from third parties, and to protect the
technology, inventions and improvements that are commercially important to the development of our business. We also rely on trade secrets that may be
important to the development of our business.
Patent Portfolio for Aramchol and Aramchol Meglumine
The patent portfolio for Aramchol contains eight patent families including pending patent applications and granted patents directed to composition
of matter, manufacturing methods and methods of use.
All patents in this family are expired (term ended).
A patent family directed to topical uses of FABAC compounds (anti-acne) was granted in Europe and maintained in Germany, France, Italy, the
Netherlands and the United Kingdom. Expected term is 2033.
A patent family discloses and claims second generation FABAC salt compounds include Aramchol meglumine. This patent family includes
Granted U.S., Brazil, India, Europe (maintained in Albania, Austria, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Greece,
Hungary, Iceland, Italy, Latvia, Lithuania, Macedonia, Malta, Norway, Poland, Portugal, Romania, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden,
The Netherlands, Turkey, Belgium, France, Germany, Ireland, Luxembourg, Malta, Monaco, Switzerland and United Kingdom), China, Hong Kong,
Macau, Canada, Israel, Korea, Japan, and Australia patents. If the appropriate maintenance, renewal, annuity or other governmental fees are paid, the
expected term for this patent family is December 2034.
A patent family having one U.S. patent application, discloses and claims compositions comprising low doses of the second generation FABAC
compounds Aramchol meglumine and other salts which was granted by the USPTO. When the appropriate maintenance, renewal, annuity or other
governmental fees are paid, the expected term for this patent family is December2034.
A family is directed to treatment for modulating gut microbiota and/or dysbiosis using Aramchol. This patent family includes a granted patents in
Israel, U.S. and in Mexico; and pending foreign patent applications in Brazil, Canada, China, Europe, Hong Kong and Japan. Expected term for this patent
family is 2037,expect for U.S. where the term is 2038.
A patent family and eighth family are directed to uses of Aramchol and Aramchol meglumine for treating and inhibiting fibrosis. The families
have pending patent applications in in Australia, Brazil, Canada, China, Europe, Hong-Kong, Israel, Japan, Korea, Mexico and US. It was granted in
Canada, Europe, Japan and Mexico; and the treatment of pulmonary fibrosis was granted in Mexico and Japan (also dermal fibrosis in Japan). Expected
term of this patent family is 2037. Additionally, a U.S. patent application directed to a method for treating hepatic fibrosis non-associated with non-
alcoholic fatty acid liver disease – was granted, and the expected term is 2037. In addition, a US applications have been filed and claims the treatment
pulmonary, kidney, dermal, gastro intestinal and heart fibrosis by Aramchol. The improved bio-availability of Aramchol is supported by the
pharmacological model based on the preclinical and the ARREST data. Also, treatment and inhibition of fibrosis by a regimen of 300 mg of Aramchol
twice daily is pending in: Australia and China and granted in Israel. Expected term of this patent family is 2039.
75
A patent family is directed to a combination therapy of aramchol and MGL3196 for treating fatty liver disease; and has a PCT application which
entered National Phase in: Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, India, Japan, Korea, Mexico and U.S. It was granted in Canada,
Europe and Mexico. Expected term for this patent family is 2039.
Patent Portfolio for Amilo-5MER
The patent portfolio for Amilo-5MER contains two patent families including pending patent applications and granted patents directed to
composition of matter and methods of use.
A t patent family is directed to Amilo-5MER and anti-inflammatory compositions thereof. Galmed Research and Development Ltd. has an
exclusive license to the U.S. granted patent within this family, and the expected term of this U.S. patent is 2035. Galmed Research and Development Ltd.
has also exclusive licenses to the corresponding granted patents in Europe, Australia, Japan, China and India. The corresponding applications in Brazil,
Korea and Canada are pending. The non-US expected patent term is 2035. A divisional application claiming the use of Amilo-5MER for the treatment of
inflammatory diseases was granted in 2023.
A patent family is directed to peptides for treating acute respiratory distress syndrome. This family includes a pending PCT international patent
application. Galmed Research and Development Ltd. is a co-applicant in this PCT application with Yissum. The expected patent term for this patent family
is 2041.
Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection of our current and other
product candidates and the methods used to develop and manufacture them, as well as successfully defending these patents against third-party challenges.
Our ability to stop third parties from making, using, selling, offering to sell or importing our products depends on the extent to which we have rights under
valid and enforceable patents or trade secrets that cover these activities. We believe that our patents provide broad and comprehensive coverage of
Aramchol and the Amilo-5MER and uses thereof. However, the patent positions of biopharmaceutical companies, such as ourselves, are generally
uncertain and involve complex legal and factual questions. Our ability to maintain and solidify our proprietary position for the technology will depend on
our success in obtaining effective claims and enforcing those claims once granted. There is no certainty that any of the Company’s pending patent
applications will result in the issuance of any patents. The issued patents and those that may be issued in the future, may be challenged, narrowed,
circumvented or found to be invalid or unenforceable, which could limit our ability to stop competitors from marketing related products or the length of
term of patent protection that we may have for our products. In addition, our competitors may independently develop similar technologies or duplicate any
technology developed by us, and the rights granted under any issued or future patents may not provide us with any meaningful competitive advantages
against these competitors. Furthermore, because of the extensive time required for development, testing and regulatory review of a potential product, before
any of our products can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby
reducing any advantage of such patent. For more risks associated with the protection of our licensed intellectual property, see “Item 3. Key Information—
Risk Factors—Risks Related to Our Intellectual Property.”
Trade Secrets
In addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. Trade secrets and know-how can
be difficult to protect. We seek to protect our proprietary processes, in part, by confidentiality agreements and invention assignment agreements with our
employees, consultants, scientific advisors, contractors and commercial partners. These agreements are designed to protect our proprietary information. We
also seek to preserve the integrity and confidentiality of our data, trade secrets and know-how by maintaining physical security of our premises and
physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, such
agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise
become known or be independently discovered by competitors or others.
76
Seasonality
Our business and operations are generally not affected by seasonal fluctuations or factors.
Raw Materials and Suppliers
We believe that the raw materials that we require to manufacture Aramchol are readily available commodities commonly used in the
pharmaceutical industry.
Manufacturing
We do not own or operate manufacturing facilities for the production of Aramchol or any other product candidate, nor do we have plans to develop
our own manufacturing operations in the foreseeable future. We currently rely on third-party contract manufacturers for all of our required raw materials,
API and finished product for our non-clinical research and clinical trials. We do not have long term agreements with any of these third parties. We also do
not have any current contractual relationships for the manufacture of commercial supplies of Aramchol if it is approved. If Aramchol or any other product
candidate are approved by any regulatory agency, we intend to enter into agreements with a third-party contract manufacturer or collaboration partner and
one or more back-up manufacturers for the commercial production of those products. Development and commercial quantities of any products that we
develop will need to be manufactured in facilities, and by processes, that comply with the requirements of the FDA and the regulatory agencies of other
jurisdictions in which we are seeking approval. We currently employ internal resources to manage our manufacturing contractors. The relevant
manufacturers of our drug substance and drug products for our current pre-clinical and clinical trials have advised us that they are compliant with both
cGMP and, cGLP.
There can be no assurance that Aramchol, if approved, can be manufactured in sufficient commercial quantities, in compliance with regulatory
requirements and at an acceptable cost. We and our contract manufacturers are, and will be, subject to extensive governmental regulation in connection
with the manufacture of any pharmaceutical products or medical devices. We and our contract manufacturers must ensure that all of the processes, methods
and equipment are compliant with cGMP and cGLP for drugs on an ongoing basis, as mandated by the FDA and other regulatory authorities, and conduct
extensive audits of vendors, contract laboratories and suppliers.
Contract Research Organizations
We outsource certain clinical trial activities to CROs. Our clinical CROs comply with guidelines from the International Conference on
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, which attempt to harmonize the FDA, the EMA, and the
Pharmaceuticals and Medical Devices Agency of Japan regulations and guidelines. We create and implement the drug development plans and manage the
CROs according to the specific requirements of the drug candidate under development. To the extent clinical research is overseen by the CROs (or directly
by us), compliance with certain federal regulations, including but not limited to 21 C.F.R. parts 50, 54, 56, 58 and 312, which pertain to, among other
things, IRBs, informed consent, financial conflicts of interest by investigators, correct administration of treatment, follow up of adverse events, good
laboratory practices and submitting IND applications, may be required.
Marketing, Sales and Commercialization
Given our stage of development, we do not have any internal sales, marketing or distribution infrastructure or capabilities. In the event we receive
regulatory approval for any product candidate we intend, where appropriate, to pursue commercialization relationships, including strategic alliances and
licensing, with pharmaceutical companies and other strategic partners, which are equipped to market and/or sell our product candidates through their well-
developed sales, marketing and distribution organizations in order to gain access to global markets. In addition, we may out-license some or all of our
worldwide patent rights to more than one party to achieve the fullest development, marketing and distribution of any products we develop. Over the longer
term, we may consider ultimately building an internal marketing, sales and commercial infrastructure. See “Item 4. Information on the Company—
Business Overview—Strategic Collaborations, Research Arrangements and other Material Agreements—Samil Pharm Co.” for information regarding the
license agreement we entered with Samil for the commercialization of Aramchol (with an option to manufacture) for the treatment of fatty liver indications
including NASH, in the Republic of Korea.
77
Environmental Matters
We, our agents and our service providers, including our manufacturers, may be subject to various environmental, health and safety laws and
regulations, including those governing air emissions, water and wastewater discharges, noise emissions, the use, management and disposal of hazardous,
radioactive and biological materials and wastes and the cleanup of contaminated sites. We believe that our business, operations and facilities, including, to
our knowledge, those of our agents and service providers, are being operated in compliance in all material respects with applicable environmental and
health and safety laws and regulations. All information with respect to any chemical substance is filed and stored as a Material Safety Data Sheet, as
required by applicable environmental regulations. Based on information currently available to us, we do not expect environmental costs and contingencies
to have a material adverse effect on us. However, significant expenditures could be required in the future if we, our agents or our service providers are
required to comply with new or more stringent environmental or health and safety laws, regulations or requirements.
Government Regulation and Product Approval
Governmental authorities in the United States and in other countries extensively regulate, among other things, the research, development, testing,
manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing and export and import of products such as those we are
developing. Aramchol or any other product candidate must be approved by the FDA through the NDA process before they may be legally marketed in the
United States and by the Committee on Human Medicinal Products, or CHMP, via the EMA and European Commission through the MAA process before
they may be legally marketed in Europe, or MHRA through its authorization procedures before they may be legally marketed in the UK. Aramchol or any
other product candidate will be subject to similar requirements in other countries prior to marketing in those countries. The process of obtaining regulatory
approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time
and financial resources.
United States Government Regulation
NDA Approval Processes
In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and implementing regulations and
guidance documents. Failure to comply with the applicable U.S. requirements at any time during the product development process or approval process, or
after approval, may subject an applicant to administrative or judicial sanctions, any of which could have a material adverse effect on us. These sanctions
could include refusal to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product
seizures, total or partial suspension of production or distribution, injunctions, fines, disgorgement, and civil or criminal penalties.
The process required by the FDA before a drug may be marketed in the United States generally involves the following:
●
●
●
●
completion of pre-clinical laboratory tests, animal studies and formulation studies conducted according to GLPs, or other applicable
regulations;
submission to the FDA of an IND application, which must become effective before human clinical trials may begin;
performance of adequate and well-controlled human clinical trials according to GCPs, to establish the safety and efficacy of the proposed
drug for its intended use;
submission to the FDA of an NDA;
78
●
●
●
satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess
compliance with cGMPs to assure that the facilities, methods and controls are adequate to preserve the drug’s identity, strength, quality
and purity;
satisfactory completion of FDA inspections of clinical sites and GLP toxicology studies; and
FDA review and approval of the NDA.
The testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for
Aramchol, Amilo-5MER or any other product candidate will be granted on a timely basis, if at all.
Once a product candidate is identified for development, it enters the pre-clinical testing stage. Pre-clinical tests include laboratory evaluations of
product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the pre-clinical tests, together with
manufacturing information and analytical data, to the FDA as part of the IND. Some pre-clinical testing may continue after the IND is submitted. In
addition to including the results of the pre-clinical studies, the IND will also include a clinical trial protocol detailing, among other things, the objectives of
the clinical trial, the parameters to be used in monitoring safety and, depending on the phase of the study, the effectiveness criteria to be evaluated. The
IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the IND on clinical hold. In
such a case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. A clinical hold may occur at any time
during the life of an IND, due to safety concerns or non-compliance, and may affect one or more specific studies or all studies conducted under the IND.
All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with the FDA’s GCP regulations.
These regulations include the requirement that all research subjects provide informed consent. Further, an IRB must review and approve the plan for any
clinical trial, including the informed consent document, before it commences at any institution. An IRB considers, among other things, whether the risks to
individuals participating in the trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the investigator brochure
and other information about the trial distributed by the sponsor and the consent form that must be provided to each trial subject or his or her legal
representative and must monitor the study until completed. All clinical trials must be conducted under protocols detailing the objectives of the trial, dosing
procedures, research subject inclusion and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to
the FDA as part of the IND, and progress reports detailing the status of the clinical trials must be submitted to the FDA annually. Sponsors must also report
within set timeframes to FDA serious and unexpected adverse reactions, any clinically important increase in the rate of a serious suspected adverse reaction
over that listed in the protocol or investigation brochure, or any findings from other studies or animal or in-vitro testing that suggest a significant risk in
humans exposed to the drug. Sponsors must also report to FDA certain amendments to the protocol and other essential information concerning the IND that
does not fall within the scope of other required reports.
Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:
●
●
●
Phase 1. The drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism,
distribution and elimination. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the
product may be inherently too toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.
Phase 2. Clinical trials are performed on a limited patient population intended to identify possible adverse effects and risks, to
preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.
Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at
geographically dispersed clinical study sites. Phase 3 clinical trials are conducted to provide sufficient data for the statistically valid
evidence of safety and efficacy.
79
●
Phase 4. The FDA may require that the sponsor conduct additional clinical trials following new drug approval. The purpose of these
trials, known as Phase 4 studies, is to monitor long-term risks and benefits, study different dosage levels or evaluate safety and
effectiveness. In recent years, the FDA has increased its reliance on these trials. Phase 4 studies usually involve thousands of participants.
Phase 4 studies also may be initiated by the company sponsoring the new drug to gain broader market value for an approved drug.
Human clinical trials are inherently uncertain and Phase 1, Phase 2, Phase 3 and Phase 4 testing may not be successfully completed. The FDA or
the sponsor may suspend a clinical trial at any time for a variety of reasons, including a finding that the research subjects or patients are being exposed to
an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted
in accordance with the IRB’s requirements or if the drug has been associated with unexpected serious harm to patients.
During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points are typically prior to
the submission of an IND, at the end of Phase 2 and before an NDA is submitted. Meetings at other times may also be requested. These meetings can
provide an opportunity for the sponsor to share information about the data gathered to date and for the FDA to provide advice on the next phase of
development. Sponsors typically use the meeting at the end of Phase 2 to discuss their Phase 2 clinical results and present their plans for the pivotal Phase 3
clinical trial that they believe will support the approval of the NDA.
Concurrent with clinical trials, sponsors usually complete any remaining animal safety studies and also develop additional information about the
chemistry and physical characteristics of the drug and finalize a process for manufacturing commercial quantities of the product in accordance with cGMP
requirements. The manufacturing process must be capable of consistently producing quality batches of the drug and the manufacturer must develop
methods for testing the quality, purity and potency of the drug. Additionally, appropriate packaging must be selected and tested and stability studies must be
conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its proposed shelf-life.
The results of product development, pre-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests
and other control mechanisms, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market
the product for one or more specified indications. The submission of an NDA is subject to the payment of an application fee, but a waiver of such fees may
be obtained under specified circumstances. We will seek a waiver of these fees as a small business submitting its first human drug application to the FDA.
If the waiver is granted it would not extend to establishment or product fees. The FDA reviews all NDAs submitted to ensure that they are sufficiently
complete for substantive review before it accepts them for filing. It may request additional information rather than accept an NDA for filing. In this event,
the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.
Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA may refuse to approve an NDA if the applicable
statutory and regulatory criteria are not satisfied or may require additional clinical or other data. Even if such data are submitted, the FDA may ultimately
decide that the NDA does not satisfy the criteria for approval. The FDA reviews an NDA to determine, among other things, whether a product is safe and
effective for its intended use and whether its manufacturing is cGMP-compliant. The FDA may refer the NDA to an advisory committee for review and
recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an
advisory committee, but it generally follows such recommendations. Before approving an NDA, the FDA will typically inspect the facility or facilities
where the product is manufactured and tested. The FDA will also inspect selected clinical sites that participated in the clinical studies and may inspect the
testing facilities that performed the GLP toxicology studies cited in the NDA.
80
Expedited Review and Approval
The FDA has various specific programs, including Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval, which, in
different ways, are each intended to expedite the process for reviewing and approving drugs. Even if a drug qualifies for one or more of these programs, the
FDA may later decide that the drug no longer meets the conditions for qualification or that the time period for FDA review or approval will be shortened.
Generally, drugs that are eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical
needs and those that offer meaningful benefits over existing treatments. For example, Fast Track is a process designed to facilitate the development and
expedite the review of drugs to treat serious or life-threatening diseases or conditions and fill unmet medical needs, and Breakthrough Therapy designation
is designed to expedite the development and review of drugs that are intended to treat a serious condition where preliminary clinical evidence indicates that
the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s). Priority review is designed to give drugs
that offer major advances in treatment or provide a treatment where no adequate therapy exists an initial review within six months as compared to a
standard review time of ten months. Although Fast Track, Breakthrough Therapy designation and priority review do not affect the standards for approval,
the FDA will attempt to facilitate early and frequent meetings with a sponsor of a Fast Track or Breakthrough Therapy designated drug and expedite review
of the application for a drug designated for priority review. The FDA will also provide Breakthrough Therapy designated drugs intensive guidance on an
efficient drug development program and provide these drug developers with an organizational commitment from the FDA involving senior managers. Since
sponsors can design clinical trials in a number of ways, in providing its guidance for drugs designated as breakthrough therapies, the FDA will seek to
ensure that the sponsor of the product designated as a breakthrough therapy receives timely advice and interactive communications in order to help the
sponsor design and conduct a development program as efficiently as possible. During these interactions, the FDA may suggest, or a sponsor can propose,
alternative clinical trial designs (e.g., adaptive designs, an enrichment strategy, use of historical controls) that may result in smaller trials or more efficient
trials that require less time to complete. Such trial designs could also help minimize the number of patients exposed to a potentially less efficacious
treatment (i.e., the control group treated with available therapy). On September 23, 2014, the FDA granted Fast Track designation status to Aramchol for
the treatment of patients who are overweight or obese and have pre diabetes or type II diabetes mellitus with NASH.
Accelerated Approval, which is described in 21 C.F.R. § 314.500 et seq., provides for approval of a new drug that is intended to treat a serious or
life-threatening disease or condition and that fills an unmet medical need based on a surrogate endpoint. A surrogate endpoint is a laboratory measurement
or physical sign used as an indirect or substitute measurement representing a clinically meaningful outcome. To be used in accelerated approval, a surrogate
endpoint must be “reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence to predict benefit on irreversible morbidity
or mortality.” The term “reasonably likely” implies that some uncertainty remains about the relationship of the surrogate to the clinical benefit to the
patient. Therefore, accelerated approval is typically contingent on a sponsor’s agreement to conduct additional post-approval studies to verify and describe
the drug’s clinical benefit. Accelerated Approval does not change the standards for approval, but by allowing a demonstration of efficacy based on a
surrogate endpoint may expedite the approval process.
FDA Guidance
In December 2018, the FDA issued “Noncirrhotic Nonalcoholic Steatohepatitis with Liver Fibrosis: Developing Drugs for Treatment”, or “the
December Guidance”. The December Guidance, though nonbinding on the FDA or us, is intended to assist sponsors in the clinical development of drugs
for the treatment of noncirrhotic NASH with liver fibrosis, describes the FDA’s current thinking regarding the necessary components of a drug
development program for noncirrhotic NASH with liver fibrosis and identifies knowledge gaps that represent important challenges in the development of
drugs for the indication. According to the FDA, the ultimate goal of NASH treatment is to slow the progress of, halt, or reverse disease progression and
improve clinical outcomes (i.e., prevent progression to cirrhosis and cirrhosis complications, reduce the need for liver transplantation, and improve
survival). Because of the slow progression of NASH and the time required to conduct a trial that would evaluate clinical endpoints such as progression to
cirrhosis or survival, the FDA recommends sponsors consider the following liver histological improvements as endpoints reasonably likely to predict
clinical benefit to support accelerated approval under the regulations:
●
Resolution of steatohepatitis on overall histopathological reading and no worsening of liver fibrosis on NASH CRN fibrosis score.
Resolution of steatohepatitis is defined as absent fatty liver disease or isolated or simple steatosis without steatohepatitis and a NAS score
of 0–1 for inflammation, 0 for ballooning, and any value for steatosis; or
81
●
Improvement in liver fibrosis greater than or equal to one stage (NASH CRN fibrosis score) and no worsening of steatohepatitis (defined
as no increase in NAS for ballooning, inflammation, or steatosis)
Further, according to the FDA, for NASH drugs approved on the basis of liver histology under the accelerated approval pathway, randomized,
double-blind, placebo-controlled clinical trials designed to describe and verify the drug’s clinical benefit should be underway at the time of submission of
the marketing application. Clinical benefit can be verified by demonstrating superiority to placebo in delaying disease progression measured by a
composite endpoint.
The EMA also issued a reflection paper to provide guidance on drug development in the field of NASH. However, the EMA indicated, among
other things, that both resolution of NASH without worsening of fibrosis and improvement in fibrosis without worsening of NASH would both be required
as intermediate endpoints for demonstrating statistical significance for stage 2 and 3 fibrosis.
See also “Item 3. Key Information—Risk Factors—Risk Factors—Risks Related to Our Business, Industry and Regulatory Requirements - We are
developing Aramchol for the treatment of NASH, an indication for which there are no approved products, and there is significant uncertainty regarding the
regulatory approval process. This makes it difficult to predict the timing and costs of the clinical development of Aramchol for the treatment of NASH.”
Patent Term Restoration and Marketing Exclusivity
Depending upon the timing, duration and specifics of FDA approval of the use of Aramchol or any other product candidate, U.S. patents may be
eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as
compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the
remaining term of a patent beyond a total of 14 years from the product’s approval date. The patent term restoration period is generally one-half the time
between the effective date of an IND, and the submission date of an NDA, plus the time between the submission date of an NDA and the approval of that
application. Only one patent applicable to an approved drug is eligible for the extension and the application for extension must be made prior to expiration
of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future,
we intend to apply for restorations of patent term for some of our currently owned patents to add patent life beyond their current expiration date, depending
on the expected length of clinical trials and other factors involved in the submission of the relevant NDA.
Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain applications. The FDCA provides a five-
year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug
is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion
responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application, or
ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of
reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or
non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an approved NDA if new
clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the
approval of the application, for example, for new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the
conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active
agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would be
required to conduct or obtain a right of reference to all of the pre-clinical studies and adequate and well-controlled clinical trials necessary to demonstrate
safety and effectiveness.
82
Post-approval Requirements
Once an approval is granted, the FDA, European authorities and other regulatory authorities may withdraw the approval if compliance with
regulatory requirements is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with
a product may result in restrictions on the product or even complete withdrawal of the product from the market. After approval, some types of changes to
the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further regulatory authority
review and approval. Some of these modifications, especially adding indications, would likely require additional clinical studies. In addition, the FDA may
require testing and surveillance programs to monitor the effect of approved products that have been commercialized, and the FDA has the power to prevent
or limit further marketing of a product based on the results of these post-marketing programs.
Any drug product manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including,
among other things record-keeping requirements; cGMPs; reporting of adverse experiences with the drug; providing the FDA with updated safety and
efficacy information; drug sampling and distribution requirements; notifying the FDA and gaining its approval of specified manufacturing or labeling
changes; and complying with FDA promotion and advertising requirements.
Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments
with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and some state agencies for compliance with
cGMP and other laws.
We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of Aramchol. Future FDA and
state inspections may identify compliance issues at the facilities of our contract manufacturers that may disrupt production or distribution, or require
substantial resources to correct.
From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the
approval, manufacturing and marketing of products regulated by the FDA. In addition, FDA regulations and guidance are often revised or reinterpreted by
the agency in ways that may significantly affect our business and our products. It is impossible to predict whether legislative changes will be enacted, or
FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may be. In particular, it is unknown whether any of the
provisions of the 2016 21st Century Cures Act that are intended to accelerate drug approval will result in any change in the current approval pathway for
Aramchol.
Pursuant to the Affordable Care Act (discussed in greater detail below), the Centers for Medicare & Medicaid Services (CMS) is required to
collect and publish information reported by applicable manufacturers about payments and other transfers of value manufacturers have made to physicians
and teaching hospitals. Such a law, when applicable to our products, could increase the company’s regulatory liability through the imposition of additional
reporting and regulatory requirements. There are also an increasing number of state laws that require manufacturers to make similar reports to states on
pricing and marketing information.
Reimbursement
We face uncertainties over the pricing of pharmaceutical products. Sales of Aramchol or any other product candidate will depend, in part, on the
extent to which the costs of Aramchol or any other product candidate will be covered by third-party payors, such as federal health programs, commercial
insurance and managed care organizations. These third-party payors are increasingly challenging the prices charged for medical products and services.
Additionally, the containment of healthcare costs has become a priority of federal and state governments and the prices of drugs have been a focus in this
effort. The U.S. government, state legislatures, foreign governments and third party payors have shown significant interest in implementing cost-
containment programs, including price controls, pricing transparency disclosure obligations, restrictions on reimbursement and requirements for
substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with
existing controls and measures, could further limit our net revenue and results. If these third-party payors do not consider Aramchol or any other product
candidate to be cost-effective compared to other therapies, they may not cover Aramchol or any other product candidate after approved as a benefit under
their plans or, if they do, the level of payment may not be sufficient to allow us to sell Aramchol or any other product candidate on a profitable basis.
83
The Medicare Modernization Act imposed new requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries
under Part D. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient
prescription drugs. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug
formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each
therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. The Centers for Medicare &
Medicaid Services published a final rule in 2014 implementing the Medicare Modernization Act. Contrary to the proposed rule, which would have enabled
Part D plans to offer fewer drugs, the final rule maintained the existing six protected classes of drug categories, but stated that some of the proposals not
included in the final rule could still be finalized in the future, which would impact payor formulary and coverage decisions.
The American Recovery and Reinvestment Act of 2009 provides funding for the federal government to compare the effectiveness of different
treatments for the same illness. A plan for the research will be developed by the Department of Health and Human Services, the Agency for Healthcare
Research and Quality and the National Institutes for Health, and periodic reports on the status of the research and related expenditures will be made to
Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is not
clear what effect, if any, the research will have on the sales of any product, if any such product or the condition that it is intended to treat is the subject of a
study. It is also possible that comparative effectiveness research demonstrating benefits in a competitor’s product could adversely affect the sales of
Aramchol or any other product candidate. If third-party payors do not consider Aramchol or any other product candidate to be cost-effective compared to
other available therapies, they may not cover Aramchol or any other product candidate as a benefit under their plans or, if they do, the level of payment
may not be sufficient to allow us to sell Aramchol or any other product candidate on a profitable basis.
The Affordable Care Act, enacted in March 2010, has had a significant impact on the health care industry. Some of the key changes made to date
pursuant to the Affordable Care Act include an expansion of coverage for the uninsured, the creation of insurance marketplaces and increased protection of
insureds with new benefits, rights and protections. With regard to pharmaceutical products, among other things, the Affordable Care Act made major
changes to the Medicare prescription drug program, which helped reduce drug costs for seniors and increased rebates and other costs for the pharmaceutical
industry.
There have been judicial and congressional challenges to the Affordable Care Act. In December 2017, Congress passed and then the President
Trump signed into law tax reform legislation that made significant changes to the Affordable Care Act including the repeal of the “individual mandate” that
was in place to strongly encourage broad participation in the health insurance markets. On December 14, 2018, a federal district court in Texas ruled that
the PPACA is unconstitutional as a result of the Tax Cuts and Jobs Act, the federal income tax reform legislation previously passed by Congress and signed
by President Trump on December 22, 2017, that eliminated the individual mandate portion of the PPACA. The case, Texas, et al, v. United States of
America, et al., (N.D. Texas), is an outlier, but in 2019, the Fifth Circuit Court of Appeals subsequently upheld the lower court decision which was then
appealed to the United States Supreme Court. The U.S. Supreme Court declined to hear the appeal on an expedited basis and so no decision is expected
until sometime in 2021 before the end of the Supreme Court’s current term. We are not able to state with any certainty what will be impact of this court
decision on our business pending further court action and possible appeals. Given these changes and other statements of political leaders, we cannot predict
the ultimate impact on the Affordable Care Act and the subsequent effect on the pharmaceutical industry at this time. In November 2020, Joseph Biden was
elected President and, in January 2021, the Democratic Party obtained control of the Senate. As a result of these electoral developments, it is unlikely that
continued legislative efforts will be pursued to repeal PPACA. Instead, it is possible that executive and regulatory initiatives, as well as legislation, will be
pursued to enhance or reform PPACA. We are not able to state with certainty what the impact of potential legislation will be on our business.
In addition, in some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed. The
requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range
of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human
use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the
profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or
reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for Aramchol, Amilo-5MER or any
other product candidate. Historically, products launched in the EU do not follow price structures of the United States and generally tend to be significantly
lower.
84
Healthcare Fraud and Abuse Laws
In the U.S., the research, development, testing, manufacturing, handling, storage, distribution, sale and promotion of drug products and medical
devices are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare &
Medicaid Services, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of
Justice, state Attorneys General, and other state and local government agencies. For example, sales, marketing and scientific/educational grant programs
must comply with the fraud and abuse provisions applicable to pharmaceutical manufacturers, including the federal “Anti-Kickback Statute”, the Civil
Monetary Penalty Statute, the Stark Law, the federal False Claims Act, as amended, state and federal “Physician Payment Sunshine Act” laws and
regulations, the privacy regulations promulgated under the Health Insurance Portability and Accountability Act, or HIPAA, and similar state laws. Pricing
and rebate programs must comply with the Medicaid Drug Rebate Program requirements of the Omnibus Budget Reconciliation Act of 1990, as amended,
and the Veterans Health Care Act of 1992, as amended. If products are made available to authorized users of the Federal Supply Schedule of the General
Services Administration, additional laws and requirements apply. All of these activities are also potentially subject to federal and state consumer protection
and unfair competition laws. Some of these health care laws include:
The Anti- Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf) to
knowingly and willfully solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business, including the purchase, order, or
prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid.
The federal False Claims Act prohibits anyone from knowingly presenting, conspiring to present, making a false statement in order to present, or
causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services, including drugs, that are false or
fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. This law also prohibits anyone from
knowingly underpaying an obligation owed to a federal program. Increasingly, U.S. federal agencies are requiring nonmonetary remedial measures, such as
corporate integrity agreements in False Claims Act settlements. The U.S. Department of Justice announced in 2016 its intent to follow the “Yates Memo,”
taking a far more aggressive approach in pursuing individuals as False Claims Act defendants in addition to the corporations.
The Physician Payment Sunshine Act, enacted in 2010 as part of the Affordable Care Act, requires certain manufacturers of pharmaceuticals and
medical devices to annually report certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists
and chiropractors) and teaching hospitals, as well as investment interests held by physicians and their immediate family members. Effective January 1,
2022, covered manufacturers will also be required to report on payments and other transfers of value to physician assistants, nurse practitioners or clinical
nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, and certified nurse-midwives during the previous year. In recent years,
several states in the United States have also enacted legislation requiring pharmaceutical companies to file periodic reports with the state, make periodic
public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as establish marketing
compliance programs. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on
us. Failure to meet these requirements, to the extent they are applicable to our activities, could also result in a variety of governmental sanctions that could
have a material adverse effect on our business.
If our operations are found to be in violation of any of the foregoing or other applicable health care laws and regulations, we may be subject to
penalties, including significant administrative, civil and criminal penalties, monetary damages, disgorgement, imprisonment, the curtailment or
restructuring of our operations, loss of eligibility to obtain approvals from the FDA, or exclusion from participation in government contracting, healthcare
reimbursement or other government programs, including Medicare and Medicaid.
85
European Economic Area
In addition to approval in the United States, we currently intend to seek regulatory approval of Aramchol in the EU. As such, a summary of the
EU regulatory processes follows below.
A medicinal product may only be placed on the market in the European Economic Area, or the EEA, composed of the 27 EU member states of the
EU, plus Norway, Iceland and Lichtenstein, when a marketing authorization has been issued by the competent authority of the respective member state
pursuant to member states’ law based on Directive 2001/83/EC, as amended, or an authorization has been granted under the centralized procedure in
accordance with Regulation (EC) No. 726/2004, as amended, or its predecessor, Regulation 2309/93. There are essentially three community procedures
created under prevailing European pharmaceutical legislation that, if successfully completed, allow an applicant to place a medicinal product on the market
in the respective EU or EEA member states.
The withdrawal of the United Kingdom (UK) from the EU took effect on January 1, 2021, and there are 27 member states remaining in the EU. As
of January 1, 2021, the UK is a “third country” with regard to the EU (subject to the terms of the EU UK Trade Agreement) and EU law ceased to apply
directly in the UK. However, the UK has retained the EU medicines regulatory regime with certain modifications as standalone UK legislation. Therefore,
the UK regulatory regime is currently similar to EU regulations, but under new legislation, the Medicines and Medical Devices Act 2021, the UK may
adopt changed regulations that may diverge from the EU legislative regime for medicines and their research, development and commercialization. In order
to market a medicinal product in the UK, a license or marketing authorization must be obtained from the UK Medicines and Healthcare Products
Regulatory Agency (MHRA). The UK legislation includes multiple assessment routes for applications for medicinal products, including a 150-day national
assessment or a rolling review application. Further, and for a transitional period until 31 December 2022, the MHRA may rely on a decision taken by the
European Commission on the approval of a new marketing authorization in the centralized procedure. In addition, the MHRA has the power to have regard
to marketing authorizations approved in EU member states through the decentralized and mutual recognition procedures.
Centralized Procedure
Regulation 726/2004/EC, as amended, governs the centralized procedure when a marketing authorization is granted by the European Commission,
acting in its capacity as the European Licensing Authority on the advice of the EMA. That authorization is valid throughout the entire community and
directly or (as to Norway, Iceland and Liechtenstein) indirectly allows the applicant to place the product on the market in all member states of the EEA. The
EMA is the administrative body responsible for coordinating the existing scientific resources available in the member states for evaluation, supervision and
pharmacovigilance of medicinal products. Certain medicinal products, as described in the Annex to Regulation 726/2004, must be authorized centrally.
These are products that are developed by means of certain biotechnological processes in accordance with Paragraph 1 to the Annex to the Regulation.
Medicinal products for human use containing a new active substance that, on the date of effectiveness of the Regulation, was not authorized in the
European Union, and for which the therapeutic indication is the treatment of acquired immune deficiency syndrome, or AIDS, cancer, neurodegenerative
disorder or diabetes, autoimmune diseases and other immune dysfunctions and viral diseases must also be authorized centrally. Finally, all medicinal
products that are designated as orphan medicinal products pursuant to Regulation 141/2000 and Advanced Therapy Medicinal Products (ATMP) according
to Reg. (EC) No. 1394/2007 and medicinal products for veterinary use that are used primarily as performance enhancers must be authorized under the
centralized procedure. An applicant may also opt for assessment through the centralized procedure if the medicinal product contains a new active substance
which was not authorized in the EU when Reg. (EC) No. 726/2004 entered into force, or if the applicant can show that the medicinal product constitutes a
significant therapeutic, scientific or technical innovation or that the granting of authorization centrally is in the interests of patients or animal health at the
community level. For each application submitted to the EMA for scientific assessment, the EMA is required to ensure that the opinion of the Committee for
Medicinal Products for Human Use, or CHMP, is given within 210 days after receipt of a valid application. This 210 days period does not include the time
that the applicant needs to answer any questions raised during the application procedure, the so-called ‘clock stop’ period. If the opinion is positive, the
EMA is required to send the opinion to the European Commission, which is responsible for preparing the draft decision granting a marketing authorization.
This draft decision may differ from the CHMP opinion, stating reasons for diverging from the CHMP opinion. The draft decision is sent to the applicant
and the member states, after which the European Commission takes a final decision. If the initial opinion of the CHMP is negative, the applicant is afforded
an opportunity to seek a re-examination of the opinion. In that case, the applicant may, within 15 days after receipt of the opinion, give written notice to
EMA that he wishes to request a re-examination of the opinion. The applicant is then required to forward the detailed grounds for request within 60 days
after receipt of the opinion. The CHMP is required to re-examine its opinion within 60 days following receipt of the request by the applicant. All CHMP
refusals and the reasons for refusal are made public on the EMA website. Without a centralized marketing authorization it is prohibited to place a medicinal
product that must be authorized centrally on the market in the EU. Once a centralized marketing authorization has been granted by the European
Commission, it is valid in all EEA States for 5 years on a renewable basis.
86
Mutual Recognition and Decentralized Procedures
With the exception of products that are authorized centrally, the competent authorities of the member states are responsible for granting marketing
authorizations for medicinal products placed on their national markets. If the applicant for a marketing authorization intends to market the same medicinal
product in more than one member state, the applicant may seek an authorization progressively in the community under the mutual recognition or
decentralized procedure. Mutual recognition procedure, or MRP is used if the medicinal product has already been authorized in a member state. In this
case, the holder of this marketing authorization requests the member state where the authorization has been granted to act as reference member state by
preparing an assessment report on the product or, if necessary, to update any existing assessment report that is then used to facilitate mutual recognition of
the existing authorization in the other member states in which approval is sought (the so-called concerned member state(s)). The reference member state
must prepare an updated assessment report within 90 days of receipt of a valid application. This report together with the approved Summary of Product
Characteristics, the SmPC (which sets out the conditions of use of the product), and a labeling and package leaflet are sent to the concerned member states
for their consideration. The concerned member states are required to approve the assessment report, the SmPC and the labeling and package leaflet within
90 days of receipt of these documents. The reference member state shall record the agreement of all parties, close the procedure and inform the applicant
accordingly. Each member state in which an application has been submitted shall adopt a decision in conformity with the approved documents, within 30
days after acknowledgement of the agreement. In most cases, the total procedural time of the MRP is 180 days.
The decentralized procedure, or DCP, is used in cases where the medicinal product has not received a marketing authorization in the EU at the
time of application. The applicant requests a member state of its choice to act as reference member state to prepare an assessment report that is then used to
facilitate agreement with the concerned member states and the grant of a national marketing authorization in all of these member states. In this procedure,
the reference member state must prepare, for consideration by the concerned member states, the draft assessment report, a draft SmPC and a draft of the
labeling and package leaflet within 120 days after receipt of a valid application. As in the case of mutual recognition, the concerned member states are
required to approve these documents within 90 days of their receipt. The reference member state shall record the agreement of all parties, close the
procedure and inform the applicant accordingly. Each member state in which an application has been submitted shall adopt a decision in conformity with
the approved documents, within 30 days after acknowledgement of the agreement. In most cases the total time of the DCP will be 210 days
For both MRP and DCP, if a concerned member state objects to the grant of a marketing authorization on the grounds of a potential serious risk to
public health, it shall give a detailed exposition of the reasons for its position to with the reference member state. The points of disagreement are in the first
instance referred to the Co-ordination Group on MRP and DCP to reach an agreement within 60 days of the communication of the points of disagreement.
If member states fail to reach an agreement, the reference Member State shall record the agreement, close the procedure and inform the applicant
accordingly. If the member states fail to reach an agreement within the 60-day period, then the matter is referred to the EMA and CHMP for arbitration.
The CHMP is required to deliver a reasoned opinion within 60 days of the date on which the matter is referred. The scientific opinion adopted by the
CHMP forms the basis for a binding European Commission decision.
Irrespective of whether the medicinal product is assessed centrally, de-centrally or through a process of mutual recognition, the medicinal product
must be manufactured in accordance with the principles of GMP for human use as set out in Directive 2001/83/EC and 2017/1572/EU and Delegated
Regulation 2017/1569 that have replaced Directive 2003/94/EC.
87
Directive 2017/1572/EU and Volume 4 of the rules governing medicinal products in the European Union govern GMP in the EU. Moreover, EU
law requires the clinical results in support of clinical safety and efficacy based upon clinical trials conducted in the EU to be in compliance with the
requirements of Regulation (EU) 536/2014 on clinical trials with medicinal products for human use and Implementing Regulation 556/2017 on GCP-
inspections which implement good clinical practice in the conduct of clinical trials on medicinal products for human use. Clinical trials conducted outside
the European community and used to support applications for marketing within the EU must have been conducted in a way consistent with the principles
set out in Regulation (EU) 536/2017. The conduct of a clinical trial in the EU requires, pursuant to Regulation (E) 536/2017, authorization by the relevant
national competent authority where a trial takes place, and subject to the relevant national law, an ethics committee to have issued a favorable opinion in
relation to the arrangements for the trial. It also requires that the sponsor of the trial, or a person authorized to act on his behalf in relation to the trial, be
established in the community. In comparison to the former regime, Regulation (EU) 536/2014 further harmonizes EU law on clinical trials and to some
extent facilitates clinical trials conducted in more than one EU Member State. Under Regulation (EU) 536/2014, trial sponsors submit their application for
trial approval via an EU Portal, Clinical Trials Information System (CTIS). The approvals will still have to be granted by the competent authorities of the
EU Member States where a trial takes place, however, the procedure for approval is conducted in a coordinated manner among the concerned EU Member
States as provided under Regulation (EU) 536/2014. While the process for the application and granting of the approvals was streamlined, it is still a
complex process that can significantly delay the start of a multinational clinical trial.
The UK has not adopted Regulation (EU) 536/2014 with respect to clinical trials in the UK. Instead, the Medicines for Human Use (Clinical
Trials) Regulations 2004 applies with respect to clinical trials in the UK. The UK has adopted new legislation, the Medicines and Medical Devices Act
2021 and has issued a consultation with respect to changes to clinical trial legislation to be made under this Act.
National Procedure
This procedure is available for medicinal products that do not fall within the scope of mandatory centralized authorization. Specific procedures
and timelines differ between member states, but the duration of the procedure without clock-stop time is generally 210 days and based on a risk/efficacy
assessment by the competent authority of the member state concerned, followed by determination of SmPC, package leaflet and label text/layout and
subsequently grant of the marketing authorization. Marketing authorizations granted on this basis are not mutually recognized by other member states, but
the national marketing authorization can later be used in an MRP to obtain marketing authorizations in other member states.
There are various types of applications for marketing authorizations:
●
●
Full Applications. A full application is one that is made under any of the community procedures described above and that “stands alone”
in the sense that it contains all of the particulars and information required by Article 8(3) of Directive 2001/83 (as amended) to allow the
competent authority to assess the quality, safety and efficacy of the product and in particular the balance between benefit and risk. Article
8(3)(i) in particular refers to the need to present the results of the applicant’s research on (i) pharmaceutical (physical-chemical,
biological or microbiological) tests, (ii) pre-clinical (toxicological and pharmacological) studies and (iii) clinical trials in humans. The
nature of these tests, studies and trials is explained in more detail in Annex I to Directive 2001/83/EC. Full applications would be
required for products containing new active substances not previously approved by the competent authority, but may also be made for
other products.
Abridged Applications. Article 10 of Directive 2001/83/EC contains exemptions from the requirement that the applicant has to provide
the results of its own pre-clinical and clinical research. There are three regulatory routes for an applicant to seek an exemption from
providing such results, namely (i) cross-referral to an innovator’s results without consent of the innovator, (ii) well established use
according to published literature and (iii) consent to refer to an existing dossier of research results filed by a previous applicant.
88
Cross-referral to Innovator’s Data
Articles 10(1) and 10(2)(b) of Directive 2001/83/EC provide the legal basis for an applicant to seek a marketing authorization on the basis that its
product is a generic medicinal product (a copy) of a reference medicinal product that has already been authorized, in accordance with community
provisions. A reference product is, in principle, an original product granted an authorization on the basis of a full dossier of particulars and information.
This is the main exemption used by generic manufacturers for obtaining a marketing authorization for a copy product. The generic applicant is not required
to provide the results of pre-clinical studies and of clinical trials if its product meets the definition of a generic medicinal product and the applicable
regulatory results protection period for the results submitted by the innovator has expired. A generic medicinal product is defined as a medicinal product:
●
●
having the same qualitative and quantitative composition in active substance as the reference medicinal product; having the same
pharmaceutical form as the reference medicinal product; and
whose bioequivalence with the reference medicinal product has been demonstrated by appropriate bioavailability studies.
Applications in respect of a generic medicinal product cannot be made before the expiry of the protection period. Where the reference product was
granted a national marketing authorization pursuant to an application made before October 30, 2005, the protection period is either six years or 10 years,
depending upon the election of the particular member state concerned. Where the reference product was granted a marketing authorization centrally,
pursuant to an application made before November 20, 2005, the protection period is 10 years. For applications made after these dates, Regulation 726/2004
and amendments to Directive 2001/83/EC provide for a harmonized protection period regardless of the approval route utilized. The harmonized protection
period is in total 10 years, including eight years of research data protection and two years of marketing protection. The effect is that the originator’s results
can be the subject of a cross-referral application after eight years, but any resulting authorization cannot be exploited for a further two years. The rationale
of this procedure is that the relevant particulars can, if the research data protection period has expired, be found on the originator’s file and used for
assessment of the generic medicinal product. The 10-year protection period can be extended to 11 years where, in the first eight years post-authorization,
the holder of the authorization obtains approval for a new therapeutic indication assessed as offering a significant clinical benefit in comparison with
existing therapies.
If the copy product does not meet the definition of a generic medicinal product or if bioequivalence could not be demonstrated through
bioavailability studies or in case of certain types of changes in the active substance(s) or in the therapeutic indications, strength, pharmaceutical form or
route of administration in relation to the reference medicinal product, Article 10(3) of Directive 2001/83/EC provides that the results of the appropriate pre-
clinical studies or clinical trials must be provided by the applicant.
Well-established Medicinal Use
Under Article 10a of Directive 2001/83/EC, an applicant may, in substitution for the results of its own pre-clinical and clinical research, present
detailed references to published literature demonstrating that the active substance(s) of a product have a well- established medicinal use within the
community for at least ten years with recognized efficacy and an acceptable level of safety in terms of the conditions set out in Annex I of Directive
2001/83/EC. In that event, the test and trial results shall be replaced by appropriate scientific literature. The applicant is entitled to refer to a variety of
different types of literature, including reports of clinical trials with the same active substance(s) and epidemiological studies that indicate that the
constituent or constituents of the product have an acceptable safety/efficacy profile for a particular indication. However, use of the published literature
exemption is restricted by stating that in no circumstances active substances be treated as having a well- established use if they have been used for less than
10 years from the first systematic and documented use of the substance as a medicinal product in the EU. Even after 10 years’ systematic use, the threshold
for well-established medicinal use might not be met. European pharmaceutical law requires the competent authorities to consider among other factors the
period over which a substance has been used, the amount of patient use of the substance, the degree of scientific interest in the use of the substance (as
reflected in the scientific literature) and the coherence (consistency) of all the scientific assessments made in the literature. For this reason, different
substances may reach the threshold for well-established use after different periods, but the minimum period is 10 years. If the applicant seeks approval of
an entirely new therapeutic use compared with that to which the published literature refers, additional pre-clinical and/or clinical results would have to be
provided.
89
Authorization Holder’s Consent
Under Article 10c of Directive 2001/83/EC, following the grant of a marketing authorization the holder of such authorization may consent to a
competent authority utilizing the pharmaceutical, pre-clinical and clinical documentation that it submitted to obtain approval for a medicinal product to
assess a subsequent application relating to a medicinal product possessing the same qualitative and quantitative composition with respect to the active
substances and the same pharmaceutical form.
Law Relating to Pediatric Research
Regulation (EC) 1901/2006 (as amended by Regulation (EC) 1902/2006) was adopted on December 12, 2006. This Regulation governs the
development of medicinal products for human use in order to meet the specific therapeutic needs of the pediatric population. It requires any application for
marketing authorization made after July 26, 2008 in respect of a product not authorized in the European Community on January 26, 2007 (the time the
Regulation entered into force), to include the results of all studies performed and details of all information collected in compliance with a pediatric
investigation plan agreed by the Pediatric Committee of the EMA, unless the product is subject to an agreed waiver or deferral or unless the product is
excluded from the scope of Regulation 1901/2006 (generics, hybrid medicinal products, biosimilars, homeopathic and traditional (herbal) medicinal
products and medicinal products containing one or more active substances of well-established medicinal use) according to its Art. 9. Waivers can be
granted in certain circumstances where pediatric studies are not required or desirable. Deferrals can be granted in certain circumstances where the initiation
or completion of pediatric studies should be deferred until appropriate studies in adults have been performed. The EMA does not evaluate an application for
market authorization that is not exempt from Regulation (EC) 1901/2006 if there is no agreed PIP, deferral or waiver. Moreover, this regulation imposes the
same obligation from January 26, 2009 on an applicant seeking approval of a new indication, pharmaceutical form or route of administration for a product
already authorized and still protected by a supplementary protection certificate granted under Regulation EC 469/2009 and its precursor Regulation (EEC)
1768/92 or by a patent that qualifies for the granting of such a supplementary protection certificate. The pediatric Regulation (EC) 1901/2006 also provides,
subject to certain conditions, a reward for performing such pediatric studies, regardless of whether the pediatric results provided resulted in the grant of a
pediatric indication. This reward comes in the form of an extension of six months to the supplementary protection certificate granted in respect of the
product, unless the product is subject to orphan drug designation, in which case the 10-year market exclusivity period for such an orphan product is
extended to 12 years. If any of the non-centralized procedures for marketing authorization have been used, the six-month extension of the supplementary
protection certificate is only granted if the medicinal product is authorized in all member states.
Post-authorization Obligations
In the pre-authorization phase, the applicant must provide a detailed pharmacovigilance plan that it intends to implement post- authorization. An
authorization to market a medicinal product in the EU carries with it an obligation to comply with many post- authorization organizational and behavioral
regulations relating to the marketing and other activities of authorization holders. These include requirements relating to post-authorization efficacy studies,
post-authorization safety studies, adverse event reporting and other pharmacovigilance requirements, advertising, packaging and labeling, patient package
leaflets, distribution and wholesale dealing. The regulations frequently operate within a criminal law framework and failure to comply with the
requirements may not only affect the authorization, but also can lead to financial and other sanctions levied on the company in question and responsible
officers. EU pharmacovigilance legislation has been significantly modified by the Pharmacovigilance Directive, Dir. 2010/84/EC which amended the legal
framework of pharmacovigilance for medicines marketed within the EU provided in Regulation (EC) No 726/2004 with respect to EU authorized medicinal
products and in Directive 2001/83/EC with respect to nationally authorized medicinal products (including those authorized through the mutual recognition
and decentralized systems). In addition, Commission Implementing Regulation (EU) No 520/2012 outlines the practical details to be respected by
marketing authorization holders, national competent authorities and the EMA, Regulation (EU) No 1027/2012 and Directive 2012/26/EU which further
amended the pharmacovigilance legislation to further strengthen the protection of patient health by allowing prompt notification and assessment of safety
issues and Commission Delegated Regulation (EU) No 357/2014 on post-authorization efficacy studies specifies the situations in which such studies may
be required. Furthermore, EU good pharmacovigilance practice (GVP) rules apply. With these pharmacovigilance requirements, the financial and
organizational burden on market authorization holders is significant, such as the obligation to maintain a pharmacovigilance system master file that applies
to all holders of marketing authorizations granted in accordance with Directive 2001/83/EC, as amended, or Regulation (EC) No 726/2004, as amended.
Marketing authorization holders must furthermore collect data on adverse events associated with use of the authorized product outside the scope of the
authorization. Pharmacovigilance for biological products and medicines with a new active substance is even stricter, as their authorization is subject to
additional monitoring activities.
90
Any authorization granted by member state authorities, which within three years of its granting is not followed by the actual placing on the market
of the authorized product in the authorizing member state, ceases to be valid (Art. 24 (4) Directive 2001/83/EC). When an authorized product previously
placed on the market in the authorizing member state is no longer actually present on the market for a period of three consecutive years, the authorization
for that product shall cease to be valid (Art. 24 (5) Directive 2001/83/EC). The same two three-year periods apply to authorizations granted by the
European Commission based on the centralized procedure (Art. 14 (4) and (5) Regulation (EC) 726/2004).
Other Countries
In addition to regulations in the United States, the EU, the UK and Israel, we are subject to a variety of other regulations governing clinical trials
and commercial sales and distribution of drugs in other countries. Whether or not Aramchol or any other product candidate receive approval from the FDA,
approval of such product candidates must be obtained by the comparable regulatory authorities of countries other than the United States before we can
commence clinical trials or marketing of the product in those countries. The approval process varies from jurisdiction to jurisdiction, and the time may be
longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials and product licensing vary greatly from
country to country.
The requirements that we and our collaborators must satisfy to obtain regulatory approval by government agencies in other countries prior to
commercialization of Aramchol or any other product candidate in such countries can be rigorous, costly and uncertain. In the European countries, UK,
Canada and Australia, regulatory requirements and approval processes are similar in principle to those in the United States. Additionally, depending on the
type of drug for which approval is sought, there are currently two potential tracks for marketing approval in the European countries: mutual recognition and
the centralized procedure. These review mechanisms may ultimately lead to approval in all EU countries, but each method grants all participating countries
some decision-making authority in product approval. The UK has a separate review period but for a transitional period until 31 December 2022, may rely
on approvals under the EU mutual recognition and/or centralized procedure. Foreign governments also have stringent post-approval requirements including
those relating to manufacture, labeling, reporting, record keeping and marketing. Failure to substantially comply with these on-going requirements could
lead to government action against the product, us and/or our representatives.
Related Matters
From time to time, legislation is drafted, introduced and passed in governmental bodies that could significantly change the statutory provisions
governing the approval, manufacturing and marketing of products regulated by the FDA, MHRA or EMA and other applicable regulatory bodies to which
we are subject. In addition, regulations and guidance are often revised or reinterpreted by the national agency in ways that may significantly affect our
business and our therapeutic candidates. It is impossible to predict whether such legislative changes will be enacted, whether FDA, MHRA or EMA
regulations, guidance or interpretations will change, or what the impact of such changes, if any, may be. We may need to adapt our business and therapeutic
candidates and products to changes that occur in the future.
C. Organizational Structure
See “Item 4. Information on the Company—Historical Background and Corporate Structure” above.
91
D. Description of Property and Facilities
Our principal executive offices and registered office in Israel is located at 16 Abba Hillel Road, Ramat Gan, Israel 5250608 and our telephone
number is +972-3-693-8448. Our lease at our prior principal executive offices expired on March 21, 2024. We did not extend the lease and are currently
headquartered in Ramat Gan, Israel while we are in the process of searching for a new permanent location for our principal executive offices.
ITEM 4A. Unresolved Staff Comments.
None.
ITEM 5. Operating and Financial Review and Prospects.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial
statements and related notes that appear elsewhere in this annual report. In addition to historical financial information, the following discussion contains
forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-
looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this prospectus, particularly
in the sections titled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements.” Our discussion and analysis for the year ended
December 31, 2022 can be found in our Annual Report on Form 20-F for the fiscal year ended December 31, 2022, filed with the SEC on March 29, 2023
(File No. 001-36345).
Overview
We are a biopharmaceutical company focused on the development of Aramchol. We have focused almost exclusively on developing Aramchol for
the treatment of liver disease and are currently developing Aramchol for PSC and exploring the feasibility of developing Aramchol for other fibro-
inflammatory indications outside of liver disease. We are also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino
acid synthetic peptide.
To date, we have not generated revenue from the sale of any product, excluding the licensing revenue we recorded in connection with the Samil
Agreement, and we do not expect to generate any significant revenue other than the amortization of the upfront payments under the license agreement with
Samil and of the subsequent royalties and/or milestones that may be earned in connection with the Samil Agreement or potential other license Agreements,
unless and until we commercialize Aramchol, or license the product to additional third parties. As of December 31, 2023, we had an accumulated deficit of
approximately $193.0 million.
Our financing activities are described below under “Liquidity and Capital Resources.” Obtaining approval of an NDA, MMA, or other similar
application is an extensive, lengthy, expensive and uncertain process, and the FDA, EMA, MHRA and other regulatory agencies may delay, limit or deny
approval of Aramchol, Amilo-5MER or any other product candidate.
Financial Overview
To date, we have funded our operations primarily through proceeds from private placements and public offerings. At December 31, 2023, we had
current assets of $13.2 million, which is mainly comprised of cash and cash equivalents of $2.9 million, restricted cash of $0.1 million, short-term deposits
of $2.3 million and short-term marketable securities of $7.5 million. This compares with current assets of $14.7 million at December 31, 2022, which is
mainly comprised of cash and cash equivalents of $2.0 million, restricted cash of $0.1 million and short-term marketable securities of $11.8 million. We
believe that such existing funds will be sufficient to continue our business and operations as currently conducted for more than 12 months from the date of
issuance of this annual report. However, significant additional funding will be necessary to fund our ARMOR Study, our Amilo-5MER program and
ongoing research and development work and to advance our product candidates through regulatory approval and into commercialization, if approved.
Subject to our strategic review, we intend to obtain additional funding through debt or equity financings, governmental grants or through entering into
collaborations, strategic alliances or license agreements to increase the funds available to support our operating and capital needs. Although we have been
successful in raising capital in the past, there is no assurance that we will be successful in obtaining additional financing on terms acceptable to us. If funds
are not available, we may be required to delay, reduce the scope of or eliminate research or development plans for, or commercialization efforts with
respect to Aramchol, Amilo-5MER and/or our other pre-clinical and clinical programs. This may raise substantial doubts about our ability to continue as a
going concern.
92
Revenues
We have entered into the Samil Agreement for the commercialization of Aramchol in Korea. Under the terms of the Samil Agreement, we have
received upfront and milestone payments of $3.6 million, and may be eligible to receive up to approximately $4.5 million in additional payments for
development and regulatory milestones for Aramchol in the licensed territories.
In accordance with ASC 606 the Company determined that the Agreement included a combined performance obligation representing the delivery
of the exclusive license and completion of the ARREST study.
As of December 31, 2023, management evaluated the remaining clinical and regulatory milestones and determined that the variable consideration
should not be recorded as revenue for the period ended December 31, 2023. The Company will re-evaluate the transaction price in each reporting period
when events whose outcomes are resolved or other changes in circumstances occur that would indicate it is appropriate to recognize variable consideration
as revenue
Costs and Operating Expenses
Our current costs and operating expenses consist of two components: (i) research and development expenses; and (ii) general and administrative
expenses.
Research and Development Expenses
Our research and development expenses consist primarily of outsourced development expenses, salaries and related personnel expenses and fees
paid to external service providers, patent and regulatory related legal fees, costs of pre-clinical studies and clinical trials and drug and laboratory supplies.
We account for all research and development expenses as they are incurred. Subject to our strategic review, we expect our research and development
expense to remain our primary expense in the near future as we continue to develop Aramchol and Amilo-5MER. Increases or decreases in research and
development expenditures are primarily attributable to the number and/or duration of the pre-clinical and clinical studies that we conduct.
We expect that a substantial amount of our research and development expense in the future will be incurred in support of our current and
anticipated pre-clinical and clinical development projects. Due to the inherently unpredictable nature of pre-clinical and clinical development studies, we
are unable to estimate with any certainty the costs we will incur in the continued development of Aramchol, Amilo-5MER and any other potential product
candidate. Clinical development timelines, the probability of success and development costs can differ materially from expectations. We currently expect to
continue testing Aramchol and Amilo-5MER in pre-clinical studies for toxicology, safety and efficacy, and to conduct additional clinical trials for
Aramchol and to initiate a first-in-human clinical study for Amilo-5MER.
While we are currently focused on advancing Aramchol’s and Amilo-5MER’s development, our future research and development expenses will
depend largely on the outcome of our strategic review, the duration of the ARMOR study, the number of enrolled patients, the clinical success of Aramchol,
as well as ongoing assessments of the Aramchol’s commercial potential. As we obtain results from clinical trials, we may elect to discontinue or delay
clinical trials for our product candidate in certain indications in order to focus our resources on more promising indications for such product candidate.
Completion of clinical trials may take several years or more, but the length of time generally varies according to the type, complexity, novelty and intended
use of a product candidate.
We expect our research and development expenses to increase in the future from current levels as we continue to advance our clinical product
development into a pivotal stage trial and, potentially, the in-licensing of additional product candidates.
93
The lengthy process of completing clinical trials and seeking regulatory approval for Aramchol and Amilo-5MER or any other product candidate
requires the expenditure of substantial resources. Any failure or delay in completing clinical trials, or in obtaining regulatory approvals, could cause a delay
in generating product revenue and cause our research and development expenses to increase and, in turn, have a material adverse effect on our operations.
Because of the factors set forth above, we are not able to estimate with any certainty when we would recognize any net cash inflows from our projects.
General and Administrative Expenses
General and administrative expenses consist primarily of compensation for employees in executive and operational roles, including finance,
/accounting, legal and other operating positions in connection with our activities. Our other significant general and administrative expenses include non-
cash stock-based compensation costs and facilities costs (including the rental expense for our offices in Tel Aviv, Israel), professional fees for outside
accounting and legal services, travel costs, investors relations, insurance premiums and depreciation.
Financial Income, Net
Our financial income consists mainly of interest income from marketable debt securities, as well as gains from realization of marketable debt
securities, income from change in fair value of convertible note and foreign currency gains. Our financial expense consists of fees associated with banking
activities and losses from realization of marketable debt securities and foreign currency losses.
A. Results of Operations
The table below provides our results of operations for the year ended December 31, 2023 as compared to the year ended December 31, 2022.
Research and development expenses
General and administrative expenses
Operating loss
Financial loss (income), net
Net loss
Comprehensive loss
Basic and diluted net loss per share from continuing operations
Research and Development Expenses
Year Ended December 31,
2022
2023
(thousands)
$
$
$
$
12,995 $
4,656
17,651
215
17,866
18,440 $
10.65 $
3,569
3,923
7,492
(580)
6,912
6,621
2.50
Our research and development expenses amounted to approximately $3.6 million during the year ended December 31, 2023, representing a
decrease of approximately $9.4 million, or approximately 72%, compared to approximately $13.0 million for the year ended December 31, 2022. The
decrease primarily resulted from a decrease in clinical trial expenses in the amount of approximately $5.9 million as well as a decrease in drug development
expenses in the amount of approximately $1.8 million.
General and Administrative Expenses
Our general and administrative expenses amounted to approximately $3.9 million for the year ended December 31, 2023, representing a decrease
of approximately $0.8 million, or 15%, compared to approximately $4.7 million for the year ended December 31, 2022. The decrease primarily resulted
from a decrease in insurance premium expenses of $0.3 million, as well as a decrease in non-cash stock based compensation expenses of approximately
$0.2 million.
94
Operating Loss
As a result of the foregoing research and development and general and administrative expenses, as well as our failure to generate substantial
operating revenues, our operating loss for the year ended December 31, 2023 was approximately $7.5 million, representing a decrease in our operating loss
of approximately $10.2 million, or approximately 58%, compared to approximately $17.7 million for the year ended December 31, 2022.
Financial Loss (income), Net
Our financial income, net, for the year ended December 31, 2023 was approximately $0.6 million, representing an increase of approximately $0.8
million, compared to a financial loss of approximately $0.2 million for the year ended December 31, 2022. The increase primarily resulted from a decrease
in loss of realization of marketable securities of approximately $0.5 million as compared to such loss for the comparable period in 2022, as well as from
income from change in the fair value of convertible SAFE note of $0.3 million.
Net Loss
Our net loss for the year ended December 31, 2023 was approximately $6.9 million, representing a decrease of approximately $11.0 million, or
approximately 61%, compared to approximately $17.9 million for the year ended December 31, 2022. The decrease primarily resulted from the above-
mentioned decrease in research development expenses and as well from the increase in financial income.
B. Liquidity and Capital Resources
Overview
To date, we have funded our operations primarily through proceeds from private placements and public offerings.
We have incurred substantial losses since our inception. As of December 31, 2023, we had an accumulated deficit of approximately $193.0 million
and working capital (current assets less current liabilities) of approximately 10.5 million. Due to our expectation that we will continue to not generate
substantial revenues for the foreseeable future, we expect that losses will continue for the foreseeable future.
As of December 31, 2023, we had cash and cash equivalents of approximately $2.9 million, restricted cash of $0.1 million, short-term deposits of
$2.3 million and short-term marketable debt securities of approximately $7.5 million invested in accordance with our investment policy, totaling
approximately $12.8 million, as compared to cash and cash equivalents of approximately $2.0 million, restricted cash of $0.1 million and short-term
marketable debt securities of approximately $11.8 million, totaling approximately $13.9 million as of December 31, 2022. Our cash requirements from
known contractual obligations within the next twelve months include lease obligations of approximately $0.04 million.
We generally enter into contracts in the ordinary course of business with CROs for clinical trials and clinical supply manufacturing and with
vendors for pre-clinical research studies and other services and products for operating purposes, which generally provide for termination within 30 to 90
days of notice, and therefore are cancelable contracts and not included in the discussion above. We have included as purchase obligations our commitments
under agreements to the extent they are quantifiable and are not cancelable.
Other than as described above, we did not have any material commitments for capital expenditures, including any anticipated material acquisition
of plant and equipment or interests in other companies, as of December 31, 2023.
Cash Flow from Operating Activities
We had negative cash flow from operating activities of approximately $6.1 million for the year ended December 31, 2023 as compared to a
negative cash flow from operating activities of approximately $18.5 million for the year ended December 31, 2022. The negative cash flow from operating
activities for the year ended December 31, 2023 was mainly attributable to our net loss of approximately $6.9 million, as well as a decrease in trade
payables of approximately $0.7 million, partially offset by non-cash stock based compensation expenses of approximately $1.0 million.
95
Cash Flow from Investing Activities
We had positive cash flow from investing activities of approximately $0.8 million for the year ended December 31, 2023 as compared to a positive
cash flow from investing activities of approximately $17.6 million for the year ended December 31, 2022. The positive cash flow from investing activities
for the year ended December 31, 2023 was primarily due to the net sale of marketable debt securities in the amount of approximately $4.5 million, partially
offset by an investment of $1.5 million in an associate and a net investment of $2.2 million in short-term deposits.
Cash Flow from Financing Activities
We had positive cash flow from financing activities of approximately $6.2 million for the year ended December 31, 2023 as compared to a
positive cash flow from financing activities of $0.1 million for the year ended December 31, 2022. The positive cash flow from financing activity for the
year ended December 31, 2022 was due to net proceeds from our public offering in July 2023.
On March 26, 2021, we entered into a Sales Agreement with Cantor and Canaccord Genuity LLC as sales agents, or the Sale Agents, pursuant to
which we may offer and sell our ordinary shares having an aggregate offering price of up to $50.0 million, from time to time through the Sales Agents.
Under the new Sales Agreement, we may sell, from time to time, up to approximately $50.0 million of additional ordinary shares subject to limitations
under the Baby Shelf Rule. As of December 31, 2023, we sold 7,721 ordinary shares under our ATM program for total net proceeds of approximately $0.1
million. We did not sell any ordinary shares under our ATM program in 2023.
On July 14, 2023, we entered into a definitive securities purchase agreement with investors for the purchase and sale in a public offering of (i)
380,000 of our ordinary shares, (ii) 5,220,000 pre-funded warrants to purchase 5,220,000 ordinary shares, or the Pre-Funded Warrants, and (iii) 5,600,000
warrants to purchase 5,600,000 ordinary shares, or the Investor Warrants, at a purchase price of $1.25 per Share and accompanying Investor Warrant and
$1.249 per Pre-Funded Warrant and accompanying Investor Warrant. The net proceeds to the offering were approximately $6.5 million before deducting
estimated offering expenses payable by us. As of the date hereof, 3,940,000 Pre-Funded Warrants have been exercised into 3,937,312 ordinary shares.
Current Outlook
Although we provide no assurance, we believe that our existing funds will be sufficient to continue our business and operations as currently
conducted for more than 12 months from the date of issuance of this Annual Report on Form 20-F. However, significant additional funding will be
necessary to fund our ARMOR Study, our Amilo-5MER program and ongoing research and development work and to advance our product candidates
through regulatory approval and into commercialization, if approved. Subject to our strategic review, we intend to obtain additional funding through debt or
equity financings, governmental grants or through entering into collaborations, strategic alliances or license agreements to increase the funds available to
support our operating and capital needs. Although we have been successful in raising capital in the past, there is no assurance that we will be successful in
obtaining additional financing on terms acceptable to us. If funds are not available, we may be required to delay, reduce the scope of or eliminate research
or development plans for, or commercialization efforts with respect to Aramchol, Amilo-5MER and/or our other pre-clinical and clinical programs. This
may raise substantial doubts about our ability to continue as a going concern.
The extent of our future capital requirements will depend on many other factors, including:
●
the outcome of our review of our strategic alternatives:
96
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
the progress and costs of our pre-clinical studies, clinical trials and other research and development activities;
the regulatory pathway of Aramchol, Amilo-5MER or any other product candidate;
the scope, prioritization and number of our clinical trials and other collaboration, research and development programs;
the amount of revenues and contributions we receive under future licensing, development and commercialization arrangements with
respect to Aramchol, Amilo-5MER or any other product candidate;
the costs of the development and expansion of our operational infrastructure;
the costs and timing of obtaining regulatory approval for Aramchol, Amilo-5MER or any other product candidate;
the ability of us, or our collaborators, to achieve development milestones, marketing approval and other events or developments under
our potential future licensing agreements;
the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;
the costs and timing of securing manufacturing arrangements for clinical or commercial production;
the costs of contracting with third parties to provide sales and marketing capabilities for us;
the costs of acquiring or undertaking development and commercialization efforts for any future products, product candidates or
platforms;
the magnitude of our general and administrative expenses;
any cost that we may incur under future in- and out-licensing arrangements relating to Aramchol, Amilo-5MER or any other product
candidate;
market conditions;
our ability to maintain the listing of our ordinary shares on The Nasdaq Capital Market; and
the impact of any resurgence of the COVID-19 pandemic and the war between Hamas and Israel, which may exacerbate the magnitude of
the factors discussed above.
C. Research and Development, Patents and Licenses
For information concerning our research and development policies and a description of the amount spent during each of the last three fiscal years
on company-sponsored research and development activities, see “Item 5. Operating and Financial Review and Prospects—Results of Operations.”
D. Trend Information
We are a development stage company and it is not possible for us to predict with any degree of accuracy the outcome of our research, development
or commercialization efforts. As such, it is not possible for us to predict with any degree of accuracy any known trends, uncertainties, demands,
commitments or events that are reasonably likely to have a material effect on our net sales or revenues, income from continuing operations, profitability,
liquidity or capital resources, or that would cause reported financial information to not necessarily be indicative of future operating results or financial
conditions. However, to the extent possible, certain trends, uncertainties, demands, commitments and events are in this “Operating and Financial Review
and Prospects.”
97
E. Critical Accounting Policies and Estimates
We prepare our financial statements in accordance with U.S. GAAP. In doing so, we must make estimates and assumptions that affect our reported
amounts of assets, liabilities and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could reasonably have used
different accounting policies and estimates. Changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly, actual
results could differ materially from our estimates. To the extent that there are material differences between these estimates and actual results, our financial
condition or results of operations will be affected.
While our significant accounting policies are described in more detail in the notes to our audited consolidated financial statements appearing
elsewhere in this Annual Report on Form 20-F we believe that the following accounting policies are those most critical to the judgments and estimates used
in the preparation of our consolidated financial statements:
Accounting for stock-based compensation:
We grant equity-based awards under share-based compensation plans. We estimate the fair value of share-based payment awards using the Black-
Scholes option valuation model. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the
underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately
expected to vest, and therefore is reduced by expected forfeitures. Changes in assumptions used under the Black-Scholes option valuation model could
materially affect our net loss and net loss per share.
Accounting for Marketable Debt Securities
Our debt securities are classified as available-for-sale and recorded at fair value. We determine the appropriate classification of investments in debt
securities at the acquisition date and re-evaluates the classification at each balance sheet date. Unrealized gains and losses during the year, net of the related
tax effect applicable to available-for-sale are excluded from income and reflected in other comprehensive income (loss) as a separate component of
shareholders’ equity until realized. As the result of the adoption of Accounting Standards Update (“ASU”) 2016-13, Financial Instruments-Credit Losses
(Topic 326): Measurement of Credit Losses on Financial Instrument (“ASU 2016-13”) we assess the need at each period end to record an allowance for
credit loss. Any portion of the market decline related to debt securities that is believed to arise from factors other than credit is recorded as a component of
other comprehensive income (loss) rather than against income.
Accounting for Investment in Associate at Fair Value
We hold an equity investment of a privately-owned company Onkai, over which have the ability to exercise significant influence, but not control.
The investment was included as a non-current asset in our balance sheet as of December 31, 2023. We have elected the fair value option allowed by
Accounting Standards Codification 825, Financial Instruments, with respect to this investment because our management believes this approach will better
reflect the economics of our equity interest. Under the fair value option, the investment is remeasured at fair value (level 3) at each reporting period with
changes in fair value, if any, recorded in the statement of operations.
98
ITEM 6. Directors, Senior Management and Employees.
A. Directors and Senior Management.
Set forth below is information concerning the directors, senior management and executive officers of the Company as of March 27, 2024, the
latest practicable date for inclusion in this annual report. The business address for each of our directors, senior management and corporate officers is c/o
Galmed Pharmaceuticals Ltd., 16 Abba Hillel Road, Ramat Gan, Israel 5250608.
Name
Allen Baharaff
Dr. Liat Hayardeny
Doron Cohen
Yohai Stenzler
Guy Nehemya
David Sidransky, M.D.(1)(2)(3)(4)(5)
Shmuel Nir(2)(3)(4)(5)
Amir Poshinski(2)(3)(4)(5)
Carol L. Brosgart, M.D. (1) (2)
Age
Position
59
57
57
41
39
63
62
63
72
President and Chief Executive Officer, Class II Director
Chief Scientist Officer
Chief Financial Officer
Chief Accounting Officer
Chief Operating Officer and Data Protection Officer
Lead Independent Director and Chairman of the R&D Committee, Chairman of
our Nomination Committee, Chairman of our Remuneration Committee, and
Class III director
Class I Director
Chairman of our Audit Committee, Class III director
Class I Director
(1) A member of our research & development committee.
(2) Independent director under applicable Nasdaq Capital Market and SEC rules, as affirmatively determined by our Board.
(3) A member of our audit committee.
(4) A member of our remuneration committee.
(5) A member of our nomination committee.
Allen Baharaff, our President and Chief Executive Officer of our Board, co-founded the Group in 2000, served as the Chief Financial Officer of
GHI from 2000 until January 2015, and has served as our Chief Executive Officer since January 2012 and as our President since March 2015. Previously,
he held a senior executive position at Isramex Projects Ltd., an energy project financing company, and Managing Director of T+M Trusteeship &
Management Services (Israel) Ltd., a subsidiary of a Swiss company providing trust and similar services. Since 2005, Mr. Baharaff serves as a Director of
the Rubin Museum. Since October 2023, Allen serves as a director of Onkai Inc, a private US-based technology company Mr. Baharaff holds a Bachelor of
Science degree in economics from the London School of Economics, University of London and LLB and MA degrees from Cambridge University. Since
1993, Mr. Baharaff has been a member of the Israel Bar Association.
Dr. Liat Hayardeny, our Chief Scientific Officer joined the Company in September 2016 bringing more than 17 years of experience in drug
development at all stages as part of Teva Pharmaceuticals’ global Research and Development Division. Prior to joining Galmed, Dr. Hayardeny served as
Teva’s Senior Director and Head of Research Scientific Affairs. In that capacity, Dr. Hayardeny established the scientific positioning of Teva’s innovative
compounds. Additionally, Dr. Hayardeny was responsible for Teva’s relationship with institutions of higher education; managing Teva’s global research
collaborations and publications. Dr. Hayardeny holds a Ph.D. from Sackler School of Medicine and an MBA from Recanati Business School at Tel Aviv
University.
99
Doron Cohen, our Chief Financial Officer, joined the Company in February 2022, after providing the Company consulting services, including with
respect to management of the Company’s funds, since 2018. Mr. Cohen brings more than twenty-five years of experience in the global financial markets,
including significant experience on the buy side of life sciences companies. Since 2016, Mr. Cohen has served as Chief Executive Officer at Tangram
Strategic Ltd., a boutique investment firm offering strategic solutions in economic & financial research, risk and regulation. Before that, between 1992 and
2017, Mr. Cohen served as Research Director at Gems Investments Research Ltd., an investment research company. During his tenure there, he provided
research to hedge funds and managed three teams of analysts, focusing on investment research, operations research, and risk analysis. Prior to that from
1990 to 1992, Mr. Cohen served as Director of Public Relations at the World Union of Jewish Students. Since October 2023, Doron serves as the interim
CFO of Onkai Inc, a private US-based technology company Mr. Cohen holds a Master of Science degree in management from Boston University, and a
Bachelor’s degree in philosophy and political science from the University of New South Wales.
Yohai Stenzler, our Chief Accounting Officer, has served in such capacity since February 2022. Mr. Stenzler joined the Company in June 2014 as
the Company’s corporate controller, and later on served as the Company’s Director of Finance. Between February 2017 to February 2022, Mr. Stenzler
served as our Chief Financial Officer. Mr. Stenzler has six years of financial management experience as an accountant at the real estate department at Ernst
& Young LLP, where he was involved in financing, taxes, auditing, advising and accounting of public and private companies, both domestic and
international. Mr. Stenzler is a certified CPA and holds a MBA in Finance from Recanati Business School at Tel Aviv University, and a BA in Economics
and Accounting from Ben-Gurion University of the Negev.
Guy Nehemya, our Chief Operating Officer and Data Protection Officer, has served in each role since January 2019 and March 2021, respectively.
Between March 2017 and January 2019, Mr. Nehemya served as our Vice President, Operations. Mr. Nehemya joined the Company in October 2013 as the
Company’s Director of Operations, after completing his internship at Agmon, Rosenberg, HaCohen & Co. Law Offices. Mr. Nehemya was a key member
of management during the Company’s initial public offering and execution thereof. Mr. Nehemya holds a LL.B. from the College of Management and is
currently completing his MBA degree at the IDC Herzliya. Mr. Nehemya has been a member of the Israeli Bar Association since 2012.
David Sidransky, M.D., the chairman of our Nomination, Remuneration and R&D Committees, joined our Board in June 2014, originally as an
external director. Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians
and scientists in America, recognized for his work with early detection of cancer. He serves as the Director of the Head and Neck Cancer Research Program
at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. He is a Professor of Oncology, Otolaryngology, Cellular & Molecular
Medicine, Urology, Genetics, and Pathology at Johns Hopkins University and Hospital. Dr. Sidransky has written over 600 peer-reviewed publications and
has contributed to more than 60 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous
biotechnology patents. He has been the recipient of many awards and honors, including the 1997 Sarstedt International prize from the German Society of
Clinical Chemistry, 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians and the 2004 Hinda Rosenthal
Award and 2017 Team Award presented by the American Association of Cancer Research. Dr. Sidransky has served as Vice Chairman of the Board of
Directors of ImClone. He is Chairman of the Board of Ayala Pharma (Nasdaq: AYLA), and is a lead director at Champions Oncology and on the board of
directors of Orgenesis (Nasdaq: ORGS) and Ascentage Pharma. He is serving and has served on scientific advisory boards of corporations and institutions,
including Amgen, MedImmune, Roche and Veridex, LLC (a Johnson & Johnson diagnostic company), among others. In addition, Dr. Sidransky served as
Director of American Association for Cancer Research from 2005 to 2008. Dr. Sidransky received his B.A. from Brandeis University and his M.D. from
the Baylor College of Medicine.
Shmuel Nir, a director of the Company since 2007, serves as President and Chief Executive Officer of Tushia Consulting Engineers Ltd., an
investment and management services company. From January 2001 to January 2016, Mr. Nir served as Chairman of the board of directors of Matan Digital
Printers Ltd. From March 1998 to January 2008, he served as President and Chief Executive Officer of Macpell Industries Ltd., a leading industrial group.
Between January 1991 and March 1998, Mr. Nir was an Executive Vice President of Operations at Macpell Industries Ltd. and President and Chief
Executive Officer of two of its subsidiaries, New Net Industries Ltd. and New Net Assets Ltd. Prior to January 1991, Mr. Nir had held various positions
with Intel Corporation in Jerusalem, Israel and Tefen Management Consulting. Between 1999 and 2006, Mr. Nir served as managing partner at Spring
Venture Capital Fund. Mr. Nir holds a B.Sc. in Industrial Engineering and Management from the Technion - Israel Institute of Technology in Haifa, which
was awarded in 1989.
100
Amir Poshinski, joined our Board in June 2020. Mr. Poshinski is an entrepreneur with over 20 years’ management and leadership experience
across multiple industries, including technology, biotechnology, banking and real estate. Mr. Poshinski is the owner of DAP Holdings, through which he
has acted since 2010 as a management consultant and strategic advisor to global companies. Mr. Poshinski currently serves as a member of the advisory
board of Benson Oak Ventures, a venture focused fund, as well as several other private companies. Prior to 2010, Mr. Poshinski served as Deputy CEO of
Primsa Investment House, which at the time was Israel’s largest investment house, Deputy CEO of Discount Mortgage Bank, the real estate lending arm of
one of Israel’s largest banks, VP of Marketing at Comverse, a telecommunications software company that was listed on Nasdaq, VP Marketing, Sales and
Advertising of Mifal Hapayis, Israel’s national lottery, and VP and Deputy CEO of the Economic Company of the Israeli Local Authorities Association.
Mr. Poshinski previously served on the board of directors of each of TAS-AGT (a TATA joint venture), Excellence Nessuah Mutual Funds, and Therapix
Biosciences (Nasdaq: TRPX) as well as several other private companies. Mr. Poshinski holds a B.A. in Business Administration and Marketing from the
New York Institute of Technology.
Carol L. Brosgart, M.D. joined our Board on June 7, 2017. Dr. Brosgart served as a member of Tobira Therapeutics’s Board of Directors from
2009 until it was acquired by Allergan in 2016 and on the Board of Juvaris, a vaccine company acquired by Bayer. Since January 2018, she serves on the
Board of Directors of Abivax, a biotechnology company, headquartered in Paris, working on HIV Cure and inflammatory diseases. Since 2022 Dr. Brosgart
also seves on the Board of of Eradivir Biotech and Merlin Biotech. Since June 2021, Dr. Brosgart also serves on the Board of Intrivo Diagnostic. Dr.
Brosgart also served on the Board of Mirum Pharmaceuticals Inc. (Nasdaq: MIRM) from 2021 to 2023, and serves since then as a clinical consultant to
Mirum. Dr. Brosgart serves as a consultant to Dynavax, Allergan and a number of biotechnology companies in the areas of liver diseases and infectious
diseases and on the Board of Renovaro Inc. (Nasdaq: RENB), focusing on HIV Cure. Dr. Brosgart also currently serves as a consultant for Dynavax
Technologies Corp (Nasdaq: DVAX). Dr. Brosgart currently serves on the Steering Committee of the National Viral Hepatitis Roundtable, the Executive
Committee of the Forum for Collaborative Research, the Steering Committee of the HBV Cure Group at the Forum, and is on the Board of Directors of the
Hepatitis B Foundation and the Northern California American Liver Foundation and the Board of Berkeley Community Scholars. She is active in the public
policy arena for AASLD and IDSA/HIVMA. Dr. Brosgart served as Senior Advisor on Science and Policy to the Division of Viral Hepatitis at the CDC
and to the Viral Hepatitis Action Coalition at the CDC Foundation from 2011 to 2013. Dr. Brosgart has also served as a member of the clinical faculty of
the School of Medicine at the University of California, San Francisco for the past four decades, where she is a Clinical Professor of Medicine, Biostatistics
and Epidemiology in the Division of Global Health and Infectious Diseases. In 2011, Dr. Brosgart served as Chief Medical Officer at biotechnology
company Alios BioPharma, Inc. Prior to Alios, Dr. Brosgart served as Senior Vice President and Chief Medical Officer of Children’s Hospital & Research
Center in Oakland, California, from 2009 until February 2011. Previously, she served for eleven years, from 1998 until 2009, at the biopharmaceutical
company Gilead Sciences, Inc., where she held a number of senior management roles, most recently as Vice President, Public Health and Policy and earlier
as Vice President, Clinical Research and Vice President, Medical Affairs. Prior to Gilead, Dr. Brosgart was the Medical Director of the East Bay AIDS
Center in Berkeley, California (1987-1998) and the Medical Director of the Central Health Center for the Alameda County Public Health Department
(1978-1987). Dr. Brosgart received a B.S. in Community Medicine from the University of California, Berkeley and received an M.D. from the University
of California, San Francisco. Her residency training was in pediatrics, public health and preventive medicine at UCSF and UC Berkeley School of Public
Health. She has published extensively in the areas of HIV, HBV, CMV, and liver disease.
There are no family relationships between any director or executive officer. There are no arrangements or understandings with major shareholders,
customers, suppliers or others, pursuant to which any director or executive officer was selected as a director or member of senior management, as the case
may be.
Board Diversity Matrix (As of March 27, 2024)
Country of Principal Executive Offices
Foreign Private Issuer
Disclosure Prohibited under Home Country Law
Total Number of Directors
Israel
Yes
No
5
101
Part I: Gender Identity
Directors
Part II: Demographic Background
Underrepresented Individual in Home Country Jurisdiction
LGBTQ+
Did Not Disclose Demographic Background
Scientific Advisory Board
Female
1
Male
4
Non-Binary
0
0
0
0
Did Not Disclose
Gender
0
We seek advice from our Scientific Advisory Board generally on scientific and medical matters. Our Scientific Advisory Board includes the
following: Professor Vlad Ratziu from the University Pierre et Marie Curie in Paris, France and coordinator of the EU FP7 FLIP consortium; Professor
Scott Friedman from the Icahn School of Medicine at Mount Sinai in New York, United States; Professor Arun Sanyal, from the Virginia Commonwealth
University in Richmond, Virginia; Professor Jose Mato, from CIC bioGUNE Spain; and Professor Shomron Ben-Horin, Chief of the Gastroenterology
Department at Sheba Medical Center.
B. Compensation.
Certain Approvals Required for Office Holders’ Compensation of the Companies Law
Pursuant to the Companies Law, the Company is required to adopt a compensation policy regarding the terms of office and employment of its
Office Holders (as such terms are defined below), which includes exemption and release of the Office Holders from liability for breach of his or her duty of
care to the Company, an undertaking to indemnify the Office Holder, post factum indemnification or insurance; any grant, payment, remuneration,
compensation, or other benefit provided in connection with termination of service; and any benefit, other payment or undertaking to provide any payment
as aforesaid, or the Terms of Office and Employment.
The Company’s current amended and restated compensation policy with respect to the terms of office and employment of the Company’s Office
Holders, or the Compensation Policy, was adopted by the Board on May 30, 2023, and will remain in effect for a period of three years according to the
Companies Law, unless replaced prior. The Compensation Policy was approved in accordance with the mechanism set forth in the Companies Law, which
allows the Board to approve the Compensation Policy, notwithstanding the resolution of the general meeting on May 11, 2023, provided that the
remuneration committee and thereafter the Board have concluded, following further and detailed discussion of the matter and for specified reasons, that
such approval is in the Company’s best interests. To that end, the remuneration committee and our Bord considered the results of the general meeting vote,
details of the Compensation Policy and its alignment with the Company’s compensation philosophy and other relevant considerations and thereafter
determined that the approval of the Compensation Policy is in the best interest of the Company.
The term ‘Office Holder’ as defined in the Companies Law includes a general manager, chief business manager, deputy general manager, vice
general manager, any other person fulfilling or assuming the responsibilities of any of the foregoing positions without regard to such person’s title, as well
as a director, or a manager directly subordinate to the general manager or the chief executive officer.
Pursuant to the Companies Law, arrangements between the Company and its Office Holders must generally be approved by the remuneration
committee and the Board and be consistent with the Compensation Policy. However, under certain circumstances, the Company may approve an
arrangement that is not consistent with the Compensation Policy, if such arrangement is approved by a majority of the Company’s shareholders, provided
that (i) such majority includes a majority of the votes cast by shareholders who are not controlling shareholders and who do not have a personal interest in
the matter, present and voting (abstentions are disregarded), or (ii) the votes cast by shareholders who are not controlling shareholders and who do not have
a personal interest in the matter who were present and voted against the arrangement constitute two percent or less of the voting power of the company, or
the Special Majority.
102
The terms of office and employment of directors (including an officer who is a director but is not a controlling shareholder) further require the
approval of the shareholders by a simple majority in addition to the approval of the Remuneration Committee and the Board, in that order, and under
certain circumstances, a Special Majority; with respect to a chief executive officer who is not also a director or an officer who is a controlling shareholder,
the approval of the shareholders must be made by the Special Majority. In addition, under certain circumstances, a company may be temporarily exempt
from receiving the shareholders’ approval with respect to the terms of office and employment of a non-affiliated candidate for chief executive officer.
Under certain circumstances, if the terms of office and employment of Office Holders (who are not directors or controlling shareholders) are not
approved by the shareholders, where such approval is required, the remuneration committee and the Board may subsequently override the resolution of the
shareholders following a new discussion of the matter and for specified reasons. In addition, amendment of terms of office and employment of Office
Holders (who are not directors or controlling shareholders) requires the approval of the remuneration committee only, if the remuneration committee
determines that the amendment is not material.
Aggregate Executive Compensation
The aggregate compensation, including share-based compensation, paid by us to all of our Office Holders as a group, with respect to the year
ended December 31, 2023, was approximately $2.76 million. This amount includes approximately $0.3 million set aside or accrued to provide pension,
severance, retirement, vacation or similar benefits or expenses, but does not include business travel, relocation, professional and business association dues
and expenses reimbursed to Office Holders, and other benefits commonly reimbursed or paid by companies in our industry. In addition to the five current
members of the Board (including the Company’s President and Chief Executive Officer), the Company considers four other individuals, namely, the Chief
Scientist Officer, Chief Financial Officer, Chief Accounting Officer and the Chief Operating Officer, to have been Office Holders in 2023.
As of December 31, 2023, options to purchase 217,273 of our ordinary shares granted to our Office Holders as a group were outstanding, of which
options to purchase 165,955 of our ordinary shares have vested, with a weighted average exercise price of $49.61 per ordinary share and 1,315,000
restricted share units, or RSUs granted to our Office Holders were outstanding, of which none were settled.
For outstanding equity-based awards granted to our Office Holders, see below under “Item 6. Directors, Senior Management and Employees—E.
Share Ownership—Certain Information Concerning Equity Awards to Office Holders.”
Individual Compensation of Covered Executives
The following table sets forth the compensation granted to the five most highly compensated Office Holders during or with respect to the year
ended December 31, 2023. All amounts reported in the table reflect the cost to the Company, as recognized in its financial statements for the year ended
December 31, 2023. The five individuals for whom disclosure is provided are referred to herein as “Covered Executives.”
Information Regarding the Covered Executives
Compensation for Services(1)
Name and Principal Position(1)
Allen Baharaff (President and Chief Executive Officer)
Benefits
and
Base
Salary Perquisites
($)
550,874
($)(2)
145,056
Cash Equity-Based
Compensation
Bonus
($)(4)
($)(3)
236,228
384,026
Other
($)(5)
40,000
Total ($)
1,356,183
Yohai Stenzler (Chief Accounting Officer)
167,855
50,733
71,980
87,751
-
378,319
Guy Nehemya (Chief Operating Officer and Data
Protection Officer)
167,855
47,201
71,980
87,744
-
374,799
Doron Cohen (Chief Financial Officer)
145,820
37,631
62,531
27,828
273,792
Dr. Liat Hayardeny (Chief Scientific Officer)
37,330
10,604
66,756
-
114,690
(1) The above-mentioned executives are all full-time employee of the Company. Cash compensation amounts denominated in currencies other than
the Dollar were converted into Dollars at an exchange rate of NIS 3.62 = $1.00, which reflects the average conversion rate for fiscal year ended
December 31, 2023.
103
(2) Amounts reported in this column include benefits and perquisites, including those mandated by applicable law. Such benefits and perquisites may
include, to the extent applicable to the Covered Executives, payments, contributions and/or allocations for savings funds, pension, severance,
vacation, car allowance, risk insurance (e.g., life, disability, accident), telephone, convalescence pay, payments for social security and other
benefits and perquisites consistent with the Company’s policies.
(4) Amounts reported in this column represent the expense recorded in the Company’s financial statements for the year ended December 31, 2023
with respect to equity-based compensation. Assumptions and key variables used in the calculation of such amounts are discussed in Note 10 to the
Financial Statements. For outstanding equity-based awards granted to Covered Executives see below under “Item 6. Directors, Senior
Management and Employees—E. Share Ownership—Certain Information Concerning Equity Awards to Office Holders.”
(3) Amounts reported in this column refer to the cash bonuses provided by the Company with respect to 2023, which have been provided for in the
Company’s financial statements for the year ended December 31, 2023 (including if such bonuses were paid in 2024). They exclude bonuses paid
in 2023 which were provided for in the Company’s financial statements for previous years. Cash bonuses are paid in accordance with the
Company’s 2023 Annual Cash Bonus Plan and are intended to promote the Company’s work plan and business strategy by rewarding officers for
achievement of the Company’s business and financial goals through teamwork and collaboration. Key performance indicators which are factored
into cash bonus determinations are based both on personal
(5) Amounts reported in this column include payments made with respect to the year 2023 and recorded in the financial statements for the year ended
December 31, 2023 relating to directors’ fees.
Compensation of Directors
As approved by our shareholders at our 2020 annual meeting of shareholders, in connection with their services as directors of the Company, each
of our directors from time to time, is entitled to an annual payment of $40,000, plus value-added tax, or VAT, if applicable, and with respect to an expert
external director (if applicable), $50,000 plus VAT, payable quarterly at the end of each quarter, and, upon first becoming a member of the Board. As
approved by our shareholders at our 2023 special meeting of shareholders, (i) each of our non-management directors, except Dr. Carol L. Brosgart,
received a grant of RSU’s to purchase 75,000 ordinary shares, or the Director RSUs. The Director RSUs were granted under the 2013 Plan and (ii) our
director, Dr. Carol L. Brosgart, received a grant of options to purchase 75,000 ordinary shares, or the Director Options. The Director Options were granted
under the 2013 Plan at an exercise price equal to $0.92, the closing price of our Ordinary Shares on the Nasdaq Stock Market on August 6, 2023, the day
prior to the meeting of the Board approving such grant. The Director RSUs and the Director Options vest over a period of three years, such that Director
RSUs and the Director Options will vest with respect to 1/3 of the underlying Ordinary Shares on the first anniversary of the grant (i.e., the date of the
Board’s approval on August 7, 2023), and thereafter, Director RSUs and the Director Options will vest with respect to the additional 2/3 of the underlying
ordinary shares on an equally quarterly basis, provided that each non-management director continues to serve as a director of us or our affiliates throughout
each such vesting date. All unvested options held by a non-management director in office will automatically vest and become exercisable upon the
consummation of a Transaction, as such term is defined in the 2013 Plan. The grant is subject to the execution by each director of an option agreement with
us confirming the terms and conditions applying to the grant.
Our Board has determined that each of Mr. Nir, Mr. Poshinski, and Dr. Sidransky are entitled to receive compensation equivalent to what an
‘expert external director’ would have received. See also “Item 6. Directors, Senior Management and Employees—C. Board Practices—External Directors”
and “Item 7. Major Shareholders and Related Party Transactions—C. Related Party Transactions” below.
For the outstanding equity-based awards granted to our directors, see below under “Item 6. Directors, Senior Management and Employees—E.
Share Ownership—Certain Information Concerning Equity Awards to Office Holders.”
104
Employment Agreements and Arrangements with Directors and Related Parties
We entered into written employment agreements with each of our executive officers. These agreements provide for notice periods of varying
duration for termination of the agreement by us or by the relevant executive officer, during which time the executive officer will continue to receive base
salary and benefits. These agreements also contain customary provisions regarding non-competition, confidentiality of information and assignment of
inventions. However, the enforceability of the non-competition and assignment of inventions provisions may be limited under applicable law. See “Item 3.
Key Information—Risk Factors—Risks Related to Our Business, Industry and Regulatory Requirements.”
Employment Agreement with Our President and Chief Executive Officer
On December 30, 2013, we entered into a personal employment agreement with our controlling shareholder, Mr. Allen Baharaff who serves as our
president and chief executive officer and as the chairman of our Board, as amended on March 15, 2016, July 20, 2017, August 1, 2019, and August 30,
2021 which provides that Mr. Baharaff’s terms of office and employment are for an undefined term, subject to re-approval under the Companies Law and
termination in accordance with the terms of the employment agreement.
Under the current terms of his employment agreement, Mr. Baharaff is entitled to a gross monthly salary of NIS 170,000, following shareholder
approval which was obtained at our 2021 annual meeting of shareholders. In addition, Mr. Baharaff will be entitled to an annual cash bonus based on
achievement of qualitative and quantitative performance goals and objectives. As approved at our 2021 annual meeting of shareholders the annual cash
bonus amount may be of up to six times Mr. Baharaff’s monthly base salary, and the actual bonus paid in a given year shall be determined based on the
achievement of certain qualitative and quantitative performance goals and objectives set by our remuneration committee and Board, which effective as of
January 1, 2022, does not require further shareholder approval.
Mr. Baharaff is also entitled to receive the following bonuses (i) upon execution of a Strategic Agreement (as defined below), and subject to the
discretion of the Board, a cash bonus in an amount of up to twelve times his monthly base salary. A “Strategic Agreement” means: a license agreement or
any other strategic agreement (i.e. research and development, manufacture, distribution, etc.) for the U.S., Europe, Japan or China; (ii) upon consummation
of a fund raising (excluding funds received from a Strategic Agreement), and, subject to the discretion of the Board, a cash bonus in an amount of up to ten
times his monthly base salary if the funds received by the Company are between $8 Million to $10 million and up to twelve times his monthly base salary
if the funds received by the Company are $10 million or more; (iv) upon a Change of Control Event (as defined below), and, subject to the discretion of the
Board, a cash bonus in an amount of up to twelve times his monthly base salary, a “Change of Control Event” means: (a) the acquisition of the Company by
another entity or individual or group of individuals by means of any transaction or series of related transactions (including, without limitation, any
reorganization, merger, share purchase or consolidation), unless the Company’s shareholders of record as constituted immediately prior to any such
transaction will, immediately after such transaction (by virtue of securities issued as consideration for the Company’s share capital, assets or otherwise)
hold more than 50% of the voting power of the surviving or acquiring entity; or (b) a sale of all or substantially all of the assets of the Company.
Mr. Baharaff will also be entitled to the following equity based compensation: (i) in the event that our options are cashed-out upon a Change of
Control Event, all unvested options granted to Mr. Baharaff will vest immediately prior to the consummation of the Change of Control Event; (ii) if upon a
Change of Control Event (a) Mr. Baharaff’s employment as chief executive officer of the Company or the surviving entity is terminated within twelve
months as of the Change of Control Event, and (b) unvested options are replaced for new options of the surviving entity as part of the Change of Control
Event with a vesting schedule and terms identical to the replaced options, or the Replacement Options, then (x) all unvested Replacement Options granted
to Mr. Baharaff will vest immediately prior to the termination of Mr. Baharaff’s employment, and (y) Mr. Baharaff’s Replacement Options will be
exercisable until the earlier of (a) two years from termination, and (b) expiration of the Replacement Options.
105
Mr. Baharaff will also receive other benefits required under Israeli law or that are customary for senior executives in Israel such as confidentiality,
reimbursement of expenses, payment for absence days, sick leave, pension and/or a manager’s insurance policy and study fund.
Mr. Baharaff is also entitled to accumulate vacation days for no more than two years. As approved at our 2021 annual meeting of shareholders,
unused accumulated vacation days that exceed the number of vacation days that may be accumulated over a two-year period (currently, 48 vacation days)
shall be redeemed once a year, on March 1, provided that the redemption will not result in the number of accumulated vacation days following the
redemption being less than 48 days, or as otherwise required by law. Accumulated vacation days shall also be redeemed in the event of termination of
employment of Mr. Baharaff.
Mr. Baharaff’s employment agreement is terminable by either party upon six months prior written notice, or Prior Notice Period, and contains
customary provisions regarding noncompetition, confidentiality of information and assignment of inventions. Upon termination, provided such termination
was not for cause, Mr. Baharaff shall be entitled, in addition to the Prior Notice Period, to a payment in an amount of up to twelve times his monthly base
salary, to be paid in twelve equal monthly installments, in exchange for Mr. Baharaff’s undertaking not to compete with the Company for a period of twelve
months, or Non-Compete Grant. Other than in case of resignation by Mr. Baharaff, excluding resignation for a Good Reason Event (as defined below), or
termination for cause: (i) all Mr. Baharaff’s unvested options will vest upon termination; and (ii) unexercised options granted to Mr. Baharaff may be
exercised until the earlier of (a) two years from his termination, and (b) expiration of his options. A “Good Reason Event” means: any of the following
events, provided that the event is effected by the Company without the written consent of Mr. Baharaff: (i) a material reduction or adverse change in Mr.
Baharaff’s authority, duties or responsibilities; (ii) a reduction in Mr. Baharaff’s monthly base salary, other than a reduction of no more than 10% of his
then current monthly base salary as part of an across the board reduction in all salaries for employees of the Company; (iii) a material breach by the
Company of Mr. Baharaff’s employment agreement or any other agreements pertaining directly to Mr. Baharaff’s compensation or employment or (iv)
death, disability or severe illness. Upon termination for cause by the Company, Mr. Baharaff shall not be entitled to any Prior Notice Period, Non-Compete
Grant or any other payment, and any unvested outstanding equity awards shall terminate immediately upon the date of such termination for cause.
For cash bonuses granted to Mr. Baharaff see “Item 6. Directors, Senior Management and Employees— B. Compensation—Individual
Compensation of Covered Executives.” For outstanding equity-based awards granted to Mr. Baharaff see below under “Item 6. Directors, Senior
Management and Employees—E. Share Ownership—Certain Information Concerning Equity Awards to Office Holders.”
C. Board Practices.
We are incorporated in Israel, and, therefore, we are subject to various corporate governance practices under Israeli law relating to such matters as
external directors (if required), independent directors, audit committees, remuneration committees and internal auditors. These Israeli law requirements are
in addition to the requirements of the Nasdaq Listing Rules and other relevant provisions of U.S. securities laws. Under such Nasdaq Listing Rules, a
foreign private issuer may generally follow its home country practices for corporate governance in lieu of such comparable listing rules’ requirements,
except for certain matters such as composition and responsibilities of the audit committee and the SEC-mandated standards for the independence of its
members. See below under “Item 16G. Corporate Governance” for further information.
Membership of the Board
Our Articles provide that the minimum number of members of the Board is three and the maximum number of members is eleven. The Board is
presently comprised of five members. Pursuant to regulations promulgated under the Companies Law, or the Relief Regulations,, companies with no
controlling shareholder whose shares are listed for trading on specified exchanges outside of Israel, including the Nasdaq Capital Market, may adopt
exemptions from various corporate governance requirements of the Companies Law so long as the company satisfies the applicable foreign country laws
and regulations, including applicable stock exchange rules, that apply to companies organized in that country relating to the appointment of independent
directors and the composition of audit and remuneration committees. Such exemptions include an exemption from the requirement to appoint external
directors and the requirement that an external director be a member of the audit and remuneration committees.
106
In March 2020, our Board adopted this exemption , and our directors then in office who were elected and classified as an external director, were
no longer classified as such under the Companies Law.
The minimum and maximum number of directors may be changed, at any time and from time to time, by a majority vote of our directors then in
office, provided that no decrease in the number of directors shall shorten the term of any incumbent director. Under our Articles, the Board consists of three
classes of directors which are appointed for fixed terms of office in accordance with the Companies Law and our Articles, with one class being elected each
year for a term of approximately three years by our shareholders at our annual general meeting.
Directors so elected cannot be removed from office by the shareholders until the expiration of their term of office. The directors do not receive any
benefits upon the expiration of their term of office.
The three classes of directors are Class I Directors, Class II Directors and Class III Directors. Shmuel Nir and Dr. Carol Brosgart serve as our
Class I Directors until the close of the annual general meeting to be held in 2024; Allen Baharaff serves as our Class II Director until the close of the annual
general meeting to be held in 2025; and Dr. David Sidransky and Amir Poshinski serve as our Class III Directors until the close of the annual general
meeting to be held in 2026.
In accordance with the Articles, any vacancies on the Board of, including unfilled positions, may be filled by a vote of a majority of the directors
then in office, and each director chosen in this manner would hold office until the next annual general meeting of the Company (or until the earlier
termination of his or her appointment as provided for in the Companies Law or the Articles).
Any amendment of our Articles regarding the election of directors, as described above, requires the affirmative vote of at least 75% of the voting
rights in the Company, represented personally or by proxy and voting thereon at a general meeting. See “Item 6. Directors, Senior Management and
Employees—C. Board Practices—External Directors” for a description of the procedure for the election of external directors.
A nominee for service as a director in a public company may not be elected without submitting a declaration to the company, prior to election,
specifying that he or she has the requisite qualifications to serve as a director, independent director or external director (if required), as applicable, and the
ability to devote the appropriate time to performing his or her duties as such.
A director, who ceases to meet the statutory requirements to serve as a director, external director or independent director, as applicable, must
notify the company to that effect immediately and his or her service as a director will expire upon submission of such notice.
Alternate Directors
Our Articles provide, as allowed by the Companies Law, that any director may, subject to the conditions set thereto, appoint a person as an
alternate to act in his place, to remove the alternate and appoint another in his place and to appoint an alternate in place of an alternate whose office is
vacated for any reason whatsoever. Under the Companies Law, a person who is not qualified to be appointed as a director, a person who is already serving
as a director or a person who is already serving as an alternate director for another director, may not be appointed as an alternate director. Nevertheless, a
director who is already serving as a director may be appointed as an alternate director for a member of a committee of the board of directors so long as he
or she is not already serving as a member of such committee. A person who is not qualified to be appointed as an independent director, pursuant to the
Companies Law, may not be appointed as an alternate director of an independent director qualified as such under the Companies Law. Unless the
appointing director limits the time or scope of the appointment, the appointment is effective for all purposes until the appointing director ceases to be a
director or terminates the appointment.
107
External Directors
Generally, unless a regulatory relief is available, under the Companies Law and the regulations promulgated pursuant thereto, Israeli companies
whose shares have been offered to the public, or that are publicly traded outside of Israel, which we refer to as a public company, are required to appoint at
least two natural persons as “external directors.”
Pursuant the Relief Regulations, companies with shares traded on certain U.S. stock exchanges, including Nasdaq, which do not have a
“controlling shareholder,” may, subject to certain conditions, “opt out” from the Companies Law requirements to appoint external directors and related
Companies Law rules concerning the composition of the audit committee and remuneration committee of the board of directors. In accordance with these
regulations, in March 2020, our Board elected to “opt out” from the Companies Law requirement to appoint external directors and related Companies Law
rules concerning the composition of the audit committee and remuneration committee of our Board.
Director Independence
Following our “opt-out” of the requirement to have external directors serving on our Board, we comply with the director independence
requirements and the audit committee and the remuneration committee composition requirements under U.S. laws (including applicable Nasdaq Capital
Market rules) applicable to U.S. domestic issuers. Our Board has undertaken a review of the independence of each director. Based on information provided
by each director concerning their background, employment and affiliations, our Board has determined that Mr. Nir, Mr. Poshinski, Dr. Sidransky, and Dr.
Brosgart do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that
each of these directors is “independent” as that term is defined under the listing standards of the Nasdaq. In making these determinations, our Board
considered the current and prior relationships that each non-employee director has with our company and all other facts and circumstances our Board
deemed relevant in determining their independence, including the beneficial ownership of our capital shares by each non-employee director.
Committees of the Board
Our Articles also provide that the Board may delegate any, or all, of its powers to one or more committees of the Board, and may entrust to and
confer upon a “managing director” such of its powers as it deems appropriate. However, the Companies Law provides that certain powers and authorities
(for example, the power to approve the financial statements) may not be delegated and may be exercised only by the Board. Notwithstanding the foregoing,
we currently do, and intend to continue to, comply with the corporate governance requirements of the Nasdaq Capital Market, except to the extent indicated
elsewhere in this annual report, including as set forth under “Item 16G. Corporate Governance” below. The Companies Law requires public companies
such as the Company to appoint an audit committee and a remuneration committee.
Audit Committee
The Companies Law requires public companies to appoint an audit committee comprised of at least three directors, including all of the external
directors, if any the majority of whom must be independent directors under the Companies Law. The Companies Law further stipulates that the following
may not be members of the audit committee: (i) the chairman of the board of directors; (ii) any director employed by or providing services on an ongoing
basis to the company, to a controlling shareholder of the company or an entity controlled by a controlling shareholder of the company; (iii) a director whose
livelihood mainly depends on a controlling shareholder; and (iv) a controlling shareholder or any relative of a controlling shareholder.
The Companies Law further requires that: (i) the chairperson of the audit committee must be an external director; (ii) generally, any person who is
not entitled to be a member of the audit committee may not attend the audit committee’s meetings and voting sessions, unless such person was invited by
the chairperson of the committee for the purpose of presenting a specific subject matter thereof; and (iii) the quorum required for the convening of meetings
of the audit committee and for adopting resolutions by the audit committee is a majority of the members of the audit committee, provided that the majority
of the members present are independent directors and at least one of them is an external director. As noted, under the Relief Regulation, companies with no
controlling shareholder whose shares are listed for trading on specified exchanges outside of Israel, including the Nasdaq Capital Market, may adopt
exemptions from various corporate governance requirements of the Companies Law so long as the company satisfies the applicable foreign country laws
and regulations, including applicable stock exchange rules, that apply to companies organized in that country relating to the appointment of independent
directors and the composition of audit and remuneration committees. Such exemptions include an exemption from the requirement to appoint external
directors and the requirement that an external director be a member of certain committees. In accordance with these Regulations, we elected to “opt out”
from such requirements of the Companies Law.
108
The responsibilities of the audit committee under the Companies Law include: (i) identifying flaws in the management of a company’s business
and making recommendations to the board of directors as to how to correct them; (ii) with respect to certain actions involving conflicts of interest and with
respect to certain related party transactions, deciding whether such actions are material actions and whether such transactions are extraordinary
transactions, respectively, all for the purpose of approving such actions or transactions; (iii) reviewing and deciding whether to approve certain related party
transactions and certain actions involving conflicts of interest; (iv) reviewing the internal auditor’s work program; (v) examining the company’s internal
control structure and processes, the performance of the internal auditor and whether the internal auditor has at his or her disposal the tools and resources
required to perform his or her duties, considering, inter alia, the special needs of the company and its size; (vi) examining the independent auditor’s scope
of work as well as the independent auditor’s fees and providing its recommendations to the appropriate corporate organ; (vii) providing for arrangements as
to the manner in which the company will deal with employee complaints with respect to deficiencies in the management of the company’s business and the
protection to be provided to such employees; and (viii) with respect to related party transactions with a controlling shareholder, regardless of whether such
transactions are extraordinary transactions, that prior to entering into such transaction, to establish the requirement of having a competitive process under
the supervision of the audit committee or any individual, committee or body on its behalf and according to criteria established by the audit committee and
to determine procedures for approving certain related party transactions with a controlling shareholder, which were determined by the audit committee to
be non-extraordinary transactions, but which are not negligible transactions.
Our Board has adopted an audit committee charter setting forth the responsibilities of the audit committee consistent with the rules of the SEC and
the Nasdaq Listing Rules, as well as the requirements for such committee under the Companies Law, as described below.
Our audit committee oversees the accounting and financial reporting processes of the Company. It also provides assistance to the Board in
fulfilling its legal and fiduciary obligations with respect to matters involving the accounting, auditing, financial reporting and internal control functions of
the Company. In carrying out its duties, our audit committee meets with management at least once a quarter, at which time, among other things, it reviews,
and either approves or disapproves, the financial results of the Company for the immediately preceding calendar quarter and conveys its conclusions in this
regard to the Board. Our audit committee also monitors generally the services provided by the Company’s independent auditors to ensure their
independence and reviews all audit and non-audit services provided by them.
Our Board has resolved to delegate to the audit committee the power to pre-approve non-auditing services rendered by the Company’s
independent auditors without the need for further approval by our Board. As such, on March 15, 2016, our audit committee approved the adoption of a pre-
approval policy, such that the Chairman of the audit committee is authorized to pre-approve any engagement of our independent auditors during a period of
twelve months from the date of such approval, for the provision of non-auditing services, for fees not to exceed $20,000, and any such engagement which
exceeds $20,000 shall require a pre-approval by the entire audit committee. Once services have been pre-approved, our management must then report to the
audit committee on a periodic basis regarding the extent of services actually provided in accordance with the pre-approval policy, and regarding the fees for
the services performed.
The Company’s independent and internal auditors also report regularly to our audit committee, and our audit committee discusses with the
Company’s independent auditors the quality, not just the acceptability, of the accounting principles, the reasonableness of significant judgments and the
clarity of disclosures in the Company’s financial statements, as and when it deems it appropriate to do so.
Under the provisions of the Sarbanes-Oxley Act, the audit committee is directly responsible for the appointment, compensation and oversight of
the work of the company’s independent auditors. However, under Israeli law, the appointment of independent auditors and their compensation require the
approval of the shareholders of a public company. Pursuant to Israeli law, the shareholders may delegate the authority to determine the compensation of the
independent auditors to the board of directors. In addition, pursuant to the Companies Law, the audit committee is required to examine the independent
auditors’ fees and to provide its recommendations with respect thereto to the appropriate corporate body. Accordingly, the appointment of our independent
auditors is required to be approved and recommended to the shareholders by our audit committee and Board and approved by the shareholders. The
compensation of the independent auditors for audit services is required to be approved and recommended to the Board by our audit committee and
approved by the Board. The Board has delegated its authority to approve the compensation of independent auditors for non-auditing services to the audit
committee.
109
Mr. Nir, Mr. Poshinski and Dr. Sidransky are the current members of our audit committee, with Mr. Poshinski serving as chairperson. Each of our
audit committee members are “independent directors” in accordance with the Nasdaq Capital Market corporate governance requirements, as affirmatively
determined by our Board. In addition, our Board has affirmatively determined that Mr. Poshinski also qualifies as an audit committee financial expert
pursuant to the applicable SEC rules, and accordingly has the necessary financial sophistication as required by the Nasdaq Capital Market rules.
Remuneration Committee
The Companies Law requires public companies to appoint a remuneration committee comprised of at least three directors, including all of the
external directors, who must generally also constitute a majority of the members. All other members of the committee, who are not external directors, must
be directors who receive compensation consistent with that of external directors and that is in compliance with the compensation related regulations
promulgated under the Companies Law. In addition, the chairperson of the remuneration committee must be an external director. As noted, under the Relief
Regulations, we elected to “opt out” from such requirements of the Companies Law.
The Companies Law further stipulates that directors who are not qualified to serve on the audit committee, as described above, may not serve on
the remuneration committee either and that similar to the audit committee, generally, any person who is not entitled to be a member of the remuneration
committee may not attend the remuneration committee’s meetings. Our Board has adopted a remuneration committee charter setting forth the
responsibilities of our remuneration committee, as described below.
The responsibilities of the remuneration committee under the Companies Law include: (i) making recommendations to the board of directors with
respect to the approval of the compensation policy and any extensions thereto; (ii) periodically reviewing the implementation of the compensation policy
and providing the board of directors with recommendations with respect to any amendments or updates thereto; (iii) reviewing and resolving whether or not
to approve transactions with respect to the terms of office and employment of Office Holders; and (iv) resolving, under certain circumstances prescribed
under the Companies Law, whether or not to exempt a transaction with a candidate for chief executive officer who meets non-affiliation criteria from
shareholder approval.
Our remuneration committee also oversees the administration of the Company’s various compensation plans and arrangements, in particular, the
incentive compensation, deferred compensation and equity based plans of the Company (and to the extent appropriate, of the subsidiaries of the Company)
and assists the Board in fulfilling its responsibilities relating to the compensation of directors, the Chief Executive Officer and other Office Holders of the
Company. In carrying out these duties, our remuneration committee meets on an ad hoc basis. Under the Companies Law, our remuneration committee may
need to seek the approval of the Board and the shareholders for certain compensation decisions as described above. Each member of our remuneration
committee is an “independent director” in accordance with the Nasdaq Capital Market corporate governance requirements, as affirmatively determined by
our Board. Mr. Nir, Mr. Poshinksi and Dr. Sidransky are the current members of our remuneration committee, with Dr. Sidransky serving as chairperson.
110
Compensation Policy
As approved by our shareholders, and as required by the Companies Law, we have adopted a Compensation Policy regarding the terms of office
and employment of our “office holders” (as defined under the Companies Law, which includes directors, the CEO, other executive officers and any other
managers directly subordinate to the CEO), including cash compensation, equity-based awards, releases from liability, indemnification and insurance,
severance and other benefits. Each of the named executive officers is an “office holder” within the meaning of the Companies Law. The Compensation
Policy is reviewed from time to time by our remuneration committee and our Board to ensure its appropriateness, and is required to be brought at least once
every three years to our shareholders for approval. See “Item 6. Directors, Senior Management and Employees — B. Compensation — Certain Approvals
Required for Office Holders’ Compensation of the Companies Law”.
Our current Compensation Policy was approved and adopted on May 30, 2023 and will be in effect for a period of three years until May 29, 2026,
unless replaced in accordance with the Companies Law prior. The Compensation Policy links pay to performance and aligns our executive officers’
interests with those of the Company and of our shareholders. It allows us to provide meaningful incentives that reflect both our short and long-term goals
and performance, as well as the executive officers’ individual performance and impact on shareholder value, while providing compensation that is
competitive in the global marketplace in which we recruit talent and is designed to reduce incentives for our executive officers to take excessive risks.
The Compensation Policy emphasizes each executive officer’s individual characteristics (such as his or her respective position, education, scope
of responsibilities and contribution to the attainment of our goals) as the basis for compensation variation among executive officers, taking into account the
internal ratios between compensation of our executive officers and directors and other employees of the Company. Pursuant to the Compensation Policy,
the compensation that may be granted to an executive officer may include: base salary and benefits, annual cash bonuses and other cash bonuses (such as
retention and special bonuses), as well as equity-based compensation, retirement and termination of employment benefits, change of control provisions and
other benefits. The cash bonuses that may be granted under the Compensation Policy are limited to a maximum amount linked to the executive officer’s
base salary.
Under the Compensation Policy, an annual cash bonus that will be awarded to executive officers (other than the CEO) will be based on
performance objectives and a discretionary evaluation of the executive officer’s overall performance by the CEO and may be subject to minimum
thresholds. The remuneration committee and the Board will determine any applicable minimum thresholds that must be met for entitlement to the annual
cash bonus (all or any portion thereof) and the formula for calculating any annual cash bonus payout on the basis of, but not limited to, company and
individual objectives. Notwithstanding the above, we may determine that, with respect to any executive officer subordinated to the CEO, which does not
serve as a director, a portion or all of his or her annual cash bonus will be based on the evaluation of the CEO.
The Compensation Policy provides that the annual bonus awarded to the Company’s CEO will be mainly based on measurable objectives of the
Company, subject to a minimum threshold on the basis of, but not limited to, company and personal objectives. 30% or less of the annual cash bonus
granted to the Company’s CEO may be based on a discretionary evaluation of the CEO’s overall performance by the remuneration committee and the
Board. The measurable objectives will be determined annually by the remuneration committee and the Board at the commencement of each calendar year,
or upon engagement, in case of newly hired CEO, or in other special circumstances as set forth in the Compensation Policy.
The equity-based compensation under the Compensation Policy for our executive officers is designed in a manner intended to attract and retain
officers and align their interests with shareholders’ interests to maximize creation of long-term economic value for the Company, and to strengthen the
retention and the motivation of executive officers in the long term. Equity-based awards may be granted from time to time in the form of options and/or
other equity- based awards, such as RSUs in accordance with our 2013 Plan as may be updated from time to time.
The Compensation Policy contains compensation recovery provisions in the event of accounting restatement, which would allow us, under certain
conditions, to recover bonuses or performance-based equity paid in excess of what would have been paid under the financial statements, as restated. The
Compensation Policy also contains provisions that allow us to exculpate, indemnify and insure our executive officers and directors subject to certain
updated limitations set forth in the Compensation Policy.
111
The Compensation Policy also governs the compensation of our non-management Board members and provides that our directors will be entitled
to an annual cash fee retainer, which shall not exceed US$100,000 plus VAT, or the Maximum Amount, and with respect to an Expert External Director, as
defined in the compensation related regulations promulgated under the Companies Law, plus 33% to the Maximum Amount. Our non-management Board
members may also receive equity awards up to the limits set forth in the Compensation Policy.
Nominating Committee
The Nasdaq Capital Market corporate governance requires each company adopting a nominating committee to certify that it has adopted a formal
written charter or board resolution, as applicable, addressing the nominations process and such related matters as may be required under U.S. federal
securities laws. Although not required as a foreign private issuer to adopt a nominating committee, we have decided to follow such requirement.
Our Board has adopted a nominating committee charter setting forth the responsibilities of the nominating committee consistent with the Nasdaq
Listing Rules.
The nominating committee is responsible for identifying individuals qualified to be appointed as board members, and recommending to the Board
appropriate director nominees for election at the general meeting of shareholders.
Independent director oversight of nominations enhances investor confidence in the selection of well-qualified director nominees, as well as
independent nominees as required by the rules. The Nasdaq Capital Market listing rule is also intended to provide flexibility for a company to choose an
appropriate board structure and reduce resource burdens, while ensuring that independent directors approve all nominations.
Mr. Nir, Mr. Poshinski, and Dr. Sidransky are the current members of our nominating committee, with Dr. Sidransky serving as chairperson.
Nasdaq Capital Market Listing Rule 5605(e) requires that our nominating committee be comprised solely of independent directors unless the nominating
committee is comprised of at least three members and the Board determines that such non-independent director’s membership, which shall not be longer
than two years, is required by the best interests of the Company and our shareholders.
R&D Committee
Our R&D Committee, which was established by the Board on May 2014, advises and assists the Board in its oversight of our research and
development programs, including the rationale and timeline of clinical trials and other studies, as well as market surveys in connection therewith. The R&D
Committee operates in accordance with the purposes and objectives determined by the Board from time to time. Dr. Sidransky, Dr. Brosgart and Mr.
Baharaff are the current members of our R&D Committee, with Dr. Sidransky serving as chairperson.
Internal Auditor
Under the Companies Law, the board of directors of an Israeli public company must appoint an internal auditor recommended by the audit
committee and nominated by the board of directors. The role of the internal auditor is to examine, among other things, our compliance with applicable law
and orderly business procedures. An internal auditor should comply with the requirements of the Companies Law and the Internal Audit Law, 5752-1992,
and may not be:
(a) a person (or a relative of a person) who holds more than 5% of the Company’s outstanding shares or voting rights;
(b) a person (or a relative of a person) who has the power to appoint a director or the general manager of the Company;
(c) an Office Holder, including a director, of the Company (or a relative thereof); or
(d) a member of the Company’s independent accounting firm, or anyone on his or her behalf.
Pursuant to Israeli law, an internal auditor’s tenure cannot be terminated without his or her consent, nor can he or she be suspended from such
position unless the board of directors of the company has so resolved following the recommendations of the company’s audit committee and, after
providing the internal auditor with the opportunity to present his or her position to the board of directors of the company and to the audit committee.
112
On January 12, 2021, our Board appointed Zach Refaeli, CPA, from Ernst & Young Israel - Kost Forer Gabbay & Kasierer, Tel Aviv, Israel, as the
Company’s internal auditor for a period of three years, effective as of January 12, 2021.
Exculpation and Indemnification of Directors and Officers
Under the Companies Law, a company may not exculpate an Office Holder from liability for a breach of the duty of loyalty. An Israeli company
may exculpate an Office Holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of
the duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our Articles include such a provision. The
Company may not exculpate in advance a director from liability arising out of a prohibited dividend or distribution to shareholders.
Under the Companies Law, and the Israeli Securities Law, 5738—1968, or the Securities Law, a company may indemnify, or undertake in advance
to indemnify, an Office Holder for the following liabilities and expenses, imposed on Office Holder or incurred by Office Holder due to acts performed by
him or her as an Office Holder, provided its articles of association include a provision authorizing such indemnification:
●
●
●
●
●
●
a monetary liability incurred by or imposed on him or her in favor of another person pursuant to a judgment, including a settlement or
arbitrator’s award approved by a court. However, if an undertaking to indemnify an Office Holder with respect to such liability is
provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen
based on the company’s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by
the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and
amount or criteria;
reasonable litigation expenses, including attorneys’ fees, incurred by the Office Holder as a result of an investigation or proceeding
instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was
filed against such Office Holder as a result of such investigation or proceeding; and (ii) no financial liability was imposed upon him or
her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it
was imposed with respect to an offense that does not require proof of criminal intent or as a monetary sanction;
a monetary liability imposed on him or her in favor of an injured party at an Administrative Procedure (as defined below) pursuant to
Section 52(54)(a)(1)(a) of the Securities Law;
expenses incurred by an office holder or certain compensation payments made to an injured party that were instituted against an office
holder in connection with an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable
attorneys’ fees; and
reasonable litigation expenses, including attorneys’ fees, incurred by the Office Holder or imposed by a court in proceedings instituted
against him or her by the company, on its behalf, or by a third-party, or in connection with criminal proceedings in which the Office
Holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent.
An “Administrative Procedure” is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities
Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to prevent
Procedures or Interruption of procedures subject to conditions) to the Securities Law.
113
Under the Companies Law and the Securities Law, a company may insure an Office Holder against the following liabilities incurred for acts
performed by him or her as an Office Holder if and to the extent provided in the company’s articles of association:
●
●
●
●
●
a breach of the duty of loyalty to the company, provided that the Office Holder acted in good faith and had a reasonable basis to believe
that such act would not prejudice the company;
a breach of the duty of care to the company or to a third-party;
a monetary liability imposed on the Office Holder in favor of a third-party;
a monetary liability imposed on the office holder in favor of an injured party at an Administrative Procedure pursuant to Section 52(54)
(a)(1)(a) of the Securities Law; and
expenses incurred by an office holder in connection with an Administrative Procedure instituted against him or her, including reasonable
litigation expenses and reasonable attorneys’ fees.
Nevertheless, under the Companies Law, a company may not indemnify, exculpate or insure an Office Holder against any of the following:
●
●
●
●
a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company in the event
Office Holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;
a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the Office
Holder;
an act or omission committed with intent to derive unlawful personal benefit; or
a fine, monetary sanction, penalty or forfeit levied against the Office Holder.
Under the Companies Law, exculpation, indemnification and insurance of Office Holders require the approval of the remuneration committee,
board of directors and, in certain circumstances, the shareholders, as described above under “Item 6—Directors, Senior Management and Employees—B.
Compensation.”
Our Articles permit us to exculpate, indemnify and insure our Office Holders to the fullest extent permitted by the Companies Law. Each of our
Office Holders have entered into an indemnification agreement with us, exculpating them, to the fullest extent permitted by Israeli law, from liability to us
for damages caused to us as a result of a breach of the duty of care and undertaking to indemnify them to the fullest extent permitted by Israeli law,
including with respect to liabilities resulting from certain acts performed by such Office Holders in their capacity as an Office Holder of the Company, our
subsidiaries or our affiliates.
In the opinion of the SEC, indemnification of directors and Office Holders for liabilities arising under the Securities Act, however, is against
public policy and therefore unenforceable.
Agreements with Directors
Other than a written agreement with our President, Chief Executive Officer and Chairman, as detailed in “Item 6. Directors, Senior Management
and Employees—B. Compensation—Employment Agreements and Arrangements with Directors and Related Parties—Employment Agreement with Our
President, Chief Executive Officer and Chairman of the Board,” we do not have written agreements with any director providing for benefits upon the
termination of his or her services with our Company.
114
D. Employees.
As of December 31, 2023, we had eight employees, of which three were full-time employees and five were part-time employees. Four of our
employees were involved in our clinical and product development operations and 4 served in general and administrative capacities.
While none of our employees are party to any collective bargaining agreements or represented by any labor unions, certain provisions of the Israeli
labor laws and certain collective bargaining agreements between the Histadrut (General Federation of Labor in Israel) and the Coordination Bureau of
Economic Organizations (including the Industrialists’ Associations) are applicable to our employees by order of the Israel Ministry of Economics. These
provisions primarily concern the length of the workday, minimum daily wages for professional workers, pension fund benefits for all employees, insurance
for work-related accidents, procedures for dismissing employees, determination of severance pay and other conditions of employment. We generally
provide our employees with benefits and working conditions beyond the required minimums. We have never experienced any employment-related work
stoppages and believe our relationship with our employees is favorable.
E. Share Ownership.
The following table sets forth information regarding beneficial ownership of our ordinary shares as of March 27, 2024, the latest practicable date
for inclusion in this annual report, held by our directors and executive officers, individually and as a group and beneficial owners of more than 5% of our
outstanding shares.
Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to ordinary
shares. Ordinary shares issuable under share options, warrants or other conversion rights currently exercisable or that are exercisable within 60 days after
March 27, 2024 are deemed outstanding for the purpose of computing the percentage ownership of the person holding the options, or other conversion
rights, but are not deemed outstanding for the purpose of computing the percentage ownership of any other person. Percentage of shares beneficially owned
is based on 6,009,654 ordinary shares outstanding on March 27, 2024.
Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment
power and the right to receive the economic benefit of ownership with respect to all ordinary shares held by that person.
Unless otherwise stated, the address for our directors and senior management is c/o Galmed Pharmaceuticals Ltd., 16 Abba Hillel Road, Ramat
Gan, Israel 5250608.
More than 5% Holders
CVI Investments, Inc. (2)
Directors and Executive Officers
Allen Baharaff(3)
Shmuel Nir(4)
Dr. David Sidransky(5)
Dr. Carol L. Brosgart(6)
Dr. Liat Hayardeny(7)
Yohai Stenzler(8)
Guy Nehemya(9)
Amir Poshinski(10)
Doron Cohen(11)
All directors and executive officers as a group (9 persons)
*Less than 1%.
Number of ordinary
shares beneficially
owned(1)
Percentage of ordinary
shares beneficially
owned
414,827
340,095
9,093
6,331
4,498
12,997
12,206
12,206
3,165
1,333
401,923
6.9%
5.6%
*
*
*
*
*
*
*
*
6.6%
(1) All options included are either currently exercisable or will be exercisable within 60 days of March 27, 2023.
115
(2) Based upon information contained in a Schedule 13G/A filed by the shareholder on February 14, 2024. Shares beneficially owned consist of (i)
269,238 ordinary shares and (ii) 145,589 ordinary shares issuable upon the exercise of warrants. The warrants are subject to a beneficial ownership
limitation of 9.99%, which such limitation restricts the holder from exercising that portion of the warrants that would result in the holder and its affiliates
owning, after exercise, a number of ordinary share in excess of the beneficial ownership limitation. Heights Capital Management, Inc., the authorized agent
of CVI Investments, Inc. (“CVI”), has discretionary authority to vote and dispose of the shares held by CVI and may be deemed to be the beneficial owner
of these shares. Martin Kobinger, in his capacity as Investment Manager of Heights Capital Management, Inc., may also be deemed to have investment
discretion and voting power over the shares held by CVI. Mr. Kobinger disclaims any such beneficial ownership of the shares. The principal business
address of CVI is c/o Heights Capital Management, Inc., 101 California Street, Suite 3250, San Francisco, California 94111.
(3) Consists of (i) 227,790 ordinary shares are held through G. Yarom Medical Research Ltd., a company incorporated under the laws of the State
of Israel, of which Mr. Baharaff is the controlling shareholder and the chairman of its board of directors; and (ii) options to purchase 112,305 ordinary
shares that are currently exercisable within 60 days as of March 27, 2024. Of the 340,095 ordinary shares, Mr. Baharaff exercises sole voting and
dispositive power over 112,305 shares beneficially owned and shared voting and dispositive power with G. Yarom Medical Research Ltd. over 227,790
shares.
(4) Consists of (i) 500 ordinary shares held by Mr. Nir; and (ii) 2,762 ordinary shares are held through Tushia Consulting Engineers Ltd., of which
Shmuel Nir is its controlling shareholder and (iii) 5,831 ordinary shares issuable upon the exercise of options that are currently exercisable or will be
exercisable within 60 days as of March 27, 2024.
(5) Consists of (i) 500 ordinary shares held by Dr. Sidransky; and (ii) 5,831 ordinary shares issuable upon the exercise of options that are currently
exercisable or will be exercisable within 60 days as of March 27, 2024.
(6) Consists of 4,498 ordinary shares issuable upon the exercise of options that are currently exercisable or will be exercisable within 60 days as of
March 27, 2024.
(7) Consists of 12,997 ordinary shares issuable upon the exercise of options that are currently exercisable or will be exercisable within 60 days as
of March 27, 2024.
(8) Consists of (i) 375 ordinary shares held by Mr. Stenzler; and (ii) 11,831 ordinary shares issuable upon the exercise of options that are currently
exercisable or will be exercisable within 60 days as of March 27, 2024.
(9) Consists of (i) 375 ordinary shares held by Mr. Nehemya; and (ii) 11,831 ordinary shares issuable upon the exercise of options that are
currently exercisable or will be exercisable within 60 days as of March 27, 2024.
(10) Consists of 3,165 ordinary shares issuable upon the exercise of options that are currently exercisable or will be exercisable within 60 days as
of March 27, 2024.
(11) Consists of 1,133 ordinary shares issuable upon the exercise of options that are currently exercisable or will be exercisable within 60 days as
of March 27, 2024.
Change in Control
To our knowledge, (i) we are not directly or indirectly owned or controlled by another corporation, by any foreign government or by any other
natural or legal person severally or jointly, except as disclosed in the above table regarding our major shareholders, and (ii) there are no arrangements
which would result in our change in control at a subsequent date.
116
Significant Changes in the Ownership of Major Shareholders
To our knowledge, other than as disclosed in the table above, our other filings with the SEC and this annual report, there has been no significant
change in the percentage ownership held by any major shareholder since January 1, 2020.
Major Shareholders Voting Rights
Our major shareholders do not have different voting rights.
Record Holders
To our knowledge, as of March 27, 2024, we had one holder of record of our ordinary shares with a U.S. address, Cede & Co., the nominee of The
Depository Trust Company. This holder held in the aggregate 5,779,871 ordinary shares, or 96.2% of our outstanding ordinary shares as of March 27, 2024.
The number of record holders in the United States is not representative of the number of beneficial holders of our ordinary shares nor is it representative of
where such beneficial holders are resident since many of these ordinary shares were held by brokers or other nominees.
2013 Incentive Share Option Plan
We maintain one equity-based incentive plan, our 2013 Plan. As of March 27, 2024, the latest practicable date for inclusion in this annual report, a
total of 2,000,000 shares were reserved for issuance under our 2013 Plan, of which (1) options to purchase 240,970 ordinary were issued and outstanding
thereunder (i.e., were granted but not canceled, expired or exercised); (2) RSU’s to purchase 1,315,000 ordinary shares were issued and outstanding; (3)
options to purchase 72,737 ordinary shares were exercised and 4,267 ordinary shares were issued upon vesting of RSUs; and (3) 367,026 shares remain
unallocated for future equity awards pursuant to our 2013 Plan.
Our 2013 Plan, which was adopted by our Board on September 2, 2013, and approved by our shareholders in December 30, 2013 (as amended on
March 30, 2015, May 11, 2015, August 30, 2018 and August 7, 2023), will be in effect until October 4, 2026 and provides for the grant of options to
purchase our ordinary shares and the issuance of RSUs to our officers, directors, employees, service providers and consultants. Our 2013 Plan provides for
such equity-based compensation under various and different tax regimes, including those detailed below.
The 2013 Plan is administered by our Board, which, on its own or upon the recommendation of our remuneration committee or any other similar
committee of the Board, shall determine, subject to applicable law, the identity of grantees of awards and various terms of the grant. Consistent with our
Compensation Policy, the 2013 Plan provides for granting options to purchase our ordinary shares pursuant to Section 102 of the Israeli Income Tax
Ordinance, or the Ordinance, under the capital gains route, to directors, officers and employees who are Israeli residents holding (or have a right to hold or
to purchase) less than 10% of our total share capital and do not have a right to receive 10% or more of the Company’s profits.
Section 102 of the Ordinance allows Israeli employees, directors and officers, who are not controlling shareholders to receive favorable tax
treatment for compensation in the form of shares or options. However, under this route we are not allowed to deduct any expense with respect to the
issuance of the options or shares. Israeli non-employee service providers, consultants and shareholders who hold 10% or more of our total share capital or
are otherwise controlling shareholders, may be granted options pursuant to Section 3(i) of the Ordinance, which does not provide for similar tax benefits. In
order to comply with the terms of the capital gains route pursuant to Section 102 of the Ordinance, the granted options as well as the ordinary shares issued
upon exercise of these options and other shares received subsequently following any realization of rights with respect to such options (such as share
dividends and share splits), must be granted to a trustee for the benefit of the relevant grantee and should be held by the trustee for at least two years after
the date of the grant. If such options or shares are sold by the trustee or are transferred to the grantee before the end of the two-year period, then the grantee
would be taxed at top marginal rates upon selling the shares.
117
For residents, or deemed residents, of the United States, the 2013 Plan provides grants, which are pursuant to Section 422 of the Internal Revenue
Code of 1986, as amended, or the Code, as incentive stock options, or ISOs, and any other participants which do not qualify for ISOs, as non-statutory
stock options, or NSOs, pursuant to the Code.
Section 422 of the Code allows employees, directors and officers, who are non-controlling shareholders (e.g., less than 10% shareholders) and are
considered residents of the United States or those who are deemed to be residents of the United States for purposes of the payment of tax, or are otherwise
subject to taxation in the United States with respect to the grant of awards, to receive favorable tax treatment for compensation in the form of shares or
ISOs. 10% shareholders or persons which are not service providers will receive NSOs, which do not entitle them to receive similar tax benefits. Section
422(b) of the Code provides for the ISO track such that the individual does not have to pay ordinary income tax (nor employment taxes) on the difference
between the exercise price and the fair market value of the shares issued (however, the holder may have to pay U.S. alternative minimum tax instead).
However, if the shares are held for one year from the date of exercise and two years from the date of grant, then the profit (if any) made on sale of the
shares is taxed as long-term capital gain. Section 422 of the Code requires that any grant of awards shall not be made at a price which is less than 100% of
the fair market value of such awards on the date of the grant, all pursuant to the terms of Section 409A of the Code. However, under this ISO track, we are
not allowed to deduct any expense with respect to the issuance of the options or shares. In order to comply with the terms of the ISO track, the option
granted thereunder must meet the requirements of Section 422 of the Code when granted and at all times until the exercise thereof.
Options and RSUs granted under the 2013 Plan will vest in accordance with the vesting dates as determined by the Board following the
recommendation of the remuneration committee or any other similar committee of the Board with respect to each grant. Generally, options that are not
exercised within ten years from the grant date expire, unless otherwise determined by the Board and the remuneration committee, as applicable, provided,
however, that, pursuant to our Compensation Policy, any equity-based awards to Office Holders must include both a gradual vesting period of at least three
years from the date of grant, and an exercise period of no more than ten years from the date of grant.
Upon such date or dates designated in the applicable award agreement, unless earlier forfeited, subject to the receipt of any approvals required
from any relevant tax authority, we shall settle each RSU upon vesting by delivering one ordinary share.
In case of termination for reasons of disability or death, the grantee or his legal successor may exercise options that have vested prior to
termination within a period of twelve months from the date of disability or death. If we terminate a grantee’s employment or service for cause, all of the
grantee’s vested and unvested unexercised options will expire and terminate on the date of termination. If a grantee’s employment or service is terminated
for any other reason, the grantee may exercise his or her vested options within 90 days of the date of termination or within a longer period under specified
circumstances determined by our Board. Any expired or unvested options shall return to the option pool reserved under the 2013 Plan for reissuance.
In the event of grantee’s termination prior to a vesting date by reason of such grantee’s death or disability, all of such grantee’s RSUs shall
immediately become vested as of the date of such termination. In the event of a grantee’s termination for cause prior to settlement, all of such grantee’s
RSUs shall immediately be forfeited for no consideration as of the date of such termination. If a grantee’s employment or service is terminated for any
other reason, (1) all vesting with respect to such grantee’s RSUs shall cease, (2) all of such grantee’s unvested RSUs shall immediately be forfeited for no
consideration as of the date of such termination, and (3) to the extent not already settled, all of such grantee’s vested RSUs shall be settled in accordance
with the settlement schedule set forth in the applicable award agreement.
In the event of a merger or consolidation of our company subsequent to which we would no longer exist as a legal entity, or a sale of all, or
substantially all, of our ordinary shares or assets or other transaction having a similar effect on us, or a Transaction, any unexercised options then
outstanding will be cancelled. Notwithstanding the foregoing, the Board, or the relevant committee of the Board, may determine that the options will not be
cancelled but will be assumed or substituted for an appropriate number of the same type of shares or other securities of the successor company as were
distributed to the Company or the shareholders in connection with the Transaction. In addition, the Board, or the relevant committee of the Board, may
determine to include in certain option agreements either a clause that provides for acceleration of vesting of all or part of the unvested options in the event
of a Transaction or the occurrence of another event or a clause which provides that if the optionee’s employment with the successor company is terminated
by the successor company without cause within a certain period, not to exceed two years from the closing of such Transaction, all or part of the unvested
options shall be accelerated.
118
Certain Information Concerning Equity Awards to Office Holders
The following tables set forth information, as of March 27, 2024 concerning all outstanding equity awards to Office Holders as of such date.
Options
Name of Office Holder
Date of grant
December 30,
Exercise
price per
share ($)*
Shares
subject
to the option
Shares
vested and
unexercised
Shares
unvested
Schedule date
of expiration
Allen Baharaff
2013
NIS 0.15
16,069
16,069(**)
December 30,
2013
February 4, 2016 $
February 4, 2016 $
July 10, 2018 $
December 17,
NIS 0.15
82.35
89.1
173.4
5,585
9,333
11,333
14,666
5,585(**)
9,333
11,333
14,666
0
0
0
0
0
Dec-12-2028
Dec-12-2028
Feb-04-2026
Feb-04-2026
Jul-10-2028
2019 $
76.8
14,666
14,666
55,000
Dec-17-2029
November 10,
2020 $
49.95
11,000
3,666
1,8330
Nov-17-2030
Shmuel Nir
Amir Poshinski
David Sidransky
Dr. Liat Hayardeny (***)
Yohai Stenzler (***)
Guy Nehemya (***)
Carol L. Brosgart
May 11, 2015 $
February 4, 2016 $
July 10, 2018 $
July 15, 2021 $
August 13, 2020 $
July 15, 2021 $
May 11, 2015 $
February 4, 2016 $
July 10, 2018 $
July 15, 2021 $
September 6,
2016 $
January 31, 2017 $
July 10, 2018 $
December 17,
82.35
89.1
173.4
46.5
71.55
46.5
82.35
89.1
173.4
46.5
5.7
5.7
5.7
666
2,000
2,000
1,133
2,000
1,333
666
2,000
2,000
1,133
2,666
2,166
2,666
666
2,000
2,000
998
2,000
998
666
2,000
2,000
998
2,666
2,166
2,666
2019 $
5.7
2,666
2,666
November 10,
0 May-11-2025
Feb-04-2026
0
Jul-10-2028
0
Jul-10-2031
335
5,000 August 13, 2030
Jul-10-2031
335
0 May-11-2025
Feb-04-2026
0
Jul-10-2028
0
Jul-10-2031
335
0
0
0
0
Sep-06-2026
Jan-31-2026
Jul-10-2028
Dec-17-2029
2020 $
5.7
1,833
1,833
0
Nov-10-2030
December 30,
2014 $
January 3, 2016 $
November 7,
2017 $
July 10, 2018 $
December 17,
5.7
5.7
5.7
5.7
233
1,500
1,333
2,666
233
1,500
1,333
42,666
2019 $
5.7
2,666
2,666
November 10,
0
0
0
0
0
Dec-30-2024
Jan-03-2026
Nov-07-2020
Jul-10-2028
Dec-17-2029
2020 $
5.7
2,666
2,000
666
Nov-10-2030
December 30,
2014 $
January 3, 2016 $
July 10, 2018 $
December 17,
5.7
5.7
5.7
733
1,500
2,666
733
1,500
2,666
2019 $
5.7
2,666
2,666
November 10,
0
0
0
0
Dec-30-2024
Jan-03-2026
Jul-10-2028
Dec-17-2029
2020 $
5.7
2,666
1,933
733
Nov-10-2030
April 25, 2017 $
July 10, 2018 $
July 15, 2021 $
August 7, 2023 $
73.05
173.4
46.5
1.05
1,333
2,000
1,333
75,000
1,333
2,000
998
0
0
0
335
75,000
Apr-25-2027
Jul-10-2028
Jul-10-2031
Augt-7-2033
Doron Cohen (***)
2022 $
5.7
2,666
1,500
1,166
Feb-23-2032
February 23,
(*) All exercise prices are in USD unless otherwise specified.
(**) In September 2023, we extended the exercise period of 21,654 outstanding options previously granted our Chief Executive Officer (and director), by
approximately five years to December 31, 2028.
(***) On May 11, 2023, we repriced outstanding options to purchase an aggregate of 35,598 ordinary shares held by several Office Holders to $5.70 per
share and extended their terms for one year following the date of termination of an optionee’s employment or service with us or an affiliate.
119
RSUs
Name of Office
Holder
Allen Baharaff
Shmuel Nir
David Sidransky
Amir Poshinski
Yohai Stenzler
Guy Nehemya
Doron Cohen
Date of grant
Shares
subject to
the RSUs
Shares
vested
Shares
unvested
Aug-7-2023
640,000
Feb-04-2016
Aug-7-2023
Feb-04-2016
Aug-7-2023
Aug-7-2023
Jan-03-2016
Aug-7-2023
Jan-03-2016
Aug-7-2023
500
75,000
7,500
75,000
75,000
5,625
150,000
5,625
150,000
Aug-7-2023
150,000
0
500
0
7,500
0
0
5,625
0
5,625
0
0
640,000
0
75,000
0
75,000
75,000
0
150,000
0
150,000
150,000
F. Disclosure of a registrant’s action to recover erroneously awarded compensation.
Not applicable.
ITEM 7. Major Shareholders and Related Party Transactions.
A. Major Shareholders.
Except as set forth in “Item 6. Directors, Senior Management and Employees—E. Share Ownership,” to the best of our knowledge, no other
person who we know beneficially owns 5% or more of the Company’s ordinary shares outstanding as of March 27, 2024, the latest practicable date for
inclusion in this annual report. None of our shareholders has different voting rights from other shareholders. Other than as described herein, to the best of
our knowledge, we are not owned or controlled, directly or indirectly, by another corporation, by any foreign government or by any natural person or legal
persons, severally or jointly, and we are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company.
B. Related Party Transactions.
The following is a summary description of the material terms of those transactions with related parties to which we, or our subsidiaries, are party
and which were in effect since January 1, 2023.
Financing Agreement with GRD
We have provided financing to GRD from time to time, pursuant to which the Company and GRD have executed several capital notes for an
aggregate outstanding principal amount of approximately $147.0 million. The par value of such notes is in NIS, and they bear no interest nor repayment
date; provided, however, that no repayment shall be made before the fifth anniversary from the issuance date of each note.
120
Agreements with Directors and Officers
Employment and Consulting Agreements. We have entered into written employment or consulting agreements with certain of our Office Holders.
These agreements provide for notice periods of varying duration for termination of the agreement by us or by the relevant Office Holder, during which time
the Office Holder will continue to receive base salary and benefits. We have also entered into customary non-competition, confidentiality of information
and ownership of inventions arrangements with these Office Holders. However, the enforceability of the noncompetition provisions may be limited under
applicable law.
Options. Since our inception, we have granted options to purchase our ordinary shares to certain of our Office Holders. Such option agreements
may contain acceleration provisions upon certain merger, acquisition, or change of control transactions. During November 2022, we effected a repricing of
certain options. See also “Item 6. Directors, Senior Management and Employees—E. Share Ownership”. We describe our 2013 Plan under “Item 6.
Directors, Senior Management and Employees—B. Compensation— 2013 Incentive Share Option Plan.” If the relationship between us and an Office
Holder is terminated except for “cause” (as defined in the 2013 Plan and/or the applicable option award agreement), options that are vested will generally
remain exercisable for 90 days after such termination; provided, however, that prior to the date of such termination, our remuneration committee may
authorize an extension of the terms of all or part of the vested options beyond the date of such termination for a period not to exceed the period during
which the options by their terms would otherwise have been exercisable, and provided further that the vested options may lose their status as incentive
stock options and/or approved 102 options if such extension extends beyond the maximum extension authorized by the Ordinance or the Code, as
applicable.
RSUs. We have granted RSUs to certain of our Office Holders. Such award agreements may contain acceleration provisions upon certain merger,
acquisition, or change of control transactions. See also “Item 6. Directors, Senior Management and Employees—E. Share Ownership.” We describe our
2013 Plan under “Item 6. Directors, Senior Management and Employees—B. Compensation—2013 Incentive Share Option Plan.” If the relationship
between us and an Office Holder is terminated, RSUs that are vested shall be settled in accordance with the settlement schedule set forth in the applicable
award agreement.
OnKai
In May 2023, we entered into the OnKai Agreement for a $1.5 million equity investment in OnKai, a US-based technology company developing an
AI-based platform to advance healthcare for underserved populations across the United States by facilitating alignment between healthcare stakeholders.
The signing of the definitive agreement followed an announcement that we made in January 2023 that we had entered into a non-binding termsheet for an
equity investment in OnKai. The OnKai Agreement provided that we will invest $1.5 million in exchange for series seed preferred shares of OnKai (which
is in addition to a $1.5 million investment that was made by us in OnKai through a SAFE and which converted at a 15% discount into series seed preferred
shares upon consummation of the Investment Round). Our investment in OnKai was part of an approximately $6 million Investment Round with other
investors that was led by us of which SAFE notes of approximately $3.8 million were converted into preferred shares. On June 19, 2023, the Investment
Round closed. Following the Investment Round, we hold approximately 23.9% of the outstanding share capital of OnKai on an as-converted and fully and
our Chief Executive Officer and director, Allen Baharaff serves as a board member of OnKai. In connection with the OnKai Agreement, our wholly-owned
subsidiary, GRD entered into the OnKai Services Agreement with OnKai. The OnKai Services Agreement provides that GRD shall on a non-exclusive
basis (i) provide support services to OnKai relating to finance, business development, strategic planning, execution and others; and (ii) lend its experience
to OnKai in building a strategy and for the development of treatments for the underserved and that OnKai shall on a non-exclusive basis (i) take part in plan
preparation to serve GDR’s vision of developing drugs for the underserved population and (ii) when relevant, design a process on the clinical trial
dashboard that could potentially serve GDR’s future trial.
C. Interests of Experts and Counsel.
Not applicable.
ITEM 8. Financial Information.
A. Consolidated Financial Statements and Other Financial Information.
See “Item 18. Financial Statements” for a list of all financial statements filed as part of this annual report.
121
Legal Matters
We are neither party to any legal or arbitration proceedings, including those relating to bankruptcy, receivership or similar proceedings and those
involving any third-party, nor any governmental proceedings pending or known to be contemplated, which may have, or have had in the recent past,
significant effects on the Company’s financial position or profitability.
Dividend Policy
We have never declared or paid any cash dividends on our ordinary shares and do not anticipate paying any cash dividends in the foreseeable
future. Payment of cash dividends, if any, in the future will be at the discretion of our Board and will depend on then-existing conditions, including our
financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our Board may deem relevant.
Payment of dividends may also be subject to Israeli withholding taxes. See “Item 10. Additional Information—E. Taxation—Certain Israeli Tax
Considerations” for additional information.
B. Significant Changes.
Other than as otherwise described in this Annual Report on Form 20-F and as set forth below, no significant change has occurred in our operations
since the date of our consolidated financial statements included in this Annual Report on Form 20-F.
ITEM 9. The Offer and Listing.
A. Offer and Listing Details
Our ordinary shares have been listed on the Nasdaq Capital Market under the symbol “GLMD” since March 13, 2014. Prior to that date, there was
no public trading market for our ordinary shares.
B. Plan of Distribution
Not applicable.
C. Market for Ordinary Shares
Our ordinary shares have been quoted on the NASDAQ Capital Market since March 18, 2014 under the symbol “GLMD.”
D. Selling Shareholders
Not applicable.
E. Dilution
Not applicable.
F. Expenses of the issue
Not applicable.
ITEM 10. Additional Information.
A. Share Capital.
Not applicable.
122
B. Memorandum and Articles of Association.
Our registration number is 51-495351-2. At the 2014 annual general meeting of shareholders, our shareholders adopted our Articles, which
became effective on the consummation of our initial public offering in the United States in March 2014. Under Section 2 of our Articles, the purpose of the
Company is to engage in any lawful activity.
The information set forth in Exhibit 2.1 of this Annual Report is incorporated herein by reference.
C. Material Contracts
For a description of our material agreements relating to our strategic collaborations and research arrangements and other material agreements,
please refer to “Item 4.B. Information on the Company—Business Overview—Strategic Collaborations, Research Arrangements and other Material
Agreements.” “and “Item 7.B “Related Party Transactions”.
Employment Agreements
See “Item 6. Directors, Senior Management and Employees—B. Compensation”.
D. Exchange Controls.
There are no Israeli government laws, decrees, regulations or other legislation that restrict or that affect our export or import of capital, including
the availability of cash and cash equivalents for use by us and our wholly-owned subsidiaries, or the remittance of dividends, interest or other payments to
non-resident holders of our securities, except for ownership by nationals of certain countries that are, or have been, declared as enemies of Israel or
otherwise as set forth under “Item 10. Additional Information—E. Taxation.”
E. Taxation.
The following description is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition of our
ordinary shares. You should consult your own tax advisor concerning the tax consequences of your particular situation, as well as any tax consequences that
may arise under the laws of any state, local, foreign, including Israel, or other taxing jurisdiction.
Certain Israeli Tax Considerations
The following is a brief summary of the material Israeli income tax laws applicable to us. This section also contains a discussion of material Israeli
tax consequences concerning the ownership and disposition of our ordinary shares. This summary does not discuss all the aspects of Israeli tax law that
may be relevant to a particular investor in light of his or her personal investment circumstances or to some types of investors subject to special treatment
under Israeli law. Examples of this kind of investor include residents of Israel or investors in securities who are subject to special tax regimes not covered
in this discussion. To the extent that the discussion is based on new tax legislation that has not yet been subject to judicial or administrative interpretation,
we cannot assure you that the appropriate tax authorities or the courts will accept the views expressed in this discussion. This summary is based on laws
and regulations in effect as of the date hereof and does not take into account possible future amendments which may be under consideration.
General Corporate Tax Structure in Israel
Israeli resident companies (as defined below), such as the Company, are generally subject to corporate tax at the rate of 23% on their taxable
income, as of January 1, 2018 (23% in 2023). However, the effective tax rate payable by a company that derives income from a Preferred Enterprise or a
Technology Enterprise, as discussed below, may be considerably less.
123
Capital gains derived by an Israeli resident company are generally subject to tax at the same rate as the corporate tax rate. Under Israeli tax
legislation, a corporation will be considered an “Israeli resident” if it meets one of the following: (i) it was incorporated in Israel; or (ii) the control and
management of its business are exercised in Israel.
Law for the Encouragement of Industry (Taxes), 5729-1969
The Law for the Encouragement of Industry (Taxes), 5729-1969, which we refer to as the Industry Encouragement Law, provides several tax
benefits for “Industrial Companies,” which are defined as Israeli resident-companies which were incorporated in Israel, of which 90% or more of their
income in any tax year, other than income from certain government loans, is derived from an “Industrial Enterprise” that it owns and located in Israel or in
the “Area”, in accordance with the definition under Section 3A of the Israeli Tax Ordinance. An “Industrial Enterprise” is defined as an enterprise whose
principal activity in a given tax year is industrial production. Eligibility for benefits under the Industry Encouragement Law is not contingent upon approval
of any governmental authority.
The following tax benefits, among others, are available to Industrial Companies:
●
●
●
amortization over an eight year period of the cost of purchasing a patent, rights to use a patent and rights to know-how, which are used
for the development or advancement of the company, commencing in the year in which such rights were first exercised;
under limited conditions, an election to file consolidated tax returns with related Industrial Companies controlled by it; and
deductions of expenses related to a public offering in equal amounts over a three year period commencing on the year of the offering.
We believe that we qualify as an “Industrial Company” within the meaning of the Industry Encouragement Law. There can be no assurance that
we will continue to qualify as an Industrial Company in the future or that the benefits described above will be available to us at all.
Law for the Encouragement of Capital Investments, 5719-1959
The Law for the Encouragement of Capital Investments, 5719-1959, which we refer to as the Investment Law, provides certain incentives for
capital investments in production facilities (or other eligible assets) by “Industrial Enterprises” (as defined under the Investment Law). Generally, an
investment program that is implemented in accordance with the provisions of the Investment Law, is entitled to benefits. These benefits may include cash
grants from the Israeli government and tax benefits, based upon, among other things, the geographic location in Israel of the facility in which the
investment is made. In order to qualify for these incentives, an Approved Enterprise, a Beneficiary Enterprise or a Preferred Enterprise is required to
comply with the requirements of the Investment Law.
The Investment Law was significantly amended effective April 1, 2005, further amended as of January 1, 2011, or the 2011 Amendment, and as of
January 1, 2017, or the 2017 Amendment. The 2011 Amendment introduced new benefits to replace those granted in accordance with the provisions of the
Investment Law in effect prior to the 2011 Amendment. However, companies entitled to benefits under the Investment Law as in effect up to January 1,
2011 were entitled to choose to continue to enjoy such benefits, provided that certain conditions are met, or elect instead, irrevocably, to forego such
benefits and elect the benefits of the 2011 Amendment. The 2017 Amendment introduces new benefits for Technological Enterprises, alongside the existing
tax benefits.
The following discussion is a summary of the Investment Law following its most recent amendments:
Tax Benefits Under the 2011 Amendment
The 2011 Amendment canceled the availability of the benefits granted to Industrial Companies under the Investment Law prior to 2011 and,
instead, introduced new benefits for income generated by a “Preferred Company” through its “Preferred Enterprise” (as such terms are defined in the
Investment Law) as of January 1, 2011.
124
The definition of a Preferred Company includes a company incorporated in Israel that is not fully owned by a governmental entity, and that has,
among other things, a Preferred Enterprise and is controlled and managed from Israel. Pursuant to the 2011 Amendment, beginning in 2014 and in each
year thereafter until 2016, a Preferred Company may only be entitled to a reduced corporate tax rate of 16% with respect to its preferred income derived by
its Preferred Enterprise, unless the Preferred Enterprise is located in a specified development zone, in which case the rate will be 9%. Pursuant to the 2017
Amendment, in 2017 and thereafter, the corporate tax rate for Preferred Enterprise which is located in a specified development zone was reduced to 7.5%,
while the reduced corporate tax rate for other development zones remains 16%. Income derived by a Preferred Company from a “Special Preferred
Enterprise” (as such term is defined in the Investment Law) would be entitled, during a benefit period of ten years, to further reduced tax rates of 8%, or
5% if the Special Preferred Enterprise is located in a certain development zone. As of January 1, 2017, the definition for ‘Special Preferred Enterprise’
includes less stringent conditions.
As of January 1, 2014, dividends paid to Israeli shareholders out of income attributed to a Preferred Enterprise or to a Special Preferred Enterprise
are generally subject to withholding tax at source at the rate of 20% (in the case of non-Israeli shareholders - subject to the receipt in advance of a valid
certificate from the ITA allowing for a reduced tax rate, 20%, or such a lower tax rate as may be provided under an applicable tax treaty). However, if such
dividends are paid to an Israeli company, no tax is required to be withheld (although, if such dividends are subsequently distributed to individuals or a non-
Israeli company, the aforesaid will apply).
New Tax benefits under the 2017 Amendment
The 2017 Amendment was enacted as part of the Economic Efficiency Law that was published on December 29, 2016, and is effective as of
January 1, 2017. The 2017 Amendment provides new tax benefits for two types of “Technology Enterprises”, as described below, and is in addition to the
other existing tax beneficial programs under the Investment Law.
The 2017 Amendment provides that a technology company satisfying certain conditions will qualify as a “Preferred Technology Enterprise” and
will thereby enjoy a reduced corporate tax rate of 12% on income that qualifies as “Preferred Technology Income”, as defined in the Investment Law. The
tax rate is further reduced to 7.5% for a Preferred Technology Enterprise located in development zone A. In addition, a Preferred Technology Company will
enjoy a reduced corporate tax rate of 12% on capital gain derived from the sale of certain “Benefitted Intangible Assets” (as defined in the Investment Law)
to a related foreign company if the Benefitted Intangible Assets were acquired from a foreign company on or after January 1, 2017 for at least NIS 200
million (approximately $56 million), and the sale receives prior approval from the National Authority for Technological Innovation (previously known as
the Israeli Office of the Chief Scientist), to which we refer as IIA.
The 2017 Amendment further provides that a technology company satisfying certain conditions will qualify as a “Special Preferred Technology
Enterprise” and will thereby enjoy a reduced corporate tax rate of 6% on “Preferred Technology Income” regardless of the company’s geographic location
within Israel. In addition, a Special Preferred Technology Enterprise will enjoy a reduced corporate tax rate of 6% on capital gain derived from the sale of
certain “Benefitted Intangible Assets” to a related foreign company if the Benefitted Intangible Assets were either developed by the Special Preferred
Technology Enterprise or acquired from a foreign company on or after January 1, 2017, and the sale received prior approval from IIA. A Special Preferred
Technology Enterprise that acquires Benefitted Intangible Assets from a foreign company for more than NIS 500 million will be eligible for these benefits
for at least ten years, subject to certain approvals as specified in the Investment Law.
Dividends distributed by a Preferred Technology Enterprise or a Special Preferred Technology Enterprise to Israeli shareholders, paid out of
Preferred Technology Income, are subject to withholding tax at source at the rate of 20% (in the case of non-Israeli shareholders - subject to the receipt in
advance of a valid certificate from the ITA allowing for a reduced tax rate, 20%, or such lower rate as may be provided in an applicable tax treaty).
However, if such dividends are paid to an Israeli company, no tax is required to be withheld (although, if such dividends are subsequently distributed to
individuals or a non-Israeli company, the aforesaid will apply). If such dividends are distributed to a foreign parent company holding, alone or together with
other foreign companies, at least 90% of the shares of the distributing company and other conditions are met, the withholding tax rate will be 4% (or a
lower rate under a tax treaty, if applicable, subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate).
125
After examining the impact of the 2017 Amendment, we submitted a request to receive a tax ruling from the Israel Tax Authority to be recognized
as a Preferred Technology Enterprise and we received a tax ruling from the Israel Tax Authority granting GRD a Preferred Technology Enterprise status,
subject to terms and conditions determined in the tax ruling.
Taxation of Our Israeli Individual Shareholders on Receipt of Dividends
Israeli residents who are individuals are generally subject to Israeli income tax for dividends paid on our ordinary shares (other than bonus shares
or share dividends) at a rate of 25%, or 30% if the recipient of such dividend is a Substantial Shareholder (as defined below) at the time of distribution or at
any time during the preceding 12-month period. However, dividends distributed from taxable income accrued from Preferred Enterprise or Preferred
Technology Enterprise to Israeli individuals are subject to withholding tax at the rate of 20%. However, if such dividends are distributed to an Israeli
company, no tax is imposed (although, if such dividends are subsequently distributed to individuals or a non-Israeli company, withholding tax at a rate of
20% or such lower rate as may be provided in an applicable tax treaty (subject to the receipt in advance of a valid certificate from the Israel Tax Authority
(“ITA”) allowing for a reduced tax rate will apply). An average rate will be set in case the dividend is distributed from mixed types of income (regular and
preferred income).
A “Substantial Shareholder” is generally a person who alone, or together with his or her relative or another person who collaborates with him or
her on a regular basis, holds, directly or indirectly, at least 10% of any of the “means of control” of a corporation. “Means of control” generally include the
right to vote, receive profits, nominate a director or an officer, receive assets upon liquidation or instruct someone who holds any of the aforesaid rights
regarding the manner in which he or she is to exercise such right(s), all regardless of the source of such right.
With respect to individuals, the term “Israeli resident” is generally defined under Israeli tax legislation as a person whose center of life is in Israel.
The Israeli Tax Ordinance (as amended by Amendment Law No. 132 of 2002), states that in order to determine the center of life of an individual,
consideration will be given to the individual’s family, economic and social connections, including: (i) place of permanent residence; (ii) place of residential
dwelling of the individual and the individual’s immediate family; (iii) place of the individual’s regular or permanent occupation or the place of his or her
permanent employment; (iv) place of the individual’s active and substantial economic interests; (v) place of the individual’s activities in organizations,
associations and other institutions. The center of life of an individual will be presumed to be in Israel if: (i) the individual was present in Israel for 183 days
or more in the tax year; or (ii) the individual was present in Israel for 30 days or more in the tax year, and the total period of the individual’s presence in
Israel in that tax year and the two previous tax years is 425 days or more. Such presumption may be rebutted either by the individual or by the assessing
officer.
Payers of dividends on our ordinary shares, including the Israeli stockbroker effectuating the transaction, or the financial institution through which
the securities are held, are generally required, subject to any of the foregoing exemptions, reduced tax rates and the demonstration of a shareholder
regarding his, her or its foreign residency, to withhold tax upon the distribution of dividend at the rate of 25% (whether the recipient is a Substantial
Shareholder or not), so long as the shares are registered with a nominee company.
Taxation of Israeli Resident Corporations on Payment of Dividends
Israeli resident corporations are generally exempt from Israeli corporate income tax with respect to dividends paid on ordinary shares of Israeli
resident corporations as long as the profits out of which the dividends were paid were derived in Israel.
Capital Gains Taxes Applicable to Israeli Resident Shareholders
The income tax rate applicable to real capital gains derived by an Israeli individual resident from the sale of shares that were purchased after
January 1, 2012, whether listed on a stock exchange or not, is 25%. However, if such shareholder is considered a Substantial Shareholder at the time of sale
or at any time during the preceding 12 month period and/or claims a deduction for interest and linkage differences expenses in connection with the
purchase and holding of such shares, such gain will be taxed at the rate of 30%.
126
Moreover, capital gains derived by an individual shareholder who is a dealer or trader in securities, or to whom such income is otherwise taxable
as ordinary business income, are taxed in Israel at their marginal rates applicable to business income (up to 50% in 2022 and 2023, including Excess Tax as
detailed below).
At the sale of securities traded on a stock exchange, a detailed return, including a computation of the tax due, must be filed and an advanced
payment must be paid on January 31 and July 31 of every tax year in respect of sales of securities made within the previous six months. However, if all tax
due was withheld at source according to applicable provisions of the Israeli Tax Ordinance and regulations promulgated thereunder, the aforementioned
return is not required to be filed and no advance payment must be paid. Capital gain is also reportable on the annual income tax return.
Taxation of Non-Israeli Shareholders on Receipt of Dividends
Non-Israeli residents are generally subject to Israeli income tax on the receipt of dividends paid on our ordinary shares at the rate of 25% (or 30%
for individuals, if such person is a Substantial Shareholder at the time he or she receives the dividend or on any date in the 12 months preceding such date),
or 20% if the dividend is distributed from income attributed to Preferred Enterprise unless a lower rate is provided under an applicable tax treaty between
Israel and the shareholder’s country of residence and provided that a certificate from the Israel Tax Authority allowing for a reduced withholding tax rate is
obtained in advance.
A non-Israeli resident who has dividend income derived from or accrued in Israel, from which the full amount of tax was withheld at source, is
generally exempt from the duty to file tax returns in Israel in respect of such income; provided that (i) such income was not derived from a business
conducted in Israel by the taxpayer, (ii) the taxpayer has no other taxable sources of income in Israel with respect to which a tax return is required to be
filed, and (iii) the taxpayer is not obligated to pay excess tax (as further explained below).
For example, under the Convention Between the Government of the United States of America and the Government of Israel with Respect to Taxes
on Income, as amended, or the U.S.-Israel Tax Treaty, Israeli withholding tax on dividends paid to a U.S. resident for treaty purposes may not, in general,
exceed 25%, subject to certain conditions. Where the recipient is a U.S. corporation owning 10% or more of the voting shares of the paying corporation
during the part of the paying corporation’s taxable year which precedes the date of payment of the dividend and during the entirety of its prior taxable year
(if any), the Israeli tax withheld may not exceed 12.5%, subject to certain conditions.
Payers of dividends on our ordinary shares, including the Israeli stockbroker effectuating the transaction, or the financial institution through which
the securities are held, are generally required, subject to any of the foregoing exemptions, reduced tax rates and the demonstration of a shareholder
regarding his, her or its foreign residency, to withhold tax upon the distribution of dividend at the rate of 25% (whether the recipient is a Substantial
Shareholder or not), so long as the shares are registered with a nominee company.
Capital Gains Income Taxes Applicable to Non-Israeli Shareholders
Non-Israeli resident shareholders are generally exempt from Israeli capital gains tax on any gains derived from the sale, exchange or disposition of
our ordinary shares, provided that such shareholders did not acquire their shares prior to January 1, 2009 or acquired their shares after the Company was
listed for trading on NASDAQ and such gains were not derived from a permanent business or business activity of such shareholders in Israel. These
provisions dealing with capital gain are not applicable to a person whose gains from selling or otherwise disposing of the shares are deemed to be business
income. However, non-Israeli corporations will not be entitled to the foregoing exemptions if an Israeli resident (i) has a controlling interest of more than
25% in such non-Israeli corporation or (ii) is the beneficiary of or is entitled to 25% or more of the revenues or profits of such non-Israeli corporation,
whether directly or indirectly.
127
In addition, a sale of securities by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax
treaty. For example, under the U.S.-Israel Tax Treaty, the sale, exchange or disposition of our ordinary shares by a shareholder who is a U.S. resident (for
purposes of the U.S.-Israel Tax Treaty) holding the ordinary shares as a capital asset and is entitled to claim the benefits afforded to such a resident by the
U.S.-Israel Tax Treaty, or a Treaty U.S. Resident, is generally exempt from Israeli capital gains tax unless: (i) such Treaty U.S. Resident is an individual
and was present in Israel for 183 days or more in the aggregate during the relevant taxable year; (ii) such Treaty U.S. Resident holds, directly or indirectly,
shares representing 10% or more of our voting power of the Company during any part of the 12 month period preceding such sale, exchange or disposition,
subject to certain conditions; (iii) the capital gains arising from such sale, exchange or disposition are attributable to a permanent establishment of the
Treaty U.S. Resident maintained in Israel, subject to certain conditions; (iv) the capital gains arising from such sale, exchange or disposition is attributed to
real estate located in Israel; or (v) the capital gains arising from such sale, exchange or disposition is attributed to royalties. In any such case, the sale,
exchange or disposition of our ordinary shares would be subject to Israeli tax, to the extent applicable. However, under the U.S.-Israel Tax Treaty, such
Treaty U.S. Resident would be permitted to claim a credit for such taxes against U.S. federal income tax imposed on any gain from such sale, exchange or
disposition, under the circumstances and subject to the limitations specified in the U.S.-Israel Income Tax Treaty.
Regardless of whether shareholders may be liable for Israeli income tax on the sale of our ordinary shares, the payment of the consideration may
be subject to withholding of Israeli tax at the source. Accordingly, shareholders may be required to demonstrate that they are exempt from tax on their
capital gains in order to avoid withholding at source at the time of sale. Specifically, in transactions involving a sale of all of the shares of an Israeli resident
company, in the form of a merger or otherwise, the Israel Tax Authority may require from shareholders who are not liable for Israeli tax to sign declarations
in forms specified by this authority or obtain a specific exemption from the Israel Tax Authority to confirm their status as non-Israeli resident, and, in the
absence of such declarations or exemptions, may require the purchaser of the shares to withhold taxes at source.
Excess Tax
Individuals who are subject to tax in Israel are also subject to an additional tax at a rate of 3% on annual income exceeding a certain threshold
(NIS 698,280 for 2023, which amount is linked to the annual change in the Israeli consumer price index), including, but not limited to, dividends, interest
and capital gains.
Estate and Gift Tax
Israeli law presently does not impose estate or gift taxes.
Certain Material U.S. Federal Income Tax Considerations
The following is a general summary of certain material U.S. federal income tax consequences relating to the purchase, ownership and disposition
of our ordinary shares by U.S. Holders (as defined below). This summary is based on the Code, the regulations of the U.S. Department of the Treasury
issued pursuant to the Code, or the Treasury Regulations, the income tax treaty between the United States and Israel, or the U.S.-Israel Tax Treaty, and
administrative and judicial interpretations thereof, all as in effect on the date hereof and all of which are subject to change, possibly with retroactive effect,
or to different interpretation. No ruling has been sought from the Internal Revenue Service, or the IRS, with respect to any U.S. federal income tax
consequences described below, and there can be no assurance that the IRS or a court will not take a contrary position. This summary is no substitute for
consultation by prospective investors with their own tax advisors and does not constitute tax advice. This summary applies only to U.S. Holders that hold
our ordinary shares as capital assets for U.S. federal income tax purposes (generally, property held for investment) and does not address all of the tax
considerations that may be relevant to specific U.S. Holders in light of their particular circumstances or to U.S. Holders subject to special treatment under
U.S. federal income tax law (including, without limitation, banks, insurance companies, tax-exempt entities, retirement plans, regulated investment
companies, partnerships, dealers in securities, brokers, real estate investment trusts, grantor trusts, certain former citizens or residents of the United States,
persons who acquire our ordinary shares as part of a straddle, hedge, conversion transaction or other integrated investment, persons who acquire our
ordinary shares through the exercise or cancellation of employee stock options or otherwise as compensation for their services, persons that have a
“functional currency” other than the U.S. dollar, persons that own (or are deemed to own, indirectly, or by attribution) 10% or more of our shares (by vote
or value), or persons that mark their securities to market for U.S. federal income tax purposes). This summary does not address any U.S. state or local or
non-U.S. tax considerations, any U.S. federal estate, gift or alternative minimum tax considerations, or any U.S. federal tax consequences other than U.S.
federal income tax consequences.
128
As used in this summary, the term “U.S. Holder” means a beneficial owner of our ordinary shares that is, for U.S. federal income tax purposes, (i)
an individual citizen or resident of the United States, (ii) a corporation, or other entity taxable as a corporation for U.S. federal income tax purposes, created
or organized in or under the laws of the United States, any state thereof, or the District of Columbia, (iii) an estate the income of which is subject to U.S.
federal income tax regardless of its source, or (iv) a trust with respect to which a court within the United States is able to exercise primary supervision over
its administration and one or more U.S. persons have the authority to control all of its substantial decisions, or that has a valid election in effect under
applicable Treasury Regulations to be treated as a “United States person.”
If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds our ordinary shares, the tax treatment of such entity
or arrangement treated as a partnership and each person treated as a partner thereof generally will depend upon the status and activities of the entity and
such person. A holder that is treated as a partnership for U.S. federal income tax purposes should consult its own tax advisor regarding the U.S. federal
income tax considerations applicable to it and its partners of the purchase, ownership and disposition of our ordinary shares.
Prospective investors should be aware that this summary does not address the tax consequences to investors who are not U.S. Holders. Prospective
investors should consult their own tax advisors as to the particular tax considerations applicable to them relating to the purchase, ownership and disposition
of our ordinary shares, including the applicability of U.S. federal, state and local tax laws and non-U.S. tax laws.
Taxation of U.S. Holders
Distributions. Subject to the discussion below under “Passive Foreign Investment Company,” a U.S. Holder that receives a distribution with
respect to an ordinary share generally will be required to include the amount of such distribution in gross income as a dividend (without reduction for any
Israeli tax withheld from such distribution) when actually or constructively received to the extent of the U.S. Holder’s pro rata share of our current and/or
accumulated earnings and profits (as determined under U.S. federal income tax principles). Any distributions in excess of our earnings and profits will be
applied against and will reduce (but not below zero) the U.S. Holder’s tax basis in its ordinary shares, and, to the extent they exceed that tax basis, will be
treated as gain from the sale or exchange of our ordinary shares. We do not intend to calculate our earnings and profits under U.S. federal income tax
principles. Therefore, a U.S. Holder should expect that a distribution will be reported as a dividend even if that distribution would otherwise be treated as a
non-taxable return of capital or as capital gain under the rules described above.
As noted above, we do not anticipate paying any cash dividends in the foreseeable future. If we were to pay dividends, we expect to pay such
dividends in NIS. A dividend paid in NIS, including the amount of any Israeli taxes withheld, will be includible in a U.S. Holder’s income at a U.S. dollar
amount calculated by reference to the exchange rate in effect on the date such dividend is received, regardless of whether the payment is in fact converted
into U.S. dollars. If the dividend is converted to U.S. dollars on the date of receipt, a U.S. Holder generally will not recognize a foreign currency gain or
loss. However, if the U.S. Holder converts the NIS into U.S. dollars on a later date, the U.S. Holder must include, in computing its income, any gain or loss
resulting from any exchange rate fluctuations. The gain or loss will be equal to the difference between (i) the U.S. dollar value of the amount included in
income when the dividend was received and (ii) the amount received on the conversion of the NIS into U.S. dollars. Such gain or loss generally will be
ordinary income or loss and will be U.S. source income or loss for U.S. foreign tax credit purposes. U.S. Holders should consult their own tax advisors
regarding the tax consequences to them if we pay dividends in NIS or any other non-U.S. currency.
Subject to certain significant conditions and limitations, any Israeli taxes paid on or withheld from distributions from us and not refundable to a
U.S. Holder may be credited against the U.S. Holder’s U.S. federal income tax liability or, alternatively, may be deducted from the U.S. Holder’s taxable
income. However, as a result of recent changes to the U.S. foreign tax credit rules, a withholding tax may need to satisfy certain additional requirements in
order to be considered a creditable tax for a U.S. Holder. We have not determined whether these requirements have been met and, accordingly, no assurance
can be given that any withholding tax on dividends paid by us will be creditable. The election to deduct, rather than credit, foreign taxes, is made on a year-
by-year basis and applies to all foreign taxes paid by a U.S. Holder or withheld from a U.S. Holder that year. Dividends paid on our ordinary shares
generally will constitute income from sources outside the United States and be categorized as “passive category income” or, in the case of some U.S.
Holders, as “general category income” for U.S. foreign tax credit purposes. Because the rules governing foreign tax credits are complex, U.S. Holders
should consult their own tax advisors regarding the availability of foreign tax credits in their particular circumstances.
129
Dividends paid on our ordinary shares will not be eligible for the “dividends-received” deduction generally allowed to corporate U.S. Holders with
respect to dividends received from U.S. corporations.
Certain distributions treated as dividends that are received by an individual U.S. Holder from a “qualified foreign corporation” may be classified
as “qualified dividend income,” — which is generally taxed at the lower applicable long term capital gains rates provided certain holding period and other
requirements are satisfied. A non-U.S. corporation (other than a PFIC for the taxable year in which the dividend is paid or the preceding taxable year)
generally will be considered to be a qualified foreign corporation (i) if it is eligible for the benefits of a comprehensive tax treaty with the United States
which the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes an exchange of
information program, or (ii) with respect to any dividend it pays on stock which is readily tradable on an established securities market in the United States.
We will not be a qualified foreign corporation if we are a passive foreign investment company, or PFIC, for the taxable year in which we pay a dividend or
for the preceding taxable year. As discussed below under “Passive Foreign Investment Company,” we believe that we were a PFIC for our 2023 taxable
year and expect to be a PFIC for the 2024 taxable year. Because the PFIC determination is highly fact intensive, there can be no assurance that we will not
be a PFIC in 2024 or for any other taxable year. Our ordinary shares will generally be considered to be readily tradable on an established securities market
in the United States if they are listed on the Nasdaq Capital Market, as we intend our ordinary shares will be. U.S. Holders should consult their own tax
advisors regarding the availability of the lower rate for dividends paid with respect to our ordinary shares.
The additional 3.8% “net investment income tax” (described below) may apply to dividends received by certain U.S. Holders who meet certain
modified adjusted gross income thresholds.
Sale, Exchange or Other Taxable Disposition of Ordinary Shares. Subject to the discussion under “Passive Foreign Investment Company” below,
a U.S. Holder generally will recognize capital gain or loss upon the sale, exchange, or other taxable disposition of our ordinary shares in an amount equal to
the difference between the amount realized on the sale, exchange, or other taxable disposition and the U.S. Holder’s adjusted tax basis (determined under
U.S. federal income tax rules) in such ordinary shares. This capital gain or loss will be long-term capital gain or loss if the U.S. Holder’s holding period in
our ordinary shares exceeds one year. Preferential tax rates for long-term capital gain (currently, with a maximum rate of 20%) will apply to individual U.S.
Holders. The deductibility of capital losses is subject to limitations. The gain or loss generally will be income or loss from sources within the United States
for U.S. foreign tax credit purposes, subject to certain possible exceptions under the U.S.-Israel Tax Treaty. The additional 3.8% “net investment income
tax” (described below) may apply to gains recognized upon the sale, exchange, or other taxable disposition of our ordinary shares by certain U.S. Holders
who meet certain modified adjusted gross income thresholds.
U.S. Holders should consult their own tax advisors regarding the U.S. federal income tax consequences of receiving currency other than U.S.
dollars upon the disposition of their ordinary shares.
Passive Foreign Investment Company. In general, a non-U.S. corporation will be treated as a PFIC for U.S. federal income tax purposes in any
taxable year in which either (i) at least 75% of its gross income is “passive income,” or (ii) on average at least 50% of its assets by value produce passive
income or are held for the production of passive income. Passive income for this purpose generally includes, among other things, certain dividends,
interest, royalties, rents and gains from commodities and securities transactions and from the sale or exchange of property that gives rise to passive income.
Passive income also includes amounts derived by reason of the temporary investment of funds, including those raised in a public offering. Assets that
produce or are held for the production of passive income may include cash, even if held as working capital or raised in a public offering, as well as
marketable debt securities and other assets that may produce passive income. In determining whether a non-U.S. corporation is a PFIC, a proportionate
share of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account.
130
A foreign corporation’s PFIC status is an annual determination that is based on tests that are factual in nature, and our status for any year will
depend on our income, assets, and activities for such year. Based upon our review of our financial data, we believe that we were a PFIC for our 2023
taxable year and expect to be a PFIC for the 2024 taxable year. Because PFIC status is determined annually and is based on our income, assets and
activities for the entire taxable year, it is not possible to determine with certainty whether we will be characterized as a PFIC for the 2024 taxable year until
after the close of the year, and there can be no assurance that we will not be classified as a PFIC in any future year.
Default PFIC Rules. If we are a PFIC for any tax year, a U.S. Holder who does not make a timely “qualified electing fund” election, or “QEF
election” or a mark-to-market election (as described below), referred to in this summary as a “Non-Electing U.S. Holder,” will be subject to special rules
with respect to (i) any “excess distribution” (generally, the portion of any distributions received by the Non-Electing U.S. Holder on the ordinary shares in a
taxable year in excess of 125% of the average annual distributions received by the Non-Electing U.S. Holder in the three preceding taxable years, or, if
shorter, the Non-Electing U.S. Holder’s holding period for the ordinary shares), and (ii) any gain realized on the sale or other disposition of such ordinary
shares. Under these rules:
●
●
●
the excess distribution or gain would be allocated ratably over the Non-Electing U.S. Holder’s holding period for such ordinary shares;
the amount allocated to the current taxable year and any year prior to us becoming a PFIC would be taxed as ordinary income; and
the amount allocated to each of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class
of taxpayer for that year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax
attributable to each such other taxable year.
If a Non-Electing U.S. Holder who is an individual dies while owning our ordinary shares, the Non-Electing U.S. Holder’s successor would be
ineligible to receive a step-up in tax basis of such ordinary shares. Non-Electing U.S. Holders should consult their tax advisors regarding the application of
the “net investment income tax” (described below) to their specific situation.
To the extent a distribution on our ordinary shares does not constitute an excess distribution to a Non-Electing U.S. Holder, such Non-Electing
U.S. Holder generally will be required to include the amount of such distribution in gross income as a dividend to the extent of our current and/or
accumulated earnings and profits (as determined for U.S. federal income tax purposes) that are not allocated to excess distributions. The tax consequences
of such distributions are discussed above under “Taxation of U.S. Holders—Distributions.” Each U.S. Holder is encouraged to consult its own tax advisor
with respect to the appropriate U.S. federal income tax treatment of any distribution on our ordinary shares.
If we are treated as a PFIC for any taxable year during the holding period of a Non-Electing U.S. Holder, we will continue to be treated as a PFIC
for all succeeding years during which the Non-Electing U.S. Holder is treated as a direct or indirect Non-Electing U.S. Holder even if we are not a PFIC for
such years. A U.S. Holder is encouraged to consult its tax advisor with respect to any available elections that may be applicable in such a situation,
including the “deemed sale” election of Section 1298(b)(1) of the Code (which will be taxed under the adverse tax rules described above).
We may invest in the equity of foreign corporations that are PFICs or may own subsidiaries that are PFICs (any such entity, a “lower-tier PFIC”).
If we are classified as a PFIC, under attribution rules, U.S. Holders will be subject to the PFIC rules with respect to their indirect ownership interests in
such lower-tier PFICs, such that a disposition by us of the shares of the lower-tier PFIC or receipt by us of a distribution from the lower-tier PFIC generally
will be treated as a deemed disposition of such shares or the deemed receipt of such distribution by the U.S. Holder, subject to taxation under the PFIC
rules even though the U.S. Holder does not receive any proceeds from those dispositions or distributions. There can be no assurance that a U.S. Holder will
be able to make a QEF election with respect to any lower-tier PFICs in which we invest. Each U.S. Holder is encouraged to consult its own tax advisor
with respect to tax consequences of an investment by us in a lower-tier PFIC.
131
QEF Election. Certain adverse consequences of PFIC status can be mitigated for holders of our ordinary shares if a U.S. Holder makes a QEF
election. A U.S. Holder who makes a timely QEF election, referred to in this disclosure as an “Electing U.S. Holder,” with respect to us must report for
U.S. federal income tax purposes its pro rata share of our ordinary earnings and net capital gain, if any, for our taxable year that ends with or within the
taxable year of the Electing U.S. Holder. The “net capital gain” of a PFIC is the excess, if any, of the PFIC’s net long-term capital gains over its net short-
term capital losses. The amount so included in income generally will be treated as ordinary income to the extent of such Electing U.S. Holder’s allocable
share of the PFIC’s ordinary earnings and as long-term capital gain to the extent of such Electing U.S. Holder’s allocable share of the PFIC’s net capital
gains. Such Electing U.S. Holder generally will be required to translate such income into U.S. dollars based on the average exchange rate for the PFIC’s
taxable year with respect to the PFIC’s functional currency. Such income generally will be treated as income from sources outside the United States for
U.S. foreign tax credit purposes. Amounts previously included in income by such Electing U.S. Holder under the QEF rules generally will not be subject to
tax when they are distributed to such Electing U.S. Holder. The Electing U.S. Holder’s tax basis in our ordinary shares generally will increase by any
amounts so included under the QEF rules and decrease by any amounts not included in income when distributed.
An Electing U.S. Holder will be subject to U.S. federal income tax on such amounts for each taxable year in which we are a PFIC, regardless of
whether such amounts are actually distributed to such Electing U.S. Holder. However, an Electing U.S. Holder may, subject to certain limitations, elect to
defer payment of current U.S. federal income tax on such amounts, subject to an interest charge. If an Electing U.S. Holder is an individual, any such
interest will be treated as non-deductible “personal interest.”
Any net operating losses or net capital losses of a PFIC will not pass through to the Electing U.S. Holder and will not offset any ordinary earnings
or net capital gain of a PFIC recognized by Electing U.S. Holder in subsequent years.
So long as an Electing U.S. Holder’s QEF election with respect to us is in effect with respect to the entire holding period for our ordinary shares,
any gain or loss recognized by such Electing U.S. Holder on the sale, exchange or other disposition of such shares generally will be long-term capital gain
or loss if such Electing U.S. Holder has held such shares for more than one year at the time of such sale, exchange or other disposition. Preferential tax
rates for long-term capital gain (currently, a maximum rate of 20%) will apply to individual U.S. Holders. The deductibility of capital losses is subject to
limitations.
In general, a U.S. Holder must make a QEF election on or before the due date for filing its income tax return for the first year to which the QEF
election is to apply. A U.S. Holder makes a QEF election by completing the relevant portions of and filing IRS Form 8621 in accordance with the
instructions thereto. Upon request, we expect to provide U.S. Holders with the information needed to complete IRS Form 8621 (which form would be
required to be filed with the IRS on an annual basis by the U.S. Holder) and to make and maintain a valid QEF election for any year in which we are a
PFIC. There is no assurance, however, that we will have timely knowledge of our status as a PFIC or the status of a lower-tier PFIC, or that the information
that we provide will be adequate to allow U.S. Holders to make a QEF election. A QEF election will not apply to any taxable year during which we are not
a PFIC, but will remain in effect with respect to any subsequent taxable year in which we become a PFIC.
Each U.S. Holder should consult its own tax advisor with respect to the advisability of, the tax consequences of, and the procedures for making a
QEF election with respect to us.
Mark-to-Market Election. Alternatively, if our ordinary shares are treated as “marketable stock,” a U.S. Holder would be allowed to make a
“mark-to-market” election with respect to our ordinary shares, provided the U.S. Holder completes and files IRS Form 8621 in accordance with the
relevant instructions and related Treasury Regulations. If that election is made, the U.S. Holder generally would include as ordinary income in each taxable
year the excess, if any, of the fair market value of our ordinary shares at the end of the taxable year over such holder’s adjusted tax basis in such ordinary
shares. The U.S. Holder would also be permitted an ordinary loss in respect of the excess, if any, of the U.S. Holder’s adjusted tax basis in our ordinary
shares over their fair market value at the end of the taxable year, but only to the extent of the net amount previously included in income as a result of the
mark-to- market election. A U.S. Holder’s tax basis in our ordinary shares would be adjusted to reflect any such income or loss amount. Gain realized on
the sale, exchange or other disposition of our ordinary shares would be treated as ordinary income, and any loss realized on the sale, exchange or other
disposition of our ordinary shares would be treated as ordinary loss to the extent that such loss does not exceed the net mark-to-market gains previously
included in income by the U.S. Holder, and any loss in excess of such amount will be treated as capital loss. Amounts treated as ordinary income will not
be eligible for the favorable tax rates applicable to qualified dividend income or long-term capital gains.
132
Generally, stock will be considered marketable stock if it is “regularly traded” on a “qualified exchange” within the meaning of applicable
Treasury Regulations. A class of stock is regularly traded on an exchange during any calendar year during which such class of stock is traded, other than in
de minimis quantities, on at least 15 days during each calendar quarter. To be marketable stock, our ordinary shares must be regularly traded on a qualifying
exchange (i) in the United States that is registered with the SEC or a national market system established pursuant to the Exchange Act or (ii) outside the
United States that is properly regulated and meets certain trading, listing, financial disclosure and other requirements. Our ordinary shares are expected to
constitute “marketable stock” as long as they remain listed on the Nasdaq Capital Market and are regularly traded.
A mark-to-market election will not apply to our ordinary shares held by a U.S. Holder for any taxable year during which we are not a PFIC, but
will remain in effect with respect to any subsequent taxable year in which we become a PFIC. Such election will not apply to any lower-tier PFIC that we
own. Each U.S. Holder is encouraged to consult its own tax advisor with respect to the availability and tax consequences of a mark-to-market election with
respect to our ordinary shares.
Each U.S. Holder should consult its own tax adviser with respect to the applicability of the “net investment income tax” (discussed below) where a
mark-to-market election is in effect.
In addition, U.S. Holders should consult their tax advisors regarding the IRS information reporting and filing obligations that may arise as a result
of the ownership of ordinary shares in a PFIC, including IRS Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company
or Qualified Electing Fund.
The U.S. federal income tax rules relating to PFICs, QEF elections, and mark-to market elections are complex. U.S. Holders are urged to
consult their own tax advisors with respect to the purchase, ownership and disposition of our ordinary shares, any elections available with respect
to such ordinary shares and the IRS information reporting obligations with respect to the purchase, ownership and disposition of our ordinary
shares.
Certain Reporting Requirements
Certain U.S. Holders may be required to file IRS Form 926, Return by U.S. Transferor of Property to a Foreign Corporation and IRS Form 5471,
Information Return of U.S. Persons With Respect to Certain Foreign Corporations, reporting transfers of cash or other property to us and information
relating to the U.S. Holder and us. Substantial penalties may be imposed upon a U.S. Holder that fails to comply. See also the discussion regarding Form
8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund, above.
In addition, certain U.S. Holders must report information on IRS Form 8938, Statement of Specified Foreign Financial Assets, with respect to their
investments in certain “specified foreign financial assets,” which would include an investment in our ordinary shares, if the aggregate value of all of those
assets exceeds $50,000 on the last day of the taxable year (and in some circumstances, a higher threshold). This reporting requirement applies to individuals
and certain U.S. entities.
U.S. Holders who fail to report required information could become subject to substantial penalties. U.S. Holders should consult their tax advisors
regarding the possible implications of these reporting requirements arising from their investment in our ordinary shares.
133
Backup Withholding Tax and Information Reporting Requirements
Generally, information reporting requirements will apply to distributions on our ordinary shares or proceeds on the disposition of our ordinary
shares paid within the United States (and, in certain cases, outside the United States) to U.S. Holders other than certain exempt recipients, such as
corporations. Furthermore, backup withholding (currently at 24%) may apply to such amounts if the U.S. Holder fails to (i) provide a correct taxpayer
identification number, (ii) report interest and dividends required to be shown on its U.S. federal income tax return, or (iii) make other appropriate
certifications in the required manner. U.S. Holders who are required to establish their exempt status generally must provide such certification on IRS Form
W-9.
Backup withholding is not an additional tax. Amounts withheld as backup withholding from a payment may be credited against a U.S. Holder’s
U.S. federal income tax liability and such U.S. Holder may obtain a refund of any excess amounts withheld by filing the appropriate claim for refund with
the IRS and furnishing any required information in a timely manner.
Medicare Tax on Investment Income
Certain U.S. persons, including individuals, estates and trusts, will be subject to an additional 3.8% Medicare tax, or “net investment income tax,”
on unearned income. For individuals, the additional net investment income tax applies to the lesser of (i) “net investment income” or (ii) the excess of
“modified adjusted gross income” over $200,000 ($250,000 if married and filing jointly or $125,000 if married and filing separately). “Net investment
income” generally equals the taxpayer’s gross investment income reduced by the deductions that are allocable to such income. Investment income
generally includes, among other things, passive income such as interest, dividends, annuities, royalties, rents, and capital gains. U.S. Holders are urged to
consult their own tax advisors regarding the implications of the additional net investment income tax resulting from their ownership and disposition of our
ordinary shares.
THE DISCUSSION ABOVE IS A GENERAL SUMMARY. IT DOES NOT COVER ALL TAX MATTERS THAT MAY BE OF
IMPORTANCE TO A PROSPECTIVE INVESTOR. EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR
ABOUT THE TAX CONSEQUENCES RELATING TO THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR ORDINARY SHARES
IN LIGHT OF THE INVESTOR’S OWN CIRCUMSTANCES, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN
APPLICABLE LAWS.
F. Dividends and Paying Agents.
Not applicable.
G. Statements by Experts.
Not applicable.
H. Documents on Display.
The SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically with the SEC. You may
read and copy this annual report, including the related exhibits and schedules, and any document we file with the SEC at http://www.sec.gov.
As a “foreign private issuer,” we are subject to the information reporting requirements of the Exchange Act that are applicable to foreign private
issuers, and under those requirements file reports with the SEC. Those other reports or other information may be inspected without charge at the locations
described above. As a “foreign private issuer,” we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy
statements, and our officers, directors and principal shareholders will be exempt from the reporting and “short-swing” profit recovery provisions contained
in Section 16 of the Exchange Act with respect to their purchases and sales of ordinary shares. Furthermore, as a “foreign private issuer,” we are also not
subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act.
134
We maintain a corporate website at http://www.galmedpharma.com. Information contained on, or that can be accessed through, our website is not
incorporated by reference into this annual report and does not constitute a part of this annual report. We have included our website address in this annual
report solely as an inactive textual reference.
I. Subsidiary Information.
Not applicable.
J. Annual Report to Security Holders
Not applicable.
ITEM 11. Quantitative and Qualitative Disclosures About Market Risk.
Quantitative and Qualitative Disclosure About Market Risk
We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial
position, results of operations or cash flows due to adverse changes in financial market prices and rates, including interest rates and foreign exchange rates,
of financial instruments.
Foreign Currency Exchange Risk
Our foreign currency exposures give rise to market risk associated with exchange rate movements of the Euro and NIS mainly against the U.S.
dollar because a large portion of our expenses are denominated in Euros and NIS. Our Euro expenses consist principally of payments made to sub-
contractors and consultants for pre-clinical studies, clinical trials and other research and development activities. Our NIS expenses consist principally of
payments made to employees, subcontractors and consultants for pre-clinical studies, clinical trials, professional services, other research and development
activities and general and administrative activities. We anticipate that a large portion of our expenses will continue to be denominated in currencies other
than the U.S. dollar. Our financial position, results of operations and cash flow are subject to fluctuations due to changes in foreign currency exchange
rates. Our results of operations and cash flow are, therefore, subject to fluctuations due to changes in foreign currency exchange rates and may be adversely
affected in the future due to changes in foreign exchange rates. Approximately 35% of our expected expenses are denominated in NIS. Changes of 5% and
10% in the U.S. dollar to NIS exchange rate will increase/decrease our operation expenses by 1.75% and 3.5%, respectively. Approximately 10% of our
expected expenses are denominated in Euros. Changes of 5% and 10% in the U.S. dollar to Euro exchange rate, will increase/decrease our operation
expenses by 0.5% and 1.0%, respectively. To date, fluctuations in the exchange rates have not materially affected our results of operations or financial
condition for the periods under review.
To date, we have not engaged in hedging our foreign currency exchange risk. In the future, we may enter into formal currency hedging
transactions to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal operating currencies. These measures,
however, may not adequately protect us from the material adverse effects of such fluctuations.
Interest Rate Risk
Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. We
currently do not hedge interest rate exposure. Because of the short-term maturities of our cash equivalents and investment securities, we do not believe that
an increase in market rates would have any significant impact on the realized value of our investment securities. If a 10% change in interest rates were to
have occurred on December 31, 2023, this change would not have had a material effect on the fair value of our investment portfolio as of that date.
135
Liquidity
We do not believe that our cash and cash equivalents and available for sale investments have significant risk of default or illiquidity. While we
believe our cash, cash equivalents and available for sale investments do not contain excessive risk, we cannot provide absolute assurance that in the future
our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash and cash equivalents at one or
more financial institutions that are in excess of federally insured limits.
ITEM 12. Description of Securities Other Than Equity Securities.
A. Debt Securities.
Not applicable.
B. Warrants and Rights.
Not applicable.
C. Other Securities.
Not applicable.
D. American Depositary Shares.
Not applicable.
ITEM 13. Defaults, Dividend Arrearages and Delinquencies.
Not applicable.
ITEM 14. Material Modifications to the Rights of Security Holders and Use of Proceeds.
PART II
Not applicable.
ITEM 15. Controls and Procedures.
Disclosure Controls and Procedures
We performed an evaluation of the effectiveness of our disclosure controls and procedures that are designed to ensure that information required to
be disclosed in this annual report and filed with the SEC is recorded, processed, summarized and reported timely within the time period specified in the
SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information
required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act, is accumulated and communicated to the issuer’s
management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely
decisions regarding required disclosure. There can be no assurance that our disclosure controls and procedures will detect or uncover all failures of persons
within our Company to disclose information otherwise required to be set forth in our reports. Nevertheless, our disclosure controls and procedures are
designed to provide reasonable assurance of achieving the desired control objectives. Based on our evaluation, our management, including our President,
Chief Executive Officer and Chairman and Chief Accounting Officer, have concluded that our disclosure controls and procedures (as defined in Rules 13a-
15(e) and 15(d)-15(e) of the Exchange Act) as of the end of the period covered by this annual report are effective at such reasonable assurance level.
136
Management’s Annual Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over
financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the
company’s principal executive and principal financial officers and effected by the company’s board of directors, management and other personnel, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles and includes those policies and procedures that:
●
●
●
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transaction and dispositions of the assets of
the company;
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with
authorizations of management and directors of the company; and
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s
assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation
of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate.
Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2023. In making this assessment,
our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-
Integrated Framework (2013). Based on that assessment, our management concluded that as of December 31, 2023, our internal control over financial
reporting was effective.
Changes in Internal Controls Over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the year ended December 31, 2023 that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.
ITEM 16. [RESERVED]
ITEM 16A. Audit Committee Financial Expert.
Our Board has determined that Mr. Poshinski qualifies as an audit committee financial expert pursuant to the applicable SEC rules and that Mr.
Poshinski is “independent” in accordance with the Nasdaq Capital Market corporate governance requirements. For information relating to Mr. Poshinski’s
qualifications and experience, see “Item 6. Directors, Senior Management and Employees—A. Directors and Senior Management.”
ITEM 16B. Code of Ethics.
We have adopted a Code of Business Conduct and Ethics applicable to all of our directors and employees, including our President, Chief
Executive Officer and Chairman, Chief Financial Officer, controller or principal accounting officer or other persons performing similar functions, which is
a “code of ethics” as defined in Item 16B of Form 20-F promulgated by the SEC and as required by the Nasdaq Listing Rules, which refers to Section
406(c) of the Sarbanes-Oxley Act. Section 406(c) of the Sarbanes-Oxley Act provides that a “code of ethics” means such standards as are reasonably
necessary to promote (i) honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and
professional relationships; (ii) full, fair, accurate, timely and understandable disclosure in the periodic reports required to be filed by the issuer; and (iii)
compliance with applicable governmental rules and regulation.
137
The full text of the Code of Business Conduct and Ethics is posted on our website at www.galmedpharma.com. Information contained on, or that
can be accessed through, our website does not constitute a part of this prospectus and is not incorporated by reference herein. We will provide a copy of
such code of ethics without charge upon request by mail or by telephone. If we make any amendment to the Code of Business Conduct and Ethics or grant
any waivers, including any implicit waiver, from a provision of the Code of Business Conduct and Ethics, we will disclose the nature of such amendment
or waiver on our website to the extent required by the rules and regulations of the SEC.
ITEM 16C. Principal Accountant Fees and Services.
Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network, an independent registered public accounting firm, served as our
independent public accountants for the fiscal years ended December 31, 2023 and 2022, for which audited financial statements appear in this annual report.
The following table presents the aggregate fees for professional services rendered by such accountants to us during their respective term as our
principal accountants in 2023 and 2022.
Audit Fees (1)
Audit-Related fees (2)
Tax and incentives Fees (3)
Total
2023
(US$ in thousands)
2022
(US$ in thousands)
120
40
0
160
120
20
27
167
(1)
(2)
Includes professional services rendered in connection with the audit of our annual financial statements and the review of our interim financial
statements.
Audit related services consist of services that were reasonably related to the performance of the audit or reviews of our financial statements and
not included under “Audit Fees” above, including, principally, providing consents for registration statement filings.
(3)
Tax fees consist of services related to obtaining a tax rulings t.
Audit Committee Pre-Approval Policies and Procedures
One of our audit committee’s main roles is to assist the board of directors in fulfilling its responsibility for oversight of the quality and integrity of
the accounting, auditing and reporting practices of the Company. The audit committee oversees the appointment, compensation, and oversight of the public
accounting firm engaged to prepare or issue an audit report on the financial statements of the Company. Our Board has delegated to the audit committee the
power to pre-approve non-auditing services rendered by the Company’s independent auditors without the need for further approval by the board of
directors. As such, our audit committee has adopted a pre-approval policy for the engagement of our independent registered public accounting firm to
perform certain audit and non-audit services. Pursuant to this policy, which is designed to assure that such engagements do not impair the independence of
our auditors, the audit committee pre-approves annually a list of specific audit and non-audit services in the categories of audit services, audit-related
services, tax services and other services that may be performed by our independent registered public accounting firm. The last pre-approval policy was
adopted by our audit committee on April 2, 2024 for a period of twelve months. Since its establishment in May 2014, the audit committee has approved all
of the audit-related fees, tax fees and all other fees. If a type of service that is to be provided by our auditors has not received such general pre-approval, it
will require specific pre-approval by our audit committee. The policy prohibits retention of the independent registered public accounting firm to perform
the prohibited non-audit functions defined in applicable SEC rules.
138
ITEM 16D. Exemptions from the Listing Standards for Audit Committees.
Not applicable.
ITEM 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers.
Not applicable.
ITEM 16F. Change in Registrant’s Certifying Accountant.
Not applicable.
ITEM 16G. Corporate Governance.
Our shares are listed on the Nasdaq Capital Market under the symbol “GLMD.” In addition to the corporate governance requirements of the
Sarbanes-Oxley Act and the related rules implemented by the SEC, we must comply with the Nasdaq Listing Rules. Under those Nasdaq Listing Rules, we
may elect to follow certain corporate governance practices permitted under the Companies Law in lieu of compliance with corresponding corporate
governance requirements otherwise imposed by the Nasdaq Listing Rules for U.S. domestic issuers.
In accordance with Israeli law and practice, and subject to the exemption set forth in Rule 5615 of the Nasdaq Listing Rules, we follow the
provisions of the Companies Law, rather than the Nasdaq Listing Rules, with respect to the following requirements:
●
●
●
Distribution of certain reports to shareholders. As opposed to the Nasdaq Listing Rules, which require listed issuers to make certain
reports, such as annual reports, interim reports and quarterly reports, available to shareholders in one of a number of specific manners,
Israeli law does not require us to distribute periodic reports directly to shareholders, and the generally accepted business practice in Israel
is not to distribute such reports to shareholders, but to make such reports available through a public website. In addition to making such
reports available on a public website, we plan to make our audited financial statements available to our shareholders at our offices and
will only mail such reports to shareholders upon request. As a foreign private issuer, we are generally exempt from the SEC’s proxy
solicitation rules. See “Item 10. Additional Information—Documents on Display” for a description of our Exchange Act reporting
obligations.
Quorum. While the Nasdaq Listing Rules require that the quorum for purposes of any meeting of the holders of a listed company’s
common voting stock be no less than 33.33% of the company’s outstanding common voting stock, under Israeli law, a company is
entitled to determine in its articles of association the number of shareholders and percentage of holdings required for a quorum at a
shareholders meeting. Our articles of association provide that a quorum of two or more shareholders holding at least 33.33% of the voting
rights in person or by proxy is required for commencement of business at a general meeting. However, the quorum set forth in our articles
of association with respect to an adjourned meeting consists of any two shareholders present in person or by proxy even if, between them,
they represent shares conferring 33.33% or less of the voting rights of the Company.
Nomination of directors. With the exception of directors elected by our Board due to vacancy, our directors are elected by an annual
meeting of our shareholders to hold office until the next annual meeting following three years from his or her election. See “Item 6.
Directors, Senior Management and Employees—C. Board Practices.” The nominations for directors, which are presented to our
shareholders by our Board, are made by the nominating committee itself, in accordance with the provisions of Nasdaq Capital Market
Listing Rule 5605(e), our Articles and the Companies Law.
139
●
●
●
Compensation of officers. We follow the provisions of the Companies Law with respect to matters in connection with the composition
and responsibilities of our remuneration committee, Office Holder compensation and any required approval by the shareholders of such
compensation. Israeli law and our Articles do not require that the independent members of our Board, or a remuneration committee
composed solely of independent members of our Board, determine an executive officer’s compensation, as is generally required under the
Nasdaq Listing Rules with respect to the Chief Executive Officer and all other executive officers of a company. Instead, remuneration of
Office Holders is determined and approved by our remuneration committee, and in general, by our Board as well, and in certain
circumstances, by our shareholders, as detailed above. The requirements for shareholder approval of any Office Holder compensation,
and the relevant majority or Special Majority for such approval, are all as set forth in the Companies Law. Thus, we seek shareholder
approval for all corporate actions with respect to Office Holder compensation requiring such approval under the requirements of the
Companies Law, including for our Compensation Policy and for certain Office Holder Compensation, rather than seeking approval for
such corporate actions in accordance with Nasdaq Listing Rules. All members of our remuneration committee are independent directors
under applicable Nasdaq Capital Market and SEC rules, as affirmatively determined by our Board. See “Item 6. Directors, Senior
Management and Employees—B. Compensation.”
Independent directors. Although Israeli law does not require that a majority of the directors serving on our Board be “independent,” as
defined under Nasdaq Capital Market Listing Rule 5605(a)(2), but rather requires we have at least two external directors who meet the
requirements of the Companies Law, as described above under “Item 6. Directors, Senior Management and Employees—C. Board
Practices—External Directors.”, following our “opt-out” of the requirement to appoint external directors, a majority of our Board is
independent based on the Nasdaq Capital Market rules. We are required, however, to ensure that all members of our audit committee are
“independent” under the applicable Nasdaq Capital Market and SEC criteria for independence (as we cannot exempt ourselves from
compliance with that SEC independence requirement, despite our status as a foreign private issuer). Our independent directors’ conduct
regularly scheduled meetings at which only such independent directors are present, as required by the Nasdaq Listing Rules. Our Board
has affirmatively determined that each of Mr. Nir, Mr. Poshinski, Dr. Sidransky and Dr. Brosgart qualifies as “independent” under the
Nasdaq Capital Market independence standards.
Shareholder approval. We will seek shareholder approval for all corporate actions requiring such approval under requirements of the
Companies Law, rather than seeking approval for corporate actions in accordance with Nasdaq Capital Market Listing Rule 5635. In
particular, under this Nasdaq Capital Market rule, shareholder approval is generally required for: (i) an acquisition of shares or assets of
another company that involves the issuance of 20% or more of the acquirer’s shares or voting rights or if a director, officer or 5%
shareholder has greater than a 5% interest in the target company or the consideration to be received; (ii) the issuance of shares leading to
a change of control; (iii) adoption or amendment of equity compensation arrangements; and (iv) issuances of 20% or more of the shares
or voting rights (including securities convertible into, or exercisable for, equity) of a listed company via a private placement (or via sales
by directors, officers or 5% shareholders) if such equity is issued (or sold) at below the greater of the book or market value of shares. By
contrast, under the Companies Law, shareholder approval is required for, among other things: (i) transactions with directors concerning
the terms of their service or indemnification, exemption and insurance for their service (or for any other position that they may hold at a
company), for which approvals of the remuneration committee, board of directors and shareholders are all required, (ii) Extraordinary
Transactions with controlling shareholders of publicly held companies, which require the special approval described under “Item 6.
Directors, Senior Management and Employees—C. Board Practices—Approval of Related Party Transactions under Israeli Law—
Transactions with Controlling Shareholders,” and (iii) terms of office and employment or other engagement of the controlling shareholder
of the Company or such controlling shareholder’s relative, which require the special approval described under “Item 6. Directors, Senior
Management and Employees—B. Compensation” and “Item 6. Directors, Senior Management and Employees—C. Board Practices—
Approval of Related Party Transactions under Israeli Law.” In addition, under the Companies Law, a merger requires approval of the
shareholders of each of the merging companies. See also “Compensation of officers” above.
140
ITEM 16H. Mine Safety Disclosure.
Not applicable.
ITEM 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
Not applicable.
ITEM 16J. Insider Trading Policies.
Pursuant to applicable SEC transition guidance, the disclosure required by Item 16J will only be applicable to the Company from the fiscal year
ending on December 31, 2024.
ITEM 16K. Cybersecurity.
We have developed and maintain a cybersecurity risk management program, consisting of cybersecurity policies, procedures, compliance and
awareness programs to mitigate risk and to ensure compliance with security, availability and confidentiality trust principles. The cybersecurity process has
been integrated into our overall risk management system and process, and is solely internally managed. Management is responsible for identifying risks
that threaten achievement of the control activities stated in the management’s description of the services organizations systems. Management has
implemented a process for identifying relevant risks that could affect the organization’s ability to provide secure and reliable service to its users. In
addition, we maintain cybersecurity insurance. The risk assessment occurs as business needs change, and covers identification of risks that could act against
the company’s objectives as well as specific risks related to a compromise to the security of data. See “Item 3.D Risk Factors— Risks Related to
Information Technology, Intellectual Property and Data Security and Privacy—If we or our third-party service providers experience a security breach, data
loss or other compromise, including if unauthorized parties obtain access to our customers’ data, our reputation may be harmed, demand for our products
and services may be reduced, and we may incur significant liabilities.”
The oversight of cybersecurity threats is undertaken by our IT external provider, who holds over 25 years of experience, and is supported by
management. Our audit committee is responsible for cybersecurity oversight and monitoring risk. Management informs the audit and remuneration
committee of such risk at committee meetings.
As of the date of this report, we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely
to materially affect us, including our business strategy, results of operations or financial condition.
ITEM 17. Financial Statements.
We have responded to Item 18 in lieu of responding to this item.
ITEM 18. Financial Statements.
PART III
Please refer to the financial statements beginning on page F-1. The following financial statements, financial statement schedules and related notes
are filed as part of this annual report, together with the report of the independent registered public accounting firm.
Report of Independent Registered Public Accounting Firm (PCAOB ID: 1197)
Consolidated Balance Sheets
Consolidated Statements of Operations
Consolidated Statements of Comprehensive Loss
Consolidated Statements of Changes in Shareholders’ Equity
Consolidated Statements of Cash Flows
Notes to Consolidated Financial Statements
141
Page
F-1
F-3
F-4
F-5
F-6
F-7
F-8
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the shareholders and the Board of Directors of Galmed Pharmaceuticals Ltd.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Galmed Pharmaceuticals Ltd. and subsidiaries (the “Company”) as of December 31,
2023 and 2022, the related consolidated statements of operations, comprehensive loss, changes in stockholders’ equity and cash flows, for each of the three
years in the period ended December 31, 2023, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the
consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the
results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with accounting principles
generally accepted in the United States of America.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s
consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the
applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included
performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as
well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or
required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2)
involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion
on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical
audit matter or on the accounts or disclosures to which it relates.
Marketable Debt Securities Classified as Available-for-Sale– Refer to Note 3 to the consolidated financial statements
Critical Audit Matter Description
The Company invests its excess cash primarily in available-for-sale marketable debt securities. Investments in marketable debt securities classified as
available-for-sale are reported at fair value in the financial statements. The investments totaled approximately $7.5 million as of December 31, 2023.
F-1
We identified the investments in marketable debt securities classified as available-for-sale as a critical audit matter because of the magnitude of these
investments and due to the increased extent of audit effort in relation to our audit as a whole.
How the Critical Audit Matter Was Addressed in the Audit
Our audit procedures related to the Company’s investments in marketable debt securities classified as available-for-sale included the following, among
others:
● We assessed the accuracy and completeness of the quantities of marketable debt securities held by the Company as of December 31, 2023 by
comparing the Company’s investment report to the custodians’ balance confirmations.
● We obtained independent estimates of the fair value of the investments in marketable debt securities classified as available-for-sale held by the
Company as of December 31, 2023 and compared our estimates to the Company’s estimates.
● We agreed the recorded values of investments in marketable debt securities classified as available-for-sale to the fair values indicated in the custodians’
balance confirmations.
/s/ Brightman Almagor Zohar & Co.
Brightman Almagor Zohar & Co.
Certified Public Accountants
A Firm in the Deloitte Global Network
Tel Aviv, Israel
April 4, 2024
We have served as the Company’s auditor since 2013.
F-2
GALMED PHARMACEUTICALS LTD.
Consolidated Balance Sheets
U.S. Dollars in thousands, except share data and per share data
Assets
Current assets
Cash and cash equivalents
Restricted cash
Short-term deposits
Marketable debt securities
Other receivables
Total current assets
Operating lease right-of-use assets
Property and equipment, net
Investment in associate at fair value
Investment in convertible note
Total non-current assets
Total assets
Liabilities and stockholders’ equity
Current liabilities
Trade payables
Other payables
Total current liabilities
Non-current liabilities
Operating lease liabilities, net of current portion
Total non-current liabilities
Stockholders’ equity
Ordinary shares, par value NIS 0.15 per share; Authorized 20,000,000
shares; Issued and outstanding: 5,045,324 shares as of December 31,
2023; 1,692,342 shares as of December 31, 2022 (*)
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity
Note
2023
2022
As of December 31,
10
3
4
5
6
7
7
8
5
11
$
$
$
$
$
2,861 $
117
2,253
7,528
480
13,239
42
83
3,265
-
3,390
16,629 $
1,879 $
871
2,750
- $
-
209
207,076
(454)
(192,952)
13,879
16,629 $
2,016
114
-
11,769
825
14,724
223
114
-
1,500
1,837
16,561
2,560
534
3,094
44
44
70
200,138
(745)
(186,040)
13,423
16,561
(*)
All share and per share data has been retroactively adjusted to reflect the 1 for 15 reverse share split effected on May 15, 2023 for all periods prior
to the date of the reverse share split. See Note 11A4.
Accompanying notes are an integral part of the consolidated financial statements.
F-3
GALMED PHARMACEUTICALS LTD.
Consolidated Statements of Operations
U.S. Dollars in thousands, except share data and per share data
Research and development expenses
General and administrative expenses
Total operating loss
Financial loss (income), net
Net loss
Basic and diluted net loss per share (*)
Weighted-average number of shares outstanding used in
computing basic and diluted net loss per share (*)
12
13
14
2023
Year ended December 31,
2022
2021
3,569
3,923
7,492
(580)
6,912
2.50
$
$
12,995
4,656
17,651
215
17,866 $
27,220
5,661
32,881
(414)
32,467
10.65 $
19.80
$
$
2,769,539
1,676,183
1,639,843
(*)
All share and per share data has been retroactively adjusted to reflect the 1 for 15 reverse share split effected on May 15, 2023 for all periods prior
to the date of the reverse share split. See Note 11A4.
Accompanying notes are an integral part of the consolidated financial statements.
F-4
GALMED PHARMACEUTICALS LTD.
Consolidated Statements of Comprehensive Loss
U.S. Dollars in thousands, except share data and per share data
Net loss
Other comprehensive loss:
Net unrealized loss (gain) on available for sale securities
Comprehensive loss
$
$
2023
Year ended December 31,
2022
6,912
$
17,866 $
2021
(291)
6,621
$
574
18,440 $
32,467
443
32,910
Accompanying notes are an integral part of the consolidated financial statements.
F-5
GALMED PHARMACEUTICALS LTD.
Statements of Changes in Stockholders’ Equity
U.S. Dollars in thousands, except share data and per share data
Ordinary shares (**)
Additional
paid-in
Accumulated
other
comprehensive
Accumulated
Shares
Amount
capital
income (loss)
deficit
Total
Balance - January 1, 2021
1,431,983 $
58 $ 179,530 $
272 $
(135,707) $
44,153
Stock-based compensation
—
Exercise of options and vesting of restricted stock units
1,560
—
(*)
1,886
—
(*)
—
—
—
1,886
(*)
Issuance of ordinary shares in at-the-market (“ATM”)
offering, net of issuance costs of $295
103,501
5
8,142
—
—
8,147
Issuance of ordinary shares under Underwritten Public
Offering agreement, net of issuance costs of $786
147,577
Unrealized loss from marketable debt securities
Net loss
—
—
7
—
—
9,214
—
—
—
(443)
—
—
9,221
(443)
—
(32,467)
(32,467)
Balance - December 31, 2021
1,684,621 $
70 $ 198,772 $
(171) $
(168,174) $
30,497
Stock-based compensation
-
-
1,296
Issuance of ordinary shares in ATM offering net of
issuance costs of $2
Unrealized loss from marketable debt securities
Net loss
7,721
—
—
(*)
—
—
70
—
—
-
-
(574)
-
1,296
-
—
70
(574)
—
(17,866)
(17,866)
Balance - December 31, 2022
1,692,342 $
70 $ 200,138 $
(745) $
(186,040) $
13,423
Issuance of ordinary shares, pre-funded warrants, and
warrants net of issuance costs of $815 (***)
380,000
16
6,169
Exercise of Pre-funded warrants (***)
2,972,982
123
(123)
Stock-based compensation
Unrealized gain on marketable debt securities
Net loss
-
-
-
-
-
-
892
-
-
-
-
-
291
-
-
-
-
6,185
-
892
291
-
(6,912)
(6,912)
Balance - December 31, 2023
5,045,324
209
207,076
(454)
(192,952)
13,879
(*) Represents amount less than $1
(**) All share and per share data has been retroactively adjusted to reflect the 1 for 15 reverse share split effected on May 15, 2023 for all periods prior to
the date of the reverse share split. See Note 11A4.
(***) See also Note 11A.5
Accompanying notes are an integral part of the consolidated financial statements.
F-6
GALMED PHARMACEUTICALS LTD.
Consolidated Statements of Cash Flows
U.S. Dollars in thousands, except share data and per share data
Cash flow from operating activities
Net loss for the year
Adjustments required to reconcile net loss to net cash used in
operating activities:
Depreciation
Amortization of discount (premium) on marketable debt securities
Gain (loss) on sale of marketable debt securities
Finance expenses (income)
Interest income from short-term deposits
Stock-based compensation expense
Change in fair value convertible note
Changes in operating assets and liabilities:
Decrease (increase) in other receivables
Decrease in trade payables
Increase (decrease) in other payables
Net cash used in operating activities
Cash flow from investing activities
Purchase of property and equipment
Increase in restricted deposit
Investment in available for sale securities,
Investment in Convertible note (**)
Investment in Associate (**)
Proceeds from sale of available for sale securities,
Proceeds from (investment in) short-term deposits, net
Net cash provided by investing activities
Cash flow from financing activities
Issuance of ordinary shares in at-the-market offering, net of issuance
costs (***)
Issuance of ordinary shares, pre-funded warrants, and warrants net of
issuance costs (***)
Issuance of ordinary shares net of issuance costs (***)
Proceeds from exercise of options and vesting of restricted stock units
Net cash provided by financing activities
Increase (decrease) in cash, cash equivalents and restricted cash
Cash and cash equivalents and restricted cash at the beginning of
the year
Cash, cash equivalents and restricted cash at the end of the year
Supplemental disclosure of cash flow information:
Cash received from interest
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for new operating lease
liabilities, net
Conversion of convertible note into investment in associate
(*) Represents amount less than $1
$
$
$
(**) See also Note 7
(***) See also Note 11.
2023
Year ended December 31,
2022
2021
$
(6,912)
$
(17,866) $
(32,467)
31
19
13
6
(53 )
892
(265)
345
(681)
468
(6,137)
-
-
(4,133)
-
(1,500)
8,633
(2,200)
800
-
6,185
-
-
6,185
848
35
(2)
523
(36)
-
1,296
-
300
(2,311)
(440)
(18,501)
(4)
-
(2,373)
(1,500)
-
21,440
-
17,563
70
-
-
-
70
(868)
2,130
2,978
$
2,998
2,130 $
376
$
297 $
-
1,765
$
- $
-
42
121
(37)
6
7
1,886
-
(313)
(2,175)
38
(32,892)
(11)
(1)
(13,569)
-
-
21,243
3,800
11,462
8,147
9,221
(*)
17,368
(4,062)
7,060
2,998
562
199
-
The accompanying notes are an integral part of the consolidated financial statements.
F-7
GALMED PHARMACEUTICALS LTD.
Notes to Consolidated Financial Statements
Note 1 – General
Galmed Pharmaceuticals Ltd. (the “Company”) was incorporated in Israel on July 31, 2013 and commenced operations on February 2, 2014.
The Company holds three wholly-owned subsidiaries, Galmed International Ltd., which is incorporated in Malta, and Galmed Research and
Development Ltd. (“GRD”) and Galtopa Therapeutics Ltd., both of which are incorporated in Israel. In July 2023, GRD established a new wholly-
owned subsidiary incorporated under the laws of England and Wales called Galmed Therapeutics UK Limited.
The Company is a biopharmaceutical company focused on the development of Aramchol. The Company has focused almost exclusively on developing
Aramchol for the treatment of liver disease and is currently developing Aramchol for Primary Sclerosing Cholangitis, or PSC, and exploring the
feasibility of developing Aramchol for other fibro-inflammatory indications outside of liver disease. The Company is also collaborating with the
Hebrew University in the development of Amilo-5MER. The Company has an operating history limited to pre-clinical and clinical drug development.
The Company funded its research and development programs and operations to date primarily through proceeds from private placements and public
offerings. The Company currently has no products approved for marketing and has not generated any revenue from product sales to date. As of
December 31, 2023, the Company had cash and cash equivalents of $2.9 million, restricted cash of $0.1 million, short-term deposits of $2.3 million
and marketable debt securities of $7.5 million.
The Company has incurred operating losses in each year since inception. The Company’s loss attributable to holders of its ordinary shares for the years
ended December 31, 2021, 2022, and 2023 was approximately $32.4 million, $17.9 million, and $6.9 million, respectively. As of December 31, 2023,
the Company had an accumulated deficit of $193.0 million. Substantially all of its operating losses resulted from costs incurred in connection with the
Company’s development program and from general and administrative costs associated with its operations.
The Company will need to raise substantial, additional capital to fund its operations and to develop Aramchol and Amilo-5MER for, and beyond its
current development stage and any future commercialization, as well as any additional indications.
Based on the Company’s current operating plan, the Company’s management currently estimates that its cash position will support its current
operations as currently conducted for more than 12 months from the date of issuance of these financial statements.
Note 2 – Significant Accounting Policies
A. Basis of presentation
The consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S.
GAAP”).
B. Use of estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of expenses during the
reporting period. Actual results could differ from those estimates.
F-8
GALMED PHARMACEUTICALS LTD.
Notes to Consolidated Financial Statements
Note 2 – Significant Accounting Policies (Cont.)
C. Financial statement in U.S. dollars
The functional currency of the Company and its subsidiaries is the U.S dollar (the “dollar”), because the dollar is the currency of the primary
economic environment in which the Company and its subsidiaries operate, and expect to continue operating in the foreseeable future. Transactions
and balances denominated in dollars are presented in their original amounts. Non-dollar denominated transactions and balances have been re-
measured to dollars in accordance with the provisions of ASC 830, “Foreign Currency Matters.” All transaction gains and losses from re-
measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial
income or expenses, as appropriate.
D. Principles of consolidation
The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: Galmed Research and
Development Ltd., Galmed International Ltd., Galtopa Therapeutics Ltd and Galmed Therapeutics UK Limited. All intercompany balances and
transactions have been eliminated upon consolidation.
E. Cash and cash equivalents
Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with maturities of three months or less as of the
date acquired.
F. Restricted Cash
Cash that is held for a specific purpose and is not available for immediate or general business use due to external restrictions is classified in the
Company’s consolidated balance sheets as restricted cash.
G. Short-term deposits
Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term deposits
are stated at cost which approximates fair market value. Interest rates on the Company’s short-term deposits were between 5.04%-6.64% during
the year ended December 31, 2023.
H. Marketable debt securities
The Company invests most of its excess cash primarily in debt securities.
The Company accounts for its investments in investment grade debt securities in accordance with ASC 320 “Investments - Debt and Equity
Securities”. Management determines the appropriate classification of its investments in debt securities at the time of purchase and re-evaluates
such determinations at each balance sheet date.
Marketable debt securities are considered to be available for sale and are carried at fair value on the consolidated balance sheet. Unrealized gains
and losses net of tax, if any, are reported in a separate component of stockholders’ equity in accumulated other comprehensive income (“OCI”).
Gains and losses are recognized when realized, on a specific identification basis, in the Company’s consolidated statements of operations.
Following the adoption of ASC 326, current expected credit losses on the Company’s marketable grade debt securities are recorded, if expected,
through an allowance for current expected credit losses. The amount of allowance for current expected credit losses is limited to the amount that
the fair value is less than the amortized cost basis. Any remaining unrealized losses are included in accumulated other comprehensive loss in
stockholders’ equity.
If the Company intends to sell the debt security (that is, it has decided to sell the security), or more likely than not will be required to sell the
security before recovery of its amortized cost basis, any allowance for current expected credit losses is written off and the amortized cost basis
shall be written down to the debt security’s fair value at the reporting date with any incremental impairment reported in earnings. Based on
management’s assessment, the Company does not intend to sell its securities for less than amortized cost; therefore, an allowance for current
expected credit losses has not been recorded as of December 31, 2023 and 2022.
F-9
GALMED PHARMACEUTICALS LTD.
Notes to Consolidated Financial Statements
Note 2 – Significant Accounting Policies (Cont.)
H. Concentrations of credit risk (Cont.)
Financial instruments which potentially subject the Company to credit risk consist primarily of cash, cash equivalents, marketable debt securities
and short-term deposits. The Company hold these investments in highly-rated financial institutions, and, by policy, limit the amounts of credit
exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not experienced any
credit losses in such accounts and does not believe we are exposed to any significant credit risk on these funds. The Company has no off-balance
sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.
I. Property and equipment
Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the
estimated useful lives of the assets. The annual depreciation rates are as follows:
Office furniture and equipment
Computer software and electronic equipment
Leasehold improvements
%
7–16
15–33
Shorter of the remaining lease term or useful life
The Company recorded a total of approximately $0.03 million for each of the three years ended December 31, 2023.
J. Severance pay
The Company employees are included under section 14 of the Severance Compensation Act, 1963 (“Section 14”) in Israel for a portion of their
salaries. According to Section 14, these employees are entitled to monthly deposits at a rate of 8.33% of their monthly salary, contributed on their
behalf with insurance companies. Under the Severance Compensation Act, 1963, payments in accordance with Section 14 release the Company
from any future severance payments to those employees. Therefore, the Company does not recognize a liability for severance pay due to these
employees and the deposits under Section 14 are not recorded as an asset in the Company’s consolidated balance sheets. The Company’s
contributions to the defined contribution plans are charged to the consolidated statements of operations as and when the services are received from
the Company’s employees.
F-10
GALMED PHARMACEUTICALS LTD.
Notes to Consolidated Financial Statements
Note 2 – Significant Accounting Policies (Cont.)
K. Fair value of financial instruments
The estimated fair value of financial instruments was determined by the Company using available market information and valuation
methodologies. Considerable judgment is required in estimating fair values. Accordingly, the estimates may not be indicative of the amounts the
Company could realize in a current market exchange.
The following methods and assumptions were used by the Company in estimating its fair value disclosures for financial instruments:
The carrying amounts of cash and cash equivalents, short-term deposits, other accounts receivables, trade payables and other trade payables
approximate their fair value due to the short-term maturity of such instruments.
Fair value is an exit price representing the amount that would be received upon selling an asset or that would be paid to transfer a liability in an
orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on
assumptions used by market participants in pricing an asset or a liability.
A three-tier fair-value hierarchy was established as a basis for considering such assumptions and for inputs used in the valuation methodologies in
measuring fair value:
● Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets
● Level 2 - Other inputs that are directly or indirectly observable in the marketplace; and
● Level 3 - Unobservable inputs that are supported by little or no market activity
The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when
measuring fair value.
The fair value of the Company’s assets measured at fair value on a recurring basis by level within the fair value hierarchy are as follows (in
thousands):
Corporate bonds
Treasury bills
Mutual funds
Investment in associate
Total
Corporate bonds
Mutual Funds
Investment in convertible note
Total
L. Accounting for stock-based compensation
December 31, 2023
Level 1
Level 2
Level 3
$
$
$
-
-
5,150
5,150
$
1,969
409
-
2,378
-
-
-
3,265
3,265
December 31, 2022
Level 1
Level 2
Level 3
$
-
10,629
-
10,629
1,140
-
1,500
2,640
—
—
—
—
$
$
Fair
Value
1,969
409
5,150
3,265
10,793
Fair
Value
1,140
10,629
1,500
13,269
The Company accounts for share-based compensation under ASC 718, Compensation - Stock Compensation (“ASC 718”), which requires the
measurement and recognition of compensation expense based on estimated fair values for all share-based payment awards made to employees,
non-employee consultants and directors, including options and restricted share units (“RSUs”) based on the fair value of the awards on the date of
grant. ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model.
The expense for share-based compensation cost is recognized over the requisite service period of each individual grant using the straight-line
method for service-based awards. Forfeitures are accounted for as they occur.
F-11
GALMED PHARMACEUTICALS LTD.
Notes to Consolidated Financial Statements
Note 2 – Significant Accounting Policies (Cont.)
L. Accounting for stock-based compensation (Cont.)
The Company calculates the fair value of RSUs based on the fair value on the closing trading price of the underlying shares at the date of grant
and estimates the fair value of stock options granted using a Black-Scholes option-pricing model. The option-pricing model requires a number of
assumptions, the most significant of which are the expected stock-price volatility and the expected option term (the time from the grant date until
the options are exercised or expire).
The Company’s calculations of the expected volatility were based upon actual historical stock-price movements over the period, which was equal
to the expected option term. The expected option term was calculated for options granted to employees and directors in accordance with ASC-718-
10-S99, using the “simplified” method, and grants to non-employees were based on the contractual term. Historically, the Company has not paid
dividends, and has no foreseeable plans to do so. The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon bonds with an
equivalent term.
M. Revenue Recognition
The Company only has one license agreement for which it has recognized revenues to date, from a license agreement with Samil Pharm. Co., Ltd.
(“Samil” or the “Samil Agreement”). The Samil Agreement was signed on July 28, 2016, for an exclusive, royalty-bearing license for the
commercialization of Aramchol (with an option to manufacture) for the treatment of fatty liver indications including NASH in the Republic of
Korea. Additionally, following the ARREST Study, Samil has an option to extend the license to Vietnam, which, if exercised, would increase the
clinical- and regulatory-based milestone payments.
Under the terms of the Samil Agreement, the Company received an up-front payment of approximately $2.1 million in 2016 and a milestone
payment of $1.5 million from Samil in connection with the completion of its ARREST study in 2018. Samil has also agreed to pay additional
clinical and regulatory-based milestone payments, which may aggregate up to $4.5 million, as well as tiered, double-digit royalties payable on
sales (under certain limitations).
As of December 31, 2023, management evaluated the remaining clinical and regulatory milestones and determined that the variable consideration
should not be recorded as revenue for the period ended December 31, 2023. The Company will re-evaluate the transaction price in each reporting
period when events whose outcomes are resolved or other changes in circumstances occur that would indicate it is appropriate to recognize
variable consideration as revenue.
F-12
GALMED PHARMACEUTICALS LTD.
Notes to Consolidated Financial Statements
Note 2 – Significant Accounting Policies (Cont.)
N. Research and development expenses
Research and development expenses are charged to the statements of operations as incurred.
O. Income taxes
The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”), using the liability method whereby deferred
tax assets and liability account balances are determined based on the differences between financial reporting and the tax basis for assets and
liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company
provides a valuation allowance, if necessary, to reduce deferred tax assets to the amounts that are more likely-than-not to be realized. As of
December 31, 2023 and 2022, the Company recorded a full valuation allowance against its deferred tax assets.
The Company applies a more-likely-than-not recognition threshold to uncertain tax positions based on the technical merits of the income tax
positions taken. The Company does not recognize a tax benefit unless it is more likely than not that the tax position will be sustained upon
examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit that
is recorded for these positions is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate
settlement. As of December 31, 2023 and 2022, no liability for unrecognized tax benefits was recorded due to immateriality.
P. Basic and diluted net loss per share
Basic net loss per share is computed based on the weighted-average number of shares outstanding during each year. Diluted net loss per share is
computed based on the weighted-average number of shares outstanding during each year, plus the dilutive potential of the ordinary shares
considered outstanding during the year, in accordance with ASC 260-10, “Earnings Per Share.”
All outstanding stock options, RSU’s, prefunded-warrants and warrants were excluded from the calculation of the diluted loss per share for the
years ended December 31, 2023, 2022 and 2021, because all such securities have an anti-dilutive effect.
F-13
GALMED PHARMACEUTICALS LTD.
Notes to Consolidated Financial Statements
Note 2 – Significant Accounting Policies (Cont.)
Q. Segment Reporting
The chief operating decision maker for the Company is the Chief Executive Officer. The Chief Executive Officer reviews financial information
presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. Accordingly, management has
determined that the Company operates in one operating and reportable segment.
R. Leases
The Company accounts for leases in accordance with ASC 842 “Leases.” Arrangements that are determined to be operating leases at inception are
recognized as right-of-use operating lease assets and lease liabilities in the balance sheets at lease commencement. The Company recognizes a
lease liability at the present value of the lease payments to be made over the lease term, and concurrently recognizes a right-of-use asset at the
same amount of the liability, adjusted for any prepaid or accrued lease payments, plus initial direct costs incurred in respect of the lease. The
Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the
lease payments. The subsequent measurement depends on whether the lease is classified as a finance lease or an operating lease. During the
reporting periods, the Company has only operating leases. Lease terms include options to extend the lease when it is reasonably certain that the
Company will exercise that option. Lease expenses for operating leases are recognized on a straight-line basis over the lease term.
The Company has made a policy election not to capitalize leases with a term of 12 months or less,.the Company made has also made a policy
election to include lease and non-lease components as a single lease component.
Payments for variable lease costs are expensed as incurred and are not included in the operating lease right-of-use assets and lease liabilities.
In accordance with ASC 360-10, management reviews operating lease assets for impairment whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable based on estimated future undiscounted cash flows. If so indicated, an
impairment loss would be recognized for the difference between the carrying amount of the asset and its fair value.
S.
Investment in Associate at Fair Value
The Company holds an equity investment of a privately-owned company, Onkai Inc. (“Onkai”), over which it has the ability to exercise significant
influence, but not control. The investment was included as a non-current asset in the balance sheet as of December 31, 2023. The Company has
elected the fair value option allowed by ASC 825, Financial Instruments, with respect to this investment because management believes this
approach will better reflect the economics of its equity interest. Under the fair value option, the investment is remeasured at fair value (level 3) at
each reporting period with changes in fair value, if any, recorded in the statement of operations.
Management determined the fair value of its investment in Onkai based on the acquisition price of the equity investment made during 2023.
Management, together with its fair valuation expert, assessed the qualitative aspects of the equity investment and macroeconomic factors as of
December 31, 2023 and determined that there was no material change in the investment as of December 31, 2023
T. Recently adopted accounting pronouncements
From time to time, new accounting pronouncements are issued by FASB, or other standard setting bodies and adopted by the Company as of the
specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material
impact on our financial position or results of operations upon adoption.
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU
expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the chief
operating decision maker (“CODM”) and included within each reported measure of segment profit or loss, an amount and description of its
composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. The ASU also allows, in addition
to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM
in assessing segment performance and deciding how to allocate resources. The ASU is effective for the Company’s Annual Report on Form 20-F
for the fiscal year ended December 31, 2024, and subsequent interim periods, with early adoption permitted. The Company is currently evaluating
the impact of adopting this ASU on its consolidated financial statements and disclosures.
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires
disclosure of specific categories in the rate reconciliation and additional information for reconciling items that meet a quantitative threshold. The
amendment also includes other changes to improve the effectiveness of income tax disclosures, including further disaggregation of income taxes
paid for individually significant jurisdictions. This ASU is effective for annual periods beginning after December 15, 2024. Adoption of this ASU
should be applied on a prospective basis. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU on its
consolidated financial statements and disclosures.
F-14
GALMED PHARMACEUTICALS LTD.
Notes to Consolidated Financial Statements
Note 3 – Marketable debt securities
The following table summarizes the Company’s marketable debt securities as of December 31, 2023 and 2022.
As of December 31, 2023
Corporate bonds
Treasury bills
Mutual funds
Total short-term investments
Corporate bonds
Mutual funds
Total short-term investments
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Estimated
Fair Value
2,123
400
5,459
7,982
$
$
(in thousands)
6 $
9
1
16 $
(160) $
-
(310)
(470) $
1,969
409
5,150
7,528
Amortized
Cost
As of December 31, 2022
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Estimated
Fair Value
1,327
11,187
12,514
$
$
$
(in thousands)
- $
30 $
30 $
(187) $
(588) $
(775) $
1,140
10,629
11,769
$
$
$
$
The contractual maturities of the aforementioned corporate bonds and treasury bills are less than one year for the year ended December 31, 2023
and one year and a half of the aforementioned corporate bonds for the year ended December 31, 2022.
Note 4– Other Receivables
Prepaid expenses
Government institutions
Other receivables
Note 5– Leases
As of December 31,
2023
2022
(in thousands)
315 $
47
118
480 $
668
124
33
825
$
$
During the year ended December 31, 2023, the Company leased, approximately 590 square meters at a facility located in Tel-Aviv, Israel. The
lease expired on March 21, 2024. The Company does not plan to extend the lease and the Company’s employees are currently working remotely
while management is in the process of searching for a new permanent location for its principal executive offices. In addition, the Company leases
vehicles under various operating lease agreements.
During 2023, 2022 and 2021, the Company recorded lease expenses in its statement of operations in the amount of $0.2 million, $0.2 million, and
$0.2 million respectively. During 2023, the Company subleased a portion of its facility for a total of $44 thousand that were recorded in its
statement of operations.
F-15
GALMED PHARMACEUTICALS LTD.
Notes to Consolidated Financial Statements
Note 5 – Leases (Cont.)
At December 31, 2023, the Company’s operating lease right-of-use assets and current lease liabilities for operating leases totaled $42 thousand and
$41 thousand, respectively, while at December 31, 2022, the Company’s operating lease assets and lease liabilities (both the current and non-
current portion) for operating leases totaled $223 thousand and $216 thousand, respectively.
The Company uses its incremental borrowing rate as the discount rate for its leases, as the implicit rate in the lease is not readily determinable. As
of December 31, 2023, the Company’s operating leases had a weighted average remaining lease term of 0.25 years and a weighted average
borrowing rate of 2.3%.
The following table summarizes the maturities of lease liabilities as of December 31, 2023:
2024
$
Imputed interest
Present value of lease liabilities
$
42
1
41
Note 6 – Property and equipment, net
Medical equipment
Office furniture and equipment
Computer software and electronic equipment
Leasehold improvements
Less - Accumulated depreciation
Net book value
As of December 31,
2023
2022
(in thousands)
737 $
55
75
235
1,102
1,019
83 $
737
54
76
235
1,102
988
114
$
$
F-16
GALMED PHARMACEUTICALS LTD.
Notes to Consolidated Financial Statements
Note 7 – Investment in an Associate
On May 4, 2023, the Company entered into a definitive agreement (the “Agreement”) for a $1.5 million equity investment in OnKai, a US-based
technology company developing an AI-based platform to advance healthcare for underserved populations across the United States by facilitating
alignment between healthcare stakeholders.
Previously, in November, 2022 the Company invested $1.5 million in OnKai through a Simple Agreement for Future Equity (“SAFE”) which
converted at a 15% discount into series seed preferred shares upon closing of the Investment Round (as defined below). The Company recorded in
its statement of operations a change in the fair value of the convertible note (the SAFE) which totaled $0.3 million for the year ended December
31, 2023.
The Company’s investment in OnKai was part of an approximately $60. million investment round (the “Investment Round”) with other investors
that was led by the Company of which SAFEs of approximately $3.8 were converted into preferred shares of Onkai upon the consummation of the
Investment Round.. On June 19, 2023, the Investment Round closed. Following the closing of the Investment Round, the Company holds
1,223,535 preferred shares which comprised approximately 24% of the outstanding share capital of OnKai on an as-converted basis as of
December 31, 2023. The Company’s Chief Executive Officer and director, Allen Baharaff, serves as one of three board member of OnKai.
Under the terms of the Agreement, during the three-year period following the closing of the Investment Round the Company will have the right to
merge with OnKai subject to the approval of the boards of directors of each of the Company and OnKai. The Company was granted certain
customary pre-emptive rights as well as registration rights, first refusal rights, co-sale, a board seat, and certain customary protective provisions.
In connection with the Agreement, the Company’s wholly-owned subsidiary, (“GRD”), entered into a services agreement (the “Services
Agreement”) with OnKai. The Services Agreement provides that GRD will on a non-exclusive basis (i) provide support services to OnKai relating
to finance, business development, strategic planning, execution and others; and (ii) lend its experience to OnKai in building a strategy and for the
development of treatments for the underserved and that OnKai shall on a non-exclusive basis (i) take part in plan preparation to serve GRD’s
vision of developing drugs for the underserved population and (ii) when relevant, design a process on the clinical trial dashboard that could
potentially serve GDR’s future trial.
In connection with the above mentioned service agreement, the Company recorded management fee income of $12 thousand in general and
administrative expenses in its statement of operations for the year ended December 31, 2023.
Attached is a summarized un-audited financial information of OnkaI:
Balance sheet as of December 31, 2023
Current assets
Non-current assets
Current liabilities
Non-current liabilities
Equity
December 31,
$
2023
(in thousands)
1,384
5
160
628
601
Statement of operations for the period from June 19, 2023 to December 31, 2023:
Total operating loss
Financial income, net
Income tax
Net Loss
F-17
(in thousands)
$
$
1,551
23
16
1,544
GALMED PHARMACEUTICALS LTD.
Notes to Consolidated Financial Statements
Note 8 – Other Payables
Employees and related
Short-term lease obligation
Other Payables
Accrued Vacation
Note 9 – Related Parties
As of December 31,
2023
2022
(in thousands)
571 $
41
-
259
871 $
160
171
7
196
534
$
$
1. As of December 31, 2023, and 2022, the Company had an accrual in the amount of approximately $0.6 million and $0.2 million, respectively,
pursuant to an employment agreements with its officers and directors’ fee.
2. As of December 31, 2023, the Company had a receivable balance of $4 thousand, pursuant to a service agreement with OnKai.
3. During 2023, 2022 and 2021, the Company recorded salary expenses, stock-based compensation expenses and directors’ fee to its related
parties in the amount of $2.8 million, $2.8 million and $4.1 million respectively.
4. During 2023, the Company recorded income from management fees pursuant to a service agreement with OnKai.
Note 10 – Commitments and Contingencies
1. As of December 31, 2023, the Company recorded a pledge on its short-term deposit in favor of its bank in the amount of approximately $117
thousand to secure the Company’s commitments to the bank, including a bank guarantee in favor Mintz K. Construction Company, the lessor
of the Company’s headquarters, totaling $66 thousands as of December 31, 2023.
2. The Company enters into contracts in the ordinary course of business with contract research organizations for clinical trials and clinical
supply manufacturing and with vendors for non-clinical research studies and other services and products for operating purposes, which
generally provide for termination upon 30 to 90 days’ notice or less, and therefore are cancelable contracts and not considered as commitment
or purchase obligations.
3. For information regarding the Company’s leases commitments, see note 5.
4. On June 28, 2021, the Company entered into a license agreement with Yissum Research Development Company of the Hebrew University of
Jerusalem (“Yissum”) pursuant to which Yissum granted to the Company a worldwide, exclusive and irrevocable license to develop and
commercialize Amilo-5Mer. Under the license agreement, the Company is responsible for carrying out the development and
commercialization of Amilo-5Mer and the prosecution and maintenance of the licensed patents under the license agreement. In consideration
for the grant of the license, the Company paid Yissum an upfront license fee of $100 thousand which was included in research and
development expenses for the period ended December 31, 2021. In addition, the Company may be required to make payments of up to $950
thousand upon meeting certain regulatory milestones and may be entitled to pay single digit royalties on any future net sales and a share of
any sublicense fees.
F-18
GALMED PHARMACEUTICALS LTD.
Notes to Consolidated Financial Statements
Note 11 – Stockholders’ equity
A. Ordinary shares
1. Ordinary shares confer upon the holders the right to receive notice to participate and vote in general meetings of the Company and the right to
receive dividends, if declared.
2. During February 2021, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co.
(the “Underwriter”) in connection with an underwritten public offering (the “Underwritten Public Offering”) of 147,577 ordinary shares (the
“Firm Shares”) of the Company (the “Ordinary Shares”). The Underwriter agreed to purchase the Firm Shares from the Company at a price of
$64.81 per share. The net proceeds to the Company were approximately $9.2 million.
3. On March 26, 2021, the Company entered into a Sales Agreement with Cantor Fitzgerald & Co. and Canaccord Genuity LLC, as sales agents,
pursuant to which the Company may offer and sell ordinary shares “at the market” having an aggregate offering price of up to $50.0 million
from time to time through the sales agents. As of December 31, 2023, the Company sold 7,721 ordinary shares under its ATM program for
total net proceeds of approximately $0.1 million.
4. On May 15, 2023, the Company effected a reverse share split of the Company’s ordinary shares at the ratio of 1-for-15, such that each fifteen
(15) ordinary shares, par value NIS 0.01 per share, were consolidated into one (1) ordinary share, par value NIS 0.15. As a result, all share
and per share amounts prior to the reverse share split were adjusted retroactively for all periods presented in these consolidated financial
statements.
5. On July 18, 2023, the Company sold to investors in a public offering (i) 380,000 ordinary shares, (ii) 5,220,000 pre-funded warrants to
purchase 5,220,000 ordinary shares (the “Pre-Funded Warrants”), and (iii) 5,600,000 warrants to purchase 5,600,000 ordinary shares (the
“Investor Warrants”), at a purchase price of $1.25 per ordinary share and accompanying Investor Warrant and $1.249 per Pre-Funded Warrant
and accompanying Investor Warrant.
The Pre-Funded Warrants are immediately exercisable at an exercise price of $0.001 per ordinary share and will not expire until exercised in
full. The Investor Warrants have an exercise price of $1.25 per ordinary share, are immediately exercisable, and may be exercised until July
18, 2028. The net proceeds to the Company were approximately $6.2 million.
6. As of December 31, 2023, a total of 2,975,000 Pre-Funded Warrants were exercised into 2,972,982 ordinary shares, out of which a total of
1,090,000 Pre-funded warrants were exercised on a cashless basis (as permitted under the terms of the Pre-Funded Warrants) into 1,087,982
ordinary shares. Subsequent to the balance sheet date, as April 3, 2024 a total of 965,000 Pre-Funded Warrants were exercised into 964,330
ordinary shares, out of which, a total of 240,000 Pre-funded Warrants were exercised on a cashless basis (as permitted under the terms of the
Pre-Funded Warrants)into 239,330 ordinary shares.
F-19
GALMED PHARMACEUTICALS LTD.
Notes to Consolidated Financial Statements
Note 11 – Stockholders’ equity (Cont.)
B. Stock-based compensation
1. The Company has an equity-based incentive plan, the 2013 Incentive Share Option Plan (the “2013 Plan”). As of December 31, 2023, based
on the latest amendment to the plan from August 7, 2023, a total of 2,000,000 ordinary shares were reserved for issuance under the 2013 Plan,
of which a total of 367,026 ordinary shares remain reserved, but unallocated for future equity awards. The 2013 Plan, which was adopted by
the Board on September 2, 2013, and approved by the Company’s shareholders on December 30, 2013 (as was amended by the Board and the
Company’s shareholders on March 30, 2015, May 11, 2015, August 30, 2018 and August 7, 2023 respectively), provides for the grant of
options to purchase the ordinary shares and the issuance of RSUs to the Company’s officers, directors, employees, service providers and
consultants. The 2013 Plan provides for such equity-based compensation under various and different tax regimes.
2. During February 2021, certain office holders exercised options into 1,249 ordinary shares of the Company for a total amount of less than $1
thousand.
3.
4.
5.
6.
In March 2021, the Company granted options to purchase 3,000 ordinary shares of the Company to an employee and a consultant. The options
are exercisable at $62.4 per share, have a 10-year term and vest over a period of four years. The aggregate grant date fair value of such
options was approximately $0.1 million.
In July, 2021, the Company granted options to purchase 6,667 ordinary shares of the Company to its non-management directors subject to
shareholders’ approval (which was obtained in August 2021). The options are exercisable at $46.5 per share, have a 10-year term and vest
over a period of three years. The aggregate grant date fair value of such options was approximately $0.2 million.
In August, 2021, the Company granted options to purchase 2,500 ordinary shares of the Company to certain service providers. The options are
exercisable at $42.45 per share, have a 10-year term and vest over a period of three years. The aggregate grant date fair value of such options
was approximately $0.01 million.
In February 2022, the Company granted options to purchase 2,667 ordinary shares of the Company to one of its officers. The options are
exercisable at $24.15 per share, have a 10-year term and vest over a period of four years.
7. On March 23, 2023, the Company received a ruling from the Israel Tax Authority (“ITA”) confirming the repricing of certain stock options.
This repricing was accounted for as a modification of a share-based payment award. The incremental compensation expense recognized as a
result of the modification during the year ended December 31, 2023 was approximately $0.1 million.
8.
9.
In August 2023, the Company granted 1,315,000 (RSUs) and 75,000 options to purchase 75,000 ordinary shares of the Company to its
officers and directors. The options are exercisable at $1.05 per share and have a 10-year term. The options and RSUs vest over a period of
three years. The aggregate grant date fair value of such RSUs and options was approximately $0.9 million.
In September 2023, the Company extended the exercise period of 21,654 options with an exercise price of 0.15 NIS previously granted to the
Company’s Chief Executive Officer (and director), by approximately five years to December 31, 2028. the exercise period represented a
modification in accordance with ASC 718. The Incremental compensation expense on the modification date was less than $1 thousand.
F-20
GALMED PHARMACEUTICALS LTD.
Notes to Consolidated Financial Statements
Note 11 – Stockholders’ equity (Cont.)
B. Stock-based compensation (Cont.)
7. A summary of the status of the Company’s outstanding options as of December 31, 2023 and 2022 and changes during the years then ended
are presented below:
Options outstanding at beginning of year
Granted
Forfeited
Outstanding at end of year
Options exercisable at year end
2023
2022
Number of
share
options
177,095 $
75,000 $
(11,351) $
240,744 $
159,229 $
$
Weighted
average
exercise
price
Number of
share
options
Weighted
average
exercise
price
54.51
1.05
36.8
38.32
55.88
189,390 $
2,666 $
(14,961) $
177,095
152,469
54.8
5.7
49.61
54.51
56.9
The following assumptions were used for the fiscal year 2023, 2022 and 2021 grants:
-
-
-
-
dividend yield of 0.00% for all periods.
risk-free interest rate between 0.80% and 1.34% for the fiscal year 2021, 1.94% for the fiscal year 2022 and 4.16% for the fiscal year 2023.
an expected life between 5 and 6.25 years for all periods.
and a volatility rate ranging between 64% and 81% for the fiscal year 2021, 65% for the fiscal year 2022 and 108% for the fiscal year 2023.
As of December 31, 2023, and 2022, the weighted-average remaining contractual term of the outstanding options, excluding the 2,575 options
granted in 2002 that have no expiration date, is 6.24 and 4.84 years, respectively.
The weighted average grant date fair value of the options granted during the years ended December 31, 2023, 2022 and 2021 is $0.63, $0.68, and
$2.19 respectively.
As of December 31, 2023, a total of 21,654 outstanding and exercisable options are “in the money” with aggregate intrinsic value of $0.001
million; while as of December 31, 2022 a total of 21,654 outstanding and exercisable options were “in the money” with aggregate intrinsic value
of $0.2 million.
The unrecognized compensation expense calculated under the fair-value method for stock options expected to vest as of December 31, 2023, 2022
and 2021 is approximately $0.3 million, $0.9 million, and $3.4 million, respectively, and is expected to be recognized over a weighted-average
period of 0.3 years, 1.41 years and 1.75 years, respectively.
For the years ended 2023, 2022 and 2021, the Company recorded a total of $0.8 million, $1.3 million, and $1.9 milliion of stock-based
compensation expenses, in connection with the above-mentioned options.
F-21
GALMED PHARMACEUTICALS LTD.
Notes to Consolidated Financial Statements
Note 11 – Stockholders’ equity (Cont.)
B. Stock-based compensation (Cont.)
On August 7, 2023, the Company issued a total of 1,315,000 RSU”s. Upon vesting, each RSU will settle by the issuance of one ordinary share.
The RSUs vest over three years. As of December 31, 2023, none of the RSU’s were vested. with respect to the above-mentioned RSU’s, the
Company recorded stock-based compensation expenses in the amount of $0.1 million for the year ended December 31, 2023.
The weighted average grant date fair value of the RSU’s granted during the year ended December 31, 2023 was $0.63.
The unrecognized compensation expense calculated for RSU’s expected to vest as of December 31, 2023, is approximately $0.7 million and is
expected to be recognized over a weighted-average period of 2.5 years.
Note 12 – Research and Development Expenses
Chemistry and formulation studies
Salaries
Stock-based compensation
Research and preclinical studies
Clinical studies
Regulatory and other expenses
Note 13 – General and Administrative Expenses
Stock-based compensation
Professional fees
Salaries and benefits
Rent and office-maintenance fees
Investor relations and business development expenses
Insurance and other expenses
2023
Year ended December 31,
2022
(in thousands)
2021
573 $
676
243
460
616
1,001
3,569 $
2,448 $
1,692
383
1,346
6,532
594
12,995 $
2023
Year ended December 31,
2022
(in thousands)
2021
649 $
908
1,428
261
14
663
3,923 $
913 $
1,084
1,164
401
59
1,035
4,656 $
5,009
2,963
660
2,163
14,937
1,488
27,220
1,225
897
1,617
530
242
1,150
5,661
$
$
$
$
F-22
GALMED PHARMACEUTICALS LTD.
Notes to Consolidated Financial Statements
Note 14 – Financial income, net
Bank fees
Interest income
Loss (gain) from sale of marketable debt securities
Change in fair value of convertible note
Foreign currency (gains) losses
Note 15 – Income Taxes
A. General
Year ended December 31,
2023
2022
(in thousands)
2021
11 $
(375)
13
(265)
36
(580) $
22 $
(297)
526
-
(36)
215 $
43
(562)
80
-
25
(414)
$
$
The Company is assessed for tax purposes on an unconsolidated basis. Each of the Company’s subsidiaries is subject to the tax rules prevailing in
its country of incorporation.
B. Corporate Taxation
Israeli Companies:
The Israeli corporate income tax rate is 23% for the years 2021, 2022 and 2023.
On February 7, 2018, the Israeli Tax Authority issued a ruling granting the Company’s Israeli subsidiary, Galmed Research and Development Ltd,
a “Preferred Technological Enterprise” status as defined under the Encouragement of Capital Investment Law -1959 (the “Approval”). The grant
of the status means that the Company’s Israeli subsidiary will be subject to a reduced Israeli corporate tax rate that will range between 6%-12% on
any future taxable “technological income” which includes sales, licenses and royalties from its IP protected products. The tax ruling applies for
five years until the end of 2022 and may be extended for further periods subject to meeting certain requirements.
Maltese subsidiary:
Taxable income of Maltese companies was subject to tax at the rate of 35% for the years 2021, 2022, and 2023.
C. Net Operating Loss Carry forward
As of December 31, 2023, the Company had approximately $165.1 million net-operating-loss carry forwards, consisting of approximately $11.7
million of Maltese net-operating-loss carry forwards and approximately $153.4 million Israeli net-operating-loss carry forward. Additionally, the
Company had approximately $3.1 million of capital loss carry forward from the sale of marketable debt securities in Israel. The Maltese and the
Israeli loss carry forwards have no expiration date.
F-23
GALMED PHARMACEUTICALS LTD.
Notes to Consolidated Financial Statements
Note 15 – Income Taxes (Cont.)
D. Deferred income taxes
As of December 31, 2023, the significant components of the Company’s deferred tax assets are net operating loss carryforward in the amount of
$165.1 million and research and development expenses in the amount of $6.4 million. The Company has evaluated the positive and negative
evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company’s history of cumulative net losses
incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has
concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation
allowance has been established against the deferred tax assets as of December 31, 2023. Management reevaluates the positive and negative
evidence at each reporting period.
E. Tax assessments
The Israeli subsidiaries received final tax assessments through the year ended December 31, 2019.
F. Effective tax expense
A reconciliation of the Company’s effective tax expense to the Company’s theoretical statutory tax benefit is as follows:
2023
Year ended December 31,
2022
(in thousands)
2021
Loss before taxes on income, as reported in the consolidated
statements of operations
$
6,912
$
17,866
$
32,467
Statutory tax rate
Theoretical tax benefit
Losses and other items for which a valuation allowance was
provided or benefit from loss carry forwards
23%
1,590
12%
2,144
(1,590)
(2,144)
Actual tax expense
$
—
$
—
$
12%
3,896
(3,896)
—
Note 16 – Subsequent event
Subsequent to the balance sheet date, as of April 3, 2024, a total of 965,000 Pre-Funded Warrants were exercised into 964,330 ordinary shares, out
of which, a total of 240,000 Pre-funded Warrants were exercised on a cashless basis (as permitted under the terms of the Pre-Funded Warrants)
into 239,330 ordinary shares.
F-24
ITEM 19. Exhibits.
Exhibit No.
Description
1.1
2.1
4.1
4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9
Amended and Restated Articles of Association of Galmed Pharmaceuticals Ltd. (19)
Description of Securities Registered under Section 12 of the Exchange Act*
Form of Indemnification Agreement (1)
Galmed Pharmaceuticals Ltd. 2013 Incentive Share Option Plan as anemded on October 4, 2023 (4)
Registration and Information Rights Agreement, dated December 2013, by and among Galmed Pharmaceuticals Ltd., Shirat HaChaim Ltd.,
David & Debora Goldfarb, Medgal S.A. and G. Yarom Medical Research Ltd. (2)
Personal Employment Agreement, dated December 23, 2013, by and between Galmed Medical Research Ltd. and Allen Baharaff (2)
Amendment No.1 to Employment Agreement by and between Galmed Research and Development Ltd. and Allen Baharaff (10)
Amendment No.2 to Employment Agreement by and between Galmed Research and Development Ltd. and Allen Baharaff(12)
Amendment No.3 to Employment Agreement by and between Galmed Research and Development Ltd. And Allen Baharaff(13)
Compensation Policy of Galmed Pharmaceuticals Ltd.(5)
Lease, dated March 22, 2015, between Galmed Research and Development Ltd. and Mintz K. Construction Company Ltd.(8)
4.10
Addendum to Lease, dated February 27, 2017, between Galmed Research and Development Ltd. and Mintz K. Construction Company Ltd.
(8)
4.11
Addendum to Lease, dated August 8, 2018, between Galmed Research and Development Ltd. and Mintz K. Construction Company Ltd.(11)
4.12
Addendum to Lease, dated March 11, 2021, between Galmed Research and Development Ltd. and Mintz K. Construction Company Ltd.(12)
4.13
Sales Agreement, dated March 26, 2021, among Galmed Pharmaceuticals Ltd., Cantor Fitzgerald & Co. and Canaccord Genuity LLC.(9)
4.14
Form of Securities Purchase Agreement (14)
4.15
Form of Placement Agency Agreement (15)
142
4.16
Form of Pre-Funded Warrant (16)
4.17
Form of Warrant (17)
4.18
Form of Placement Agent Warrant (18)
8.1
List of subsidiaries of Galmed Pharmaceuticals Ltd.*
11.1
Code of Business Conduct and Ethics of Galmed Pharmaceuticals Ltd.(7)
12.1
12.2
13.1
Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002*
Certification of Chief Accounting Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of
the Sarbanes-Oxley Act of 2002*
Certification of Chief Executive Officer and Chief Accounting Officer pursuant to Exchange Act Rules 13a-14(b) and 15d-14(b) and 18
U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
15.1
Consent of Brightman Almagor Zohar & Co.*
97.1
Executive Officer Clawback Policy*
101.INS Inline XBRL Instance Document*
101.SCH Inline XBRL Taxonomy Extension Schema Document*
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document*
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document*
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
(1)
Incorporated herein by reference to Amendment No. 1 to the Registration Statement on Form F-1, filed with the SEC on February 28, 2014.
(2)
Incorporated herein by reference to the Registration Statement on Form F-1, filed with the SEC on February 6, 2014.
(3)
Incorporated herein by reference to the Company’s Report on Form 6-K filed with the SEC on June 1, 2016.
(4)
Incorporated herein by reference to Exhibit A to the Company’s Report on Form 6-K filed with the SEC on April 2, 2015.
(5)
Incorporated herein by reference to Exhibit 10.8 to the Company’s Registration Statement on Form F-1 filed with the SEC on June 16, 2023.
(6)
Incorporated herein by reference to the Company’s Annual Report on Form 20-F filed with the SEC on March 31, 2015.
143
(7)
Incorporated herein by reference to the Company’s Annual Report on Form 20-F filed with the SEC on March 22, 2016.
(8)
Incorporated herein by reference to the Company’s Annual Report on Form 20-F filed with the SEC on March 23, 2017.
(9)
Incorporated herein by reference to Exhibit 1.1 to the Company’s Report on Form 6-K filed with the SEC on March 26, 2021.
(10) Incorporated herein by reference to the Company’s Annual Report on Form 20-F filed with the SEC on March 13, 2018.
(11) Incorporated herein by reference to the Company’s Annual Report on Form 20-F filed with the SEC on March 13, 2019.
(12) Incorporated herein by reference to the Company’s Annual Report on Form 20-F filed with the SEC on March 18, 2021.
(13) Incorporated herein by reference to the Company’s Annual Report on Form 20-F filed with the SEC on May 2, 2022.
(14) Incorporated herein by reference to Exhibit 10.1 to the Company’s Report on Form 6-K filed with the SEC on July 18, 2023.
(15) Incorporated herein by reference to Exhibit 10.2 to the Company’s Report on Form 6-K filed with the SEC on July 18, 2023.
(16) Incorporated herein by reference to Exhibit 10.3 to the Company’s Report on Form 6-K filed with the SEC on July 18, 2023.
(17) Incorporated herein by reference to Exhibit 10.4 to the Company’s Report on Form 6-K filed with the SEC on July 18, 2023.
(18) Incorporated herein by reference to Exhibit 10.5 to the Company’s Report on Form 6-K filed with the SEC on July 18, 2023.
(19) Incorporated herein by reference to Exhibit 3.1 to the Company’s Registration Statement on Form F-1 filed with the SEC on June 16, 2023.
*Filed herewith.
144
The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the
undersigned to sign this annual report on its behalf.
SIGNATURES
GALMED PHARMACEUTICALS LTD.
By: /s/ Allen Baharaff
Allen Baharaff
President, Chief Executive Officer and Chairman
Date: April 4, 2024
145
DESCRIPTION OF SECURITIES
Exhibit 2.1
The descriptions of the securities contained herein summarize the material terms and provisions of the ordinary shares of Galmed Pharmaceuticals
Ltd. (the “Company”, “we”, “our” or “us”), registered under Section 12 of the Securities Exchange Act of 1934.
General
The registered share capital of the Company is NIS 3,000,000 divided into 20,000,000 ordinary shares, NIS 0.15 par value per share.
The Nasdaq Capital Market
Our ordinary shares are listed on the Nasdaq Capital Market under the symbol “GLMD”.
Memorandum and Articles of Association
Our registration number is 51-495351-2. At the 2014 annual general meeting of shareholders, our shareholders adopted our Articles of Association
(the “Original Articles”), which became effective on the consummation of our initial public offering in the United States in March 2014. At the 2023
annual general meeting of shareholders, our shareholders approved a proposal to grant our Board of Directors (the “Board”) discretionary authority to
effect a reverse share split of our ordinary shares in the range of up to 1:15 within 12 months of the 2023 annual general meeting of shareholders, and to
amend the Original Articles accordingly. On May 15, 2023, following the approval of our Board, we effected a 1-for-15 reverse share split of our
authorized ordinary shares, including our issued and outstanding ordinary shares, and the par value of each share was accordingly increased from NIS 0.01
per share to NIS 0.15 per share and adopted our Amended and Restated Articles of Association (the “Articles”). Under Section 2 of our Articles, the
purpose of the Company is to engage in any lawful activity.
Election of Directors
Our Board consists of three classes of directors, with one class being elected each year by shareholders at the Company’s annual general meeting
for a term of approximately three years. In accordance with our Articles, directors so elected cannot be removed from office by the shareholders until the
expiration of their term of office. Ordinary shares do not have cumulative voting rights. As a result, the holders of ordinary shares that represent a simple
majority of the voting power represented at a shareholders’ meeting and voting at the meeting have the power to elect all of the directors put forward for
election.
Under our Articles, a director shall vacate his or her office if that director dies; is declared bankrupt; is declared to be legally incompetent; resigns
such office by notice in writing given to the Company; is not re-elected by the shareholders upon expiration of his or her term at the relevant annual general
meeting of shareholders; or otherwise as provided in the Israeli Companies Law, 5759-1999 (the “Companies Law”).
Our Articles provide that a director may, by written notice to the Company, appoint another person to serve as an alternate director provided that
such appointment is approved by a majority of the directors then in office, and that such appointing director may remove such alternate director. Any
alternate director shall be entitled to notice of meetings of the Board and of relevant committees and to attend and vote accordingly, except that the alternate
has no standing at any meeting at which the appointing director is present or at which the appointing director is not entitled to participate as provided in the
Companies Law. A person who is not qualified to be appointed as a director, or a person who already serves as a director or an alternate director, may not
be appointed as an alternate director.
Unless the appointing director limits the time or scope of the appointment, the appointment is effective for all purposes until the earlier of (i) the
appointing director ceasing to be a director; (ii) the appointing director terminating the appointment; or (iii) the occurrence, with respect to the alternate, of
any of the circumstances under which a director shall vacate his or her office. The appointment of an alternate director does not in itself diminish the
responsibility of the appointing director as a director. An alternate director is solely responsible for his or her actions and omissions and is not deemed an
agent of the appointing director. At present, there are no effective appointments of alternate directors for our Board.
Borrowing Powers
Our Board may from time to time, and at its reasonable discretion, borrow or secure the payment of any sum or sums of money for reasonable
Company purposes. The directors may raise or secure the repayment of such sum or sums in such manner, at such times and upon such terms and
conditions in all respects as they see fit and, in particular, by issuing bonds, perpetual or redeemable debentures, debenture stock or any mortgages, charges
or other securities on the undertaking of the whole or any part of the property of the Company, both present and future, including current uncalled capital
and called but unpaid capital.
Fiduciary Duties of Directors and Executive Officers
- 2 -
The Companies Law codifies the fiduciary duties that Office Holders (as defined in the Companies Law) owe to a company.
An Office Holder’s fiduciary duties consist of a duty of care and a duty of loyalty. The duty of care requires an Office Holder to act with the level
of care with which a reasonable Office Holder in the same position would have acted under the same circumstances. The duty of loyalty requires that an
Office Holder act in good faith and in the best interests of a company. The duty of care includes a duty to use reasonable means to obtain:
● information on the advisability of a given action brought for his or her approval or performed by virtue of his or her position; and
● all other important information pertaining to these actions.
The duty of loyalty requires an Office Holder to act in good faith and for the benefit of a company, and includes a duty to:
● refrain from any conflict of interest between the performance of his or her duties to the company and his or her other duties or personal affairs;
● refrain from any activity that is competitive with the company;
● refrain from exploiting any business opportunity of the company to receive a personal gain for himself or herself or others; and
● disclose to the company any information or documents relating to the company’s affairs which the Office Holder received as a result of his or her
position as an Office Holder.
Disclosure of Personal Interests of an Office Holder
The Companies Law requires that an Office Holder promptly disclose to the board of directors any personal interest that he or she may have
concerning any existing or proposed transaction with a company, as well as any substantial information or document with respect thereof. An interested
Office Holder’s disclosure must be made promptly and, in any event, no later than the first meeting of the board of directors at which the transaction is
considered.
Under the Companies Law, a “personal interest” includes an interest of any person in an action or transaction of a company, including a personal
interest of one’s relative or of a corporate body in which such person or a relative of such person is a 5% or greater shareholder, director or general manager
or in which he or she has the right to appoint at least one director or the general manager, but excluding a personal interest stemming from one’s ownership
of shares in a company. A personal interest furthermore includes the personal interest of a person for whom the Office Holder holds a voting proxy or the
interest of the Office Holder with respect to his or her vote on behalf of the shareholder for whom he or she holds a proxy, even if such shareholder itself
has no personal interest in the approval of the matter. An Office Holder is not, however, obliged to disclose a personal interest if it derives solely from the
personal interest of a relative of such Office Holder in a transaction that is not considered an extraordinary transaction.
Under the Companies Law, an extraordinary transaction is defined as any of the following:
● a transaction other than in the ordinary course of business;
● a transaction that is not on market terms; or
● a transaction that may have a material impact on a company’s profitability, assets or liabilities.
Approval Procedure
- 3 -
If an Office Holder has a personal interest in a transaction, approval by the board of directors is required for the transaction, unless the articles of
association of a company provide for a different method of approval. Our Articles do not provide for any such different method of approval. Further, so
long as an Office Holder has disclosed his or her personal interest in a transaction, the board of directors may approve an action by the Office Holder that
would otherwise be deemed a breach of the duty of loyalty. However, a company may not approve a transaction or action that is adverse to such company’s
interest or that is not performed by the Office Holder in good faith. Approval first by a company’s audit committee and subsequently by the board of
directors is required for an extraordinary transaction in which an Office Holder has a personal interest. Arrangements regarding the Office Holders’ terms
of office and employment (which includes compensation, indemnification or insurance) generally require the approval of the remuneration committee,
board of directors and, in certain circumstances, the shareholders, in that order, and must generally be consistent with the Company’s Compensation Policy.
Generally, a person who has a personal interest in a matter which is considered at a meeting of the board of directors or the audit committee may
not be present at such a meeting or vote on that matter unless a majority of the directors or members of the audit committee have a personal interest in the
matter, or unless the chairman of the audit committee or board of directors (as applicable) determines that he or she should be present in order to present the
transaction that is subject to approval. Generally, if a majority of the members of the audit committee and the board of directors (as applicable) has a
personal interest in the approval of a transaction, then all directors may participate in discussions of the audit committee and/or the board of directors on
such transaction and the voting on approval thereof, but shareholder approval is also required for such transaction.
Transactions with Controlling Shareholders
Pursuant to Israeli law, the disclosure requirements regarding personal interests that apply to directors and executive officers also apply to a
controlling shareholder of a public company. In the context of a transaction involving a controlling shareholder or an officer who is a controlling
shareholder of a company, a controlling shareholder also includes any shareholder who holds 25% or more of the voting rights if no other shareholder holds
more than 50% of the voting rights. Two or more shareholders with a personal interest in the approval of the same transaction are deemed to be a single
shareholder and may be deemed a controlling shareholder for the purpose of approving such transaction.
Extraordinary transactions, including private placement transactions, with a controlling shareholder or in which a controlling shareholder has a
personal interest, and engagements with a controlling shareholder or his or her relative, directly or indirectly, including through a corporation under his or
her control, regarding the company’s receipt of services from the controlling shareholder, and if such controlling shareholder is also an office holder or an
employee of the company, regarding his or her terms of service or employment, require the approval of the audit committee or remuneration committee, the
board of directors and the shareholders of a company by a Special Majority, in that order.
Arrangements regarding the terms of office and employment of a controlling shareholder who is an Office Holder, and the terms of employment of
a controlling shareholder who is an employee of a company, require the approval of the remuneration committee, board of directors and the shareholders by
a Special Majority, in that order, with respect to Office Holders’ compensation.
To the extent that any such transaction with a controlling shareholder is for a period extending beyond three years, approval is required once every
three years, unless, with respect to extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest,
the audit committee determines that the duration of the transaction is reasonable given the circumstances related thereto.
Dividends and Dividend Policy
Dividends may be distributed only out of profits available for dividends as determined by the Companies Law, provided that there is no reasonable
concern that the distribution will prevent the Company from being able to meet its existing and anticipated obligations when they become due. Under the
Companies Law, the distribution amount is further limited to the greater of retained earnings or earnings generated over the two most recent years legally
available for distribution. In the event that we do not have retained earnings or earnings generated over the two most recent years legally available for
distribution, we may seek the approval of the court in order to distribute a dividend. The court may approve our request if it is convinced that there is no
reasonable concern that the payment of a dividend will prevent us from satisfying our existing and foreseeable obligations as they become due.
- 4 -
Generally, under the Companies Law, the decision to distribute dividends and the amount to be distributed is made by a company’s board of
directors. The Articles provide that the Board may from time to time declare, and cause the Company to pay, such dividends as may appear to it to be
justified by the profits of the Company and that the Board has the authority to determine the time for payment of such dividends and the record date for
determining the shareholders entitled to receive such dividends, provided the date is not before the date of the resolution to distribute the dividend.
Declaration of dividends does not require shareholder approval.
Pursuant to our Articles, subject to the rights of holders of shares with limited or preferred rights, ordinary shares shall confer upon the holders
thereof equal rights to receive dividends and to participate in the distribution of the assets of the Company upon its winding-up, in proportion to the amount
paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being
paid or such distribution is being made, without regard to any premium paid in excess of the nominal value, if any.
We have never declared or paid any cash dividends on our ordinary shares and do not anticipate paying any cash dividends in the foreseeable
future. Payment of cash dividends, if any, in the future will be at the discretion of our Board and will depend on then-existing conditions, including our
financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our Board may deem relevant.
Payment of dividends may also be subject to Israeli withholding taxes.
Transfer of Shares
Ordinary shares which have been fully paid-up are transferable by submission of a proper instrument of transfer to the Company or its transfer
agent together with the certificate of the shares to be transferred and such other evidence, if any, as the directors may require to prove the rights of the
intending transferor in the transferred shares.
Our ordinary shares that are fully paid for are issued in registered form and may be freely transferred under our Articles, unless the transfer is
restricted or prohibited by applicable law or the rules of a stock exchange on which the shares are traded. The ownership or voting of our ordinary shares by
non-residents of Israel is not restricted in any way by our Articles or the laws of the State of Israel, except for ownership by nationals of some countries that
are, or have been, declared as enemies of Israel.
Shareholder Meetings
Our Articles provide that an annual general meeting must be held at least once in every calendar year, not later than 15 months after the last
preceding annual general meeting, at such time and place as may be determined by the Board. The Board may, in its discretion, convene additional
shareholder meetings and, pursuant to the Companies Law, must convene a meeting upon the demand of two directors or one quarter of the directors then
in office or upon the demand of the holder or holders of 10% of the Company’s issued share capital and 1% of its voting rights or upon the demand of the
holder or holders of 10% of its voting rights. All demands for shareholder meetings must set forth the items to be considered at that meeting. Pursuant to
the Companies Law, the holder or holders of 1% of the Company’s voting rights may request the inclusion of an item on the agenda of a future shareholder
meeting, provided the item is appropriate for discussion at a shareholder meeting, and if such item relates to the appointment of a director, the holder or
holders shall hold at 5% of the Company’s voting rights in order to make such request.
According to regulations promulgated pursuant to the Companies Law and governing the terms of notice and publication of shareholder meetings
of public companies, or the General Meeting Regulations, holder(s) of one percent or more of the Company’s voting rights may propose any matter
appropriate for deliberation at a shareholder meeting to be included on the agenda of a shareholder meeting, generally by submitting a proposal within
seven days of publicizing the convening of a shareholder meeting, or, if the Company publishes a preliminary notice at least 21 days prior to publicizing the
convening of a meeting (stating its intention to convene such meeting and the agenda thereof), within 14 days of such preliminary notice. Any such
proposal must further comply with the information requirements under applicable law and the Articles.
- 5 -
Pursuant to the Companies Law and regulations promulgated thereunder with respect to the convening of general meetings in a public company,
shareholder meetings generally require prior notice of not less than 21 days, and for certain matters specified in the Companies Law, not less than 35 days.
The function of the annual general meeting is to elect directors in accordance with the Articles, receive and consider the profit and loss account, the balance
sheet and the ordinary reports and accounts of the directors and auditors, appoint auditors and fix their remuneration and transact any other business which
under the Articles or applicable law may be transacted by the shareholders of a company in general meeting.
Our Articles determine that the quorum required for either an annual (regular) or an extraordinary (special) general meeting of shareholders
consists of at least two shareholders present in person or by proxy holding shares comprising in the aggregate more than 33.33% of the voting rights of the
Company. If a meeting is convened by the Board upon the demand of shareholders or upon the demand of less than 50% of the directors then in office or
directly by such shareholders or directors and no quorum is present within half an hour from the time appointed, it shall be cancelled. If a meeting is
otherwise called and no quorum is present within such time, the meeting is adjourned to the same day one week later at the same time and place or at such
other time and place as the Board may determine and specify in the notice of the general meeting and it shall not be necessary to give notice of such
adjournment. If a quorum is not present within half an hour from the time stated for such adjourned meeting, any two shareholders present in person or by
proxy at such meeting shall constitute a quorum even if, between them, they represent shares conferring 33.33% or less of the voting rights of the
Company.
Generally, under the Companies Law and the Articles, shareholder resolutions are deemed adopted if approved by the holders of a simple majority
of the voting rights represented at a meeting and voting unless a different majority is required by law or pursuant to the Articles. The Companies Law
provides that resolutions on certain matters, such as amending a company’s articles of association, assuming the authority of the board of directors in
certain circumstances, appointing auditors, appointing external directors (if applicable), approving certain transactions, increasing or decreasing the
registered share capital and approving most mergers must be made by the shareholders at a general meeting. A company may determine in its articles of
association certain additional matters in respect of which resolutions by the shareholders in a general meeting will be required.
Access to Corporate Records
Under the Companies Law, all shareholders generally have the right to review minutes of our general meetings, our shareholder register and
register of significant shareholders (as defined in the Companies Law), our articles of association, our financial statements, other documents as provided in
the Companies Law, and any document we are required by law to file publicly with the Israeli Companies Registrar. Any shareholder who specifies the
purpose of its request may request to review any document in our possession that relates to: (i) any action or transaction with a related party which requires
shareholder approval under the Companies Law; or (ii) the approval, by the board of directors, of an action in which an office holder has a personal
interest. We may deny a request to review a document if we determine that the request was not made in good faith, or if such denial is necessary to protect
our interest or protect a trade secret or patent.
Shareholder Duties
Pursuant to the Companies Law, a shareholder has a duty to act in good faith and in a customary manner toward a company and other shareholders
and to refrain from abusing his or her power in the company, including, among other things, in voting at the general meeting of shareholders and at class
shareholder meetings with respect to the following matters:
● an amendment to the company’s articles of association;
● an increase of the company’s authorized share capital;
● a merger; or
● approval of interested party transactions and acts of Office Holders that require shareholder approval.
In addition, a shareholder also has a general duty to refrain from discriminating against other shareholders.
- 6 -
Certain shareholders have a further duty of fairness toward a company. These shareholders include any controlling shareholder, any shareholder
who knows that it has the power to determine the outcome of a shareholder vote or a shareholder class vote and any shareholder who has the power to
appoint or to prevent the appointment of an Office Holder of the company or other power towards the company. The Companies Law does not define the
substance of this duty of fairness, except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach of
the duty to act with fairness, taking the shareholder’s position in the company into account.
Mergers and Acquisitions under Israeli Law
(i) Merger
The Companies Law permits merger transactions if approved by each party’s board of directors, and, unless certain requirements described under
the Companies Law are met, a majority of each party’s shareholders, by a majority of each party’s shares that are voted on the proposed merger at a
shareholders’ meeting.
The board of directors of a merging company is required pursuant to the Companies Law to discuss and determine whether in its opinion there
exists a reasonable concern that as a result of a proposed merger, the surviving company will not be able to satisfy its obligations towards its creditors,
taking into account the financial condition of the merging companies. If the board of directors has determined that such a concern exists, it may not approve
a proposed merger. Following the approval of the board of directors of each of the merging companies, the boards of directors must jointly prepare a
merger proposal for submission to the Israeli Registrar of Companies.
For purposes of the shareholder vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the shares voting at
the shareholders meeting (excluding abstentions) that are held by parties other than the other party to the merger, any person who holds 25% or more of the
means of control of the other party to the merger or any one on their behalf including their relatives or corporations controlled by any of them, vote against
the merger. In addition, if the non-surviving entity of the merger has more than one class of shares, the merger must be approved by each class of
shareholders.
If the transaction would have been approved but for the separate approval of each class of shares or the exclusion of the votes of certain
shareholders as provided above, a court may still rule that the company has approved the merger upon the request of holders of at least 25% of the voting
rights of a company, if the court holds that the merger is fair and reasonable, taking into account the appraisal of the merging companies’ value and the
consideration offered to the shareholders.
Under the Companies Law, each merging company must send a copy of the proposed merger plan to its secured creditors. Unsecured creditors are
entitled to receive notice of the merger, as provided by the regulations promulgated under the Companies Law. Upon the request of a creditor of either party
to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the
surviving company will be unable to satisfy the obligations of the target company. The court may also give instructions in order to secure the rights of
creditors.
In addition, a merger may not be completed unless at least 50 days have passed from the date that a proposal for approval of the merger was filed
with the Israeli Registrar of Companies and 30 days from the date that shareholder approval of both merging companies was obtained.
(ii) Special Tender Offer
The Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a
result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. This rule does not apply if there is
already another holder of 25% or more of the voting rights in the company. Similarly, the Companies Law provides that an acquisition of shares in a public
company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of the
voting rights in the company, if there is no other shareholder of the company who holds more than 45% of the voting rights in the company.
- 7 -
These requirements do not apply if the acquisition (i) occurs in the context of a private offering, on the condition that the shareholders’ meeting
approved the acquisition as a private offering whose purpose is to give the acquirer at least 25% of the voting rights in the company if there is no person
who holds at least 25% of the voting rights in the company, or as a private offering whose purpose is to give the acquirer 45% of the voting rights in the
company, if there is no person who holds 45% of the voting rights in the company; (ii) was from a shareholder holding at least 25% of the voting rights in
the company and resulted in the acquirer becoming a holder of at least 25% of the voting rights in the company; or (iii) was from a holder of more than
45% of the voting rights in the company and resulted in the acquirer becoming a holder of more than 45% of the voting rights in the company.
The special tender offer may be consummated only if (i) at least 5% of the voting power attached to the company’s outstanding shares will be
acquired by the offeror and (ii) the special tender offer is accepted by a majority of the votes of those offerees who gave notice of their position in respect
of the offer; in counting the votes of offerees, the votes of a holder of control in the offeror, a person who has personal interest in acceptance of the special
tender offer, a holder of at least 25% of the voting rights in the company, or any person acting on their or on the offeror’s behalf, including their relatives or
companies under their control, are not taken into account.
In the event that a special tender offer is made, a company’s board of directors is required to express its opinion on the advisability of the offer or
shall abstain from expressing any opinion if it is unable to do so, provided that it gives the reasons for its abstention. In addition, the board of directors must
disclose any personal interest each of member of the board of directors have in the offer or stems therefrom.
An office holder in a target company who, in his or her capacity as an office holder, performs an action the purpose of which is to cause the failure
of an existing or foreseeable special tender offer or is to impair the chances of its acceptance, is liable to the potential purchaser and shareholders for
damages resulting from his acts, unless such office holder acted in good faith and had reasonable grounds to believe he or she was acting for the benefit of
the company. However, office holders of the target company may negotiate with the potential purchaser in order to improve the terms of the special tender
offer, and may further negotiate with third parties in order to obtain a competing offer.
If a special tender offer was accepted by a majority of the shareholders who announced their stand on such offer, then shareholders who did not
respond to the special offer or had objected to the special tender offer may accept the offer within four days of the last day set for the acceptance of the
offer. In the event that a special tender offer is accepted, then the purchaser or any person or entity controlling it and any corporation controlled by them
shall refrain from making a subsequent tender offer for the purchase of shares of the target company and may not execute a merger with the target company
for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial
special tender offer.
(iii) Full Tender Offer
Under the Companies Law, a person may not acquire shares in a public company if, after the acquisition, he will hold more than 90% of the shares
or more than 90% of any class of shares of that company, unless a tender offer is made to purchase all of the shares or all of the shares of the particular
class. The Companies Law also provides, subject to certain exceptions, that as long as a shareholder in a public company holds more than 90% of the
company’s shares or of a class of shares, that shareholder shall be precluded from purchasing any additional shares unless tendering an offer to purchase all
of the outstanding shares of the company or the applicable class of the shares. If the shareholders who do not respond to or accept the offer hold less than
5% of the issued and outstanding share capital of the company or of the applicable class of the shares, and more than half of the shareholders who do not
have a personal interest in the offer accept the offer, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of
law. However, a tender offer will be accepted if the shareholders who do not accept it hold less than 2% of the issued and outstanding share capital of the
company or of the applicable class of the shares.
Upon a successful completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder
accepted the tender offer or not, has the right, within six months from the date of acceptance of the tender offer, to petition the court to determine that the
tender offer was for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions, the purchaser
may provide in its offer that an offeree who accepted the tender offer will not be entitled to such rights.
- 8 -
If the conditions set forth above are not met, the purchaser may not acquire additional shares of the company from shareholders who accepted the
tender offer to the extent that following such acquisition, the purchaser would own more than 90% of the company’s issued and outstanding share capital.
Anti-Takeover Measures under Israeli Law
The Companies Law allows us to create and issue shares having rights different from those attached to our ordinary shares, including shares
providing certain preferred rights, distributions or other matters and shares having preemptive rights. As of the date hereof, no preferred shares are
authorized under our Articles. In the future, if we do authorize, create and issue a specific class of preferred shares, such class of shares, depending on the
specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover or otherwise prevent our shareholders from realizing a
potential premium over the market value of their ordinary shares. The authorization and designation of a class of preferred shares will require an
amendment to our Articles, which requires the affirmative vote of at least 75% of the voting rights of the Company represented personally or by proxy and
voting thereon at a general meeting at which a quorum is present. The convening of the general meeting, the shareholders entitled to participate and the
majority vote required to be obtained at such a meeting will be subject to the requirements set forth in the Articles and the Companies Law as described
above in “— Shareholder Meetings.”
In addition, certain provisions of the Articles may have the effect of rendering more difficult or discouraging an acquisition of the Company
deemed undesirable by the Board. The classification of the Board into three classes with terms of approximately three years each, may make it more
difficult for shareholders who oppose the policies of the Board to remove a majority of the then current directors from office quickly. It may also, in some
circumstances, together with the other provisions of the Articles and Israeli law, deter or delay potential future merger, acquisition, tender or takeover
offers, proxy contests or changes in control or management of the Company.
Changes in Capital
Our Articles enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Companies Law and must be
approved by a resolution duly passed by our shareholders at a general meeting by voting on such change in the capital. In addition, transactions that have
the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient retained earnings or profits and an issuance of
shares for less than their nominal value (under certain circumstances), require the approval of both our Board and an Israeli court.
Changes in Shareholder Rights
Pursuant to our Articles, if at any time the share capital is divided into different classes of shares, the Company may by shareholder resolution,
unless otherwise provided by the terms of issue of the shares of that class, modify, convert, broaden, add or otherwise alter the rights, privileges,
advantages, restrictions and provisions related or unrelated at that time to the shares of any class with the sanction of a resolution passed by a simple
majority of those present, personally or by proxy, and voting thereon at a separate general meeting of the holders of the shares of that class. Such majority
approval is consistent with Israeli law.
Subsidiaries of Galmed Pharmaceuticals Ltd.
Jurisdiction of Incorporation
Galmed International Ltd.
Galmed Research and Development Ltd.
Galtopa Therapeutics Ltd.
Malta
Israel
Israel
Galmed Therapeutics UK Limited*
England and Wales
* Wholly-owned subsidiary of Galmed Research and Development Ltd.
Exhibit 8.1
Exhibit 12.1
I, Allen Baharaff, certify that:
1. I have reviewed this annual report on Form 20-F of Galmed Pharmaceuticals Ltd. (the “Company”);
CERTIFICATION
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
4. The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for
the Company and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the period covered by
the annual report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and
5. The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to
the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal
control over financial reporting.
By: /s/ Allen Baharaff
Allen Baharaff
President and Chief Executive Officer
Date: April 4, 2024
Exhibit 12.2
I, Yohai Stenzler, certify that:
1. I have reviewed this annual report on Form 20-F of Galmed Pharmaceuticals Ltd. (the “Company”);
CERTIFICATION
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
4. The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for
the Company and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the period covered by
the annual report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and
5. The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to
the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal
control over financial reporting.
By: /s/ Yohai Stenzler
Yohai Stenzler
Chief Accounting Officer
Date: April 4, 2024
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Exhibit 13.1
In connection with the annual report of Galmed Pharmaceuticals Ltd. (the “Company”) on Form 20-F for the period ending December 31, 2023, as filed
with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certify that to the best of our knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the
Company.
By: /s/ Allen Baharaff
Allen Baharaff
President and Chief Executive Officer
By: /s/ Yohai Stenzler
Yohai Stenzler
Chief Accounting Officer
Date: April 4, 2024
The certification set forth above is being furnished as an exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as
part of the annual report on Form 20-F for the period ended December 31, 2022, or as a separate disclosure document of the Company or the certifying
officers.
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Nos. 333-206292 and 333-227441 on Form S-8 and Registration No. 333-272722 on Form F-3
of our report dated April 4, 2024, relating to the financial statements of Galmed Pharmaceuticals Ltd., appearing in this Annual Report on Form 20-F for
the year ended December 31, 2023.
Exhibit 15.1
/s/ Brightman Almagor Zohar & Co.
Brightman Almagor Zohar & Co.
Certified Public Accountants
A Firm in the Deloitte Global Network
Tel Aviv, Israel
April 4, 2024
Exhibit 97.1
I.
Purpose
Galmed Pharmaceuticals Ltd.
Executive Officer Clawback Policy
This Executive Officer Clawback Policy describes the circumstances under which Covered Persons of Galmed Pharmaceuticals Ltd. and any of its direct or
indirect subsidiaries (the “Company”) will be required to repay or return Erroneously-Awarded Compensation to the Company.
This Policy and any terms used in this Policy shall be construed in accordance with any SEC regulations promulgated to comply with Section 954 of the
Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, including without limitation Rule 10D-1 promulgated under the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), and the rules adopted by Nasdaq, as well as the provisions of the Israeli Companies Law of 1999
(the “Companies Law”).
Each Covered Person of the Company shall sign an Acknowledgement and Agreement to the Clawback Policy in the form attached hereto as Exhibit A;
provided that this Policy shall apply to each Covered Person irrespective of whether such Covered Person shall have failed, for any reason, to have
executed such Acknowledgement and Agreement.
II.
Definitions
For purposes of this Policy, the following capitalized terms shall have the respective meanings set forth below:
(a) “Accounting Restatement” shall mean an accounting restatement (i) due to the material noncompliance of the Company with any financial reporting
requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial restatements that
is material to the previously issued financial statements (a “Big R” restatement), or (ii) that corrects an error that is not material to previously issued
financial statements, but would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current
period (a “little r” restatement). Notwithstanding the foregoing, none of the following changes to the Company’s financial statements represent error
corrections and shall not be deemed an Accounting Restatement: (a) retrospective application of a change in accounting principle; (b) retrospective
revision to reportable segment information due to a change in the structure of the Company’s internal organization; (c) retrospective reclassification
due to a discontinued operation; (d) retrospective application of a change in reporting entity, such as from a reorganization of entities under common
control; and (e) retrospective revision for share splits, reverse share splits, share dividends or other changes in capital structure.
(b) “Applicable Rules” shall mean means Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder, the listing rules of the national
securities exchange or association on which the Company’s securities are listed, and any applicable rules, standards or other guidance adopted by the
SEC or any national securities exchange or association on which the Company’s securities are listed..
(c) “Board” shall mean the Board of Directors of the Company.
(d) “Clawback-Eligible Incentive Compensation” shall mean, in connection with an Accounting Restatement, any Incentive-Based Compensation
Received by a Covered Person (regardless of whether such Covered Person was serving at the time that Erroneously-Awarded Compensation is
required to be repaid) (i) on or after the Nasdaq Effective Date, (ii) after beginning service as a Covered Person, (iii) while the Company has a class of
securities listed on a national securities exchange or national securities association and (iv) during the Clawback Period.
(e) “Clawback Period” shall mean, with respect to any Accounting Restatement, the three completed fiscal years immediately preceding the Restatement
Date and any transition period (that results from a change in the Company’s fiscal year) of less than nine months within or immediately following
those three completed fiscal years.
(f) “Committee” shall mean the Compensation Committee of the Board.
(g) “Compensation Policy” shall mean the Company’s Compensation Policy then in-effect as most recently approved by the Company’s shareholders.
(h) “Covered Person” shall mean any person who is, or was at any time, during the Clawback Period, an Executive Officer of the Company. For the
avoidance of doubt, Covered Person may include a former Executive Officer that left the Company, retired or transitioned to an employee non-
Executive Officer role (including after serving as an Executive Officer in an interim capacity) during the Clawback Period, and this Policy applies
regardless of whether the Covered Person was at fault for an accounting error or other action that resulted in, or contributed to, the Accounting
Restatement.
(i) “Erroneously-Awarded Compensation” shall mean the amount of Clawback-Eligible Incentive Compensation that exceeds the amount of Incentive-
Based Compensation that otherwise would have been Received had it been determined based on the restated amounts. This amount must be computed
without regard to any taxes paid.
(j) “Executive Officer” shall mean (i) the Company’s president, principal financial officer, principal accounting officer (or if there is no such accounting
officer, the controller), any vice-president in charge of a principal business unit, division, or function (such as sales, administration, or finance), any
other officer who performs a policy-making function, (ii) any other person (including an officer of the Company’s parent(s) or subsidiaries) who
performs similar policy-making functions for the Company or (iii) such other persons who are determined by the Committee and the Board in their
sole discretion to be an officer of the Company and are required by applicable law to be covered by this Policy. For the sake of clarity, at a minimum,
all persons who would be executive officers pursuant to Rule 401(b) under Regulation S-K shall be deemed “Executive Officers”.
(k) “Financial Reporting Measures” shall mean measures that are determined and presented in accordance with the accounting principles used in
preparing the Company’s financial statements, and all other measures that are derived wholly or in part from such measures, including, without
limitation, measures that are “non-GAAP financial measures” for purposes of Exchange Act Regulation G and Item 10(e) of Regulation S-K, as well
other measures, metrics and ratios that are not non- GAAP measures. For purposes of this Policy, Financial Reporting Measures shall include stock
price and total shareholder return (and any measures that are derived wholly or in part from stock price or total shareholder return). A Financial
Reporting Measure need not be presented within the Company’s financial statements or included in a Company filing with the SEC.
(l) “Incentive-Based Compensation” shall have the meaning set forth in Section III below.
(m) “Nasdaq” shall mean The Nasdaq Stock Market.
(n) “Nasdaq Effective Date” shall mean October 2, 2023.
(o) “Policy” shall mean this Executive Officer Clawback Policy, as the same may be amended and/or restated from time to time.
(p) “Received” shall mean Incentive-Based Compensation received, or deemed to be received, in the Company’s fiscal period during which the Financial
Reporting Measure specified in the Incentive-Based Compensation is attained, even if the payment or grant occurs after the fiscal period.
(q) “Repayment Agreement” shall have the meaning set forth in Section V below.
(r) “Restatement Date” shall mean the earlier of (i) the date the Board, a committee of the Board or the officers of the Company authorized to take such
action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting
Restatement, or (ii) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.
(s) “SARs” shall mean stock appreciation rights.
(t) “SEC” shall mean the U.S. Securities and Exchange Commission.
III.
Incentive-Based Compensation
“Incentive-Based Compensation” shall mean any compensation that is granted, earned or vested wholly or in part upon the attainment of a Financial
Reporting Measure.
For purposes of this Policy, specific examples of Incentive-Based Compensation include, but are not limited to:
● Non-equity incentive plan awards that are earned based, wholly or in part, based on satisfaction of a Financial Reporting Measure performance
goal;
● Bonuses paid from a “bonus pool,” the size of which is determined, wholly or in part, based on satisfaction of a Financial Reporting Measure
performance goal;
● Other cash awards based on satisfaction of a Financial Reporting Measure performance goal;
● Restricted stock, restricted stock units, performance share units, stock options and SARs that are granted or become vested, wholly or in part, on
satisfaction of a Financial Reporting Measure performance goal; and
● Proceeds received upon the sale of shares acquired through an incentive plan that were granted or vested based, wholly or in part, on satisfaction
of a Financial Reporting Measure performance goal.
For purposes of this Policy, Incentive-Based Compensation excludes:
● Any base salaries (except with respect to any salary increases earned, wholly or in part, based on satisfaction of a Financial Reporting Measure
performance goal);
● Bonuses paid solely at the discretion of the Committee or Board that are not paid from a “bonus pool” that is determined by satisfying a Financial
Reporting Measure performance goal;
● Bonuses paid solely upon satisfying one or more subjective standards and/or completion of a specified employment period;
● Non-equity incentive plan awards earned solely upon satisfying one or more strategic measures or operational measures; and
● Equity awards that vest solely based on the passage of time and/or satisfaction of one or more non-Financial Reporting Measures.
IV.
Determination and Calculation of Erroneously-Awarded Compensation
In the event of an Accounting Restatement, the Committee and the Board shall promptly determine the amount of any Erroneously-Awarded Compensation
for each Executive Officer in connection with such Accounting Restatement and shall promptly thereafter provide each Executive Officer with a written
notice containing the amount of Erroneously-Awarded Compensation and a demand for repayment, forfeiture or return thereof, as applicable.
(a) Cash Awards. With respect to cash awards, the Erroneously-Awarded Compensation is the difference between the amount of the cash award (whether
payable as a lump sum or over time) that was Received and the amount that should have been Received applying the restated Financial Reporting
Measure.
(b) Cash Awards Paid From Bonus Pools. With respect to cash awards paid from bonus pools, the Erroneously-Awarded Compensation is the pro rata
portion of any deficiency that results from the aggregate bonus pool that is reduced based on applying the restated Financial Reporting Measure.
(c) Equity Awards. With respect to equity awards, if the shares, options, SARs or other equity awards are still held at the time of recovery, the
Erroneously-Awarded Compensation is the number of such securities Received in excess of the number that should have been received applying the
restated Financial Reporting Measure (or the value in excess of that number). If the options, SARs or other equity awards have been exercised, vested,
settled or otherwise converted into underlying shares, but the underlying shares have not been sold, the Erroneously-Awarded Compensation is the
number of shares underlying the excess options or SARs (or the value thereof). If the underlying shares have already been sold, the Erroneously-
Awarded Compensation is the higher of the value of the stock upon vesting, exercise or sale.
(d) Compensation Based on Stock Price or Total Shareholder Return. For Incentive-Based Compensation based on (or derived from) stock price or
total shareholder return, where the amount of Erroneously-Awarded Compensation is not subject to mathematical recalculation directly from the
information in the applicable Accounting Restatement, the amount shall be determined by the Committee and the Board based on a reasonable estimate
of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was Received
(in which case, the Committee and the Board shall maintain documentation of such determination of that reasonable estimate and provide such
documentation to Nasdaq in accordance with applicable listing standards).
V.
Recovery of Erroneously-Awarded Compensation
Once the Committee and the Board have determined the amount of Erroneously-Awarded Compensation recoverable from the applicable Covered Person,
the Committee shall take all necessary actions to recover the Erroneously-Awarded Compensation. Unless otherwise determined by the Committee and
Board, the Committee shall pursue the recovery of Erroneously-Awarded Compensation in accordance with the below:
(a) Cash Awards. With respect to cash awards, the Committee shall either (i) require the Covered Person to repay the Erroneously-Awarded
Compensation in a lump sum in cash (or such property as the Committee agrees to accept with a value equal to such Erroneously-Awarded
Compensation) reasonably promptly following the Restatement Date or (ii) if approved by the Committee, offer to enter into a Repayment Agreement.
If the Covered Person accepts such offer and signs the Repayment Agreement within a reasonable time as determined by the Committee, the Company
shall countersign such Repayment Agreement.
(b) Unvested Equity Awards. With respect to those equity awards that have not yet vested, the Committee shall take all necessary action to cancel, or
otherwise cause to be forfeited, the awards in the amount of the Erroneously-Awarded Compensation.
(c) Vested Equity Awards. With respect to those equity awards that have vested and the underlying shares have not been sold, the Committee shall take
all necessary action to cause the Covered Person to deliver and surrender the underlying shares in the amount of the Erroneously-Awarded
Compensation.
In the event that the Covered Person has sold the underlying shares, the Committee shall either (i) require the Covered Person to repay the
Erroneously-Awarded Compensation in a lump sum in cash (or such property as the Committee agrees to accept with a value equal to such
Erroneously-Awarded Compensation) reasonably promptly following the Restatement Date or (ii) if approved by the Committee, offer to enter into a
Repayment Agreement. If the Covered Person accepts such offer and signs the Repayment Agreement within a reasonable time as determined by the
Committee, the Company shall countersign such Repayment Agreement.
(d) Repayment Agreement. “Repayment Agreement” shall mean an agreement (in a form reasonably acceptable to the Committee) with the Covered
Person for the repayment of the Erroneously-Awarded Compensation as promptly as possible without unreasonable economic hardship to the Covered
Person.
(e) Effect of Non-Repayment. To the extent that a Covered Person fails to repay all Erroneously-Awarded Compensation to the Company when due (as
determined in accordance with this Policy), the Company shall, or shall cause one or more other members of the Company to, take all actions
reasonable and appropriate to recover such Erroneously-Awarded Compensation from the applicable Covered Person. Unless otherwise determined by
the Committee in its discretion, the applicable Covered Person shall be required to reimburse the Company for any and all expenses reasonably
incurred (including legal fees) by the Company in recovering such Erroneously-Awarded Compensation in accordance with the immediately preceding
sentence.
The Committee shall have broad discretion to determine the appropriate means of recovery of Erroneously-Awarded Compensation based on all
applicable facts and circumstances and taking into account the time value of money and the cost to shareholders of delaying recovery. However, in no
event may the Company accept an amount that is less than the amount of Erroneously-Awarded Compensation in satisfaction of a Covered Person’s
obligations hereunder.
VI.
Discretionary Recovery
Notwithstanding anything herein to the contrary, the Company shall not be required to take action to recover Erroneously-Awarded Compensation if any
one of the following conditions are met and the Committee and the Board determine that recovery would be impracticable:
(i) The direct expenses paid to a third party to assist in enforcing this Policy against a Covered Person would exceed the amount to be recovered, after
the Company has made a reasonable attempt to recover the applicable Erroneously-Awarded Compensation, documented such attempts and
provided such documentation to Nasdaq;
(ii) Recovery would violate home country law where that law was adopted prior to November 28, 2022, provided that, before determining that it
would be impracticable to recover any amount of Erroneously-Awarded Compensation based on violation of home country law, the Company has
obtained an opinion of home country counsel, acceptable to Nasdaq, that recovery would result in such a violation and a copy of the opinion is
provided to Nasdaq; or
(iii) Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company,
to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.
VII.
Reporting and Disclosure Requirements
The Company shall file all disclosures with respect to this Policy in accordance with the requirements of the federal securities laws, including the
disclosure required by the applicable filings required to be made with the SEC.
VIII.
Effective Date
This Policy shall apply to any Incentive-Based Compensation Received on or after the Nasdaq Effective Date.
IX.
No Indemnification
The Company shall not indemnify any Covered Person against the loss of Erroneously-Awarded Compensation and shall not pay, or reimburse any
Covered Persons for premiums, for any insurance policy to fund such Covered Person’s potential recovery obligations.
X.
Administration
This Policy shall be administered, interpreted and construed by the Committee, which is authorized to make all determinations necessary, appropriate or
advisable for such purpose. The Board may re-vest in itself the authority to administer, interpret and construe this Policy in accordance with applicable law,
and in such event references herein to the “Committee” shall be deemed to be references to the Board. Subject to any permitted review by the applicable
national securities exchange or association pursuant to the Applicable Rules, all determinations and decisions made by the Committee pursuant to the
provisions of this Policy shall be final, conclusive and binding on all persons, including the Company and its affiliates, shareholders and employees. The
Committee may delegate administrative duties with respect to this Policy to one or more directors or employees of the Company, as permitted under
applicable law, including any Applicable Rules.
XI.
Amendment; Termination
The Committee and the Board may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary, including as and
when it determines that it is legally required by any federal securities laws, SEC rule, the Companies Law or the rules of any national securities exchange
or national securities association on which the Company’s securities are then listed. The Committee and the Board may terminate this Policy at any time.
Notwithstanding anything in this Section XI to the contrary, no amendment or termination of this Policy shall be effective if such amendment or
termination would (after taking into account any actions taken by the Company contemporaneously with such amendment or termination) cause the
Company to violate any federal securities laws, SEC rule, the Companies Law or the rules of any national securities exchange or national securities
association on which the Company’s securities are then listed.
XII.
Other Recoupment Rights; No Additional Payments
The Committee intends that this Policy will be applied to the fullest extent of the law. The Committee may require that any employment agreement, equity
award agreement or any other agreement entered into on or after the Adoption Date shall, as a condition to the grant of any benefit thereunder, require a
Covered Person to agree to abide by the terms of this Policy. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other rights
under applicable law, regulation or rule or pursuant to any similar policy in any employment agreement, equity plan, the Compensation Policy, equity
award agreement or similar arrangement and any other legal remedies available to the Company. However, this Policy shall not provide for recovery of
Incentive-Based Compensation that the Company has already recovered pursuant to Section 304 of the Sarbanes-Oxley Act or other recovery obligations.
In the event of a conflict between this Policy and the Compensation Policy, the Compensation Policy shall prevail, except with respect to the recovery of
any portion of Incentive-Based Compensation that is Erroneously Awarded Compensation that would not be recoverable under the Compensation Policy, in
which case this Policy shall prevail. Subject to this Section XII, the remedy specified in this Policy shall not be exclusive and shall be in addition to every
other right or remedy at law or in equity that may be available to the Company or an affiliate of the Company or is otherwise required by applicable law
and regulations.
XIII.
Successors
This Policy shall be binding and enforceable against all Covered Persons and their beneficiaries, heirs, executors, administrators or other legal
representatives.
Exhibit A
ACKNOWLEDGEMENT AND AGREEMENT
TO THE
EXECUTIVE OFFICER CLAWBACK POLICY
OF
GALMED PHARMACEUTICALS LTD.
By signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of Galmed Pharmaceuticals Ltd.
Executive Officer Clawback Policy (the “Policy”). Capitalized terms used but not otherwise defined in this Acknowledgement Form (this
“Acknowledgement Form”) shall have the meanings ascribed to such terms in the Policy.
By signing this Acknowledgement Form, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject to the Policy and
that the Policy will apply both during and after the undersigned’s employment with the Company. Further, by signing below, the undersigned agrees to
abide by the terms of the Policy, including, without limitation, by returning any Erroneously-Awarded Compensation (as defined in the Policy) to the
Company to the extent required by, and in a manner permitted by, the Policy.
Signature
Name
Date